{"PMC7525342": [["IntroductionAnecdotal reports of poor outcomes in critically ill patients with covid-19 who have had in-hospital cardiac arrest have prompted discussions on the futility of cardiopulmonary resuscitation in this patient population.1 However, data to guide these discussions are lacking.", [["cardiac", "ANATOMY", 113, 120], ["cardiopulmonary", "ANATOMY", 173, 188], ["critically ill", "DISEASE", 50, 64], ["cardiac arrest", "DISEASE", 113, 127], ["patients", "ORGANISM", 65, 73], ["patient", "ORGANISM", 211, 218], ["patients", "SPECIES", 65, 73], ["patient", "SPECIES", 211, 218], ["cardiac arrest", "PROBLEM", 113, 127], ["cardiopulmonary resuscitation", "TREATMENT", 173, 202], ["this patient population", "TREATMENT", 206, 229], ["cardiac", "ANATOMY", 113, 120], ["arrest", "OBSERVATION", 121, 127]]], ["Only two limited reports of in-hospital cardiac arrest in patients with covid-19 have been published to date.", [["cardiac", "ANATOMY", 40, 47], ["cardiac arrest", "DISEASE", 40, 54], ["cardiac", "ORGAN", 40, 47], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["cardiac arrest", "TREATMENT", 40, 54], ["covid", "TEST", 72, 77], ["cardiac", "ANATOMY", 40, 47], ["arrest", "OBSERVATION", 48, 54]]], ["A single center study from Wuhan, China included 151 patients with in-hospital cardiac arrest and found that only 3% of patients who received cardiopulmonary resuscitation survived to 30 days.2 A single center study from New York City that included 31 patients with in-hospital cardiac arrest found that no patient survived to hospital discharge.3", [["cardiac", "ANATOMY", 79, 86], ["cardiopulmonary", "ANATOMY", 142, 157], ["cardiac", "ANATOMY", 278, 285], ["cardiac arrest", "DISEASE", 79, 93], ["cardiac arrest", "DISEASE", 278, 292], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 252, 260], ["patient", "ORGANISM", 307, 314], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 252, 260], ["patient", "SPECIES", 307, 314], ["A single center study", "TEST", 0, 21], ["cardiopulmonary resuscitation", "TREATMENT", 142, 171], ["A single center study", "TEST", 194, 215], ["cardiac", "ANATOMY", 79, 86], ["arrest", "OBSERVATION", 87, 93], ["cardiac", "ANATOMY", 278, 285], ["arrest", "OBSERVATION", 286, 292]]]], "2ee32c492fb088bca33f2b2409baa37d488dae5c": [["IntroductionRegulatory T cells (Tregs), characterized by Foxp3 expression, have critical roles in suppressing pro-inflammatory immune responses, with ameliorating effects in autoimmune disease and deleterious consequences in the context of tumor clearance [1] .", [["IntroductionRegulatory T cells", "ANATOMY", 0, 30], ["Tregs", "ANATOMY", 32, 37], ["tumor", "ANATOMY", 240, 245], ["autoimmune disease", "DISEASE", 174, 192], ["tumor", "DISEASE", 240, 245], ["IntroductionRegulatory T cells", "CELL", 0, 30], ["Tregs", "CELL", 32, 37], ["Foxp3", "GENE_OR_GENE_PRODUCT", 57, 62], ["tumor", "CANCER", 240, 245], ["IntroductionRegulatory T cells", "CELL_TYPE", 0, 30], ["Tregs", "CELL_TYPE", 32, 37], ["Foxp3", "PROTEIN", 57, 62], ["autoimmune disease", "PROBLEM", 174, 192], ["deleterious consequences", "PROBLEM", 197, 221], ["tumor clearance", "PROBLEM", 240, 255], ["Foxp3 expression", "OBSERVATION", 57, 73], ["autoimmune disease", "OBSERVATION", 174, 192], ["tumor", "OBSERVATION", 240, 245]]], ["Tregs are also critical for the resolution of immune responses against pathogens.", [["Tregs", "ANATOMY", 0, 5], ["Tregs", "CELL", 0, 5], ["Tregs", "CELL_TYPE", 0, 5], ["immune responses", "PROBLEM", 46, 62], ["pathogens", "PROBLEM", 71, 80]]], ["They are required for entry of immune cells into sites of inflammation in some viral infections [2, 3] .", [["immune cells", "ANATOMY", 31, 43], ["sites", "ANATOMY", 49, 54], ["inflammation", "DISEASE", 58, 70], ["viral infections", "DISEASE", 79, 95], ["immune cells", "CELL", 31, 43], ["immune cells", "CELL_TYPE", 31, 43], ["immune cells", "TREATMENT", 31, 43], ["inflammation", "PROBLEM", 58, 70], ["some viral infections", "PROBLEM", 74, 95], ["inflammation", "OBSERVATION", 58, 70], ["some", "OBSERVATION_MODIFIER", 74, 78], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["infections", "OBSERVATION", 85, 95]]], ["Additionally, in chronic viral infections, such as those caused by HIV, simian immunodeficiency virus, Friend virus and hepatitis C virus (HCV), Tregs contribute to pathogen persistence [4] .", [["Tregs", "ANATOMY", 145, 150], ["chronic viral infections", "DISEASE", 17, 41], ["simian immunodeficiency virus", "DISEASE", 72, 101], ["Friend virus and hepatitis C", "DISEASE", 103, 131], ["HIV", "ORGANISM", 67, 70], ["simian immunodeficiency virus", "ORGANISM", 72, 101], ["Friend virus", "ORGANISM", 103, 115], ["hepatitis C virus", "ORGANISM", 120, 137], ["HCV", "ORGANISM", 139, 142], ["Tregs", "CELL", 145, 150], ["Tregs", "CELL_TYPE", 145, 150], ["HIV", "SPECIES", 67, 70], ["simian immunodeficiency virus", "SPECIES", 72, 101], ["Friend virus", "SPECIES", 103, 115], ["hepatitis C virus", "SPECIES", 120, 137], ["HIV", "SPECIES", 67, 70], ["simian immunodeficiency virus", "SPECIES", 72, 101], ["Friend virus", "SPECIES", 103, 115], ["hepatitis C virus", "SPECIES", 120, 137], ["HCV", "SPECIES", 139, 142], ["chronic viral infections", "PROBLEM", 17, 41], ["HIV", "PROBLEM", 67, 70], ["simian immunodeficiency virus", "PROBLEM", 72, 101], ["Friend virus", "PROBLEM", 103, 115], ["hepatitis C virus (HCV)", "PROBLEM", 120, 143], ["Tregs", "PROBLEM", 145, 150], ["pathogen persistence", "PROBLEM", 165, 185], ["chronic", "OBSERVATION_MODIFIER", 17, 24], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["infections", "OBSERVATION", 31, 41]]], ["On the other hand, in acute viral infections caused by pathogens that include West Nile virus (WNV), herpes simplex virus (HSV) and mouse hepatitis virus (MHV), Tregs ameliorate acute disease [5] [6] [7] .", [["Tregs", "ANATOMY", 161, 166], ["viral infections", "DISEASE", 28, 44], ["West Nile virus (WNV)", "DISEASE", 78, 99], ["herpes simplex virus (HSV) and mouse hepatitis virus", "DISEASE", 101, 153], ["West Nile virus", "ORGANISM", 78, 93], ["WNV", "ORGANISM", 95, 98], ["herpes simplex virus", "ORGANISM", 101, 121], ["HSV", "ORGANISM", 123, 126], ["mouse hepatitis virus", "ORGANISM", 132, 153], ["MHV", "ORGANISM", 155, 158], ["Tregs", "CELL", 161, 166], ["Tregs", "CELL_TYPE", 161, 166], ["West Nile virus", "SPECIES", 78, 93], ["herpes simplex virus", "SPECIES", 101, 121], ["mouse", "SPECIES", 132, 137], ["hepatitis virus", "SPECIES", 138, 153], ["West Nile virus", "SPECIES", 78, 93], ["WNV", "SPECIES", 95, 98], ["herpes simplex virus", "SPECIES", 101, 121], ["HSV", "SPECIES", 123, 126], ["mouse hepatitis virus", "SPECIES", 132, 153], ["MHV", "SPECIES", 155, 158], ["acute viral infections", "PROBLEM", 22, 44], ["pathogens", "PROBLEM", 55, 64], ["West Nile virus (WNV", "PROBLEM", 78, 98], ["herpes simplex virus (HSV", "PROBLEM", 101, 126], ["mouse hepatitis virus", "PROBLEM", 132, 153], ["acute disease", "PROBLEM", 178, 191], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["viral", "OBSERVATION_MODIFIER", 28, 33], ["infections", "OBSERVATION", 34, 44]]], ["If Tregs are depleted from mice infected with HSV or MHV, clinical disease is more severe [8, 9] .IntroductionUntil recently, Tregs were considered largely to recognize self antigens, but an increasing number of studies show that pathogenspecific Tregs are detected in infectious settings [10] [11] [12] [13] [14] .", [["Tregs", "ANATOMY", 3, 8], ["Tregs", "ANATOMY", 126, 131], ["Tregs", "ANATOMY", 247, 252], ["Tregs", "CELL", 3, 8], ["mice", "ORGANISM", 27, 31], ["HSV", "ORGANISM", 46, 49], ["MHV", "ORGANISM", 53, 56], ["Tregs", "CELL", 126, 131], ["Tregs", "CELL", 247, 252], ["Tregs", "CELL_TYPE", 3, 8], ["Tregs", "CELL_TYPE", 126, 131], ["pathogenspecific Tregs", "CELL_TYPE", 230, 252], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["HSV", "SPECIES", 46, 49], ["MHV", "SPECIES", 53, 56], ["Tregs", "PROBLEM", 3, 8], ["HSV", "PROBLEM", 46, 49], ["MHV", "PROBLEM", 53, 56], ["clinical disease", "PROBLEM", 58, 74], ["pathogenspecific Tregs", "PROBLEM", 230, 252], ["more severe", "OBSERVATION_MODIFIER", 78, 89]]], ["Further, these Tregs originate from thymus-derived pools, and are generally not generated by peripheral conversion from pathogen-specific effector CD4 T cell populations [10, 12, 13, 15] , with the exception of Tregs specific for gut pathogens [16] .", [["Tregs", "ANATOMY", 15, 20], ["thymus", "ANATOMY", 36, 42], ["CD4 T cell", "ANATOMY", 147, 157], ["Tregs", "ANATOMY", 211, 216], ["gut", "ANATOMY", 230, 233], ["Tregs", "CELL", 15, 20], ["thymus", "ORGAN", 36, 42], ["CD4", "GENE_OR_GENE_PRODUCT", 147, 150], ["Tregs", "CELL", 211, 216], ["gut", "ORGANISM_SUBDIVISION", 230, 233], ["Tregs", "CELL_TYPE", 15, 20], ["effector CD4 T cell populations", "CELL_TYPE", 138, 169], ["Tregs", "CELL_TYPE", 211, 216], ["peripheral conversion from pathogen", "PROBLEM", 93, 128], ["gut pathogens", "PROBLEM", 230, 243], ["thymus", "ANATOMY", 36, 42]]], ["Studies of autoimmune diseases, such as diabetes mellitus, showed that adoptively transferred Tregs specific for an epitope at a site of inflammation were more suppressive than bulk populations of Tregs [17, 18] .", [["Tregs", "ANATOMY", 94, 99], ["Tregs", "ANATOMY", 197, 202], ["autoimmune diseases", "DISEASE", 11, 30], ["diabetes mellitus", "DISEASE", 40, 57], ["inflammation", "DISEASE", 137, 149], ["Tregs", "CELL", 94, 99], ["Tregs", "CELL", 197, 202], ["Tregs", "CELL_TYPE", 94, 99], ["Tregs", "CELL_TYPE", 197, 202], ["autoimmune diseases", "PROBLEM", 11, 30], ["diabetes mellitus", "PROBLEM", 40, 57], ["Tregs", "TREATMENT", 94, 99], ["an epitope", "PROBLEM", 113, 123], ["inflammation", "PROBLEM", 137, 149], ["autoimmune diseases", "OBSERVATION", 11, 30], ["inflammation", "OBSERVATION", 137, 149]]], ["Tregs specific for a M. tuberculosis (Mtb) CD4 T cell epitope are more suppressive than those that recognize a non-Mtb CD4 T cell epitope [19] .", [["Tregs", "ANATOMY", 0, 5], ["CD4 T cell", "ANATOMY", 43, 53], ["CD4 T cell", "ANATOMY", 119, 129], ["Tregs", "CELL", 0, 5], ["M. tuberculosis", "ORGANISM", 21, 36], ["Mtb", "GENE_OR_GENE_PRODUCT", 38, 41], ["Tregs", "CELL_TYPE", 0, 5], ["M. tuberculosis (Mtb) CD4 T cell epitope", "PROTEIN", 21, 61], ["CD4", "PROTEIN", 119, 122], ["M. tuberculosis", "SPECIES", 21, 36], ["M. tuberculosis", "SPECIES", 21, 36], ["a M. tuberculosis", "PROBLEM", 19, 36], ["CD4 T cell epitope", "TREATMENT", 43, 61], ["tuberculosis", "OBSERVATION", 24, 36]]], ["However, whether pathogenspecific Tregs are more potent than bulk populations of Tregs obtained from wild type mice has not been addressed in any infectious setting.IntroductionMice infected with neurotropic strains of MHV develop acute encephalitis or acute and chronic demyelinating diseases [20] .", [["Tregs", "ANATOMY", 34, 39], ["Tregs", "ANATOMY", 81, 86], ["encephalitis", "DISEASE", 237, 249], ["demyelinating diseases", "DISEASE", 271, 293], ["Tregs", "CELL", 34, 39], ["Tregs", "CELL", 81, 86], ["mice", "ORGANISM", 111, 115], ["MHV", "ORGANISM", 219, 222], ["Tregs", "CELL_TYPE", 34, 39], ["Tregs", "CELL_TYPE", 81, 86], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["MHV", "SPECIES", 219, 222], ["IntroductionMice", "TREATMENT", 165, 181], ["neurotropic strains", "TREATMENT", 196, 215], ["MHV", "PROBLEM", 219, 222], ["acute encephalitis", "PROBLEM", 231, 249], ["acute and chronic demyelinating diseases", "PROBLEM", 253, 293], ["potent", "OBSERVATION_MODIFIER", 49, 55], ["Tregs", "OBSERVATION", 81, 86], ["acute", "OBSERVATION_MODIFIER", 231, 236], ["encephalitis", "OBSERVATION", 237, 249], ["acute", "OBSERVATION_MODIFIER", 253, 258], ["chronic", "OBSERVATION_MODIFIER", 263, 270], ["demyelinating", "OBSERVATION", 271, 284]]], ["Tregs are required to diminish immune-mediated disease in these mice.", [["Tregs", "ANATOMY", 0, 5], ["Tregs", "CELL", 0, 5], ["mice", "ORGANISM", 64, 68], ["Tregs", "CELL_TYPE", 0, 5], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["Tregs", "TREATMENT", 0, 5], ["immune-mediated disease", "PROBLEM", 31, 54], ["disease", "OBSERVATION", 47, 54]]], ["Thus, Treg depletion converted a nonlethal encephalitis to one with high mortality while transfer of bulk populations of Tregs to mice infected with a virulent strain of MHV prevented a lethal outcome [8] .", [["Treg", "ANATOMY", 6, 10], ["Tregs", "ANATOMY", 121, 126], ["encephalitis", "DISEASE", 43, 55], ["Treg", "CELL", 6, 10], ["Tregs", "CELL", 121, 126], ["mice", "ORGANISM", 130, 134], ["MHV", "ORGANISM", 170, 173], ["Tregs", "CELL_TYPE", 121, 126], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 130, 134], ["MHV", "SPECIES", 170, 173], ["Treg depletion", "PROBLEM", 6, 20], ["a nonlethal encephalitis", "PROBLEM", 31, 55], ["a virulent strain of MHV", "PROBLEM", 149, 173], ["nonlethal", "OBSERVATION_MODIFIER", 33, 42], ["encephalitis", "OBSERVATION", 43, 55]]], ["In addition, transfer of na\u00efve bulk populations of Tregs along with MHV-immune effector T cells to infected RAG1 2/2 (Recombination Activation Gene1 2/2 ) mice resulted in less severe clinical disease and diminished cell infiltration when compared to mice that received only effector T cells [7] .", [["Tregs", "ANATOMY", 51, 56], ["T cells", "ANATOMY", 88, 95], ["cell", "ANATOMY", 216, 220], ["effector T cells", "ANATOMY", 275, 291], ["Tregs", "CELL", 51, 56], ["immune effector T cells", "CELL", 72, 95], ["RAG1 2/2", "GENE_OR_GENE_PRODUCT", 108, 116], ["cell", "CELL", 216, 220], ["mice", "ORGANISM", 251, 255], ["T cells", "CELL", 284, 291], ["Tregs", "CELL_TYPE", 51, 56], ["immune effector T cells", "CELL_TYPE", 72, 95], ["effector T cells", "CELL_TYPE", 275, 291], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 251, 255], ["MHV", "SPECIES", 68, 71], ["mice", "SPECIES", 251, 255], ["na\u00efve bulk populations", "TREATMENT", 25, 47], ["Tregs", "PROBLEM", 51, 56], ["MHV", "TREATMENT", 68, 71], ["immune effector T cells", "TREATMENT", 72, 95], ["infected RAG1", "TREATMENT", 99, 112], ["less severe clinical disease", "PROBLEM", 172, 200], ["diminished cell infiltration", "PROBLEM", 205, 233], ["less severe", "OBSERVATION_MODIFIER", 172, 183], ["diminished", "OBSERVATION_MODIFIER", 205, 215], ["cell infiltration", "OBSERVATION", 216, 233]]], ["More recently, we identified Tregs that recognized the immunodominant CD4 T cell epitope (M133) in the brains of mice infected with the neuroattenuated rJ2.2 strain of MHV as well as in the T cell precursor pool of na\u00efve mice [12] .", [["Tregs", "ANATOMY", 29, 34], ["CD4 T cell", "ANATOMY", 70, 80], ["brains", "ANATOMY", 103, 109], ["T cell precursor pool", "ANATOMY", 190, 211], ["Tregs", "CELL", 29, 34], ["CD4 T cell epitope", "GENE_OR_GENE_PRODUCT", 70, 88], ["brains", "ORGAN", 103, 109], ["mice", "ORGANISM", 113, 117], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 152, 157], ["MHV", "ORGANISM", 168, 171], ["T cell", "CELL", 190, 196], ["mice", "ORGANISM", 221, 225], ["Tregs", "CELL_TYPE", 29, 34], ["immunodominant CD4 T cell epitope", "PROTEIN", 55, 88], ["M133", "PROTEIN", 90, 94], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 221, 225], ["mice", "SPECIES", 113, 117], ["MHV", "SPECIES", 168, 171], ["mice", "SPECIES", 221, 225], ["the neuroattenuated rJ2.2 strain of MHV", "PROBLEM", 132, 171]]], ["Tregs at sites of inflammation adapt to the milieu by expressing transcription factors such as Tbet (Th1-type), STAT-3 (Th17-type) or IRF4 (Th2-type) [21] and as expected, brain-derived M133-specific Tregs in infected mice expressed T-bet.", [["Tregs", "ANATOMY", 0, 5], ["sites", "ANATOMY", 9, 14], ["brain", "ANATOMY", 172, 177], ["Tregs", "ANATOMY", 200, 205], ["inflammation", "DISEASE", 18, 30], ["Tregs", "CELL", 0, 5], ["Tbet", "GENE_OR_GENE_PRODUCT", 95, 99], ["Th1-type", "GENE_OR_GENE_PRODUCT", 101, 109], ["STAT-3", "GENE_OR_GENE_PRODUCT", 112, 118], ["Th17-type", "GENE_OR_GENE_PRODUCT", 120, 129], ["IRF4", "GENE_OR_GENE_PRODUCT", 134, 138], ["brain", "ORGAN", 172, 177], ["M133", "GENE_OR_GENE_PRODUCT", 186, 190], ["Tregs", "CELL", 200, 205], ["mice", "ORGANISM", 218, 222], ["T-bet", "GENE_OR_GENE_PRODUCT", 233, 238], ["Tregs", "CELL_TYPE", 0, 5], ["transcription factors", "PROTEIN", 65, 86], ["Tbet", "PROTEIN", 95, 99], ["STAT-3", "PROTEIN", 112, 118], ["Th17", "PROTEIN", 120, 124], ["IRF4", "PROTEIN", 134, 138], ["Th2", "PROTEIN", 140, 143], ["brain-derived M133-specific Tregs", "CELL_TYPE", 172, 205], ["T-bet", "PROTEIN", 233, 238], ["mice", "SPECIES", 218, 222], ["mice", "SPECIES", 218, 222], ["inflammation", "PROBLEM", 18, 30], ["expressing transcription factors", "PROBLEM", 54, 86], ["Tbet", "TEST", 95, 99], ["STAT", "TEST", 112, 116], ["inflammation", "OBSERVATION", 18, 30], ["brain", "ANATOMY", 172, 177]]], ["T-bet-mediated expression of CXCR3 is necessary for Treg migration to inflamed tissues [22] .", [["Treg", "ANATOMY", 52, 56], ["tissues", "ANATOMY", 79, 86], ["T-bet", "GENE_OR_GENE_PRODUCT", 0, 5], ["CXCR3", "GENE_OR_GENE_PRODUCT", 29, 34], ["Treg", "CELL", 52, 56], ["tissues", "TISSUE", 79, 86], ["bet", "PROTEIN", 2, 5], ["CXCR3", "PROTEIN", 29, 34], ["CXCR3", "PROBLEM", 29, 34], ["Treg migration", "TREATMENT", 52, 66], ["inflamed tissues", "PROBLEM", 70, 86]]], ["These cells expressed cytokines such as IFN-c and TNF, in addition to IL-10 when stimulated with M133 peptide directly ex vivo.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["IFN-c", "GENE_OR_GENE_PRODUCT", 40, 45], ["TNF", "GENE_OR_GENE_PRODUCT", 50, 53], ["IL-10", "GENE_OR_GENE_PRODUCT", 70, 75], ["M133 peptide", "SIMPLE_CHEMICAL", 97, 109], ["cytokines", "PROTEIN", 22, 31], ["IFN", "PROTEIN", 40, 43], ["TNF", "PROTEIN", 50, 53], ["IL-10", "PROTEIN", 70, 75], ["cytokines", "TEST", 22, 31], ["IFN", "TEST", 40, 43], ["TNF", "TREATMENT", 50, 53], ["IL", "TEST", 70, 72], ["cytokines", "OBSERVATION_MODIFIER", 22, 31]]], ["Further, we showed that IFN-c production was not an in vitro phenomenon since IFN-c expression by Tregs was detected directly ex vivo in the absence of peptide stimulation if mice were treated with brefeldin A prior to sacrifice [12] .IntroductionAs is true for all pathogen-specific Tregs, few details are known about how these cells affect T cell responses, especially those responding to the cognate epitope or whether these cells are more immunosuppressive than bulk Tregs.", [["Tregs", "ANATOMY", 98, 103], ["Tregs", "ANATOMY", 284, 289], ["cells", "ANATOMY", 329, 334], ["T cell", "ANATOMY", 342, 348], ["cells", "ANATOMY", 428, 433], ["Tregs", "ANATOMY", 471, 476], ["brefeldin A", "CHEMICAL", 198, 209], ["brefeldin A", "CHEMICAL", 198, 209], ["IFN-c", "GENE_OR_GENE_PRODUCT", 24, 29], ["IFN-c", "GENE_OR_GENE_PRODUCT", 78, 83], ["Tregs", "CELL", 98, 103], ["mice", "ORGANISM", 175, 179], ["brefeldin A", "SIMPLE_CHEMICAL", 198, 209], ["Tregs", "CELL", 284, 289], ["cells", "CELL", 329, 334], ["T cell", "CELL", 342, 348], ["cells", "CELL", 428, 433], ["Tregs", "CELL", 471, 476], ["IFN", "PROTEIN", 24, 27], ["IFN", "PROTEIN", 78, 81], ["Tregs", "CELL_TYPE", 98, 103], ["Tregs", "CELL_TYPE", 284, 289], ["bulk Tregs", "CELL_TYPE", 466, 476], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 175, 179], ["IFN-c production", "PROBLEM", 24, 40], ["an in vitro phenomenon", "PROBLEM", 49, 71], ["peptide stimulation", "TREATMENT", 152, 171], ["brefeldin", "TREATMENT", 198, 207], ["Tregs", "PROBLEM", 284, 289], ["these cells", "PROBLEM", 422, 433]]], ["Addressing these questions directly in wild type mice is difficult because M133-specific Tregs comprise only a small fraction of total Tregs.", [["Tregs", "ANATOMY", 89, 94], ["Tregs", "ANATOMY", 135, 140], ["mice", "ORGANISM", 49, 53], ["Tregs", "CELL", 89, 94], ["Tregs", "CELL", 135, 140], ["Tregs", "CELL_TYPE", 89, 94], ["Tregs", "CELL_TYPE", 135, 140], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["total Tregs", "TREATMENT", 129, 140], ["small", "OBSERVATION_MODIFIER", 111, 116], ["fraction", "OBSERVATION_MODIFIER", 117, 125], ["total Tregs", "OBSERVATION", 129, 140]]], ["To circumvent this problem, we developed a mouse transgenic for the expression of an M133-specific T cell receptor [23] and used Tregs (M133 Tregs) from these mice in the current study.", [["T cell", "ANATOMY", 99, 105], ["Tregs", "ANATOMY", 129, 134], ["M133 Tregs", "ANATOMY", 136, 146], ["mouse", "ORGANISM", 43, 48], ["M133", "GENE_OR_GENE_PRODUCT", 85, 89], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 99, 114], ["Tregs", "CELL", 129, 134], ["M133 Tregs", "CELL", 136, 146], ["mice", "ORGANISM", 159, 163], ["M133", "PROTEIN", 85, 89], ["T cell receptor", "PROTEIN", 99, 114], ["Tregs", "CELL_TYPE", 129, 134], ["M133 Tregs", "CELL_TYPE", 136, 146], ["mouse", "SPECIES", 43, 48], ["mice", "SPECIES", 159, 163], ["mouse", "SPECIES", 43, 48], ["mice", "SPECIES", 159, 163], ["an M133", "TEST", 82, 89], ["Tregs (M133 Tregs", "TREATMENT", 129, 146], ["the current study", "TEST", 167, 184]]], ["The results show that Tregs function both in the draining lymph nodes (deep cervical lymph nodes, DCLN, and to a lesser extent, superficial cervical lymph nodes, CLN) and in the brain to ameliorate encephalitis severity.ResultsPreferential recruitment of M133-specific Tregs to the rJ2.2-infected brainResultsIn the natural infection, M133-specific Tregs were detected in the rJ2.2-infected brain [12] .", [["Tregs", "ANATOMY", 22, 27], ["lymph nodes", "ANATOMY", 58, 69], ["cervical lymph nodes", "ANATOMY", 76, 96], ["DCLN", "ANATOMY", 98, 102], ["superficial cervical lymph nodes", "ANATOMY", 128, 160], ["CLN", "ANATOMY", 162, 165], ["brain", "ANATOMY", 178, 183], ["Tregs", "ANATOMY", 269, 274], ["Tregs", "ANATOMY", 349, 354], ["brain", "ANATOMY", 391, 396], ["encephalitis", "DISEASE", 198, 210], ["infection", "DISEASE", 324, 333], ["Tregs", "CELL", 22, 27], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 58, 69], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 76, 96], ["DCLN", "MULTI-TISSUE_STRUCTURE", 98, 102], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 140, 160], ["CLN", "MULTI-TISSUE_STRUCTURE", 162, 165], ["brain", "ORGAN", 178, 183], ["M133", "GENE_OR_GENE_PRODUCT", 255, 259], ["Tregs", "CELL", 269, 274], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 282, 287], ["brainResults", "ORGANISM", 297, 309], ["M133", "GENE_OR_GENE_PRODUCT", 335, 339], ["Tregs", "CELL", 349, 354], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 376, 381], ["brain", "ORGAN", 391, 396], ["Tregs", "CELL_TYPE", 22, 27], ["M133", "PROTEIN", 255, 259], ["Tregs", "CELL_TYPE", 269, 274], ["rJ2.2", "DNA", 282, 287], ["M133", "PROTEIN", 335, 339], ["Tregs", "CELL_TYPE", 349, 354], ["Tregs function", "TEST", 22, 36], ["deep cervical lymph nodes", "PROBLEM", 71, 96], ["DCLN", "TEST", 98, 102], ["superficial cervical lymph nodes", "PROBLEM", 128, 160], ["ameliorate encephalitis severity", "PROBLEM", 187, 219], ["M133", "TEST", 255, 259], ["infected brainResults", "PROBLEM", 288, 309], ["the natural infection", "PROBLEM", 312, 333], ["M133", "TEST", 335, 339], ["Tregs", "OBSERVATION", 22, 27], ["draining", "OBSERVATION_MODIFIER", 49, 57], ["lymph nodes", "OBSERVATION", 58, 69], ["deep", "ANATOMY_MODIFIER", 71, 75], ["cervical", "ANATOMY", 76, 84], ["lymph nodes", "OBSERVATION", 85, 96], ["lesser", "OBSERVATION_MODIFIER", 113, 119], ["extent", "OBSERVATION_MODIFIER", 120, 126], ["superficial", "ANATOMY_MODIFIER", 128, 139], ["cervical", "ANATOMY", 140, 148], ["lymph nodes", "OBSERVATION", 149, 160], ["brain", "ANATOMY", 178, 183], ["ameliorate", "OBSERVATION_MODIFIER", 187, 197], ["encephalitis", "OBSERVATION", 198, 210], ["infected", "OBSERVATION", 288, 296], ["natural", "OBSERVATION_MODIFIER", 316, 323], ["infection", "OBSERVATION", 324, 333], ["infected", "OBSERVATION", 382, 390], ["brain", "ANATOMY", 391, 396]]], ["However, adoptively transferred bulk populations of splenic C57BL/6 (B6) Tregs (bulk Tregs) were minimally detected in the infected central nervous system (CNS) [7] .", [["C57BL/6 (B6) Tregs", "ANATOMY", 60, 78], ["Tregs", "ANATOMY", 85, 90], ["central nervous system", "ANATOMY", 132, 154], ["CNS", "ANATOMY", 156, 159], ["splenic C57BL/6 (B6)", "ORGANISM", 52, 72], ["Tregs", "CELL", 73, 78], ["bulk Tregs", "CELL", 80, 90], ["central nervous system", "ANATOMICAL_SYSTEM", 132, 154], ["CNS", "ANATOMICAL_SYSTEM", 156, 159], ["Tregs", "CELL_TYPE", 73, 78], ["bulk Tregs", "CELL_TYPE", 80, 90], ["splenic C57BL/6 (B6) Tregs (bulk Tregs", "TREATMENT", 52, 90], ["splenic", "ANATOMY", 52, 59], ["C57BL", "ANATOMY_MODIFIER", 60, 65], ["infected", "OBSERVATION", 123, 131], ["central", "ANATOMY_MODIFIER", 132, 139], ["nervous system", "ANATOMY", 140, 154]]], ["To reconcile these disparate results, we co-transferred bulk Tregs and M133 Tregs derived from uninfected Foxp3 gfp and M133 Tg-Foxp3 gfp mice, respectively.", [["Tregs", "ANATOMY", 61, 66], ["M133 Tregs", "ANATOMY", 71, 81], ["Tregs", "CELL", 61, 66], ["M133 Tregs", "CELL", 71, 81], ["Foxp3", "GENE_OR_GENE_PRODUCT", 106, 111], ["gfp", "GENE_OR_GENE_PRODUCT", 112, 115], ["M133", "GENE_OR_GENE_PRODUCT", 120, 124], ["Foxp3", "GENE_OR_GENE_PRODUCT", 128, 133], ["Tregs", "CELL_TYPE", 61, 66], ["M133 Tregs", "CELL_LINE", 71, 81], ["Foxp3", "PROTEIN", 128, 133], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 138, 142], ["Tg", "TEST", 125, 127]]], ["Approximately 0.5-1% of the CD4 T cells in the blood of M133 Tg mice expressed Foxp3; 50% of Foxp3 + and .97% of Foxp3 2 CD4 T cells (Tconv) bound I-A b /M133 tetramer ( Figure 1A) .", [["CD4 T cells", "ANATOMY", 28, 39], ["blood", "ANATOMY", 47, 52], ["Foxp3 2 CD4 T cells", "ANATOMY", 113, 132], ["CD4 T cells", "CELL", 28, 39], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["M133 Tg mice", "ORGANISM", 56, 68], ["Foxp3", "GENE_OR_GENE_PRODUCT", 79, 84], ["Foxp3", "GENE_OR_GENE_PRODUCT", 93, 98], ["Foxp3 2", "GENE_OR_GENE_PRODUCT", 113, 120], ["Tconv", "GENE_OR_GENE_PRODUCT", 134, 139], ["CD4 T cells", "CELL_TYPE", 28, 39], ["Foxp3", "PROTEIN", 79, 84], ["Foxp3", "PROTEIN", 93, 98], ["Foxp3 2 CD4 T cells", "CELL_TYPE", 113, 132], ["Tconv", "PROTEIN", 134, 139], ["I-A b", "PROTEIN", 147, 152], ["M133 tetramer", "PROTEIN", 154, 167], ["Figure 1A", "PROTEIN", 170, 179], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["the CD4 T cells", "TEST", 24, 39], ["Foxp3", "TEST", 79, 84], ["Foxp3", "TEST", 93, 98], ["Foxp3", "TEST", 113, 118], ["blood", "ANATOMY", 47, 52]]], ["Equal numbers of Violetlabeled bulk and M133 Tregs were transferred to B6 mice, some of which were infected with rJ2.2 24 hours later ( Figure 1B) .", [["bulk", "ANATOMY", 31, 35], ["M133 Tregs", "ANATOMY", 40, 50], ["Violetlabeled bulk", "CELL", 17, 35], ["M133 Tregs", "CELL", 40, 50], ["B6 mice", "ORGANISM", 71, 78], ["M133 Tregs", "CELL_LINE", 40, 50], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 74, 78], ["numbers", "OBSERVATION_MODIFIER", 6, 13], ["infected", "OBSERVATION", 99, 107]]], ["Tregs were identified in the lymphoid tissues of infected and uninfected recipient mice seven days after infection, using the gating strategy shown in Figure 1C .", [["Tregs", "ANATOMY", 0, 5], ["lymphoid tissues", "ANATOMY", 29, 45], ["infection", "DISEASE", 105, 114], ["Tregs", "CELL", 0, 5], ["lymphoid tissues", "TISSUE", 29, 45], ["mice", "ORGANISM", 83, 87], ["Tregs", "CELL_TYPE", 0, 5], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["Tregs", "PROBLEM", 0, 5], ["infection", "PROBLEM", 105, 114], ["the gating strategy", "TREATMENT", 122, 141], ["lymphoid tissues", "ANATOMY", 29, 45], ["infected", "OBSERVATION_MODIFIER", 49, 57]]], ["Equal numbers of bulk and M133 Tregs were detected in the spleen, cervical and deep cervical lymph nodes (CLN, DCLN) of uninfected mice and neither population proliferated substantially.", [["Tregs", "ANATOMY", 31, 36], ["spleen", "ANATOMY", 58, 64], ["cervical", "ANATOMY", 66, 74], ["cervical lymph nodes", "ANATOMY", 84, 104], ["CLN", "ANATOMY", 106, 109], ["DCLN", "ANATOMY", 111, 115], ["Tregs", "CELL", 31, 36], ["spleen", "ORGAN", 58, 64], ["cervical", "ORGAN", 66, 74], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 84, 104], ["CLN", "MULTI-TISSUE_STRUCTURE", 106, 109], ["DCLN", "CANCER", 111, 115], ["mice", "ORGANISM", 131, 135], ["Tregs", "CELL_TYPE", 31, 36], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 131, 135], ["Tregs", "TEST", 31, 36], ["cervical and deep cervical lymph nodes", "PROBLEM", 66, 104], ["numbers", "OBSERVATION_MODIFIER", 6, 13], ["bulk", "OBSERVATION_MODIFIER", 17, 21], ["spleen", "ANATOMY", 58, 64], ["cervical", "ANATOMY", 66, 74], ["deep", "ANATOMY_MODIFIER", 79, 83], ["cervical", "ANATOMY", 84, 92], ["lymph nodes", "OBSERVATION", 93, 104], ["uninfected mice", "OBSERVATION", 120, 135], ["population", "OBSERVATION_MODIFIER", 148, 158], ["proliferated", "OBSERVATION_MODIFIER", 159, 171], ["substantially", "OBSERVATION_MODIFIER", 172, 185]]], ["In contrast, after infection, M133 but not bulk Tregs proliferated extensively in all three peripheral lymphoid tissues.", [["Tregs", "ANATOMY", 48, 53], ["peripheral lymphoid tissues", "ANATOMY", 92, 119], ["infection", "DISEASE", 19, 28], ["M133", "CELL", 30, 34], ["bulk Tregs", "CELL", 43, 53], ["peripheral lymphoid tissues", "TISSUE", 92, 119], ["M133 but not bulk Tregs", "CELL_LINE", 30, 53], ["infection", "PROBLEM", 19, 28], ["infection", "OBSERVATION", 19, 28], ["not", "UNCERTAINTY", 39, 42], ["bulk Tregs", "OBSERVATION", 43, 53], ["all", "ANATOMY_MODIFIER", 82, 85], ["three", "ANATOMY_MODIFIER", 86, 91], ["peripheral", "ANATOMY_MODIFIER", 92, 102], ["lymphoid tissues", "OBSERVATION", 103, 119]]], ["Further, only M133 Tregs entered the infected brain to a detectable extent ( Figure 1D ).", [["Tregs", "ANATOMY", 19, 24], ["brain", "ANATOMY", 46, 51], ["M133", "CHEMICAL", 14, 18], ["Tregs", "CELL", 19, 24], ["brain", "ORGAN", 46, 51], ["Tregs", "CELL_TYPE", 19, 24], ["the infected brain", "PROBLEM", 33, 51], ["infected", "OBSERVATION", 37, 45], ["brain", "ANATOMY", 46, 51]]], ["By day 7 post infection (p.i.), the ratio of M133 to bulk Tregs ranged from 10:1 in lymphoid tissue to greater than 1000:1 in the brain ( Figure 1E ).", [["Tregs", "ANATOMY", 58, 63], ["lymphoid tissue", "ANATOMY", 84, 99], ["brain", "ANATOMY", 130, 135], ["M133", "GENE_OR_GENE_PRODUCT", 45, 49], ["Tregs", "CELL", 58, 63], ["lymphoid tissue", "TISSUE", 84, 99], ["brain", "ORGAN", 130, 135], ["M133", "PROTEIN", 45, 49], ["Tregs", "CELL_TYPE", 58, 63], ["infection", "PROBLEM", 14, 23], ["the ratio", "TEST", 32, 41], ["bulk Tregs", "TEST", 53, 63], ["infection", "OBSERVATION", 14, 23], ["lymphoid tissue", "OBSERVATION", 84, 99], ["brain", "ANATOMY", 130, 135]]], ["In addition to exhibiting less proliferation, transferred bulk Tregs in the DCLN were less activated when assessed by measuring expression of CD25, CTLA-4, CXCR3 and ICOS at day 4 p.i. ( Figure 1F ).Initial proliferation of M133-specific Tconv and Tregs occurs in the DCLNTo identify the site of initial priming and expansion of M133 Tregs compared to Tconv, we first analyzed priming of M133 Tconv (Treg-depleted CD4 T cells) by transferring CFSE-labeled cells one day prior to infection ( Figure 2A ).", [["Tregs", "ANATOMY", 63, 68], ["DCLN", "ANATOMY", 76, 80], ["Tconv", "ANATOMY", 238, 243], ["Tregs", "ANATOMY", 248, 253], ["M133 Tregs", "ANATOMY", 329, 339], ["Treg", "ANATOMY", 400, 404], ["CD4 T cells", "ANATOMY", 414, 425], ["cells", "ANATOMY", 456, 461], ["CFSE", "CHEMICAL", 443, 447], ["infection", "DISEASE", 479, 488], ["CFSE", "CHEMICAL", 443, 447], ["Tregs", "CELL", 63, 68], ["DCLN", "GENE_OR_GENE_PRODUCT", 76, 80], ["CD25", "GENE_OR_GENE_PRODUCT", 142, 146], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 148, 154], ["CXCR3", "GENE_OR_GENE_PRODUCT", 156, 161], ["ICOS", "GENE_OR_GENE_PRODUCT", 166, 170], ["M133", "CELL", 224, 228], ["Tconv", "GENE_OR_GENE_PRODUCT", 238, 243], ["Tregs", "CELL", 248, 253], ["DCLNTo", "CANCER", 268, 274], ["M133 Tregs", "CELL", 329, 339], ["Tconv", "GENE_OR_GENE_PRODUCT", 352, 357], ["M133", "CELL", 388, 392], ["Tconv", "GENE_OR_GENE_PRODUCT", 393, 398], ["Treg", "CELL", 400, 404], ["CD4 T cells", "CELL", 414, 425], ["CFSE", "SIMPLE_CHEMICAL", 443, 447], ["cells", "CELL", 456, 461], ["Tregs", "CELL_TYPE", 63, 68], ["DCLN", "CELL_TYPE", 76, 80], ["CD25", "PROTEIN", 142, 146], ["CTLA", "PROTEIN", 148, 152], ["CXCR3", "PROTEIN", 156, 161], ["ICOS", "PROTEIN", 166, 170], ["M133-specific Tconv", "CELL_LINE", 224, 243], ["Tregs", "CELL_TYPE", 248, 253], ["DCLNTo", "DNA", 268, 274], ["M133 Tregs", "CELL_LINE", 329, 339], ["Tconv", "PROTEIN", 352, 357], ["M133 Tconv", "CELL_LINE", 388, 398], ["Treg-depleted CD4 T cells", "CELL_LINE", 400, 425], ["CFSE-labeled cells", "CELL_LINE", 443, 461], ["less proliferation", "PROBLEM", 26, 44], ["CD25", "TEST", 142, 146], ["CTLA", "TEST", 148, 152], ["CXCR3", "TEST", 156, 161], ["ICOS", "TEST", 166, 170], ["M133", "TEST", 224, 228], ["Treg", "TEST", 400, 404], ["CD4 T cells", "TREATMENT", 414, 425], ["infection", "PROBLEM", 479, 488], ["less", "OBSERVATION_MODIFIER", 26, 30], ["proliferation", "OBSERVATION", 31, 44], ["bulk Tregs", "OBSERVATION", 58, 68], ["proliferation", "OBSERVATION_MODIFIER", 207, 220], ["infection", "OBSERVATION", 479, 488]]], ["Mice were sacrificed at days 3, 4 and 5 p.i. and analyzed for CFSE dilution (indicative of cell division) and for CXCR3 expression (required for T cell migration to the inflamed brain [24] ) by M133 Tconv in the spleen, CLN, DCLN, inguinal lymph nodes (ILN) and brain.", [["cell", "ANATOMY", 91, 95], ["T cell", "ANATOMY", 145, 151], ["brain", "ANATOMY", 178, 183], ["spleen", "ANATOMY", 212, 218], ["CLN", "ANATOMY", 220, 223], ["DCLN", "ANATOMY", 225, 229], ["inguinal lymph nodes", "ANATOMY", 231, 251], ["ILN", "ANATOMY", 253, 256], ["brain", "ANATOMY", 262, 267], ["CFSE", "CHEMICAL", 62, 66], ["CFSE", "CHEMICAL", 62, 66], ["Mice", "ORGANISM", 0, 4], ["CFSE", "SIMPLE_CHEMICAL", 62, 66], ["cell", "CELL", 91, 95], ["CXCR3", "GENE_OR_GENE_PRODUCT", 114, 119], ["T cell", "CELL", 145, 151], ["brain", "ORGAN", 178, 183], ["M133", "CELL", 194, 198], ["Tconv", "GENE_OR_GENE_PRODUCT", 199, 204], ["spleen", "ORGAN", 212, 218], ["CLN", "CANCER", 220, 223], ["DCLN", "CANCER", 225, 229], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 231, 251], ["ILN", "MULTI-TISSUE_STRUCTURE", 253, 256], ["brain", "ORGAN", 262, 267], ["CXCR3", "PROTEIN", 114, 119], ["M133 Tconv", "PROTEIN", 194, 204], ["Mice", "SPECIES", 0, 4], ["CFSE dilution", "TEST", 62, 75], ["CXCR3 expression", "TEST", 114, 130], ["T cell migration", "TREATMENT", 145, 161], ["DCLN", "TEST", 225, 229], ["inguinal lymph nodes (ILN) and brain", "PROBLEM", 231, 267], ["cell division", "OBSERVATION", 91, 104], ["inflamed", "ANATOMY_MODIFIER", 169, 177], ["brain", "ANATOMY", 178, 183], ["spleen", "ANATOMY", 212, 218], ["CLN", "ANATOMY", 220, 223], ["inguinal", "ANATOMY", 231, 239], ["lymph nodes", "OBSERVATION", 240, 251], ["ILN", "ANATOMY", 253, 256], ["brain", "ANATOMY", 262, 267]]], ["CFSE dilution occurred initially in the DCLN (Figure 2 , B and C).", [["DCLN", "ANATOMY", 40, 44], ["CFSE", "CHEMICAL", 0, 4], ["CFSE", "CHEMICAL", 0, 4], ["CFSE", "SIMPLE_CHEMICAL", 0, 4], ["CFSE dilution", "TEST", 0, 13]]], ["Expression of CXCR3 was upregulated within 1-2 rounds of proliferation ( Figure 2B ).", [["CXCR3", "GENE_OR_GENE_PRODUCT", 14, 19], ["CXCR3", "PROTEIN", 14, 19], ["CXCR3", "TEST", 14, 19], ["proliferation", "PROBLEM", 57, 70]]], ["By day 4 p.i., M133 Tconv accounted for 10% of all CD4 T cells in the DCLN, a frequency higher than in any other lymphoid tissues that were examined ( Figure 2D ).", [["CD4 T cells", "ANATOMY", 51, 62], ["DCLN", "ANATOMY", 70, 74], ["lymphoid tissues", "ANATOMY", 113, 129], ["CD4 T cells", "CELL", 51, 62], ["DCLN", "CANCER", 70, 74], ["lymphoid tissues", "TISSUE", 113, 129], ["M133 Tconv", "PROTEIN", 15, 25], ["CD4 T cells", "CELL_TYPE", 51, 62], ["the DCLN", "TEST", 66, 74], ["lymphoid tissues", "ANATOMY", 113, 129]]], ["While the numbers of M133 Tconvs decreased dramatically between days 4 and 5 p.i. in the DCLN ( Figure 2E) , they continued to increase in other lymphoid tissues.", [["DCLN", "ANATOMY", 89, 93], ["lymphoid tissues", "ANATOMY", 145, 161], ["Tconvs", "GENE_OR_GENE_PRODUCT", 26, 32], ["lymphoid tissues", "TISSUE", 145, 161], ["M133 Tconvs", "PROTEIN", 21, 32], ["decreased", "OBSERVATION_MODIFIER", 33, 42], ["dramatically", "OBSERVATION_MODIFIER", 43, 55], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["lymphoid tissues", "OBSERVATION", 145, 161]]], ["These results suggested that M133 Tconvs were primed in the DCLN and migrated to other sites.", [["DCLN", "ANATOMY", 60, 64], ["sites", "ANATOMY", 87, 92], ["M133 Tconvs", "GENE_OR_GENE_PRODUCT", 29, 40], ["DCLN", "CANCER", 60, 64], ["M133 Tconvs", "PROTEIN", 29, 40], ["M133 Tconvs", "TREATMENT", 29, 40]]], ["By day 5, cells that had undergone varying numbers of divisions were detected in all tissues except the brain, where only highly divided cells (complete loss of CFSE labeling) were present.Initial proliferation of M133-specific Tconv and Tregs occurs in the DCLNTo confirm the DCLN as the site of proliferation of Tconv and determine whether Tregs were also primed at this site, we transferred Violet-labeled M133-specific Tconv and Tregs in a 1:2 ratio to mice one day prior to infection ( Figure 3A ).", [["cells", "ANATOMY", 10, 15], ["tissues", "ANATOMY", 85, 92], ["brain", "ANATOMY", 104, 109], ["cells", "ANATOMY", 137, 142], ["Tconv", "ANATOMY", 228, 233], ["Tregs", "ANATOMY", 238, 243], ["DCLN", "ANATOMY", 277, 281], ["Tregs", "ANATOMY", 342, 347], ["Tregs", "ANATOMY", 433, 438], ["Violet", "CHEMICAL", 394, 400], ["infection", "DISEASE", 479, 488], ["CFSE", "CHEMICAL", 161, 165], ["Violet", "CHEMICAL", 394, 400], ["cells", "CELL", 10, 15], ["tissues", "TISSUE", 85, 92], ["brain", "ORGAN", 104, 109], ["cells", "CELL", 137, 142], ["CFSE", "SIMPLE_CHEMICAL", 161, 165], ["M133", "CELL", 214, 218], ["Tconv", "GENE_OR_GENE_PRODUCT", 228, 233], ["Tregs", "CELL", 238, 243], ["DCLNTo", "CANCER", 258, 264], ["DCLN", "CANCER", 277, 281], ["Tconv", "GENE_OR_GENE_PRODUCT", 314, 319], ["Tregs", "CELL", 342, 347], ["Violet", "SIMPLE_CHEMICAL", 394, 400], ["M133", "CELL", 409, 413], ["Tconv", "GENE_OR_GENE_PRODUCT", 423, 428], ["Tregs", "CELL", 433, 438], ["mice", "ORGANISM", 457, 461], ["M133-specific Tconv", "CELL_LINE", 214, 233], ["Tregs", "CELL_TYPE", 238, 243], ["DCLNTo", "DNA", 258, 264], ["DCLN", "DNA", 277, 281], ["Tconv", "PROTEIN", 314, 319], ["Tregs", "CELL_TYPE", 342, 347], ["M133", "PROTEIN", 409, 413], ["Tconv", "PROTEIN", 423, 428], ["Tregs", "CELL_TYPE", 433, 438], ["mice", "SPECIES", 457, 461], ["mice", "SPECIES", 457, 461], ["highly divided cells", "PROBLEM", 122, 142], ["CFSE labeling", "TEST", 161, 174], ["M133", "TEST", 214, 218], ["Tregs", "PROBLEM", 342, 347], ["a 1:2 ratio", "TREATMENT", 442, 453], ["infection", "PROBLEM", 479, 488], ["varying", "OBSERVATION_MODIFIER", 35, 42], ["brain", "ANATOMY", 104, 109], ["proliferation", "OBSERVATION_MODIFIER", 197, 210], ["infection", "OBSERVATION", 479, 488]]], ["This resulted in a 1:1 ratio because only 50% of Tregs were M133-specific ( Figure 1A ).", [["Tregs", "ANATOMY", 49, 54], ["Tregs", "CELL", 49, 54], ["M133", "GENE_OR_GENE_PRODUCT", 60, 64], ["Tregs", "CELL_TYPE", 49, 54], ["M133", "PROTEIN", 60, 64], ["a 1:1 ratio", "TEST", 17, 28], ["Tregs", "TEST", 49, 54], ["M133", "TEST", 60, 64]]], ["Cells were analyzed at days 2-4 instead of days 3-5 to capture early cell proliferation, since we had observed substantial proliferation of Tconv in the DCLN by day 3 p.i. when only Tconv were transferred ( Figure 2B ).", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 69, 73], ["DCLN", "ANATOMY", 153, 157], ["Cells", "CELL", 0, 5], ["cell", "CELL", 69, 73], ["Tconv", "GENE_OR_GENE_PRODUCT", 140, 145], ["DCLN", "CANCER", 153, 157], ["Tconv", "GENE_OR_GENE_PRODUCT", 182, 187], ["Tconv", "PROTEIN", 140, 145], ["Tconv", "PROTEIN", 182, 187], ["Cells", "TEST", 0, 5], ["cell proliferation", "OBSERVATION", 69, 87], ["substantial", "OBSERVATION_MODIFIER", 111, 122], ["proliferation", "OBSERVATION", 123, 136]]], ["By day 2 p.i, we observed five generations (4 divisions) of Violet-labeled Tconv in the DCLN but not other tissues.", [["DCLN", "ANATOMY", 88, 92], ["tissues", "ANATOMY", 107, 114], ["Violet", "CHEMICAL", 60, 66], ["Violet", "SIMPLE_CHEMICAL", 60, 66], ["Tconv", "GENE_OR_GENE_PRODUCT", 75, 80], ["DCLN", "CANCER", 88, 92], ["tissues", "TISSUE", 107, 114], ["Violet-labeled Tconv", "PROTEIN", 60, 80], ["DCLN", "CELL_LINE", 88, 92], ["Violet", "TREATMENT", 60, 66]]], ["In contrast, Treg proliferation was not detected until day 3 p.i. with Violet dilution occurring initially in the DCLN ( Figure 3B ).", [["Treg", "ANATOMY", 13, 17], ["DCLN", "ANATOMY", 114, 118], ["Treg", "CELL", 13, 17], ["Treg", "CELL_TYPE", 13, 17], ["Treg proliferation", "PROBLEM", 13, 31], ["Violet dilution", "TREATMENT", 71, 86], ["Treg proliferation", "OBSERVATION", 13, 31]]], ["By day 4 p.i., M133 Tconv and Tregs that had undergone extensive division were detected in the DCLN and CLN, with Tconv proliferation occurring to a greater extent than that of Tregs.", [["Tregs", "ANATOMY", 30, 35], ["DCLN", "ANATOMY", 95, 99], ["CLN", "ANATOMY", 104, 107], ["Tregs", "ANATOMY", 177, 182], ["M133 Tconv", "CELL", 15, 25], ["Tregs", "CELL", 30, 35], ["DCLN", "CANCER", 95, 99], ["CLN", "CANCER", 104, 107], ["Tconv", "GENE_OR_GENE_PRODUCT", 114, 119], ["Tregs", "CELL", 177, 182], ["M133 Tconv", "PROTEIN", 15, 25], ["Tregs", "CELL_TYPE", 30, 35], ["Tregs", "CELL_TYPE", 177, 182], ["Tconv proliferation", "PROBLEM", 114, 133], ["Tconv proliferation", "OBSERVATION", 114, 133], ["greater extent", "OBSERVATION_MODIFIER", 149, 163]]], ["This resulted in a dramatic increase in the ratio of Tconv to Tregs from day 3 to 4 p.i. in the DCLN and CLN ( Figure 3C ).", [["Tregs", "ANATOMY", 62, 67], ["DCLN", "ANATOMY", 96, 100], ["Tconv", "GENE_OR_GENE_PRODUCT", 53, 58], ["Tregs", "CELL", 62, 67], ["DCLN", "CANCER", 96, 100], ["Tconv", "PROTEIN", 53, 58], ["Tregs", "CELL_TYPE", 62, 67], ["a dramatic increase", "PROBLEM", 17, 36], ["dramatic", "OBSERVATION_MODIFIER", 19, 27], ["increase", "OBSERVATION_MODIFIER", 28, 36]]], ["Of note, only very few M133 CD4 T cells entered the brain at days 3 or 4 p.i., but remarkably, the majority of these cells were Tregs ( Figure 3D ).", [["M133 CD4 T cells", "ANATOMY", 23, 39], ["brain", "ANATOMY", 52, 57], ["cells", "ANATOMY", 117, 122], ["Tregs", "ANATOMY", 128, 133], ["M133 CD4 T cells", "CELL", 23, 39], ["brain", "ORGAN", 52, 57], ["cells", "CELL", 117, 122], ["Tregs", "CELL", 128, 133], ["M133 CD4 T cells", "CELL_LINE", 23, 39], ["Tregs", "CELL_TYPE", 128, 133], ["brain", "ANATOMY", 52, 57]]], ["Tregs were able to enter the brain after fewer cycles of proliferation when compared to Tconv ( Figure 3D and 4B).", [["Tregs", "ANATOMY", 0, 5], ["brain", "ANATOMY", 29, 34], ["Tregs", "CELL", 0, 5], ["brain", "ORGAN", 29, 34], ["Tregs", "CELL_TYPE", 0, 5], ["Tconv", "PROTEIN", 88, 93], ["Tregs", "PROBLEM", 0, 5], ["proliferation", "PROBLEM", 57, 70], ["brain", "ANATOMY", 29, 34], ["proliferation", "OBSERVATION", 57, 70]]], ["Exposure to M133 antigen was required for proliferation because neither M133 Tconv nor M133 Treg proliferated in mice infected with a rJ2.2 mutant (rJ2.2.M Y135Q ) in which epitope M133 expression was abrogated ( Figure 3E ).", [["Treg", "ANATOMY", 92, 96], ["M133", "CHEMICAL", 87, 91], ["M133", "CHEMICAL", 87, 91], ["M133 antigen", "GENE_OR_GENE_PRODUCT", 12, 24], ["Treg", "CELL", 92, 96], ["mice", "ORGANISM", 113, 117], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 134, 139], ["M133", "GENE_OR_GENE_PRODUCT", 181, 185], ["M133 antigen", "PROTEIN", 12, 24], ["M133 Tconv", "PROTEIN", 72, 82], ["Treg", "CELL_TYPE", 92, 96], ["rJ2.2 mutant", "PROTEIN", 134, 146], ["M133", "PROTEIN", 181, 185], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["M133 antigen", "TEST", 12, 24], ["proliferation", "PROBLEM", 42, 55], ["infected", "OBSERVATION_MODIFIER", 118, 126]]], ["Similar to M133 Tconv, we detected CXCR3Author SummaryBy repressing immune responses against pathogens, regulatory CD4 T cells are double edged swords.", [["CD4 T cells", "ANATOMY", 115, 126], ["CXCR3Author", "GENE_OR_GENE_PRODUCT", 35, 46], ["M133 Tconv", "PROTEIN", 11, 21], ["CXCR3Author", "PROTEIN", 35, 46], ["regulatory CD4 T cells", "CELL_TYPE", 104, 126], ["pathogens", "PROBLEM", 93, 102]]], ["On one hand, they ameliorate immunopathological disease, diminishing morbidity but they also potentially contribute to pathogen persistence.", [["immunopathological disease", "PROBLEM", 29, 55], ["diminishing morbidity", "PROBLEM", 57, 78], ["pathogen persistence", "PROBLEM", 119, 139], ["immunopathological", "OBSERVATION", 29, 47], ["diminishing", "OBSERVATION_MODIFIER", 57, 68], ["morbidity", "OBSERVATION", 69, 78], ["pathogen", "OBSERVATION_MODIFIER", 119, 127], ["persistence", "OBSERVATION", 128, 139]]], ["Tregs have long been thought to be primarily directed at self-antigens, but we and others recently demonstrated the presence of pathogen-specific Tregs in infected animals.", [["Tregs", "ANATOMY", 0, 5], ["Tregs", "ANATOMY", 146, 151], ["Tregs", "CELL", 0, 5], ["Tregs", "CELL", 146, 151], ["Tregs", "CELL_TYPE", 0, 5], ["Tregs", "CELL_TYPE", 146, 151], ["pathogen", "PROBLEM", 128, 136], ["thought to be", "UNCERTAINTY", 21, 34], ["infected", "OBSERVATION_MODIFIER", 155, 163]]], ["As is true for all pathogenspecific Tregs, few details are known about how these cells suppress T cell responses, especially those responding to the cognate epitope.", [["Tregs", "ANATOMY", 36, 41], ["cells", "ANATOMY", 81, 86], ["T cell", "ANATOMY", 96, 102], ["Tregs", "CELL", 36, 41], ["cells", "CELL", 81, 86], ["T cell", "CELL", 96, 102], ["Tregs", "CELL_TYPE", 36, 41], ["Tregs", "PROBLEM", 36, 41]]], ["Here, using mice with encephalitis caused by neurotropic coronavirus, we analyzed and compared the very earliest steps in the priming, proliferation and differentiation of Treg and Tconv responding to the same epitope, thereby providing new, fundamental information about these processes.", [["Treg", "ANATOMY", 172, 176], ["encephalitis", "DISEASE", 22, 34], ["neurotropic coronavirus", "DISEASE", 45, 68], ["mice", "ORGANISM", 12, 16], ["neurotropic coronavirus", "ORGANISM", 45, 68], ["Treg", "CELL", 172, 176], ["Tconv", "GENE_OR_GENE_PRODUCT", 181, 186], ["Treg", "CELL_TYPE", 172, 176], ["Tconv", "PROTEIN", 181, 186], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["neurotropic coronavirus", "SPECIES", 45, 68], ["encephalitis", "PROBLEM", 22, 34], ["neurotropic coronavirus", "PROBLEM", 45, 68]]], ["Further, we identify a new role for pathogen epitope-specific Tregs in an acute infectious disease with an immunopathological component.", [["Tregs", "ANATOMY", 62, 67], ["acute infectious disease", "DISEASE", 74, 98], ["Tregs", "CELL", 62, 67], ["pathogen epitope", "PROTEIN", 36, 52], ["Tregs", "CELL_TYPE", 62, 67], ["pathogen epitope", "TREATMENT", 36, 52], ["Tregs", "PROBLEM", 62, 67], ["an acute infectious disease", "PROBLEM", 71, 98], ["an immunopathological component", "PROBLEM", 104, 135], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["infectious", "OBSERVATION", 80, 90], ["immunopathological", "OBSERVATION_MODIFIER", 107, 125], ["component", "OBSERVATION_MODIFIER", 126, 135]]], ["Compared to bulk Tregs, they have the advantage of specifically diminishing numbers and function of pathogenic CD4 T cells responding to the same epitope without suppressing the anti-virus T cell response.", [["Tregs", "ANATOMY", 17, 22], ["CD4 T cells", "ANATOMY", 111, 122], ["anti-virus T cell", "ANATOMY", 178, 195], ["Tregs", "CELL", 17, 22], ["CD4 T cells", "CELL", 111, 122], ["anti-virus T cell", "CELL", 178, 195], ["Tregs", "CELL_TYPE", 17, 22], ["pathogenic CD4 T cells", "CELL_TYPE", 100, 122], ["diminishing numbers", "PROBLEM", 64, 83], ["pathogenic CD4 T cells", "PROBLEM", 100, 122], ["pathogenic CD4", "OBSERVATION", 100, 114]]], ["Their use in the context of encephalitis or other infections would allow targeting of pathogenic CD4 T cell responses without generally suppressing the protective components of the immune response.Author Summaryexpression on M133 Tregs within 1-2 generations of division ( Figure 3F ).Author SummaryWhile these results showed that the DCLN were the initial site of priming, M133 Tconv and Treg proliferation was also detected in the spleen and inguinal lymph nodes.", [["CD4 T cell", "ANATOMY", 97, 107], ["M133 Tregs", "ANATOMY", 225, 235], ["DCLN", "ANATOMY", 335, 339], ["Treg", "ANATOMY", 389, 393], ["spleen", "ANATOMY", 433, 439], ["inguinal lymph nodes", "ANATOMY", 444, 464], ["encephalitis", "DISEASE", 28, 40], ["infections", "DISEASE", 50, 60], ["CD4 T cell", "CELL", 97, 107], ["M133 Tregs", "CELL", 225, 235], ["DCLN", "CANCER", 335, 339], ["Tconv", "GENE_OR_GENE_PRODUCT", 379, 384], ["Treg", "CELL", 389, 393], ["spleen", "ORGAN", 433, 439], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 444, 464], ["CD4", "PROTEIN", 97, 100], ["M133 Tregs", "CELL_LINE", 225, 235], ["DCLN", "DNA", 335, 339], ["encephalitis", "PROBLEM", 28, 40], ["other infections", "PROBLEM", 44, 60], ["pathogenic CD4 T cell responses", "PROBLEM", 86, 117], ["the DCLN", "TREATMENT", 331, 339], ["Treg proliferation", "PROBLEM", 389, 407], ["encephalitis", "OBSERVATION", 28, 40], ["infections", "OBSERVATION", 50, 60], ["immune response", "OBSERVATION", 181, 196], ["Treg proliferation", "OBSERVATION", 389, 407], ["spleen", "ANATOMY", 433, 439], ["inguinal", "ANATOMY", 444, 452], ["lymph nodes", "OBSERVATION", 453, 464]]], ["To distinguish priming at these distal sites and migration after initial priming in the DCLN, we treated mice with FTY720, a drug which inhibits cell egress from lymph nodes [25] .", [["distal sites", "ANATOMY", 32, 44], ["DCLN", "ANATOMY", 88, 92], ["cell", "ANATOMY", 145, 149], ["lymph nodes", "ANATOMY", 162, 173], ["FTY720", "CHEMICAL", 115, 121], ["FTY720", "CHEMICAL", 115, 121], ["distal sites", "MULTI-TISSUE_STRUCTURE", 32, 44], ["DCLN", "CANCER", 88, 92], ["mice", "ORGANISM", 105, 109], ["FTY720", "SIMPLE_CHEMICAL", 115, 121], ["cell", "CELL", 145, 149], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 162, 173], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["initial priming in the DCLN", "TREATMENT", 65, 92], ["FTY720", "TREATMENT", 115, 121], ["a drug", "TREATMENT", 123, 129], ["cell egress from lymph nodes", "PROBLEM", 145, 173], ["distal", "OBSERVATION_MODIFIER", 32, 38], ["sites", "OBSERVATION_MODIFIER", 39, 44], ["migration", "OBSERVATION_MODIFIER", 49, 58], ["lymph nodes", "OBSERVATION", 162, 173]]], ["In these experiments, equal numbers of M133 Tconv and Tregs were transferred to B6 mice and mice were treated with the drug 0.5 hr prior to infection and then on a daily basis ( Figure 4A ).", [["Tregs", "ANATOMY", 54, 59], ["infection", "DISEASE", 140, 149], ["M133", "CELL", 39, 43], ["Tconv", "GENE_OR_GENE_PRODUCT", 44, 49], ["Tregs", "CELL", 54, 59], ["B6 mice", "ORGANISM", 80, 87], ["mice", "ORGANISM", 92, 96], ["M133 Tconv", "CELL_LINE", 39, 49], ["Tregs", "CELL_TYPE", 54, 59], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 92, 96], ["the drug", "TREATMENT", 115, 123], ["infection", "PROBLEM", 140, 149], ["infection", "OBSERVATION", 140, 149]]], ["Proliferating M133 Tconv or Tregs were barely detectable in the spleen or ILN after FTY720 treatment at day 4 p.i., but proliferation continued unabated in the DCLN and to a lesser extent, in the CLN.", [["M133 Tconv", "ANATOMY", 14, 24], ["Tregs", "ANATOMY", 28, 33], ["spleen", "ANATOMY", 64, 70], ["ILN", "ANATOMY", 74, 77], ["DCLN", "ANATOMY", 160, 164], ["CLN", "ANATOMY", 196, 199], ["FTY720", "CHEMICAL", 84, 90], ["FTY720", "CHEMICAL", 84, 90], ["Tconv", "GENE_OR_GENE_PRODUCT", 19, 24], ["Tregs", "CELL", 28, 33], ["spleen", "ORGAN", 64, 70], ["ILN", "CELL", 74, 77], ["FTY720", "SIMPLE_CHEMICAL", 84, 90], ["DCLN", "CANCER", 160, 164], ["CLN", "CANCER", 196, 199], ["M133 Tconv", "CELL_LINE", 14, 24], ["Tregs", "CELL_TYPE", 28, 33], ["Tregs", "PROBLEM", 28, 33], ["FTY720 treatment", "TREATMENT", 84, 100], ["proliferation", "PROBLEM", 120, 133], ["spleen", "ANATOMY", 64, 70], ["ILN", "ANATOMY", 74, 77], ["lesser extent", "OBSERVATION_MODIFIER", 174, 187]]], ["No transferred cells were detected in the brain after drug treatment ( Figure 4 , B and C).", [["cells", "ANATOMY", 15, 20], ["brain", "ANATOMY", 42, 47], ["cells", "CELL", 15, 20], ["brain", "ORGAN", 42, 47], ["transferred cells", "PROBLEM", 3, 20], ["drug treatment", "TREATMENT", 54, 68], ["Figure", "TEST", 71, 77], ["transferred cells", "OBSERVATION", 3, 20], ["brain", "ANATOMY", 42, 47]]], ["Further, only highly divided cells were detected in the DCLN in treated mice whereas in the absence of FTY720, cells with only partial dye dilution were detected, suggesting that the latter were newly recruited.", [["cells", "ANATOMY", 29, 34], ["DCLN", "ANATOMY", 56, 60], ["cells", "ANATOMY", 111, 116], ["FTY720", "CHEMICAL", 103, 109], ["FTY720", "CHEMICAL", 103, 109], ["cells", "CELL", 29, 34], ["DCLN", "CANCER", 56, 60], ["mice", "ORGANISM", 72, 76], ["FTY720", "SIMPLE_CHEMICAL", 103, 109], ["cells", "CELL", 111, 116], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["highly divided cells", "PROBLEM", 14, 34], ["partial dye dilution", "PROBLEM", 127, 147], ["partial", "OBSERVATION_MODIFIER", 127, 134], ["dye dilution", "OBSERVATION", 135, 147]]], ["Overall, these data demonstrate that all priming occurs in the cervical lymph nodes, predominantly in the DCLN.", [["cervical lymph nodes", "ANATOMY", 63, 83], ["DCLN", "ANATOMY", 106, 110], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 63, 83], ["DCLN", "CANCER", 106, 110], ["cervical", "ANATOMY", 63, 71], ["lymph nodes", "OBSERVATION", 72, 83]]], ["M133 Tregs inhibit M133 Tconv proliferation in, and egress from, the DCLN Since M133 Tregs and Tconv expanded at the same site, we reasoned that M133 Tregs would suppress Tconv activation and proliferation if both were present in the DCLN, and that M133 Tregs would be more suppressive than bulk Tregs since the latter did not proliferate.", [["Tregs", "ANATOMY", 5, 10], ["DCLN", "ANATOMY", 69, 73], ["M133 Tregs", "ANATOMY", 80, 90], ["Tregs", "ANATOMY", 150, 155], ["DCLN", "ANATOMY", 234, 238], ["Tregs", "ANATOMY", 254, 259], ["Tregs", "ANATOMY", 296, 301], ["M133", "CHEMICAL", 0, 4], ["M133", "CHEMICAL", 145, 149], ["M133", "CHEMICAL", 249, 253], ["M133", "CHEMICAL", 0, 4], ["M133", "CHEMICAL", 145, 149], ["Tregs", "CELL", 5, 10], ["M133 Tconv", "CELL", 19, 29], ["M133 Tregs", "CELL", 80, 90], ["Tconv", "GENE_OR_GENE_PRODUCT", 95, 100], ["Tregs", "CELL", 150, 155], ["Tconv", "GENE_OR_GENE_PRODUCT", 171, 176], ["DCLN", "CANCER", 234, 238], ["Tregs", "CELL", 254, 259], ["Tregs", "CELL", 296, 301], ["M133", "CELL_LINE", 0, 4], ["Tregs", "CELL_TYPE", 5, 10], ["M133 Tregs", "CELL_LINE", 80, 90], ["Tconv", "PROTEIN", 95, 100], ["Tregs", "CELL_TYPE", 150, 155], ["Tconv", "PROTEIN", 171, 176], ["Tregs", "CELL_TYPE", 254, 259], ["bulk Tregs", "CELL_TYPE", 291, 301], ["M133", "SPECIES", 0, 4], ["M133", "SPECIES", 249, 253], ["Tregs", "TREATMENT", 150, 155], ["Tregs", "TREATMENT", 254, 259], ["more suppressive", "OBSERVATION_MODIFIER", 269, 285]]], ["To examine these possibilities, we transferred M133 Tconv in the presence or absence of co-transferred M133 or bulk Tregs and sacrificed them at days 3-5 p.i. ( Figure 5A ).", [["M133", "ANATOMY", 103, 107], ["Tregs", "ANATOMY", 116, 121], ["Tconv", "GENE_OR_GENE_PRODUCT", 52, 57], ["M133", "CELL", 103, 107], ["Tregs", "CELL", 116, 121], ["M133 Tconv", "PROTEIN", 47, 57], ["co-transferred M133", "CELL_LINE", 88, 107], ["bulk Tregs", "CELL_TYPE", 111, 121]]], ["Bulk Tregs had no effect on numbers of M133 Tconv in the DCLN, spleen or brain at any time ( Figure 5B ).", [["Tregs", "ANATOMY", 5, 10], ["DCLN", "ANATOMY", 57, 61], ["spleen", "ANATOMY", 63, 69], ["brain", "ANATOMY", 73, 78], ["Bulk Tregs", "CELL", 0, 10], ["M133 Tconv", "GENE_OR_GENE_PRODUCT", 39, 49], ["DCLN", "CANCER", 57, 61], ["spleen", "ORGAN", 63, 69], ["brain", "ORGAN", 73, 78], ["Tregs", "CELL_TYPE", 5, 10], ["M133 Tconv", "PROTEIN", 39, 49], ["Bulk Tregs", "TEST", 0, 10], ["Tregs", "OBSERVATION", 5, 10], ["no", "UNCERTAINTY", 15, 17], ["effect", "OBSERVATION_MODIFIER", 18, 24], ["spleen", "ANATOMY", 63, 69], ["brain", "ANATOMY", 73, 78]]], ["In contrast, the presence of M133 Tregs resulted in decreased numbers of Tconv in the spleen and brain at all times p.i., suggesting an effect on Tconv proliferation.", [["M133 Tregs", "ANATOMY", 29, 39], ["spleen", "ANATOMY", 86, 92], ["brain", "ANATOMY", 97, 102], ["M133 Tregs", "CELL", 29, 39], ["Tconv", "GENE_OR_GENE_PRODUCT", 73, 78], ["spleen", "ORGAN", 86, 92], ["brain", "ORGAN", 97, 102], ["Tconv", "GENE_OR_GENE_PRODUCT", 146, 151], ["M133 Tregs", "CELL_LINE", 29, 39], ["Tconv", "PROTEIN", 73, 78], ["decreased numbers of Tconv in the spleen and brain", "PROBLEM", 52, 102], ["Tconv proliferation", "PROBLEM", 146, 165], ["M133 Tregs", "OBSERVATION", 29, 39], ["decreased", "OBSERVATION_MODIFIER", 52, 61], ["numbers", "OBSERVATION_MODIFIER", 62, 69], ["spleen", "ANATOMY", 86, 92], ["brain", "ANATOMY", 97, 102], ["effect", "OBSERVATION_MODIFIER", 136, 142], ["Tconv proliferation", "OBSERVATION", 146, 165]]], ["However, the effects of transferred M133 Tregs were more complicated in the DCLN.", [["Tregs", "ANATOMY", 41, 46], ["DCLN", "ANATOMY", 76, 80], ["M133", "CHEMICAL", 36, 40], ["DCLN", "DISEASE", 76, 80], ["M133", "CHEMICAL", 36, 40], ["Tregs", "CELL", 41, 46], ["DCLN", "CANCER", 76, 80], ["Tregs", "CELL_TYPE", 41, 46], ["Tregs", "PROBLEM", 41, 46]]], ["M133 Tconv numbers in the DCLN were increased at day 3 and 5 p.i., but decreased at day 4.Author SummaryTo probe this in more detail, M133 Tconv activation and proliferation, based on Violet dilution, was analyzed with or without co-transferred M133 Tregs ( Figure 6 ).", [["DCLN", "ANATOMY", 26, 30], ["DCLN", "CANCER", 26, 30], ["DCLN", "PROTEIN", 26, 30], ["Tconv", "PROTEIN", 139, 144], ["M133 Tregs", "CELL_LINE", 245, 255], ["the DCLN", "TREATMENT", 22, 30], ["Violet dilution", "TREATMENT", 184, 199]]], ["M133 Tconv were gated as shown in Figure 6A .", [["M133 Tconv", "PROTEIN", 0, 10]]], ["Activation was assessed by measuring levels of CD25 and CD69 on Tconv in the DCLN at day 3 p.i. ( Figure 6B ).", [["DCLN", "ANATOMY", 77, 81], ["CD25", "GENE_OR_GENE_PRODUCT", 47, 51], ["CD69", "GENE_OR_GENE_PRODUCT", 56, 60], ["Tconv", "GENE_OR_GENE_PRODUCT", 64, 69], ["DCLN", "CANCER", 77, 81], ["CD25", "PROTEIN", 47, 51], ["CD69", "PROTEIN", 56, 60], ["Tconv", "PROTEIN", 64, 69], ["CD25", "TEST", 47, 51], ["Tconv", "TREATMENT", 64, 69]]], ["Equivalent levels of CD25 and CD69 were detected on undivided M133 Tconv.", [["CD25", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD69", "GENE_OR_GENE_PRODUCT", 30, 34], ["CD25", "PROTEIN", 21, 25], ["CD69", "PROTEIN", 30, 34], ["M133 Tconv", "PROTEIN", 62, 72], ["CD25", "TEST", 21, 25], ["CD69", "TEST", 30, 34], ["CD25", "ANATOMY", 21, 25]]], ["However, even though expression of CD25 and CD69 followed similar kinetics in the presence or absence of Tregs, levels of both molecules were lower in the presence of Tregs after cells began to divide.", [["Tregs", "ANATOMY", 105, 110], ["Tregs", "ANATOMY", 167, 172], ["cells", "ANATOMY", 179, 184], ["CD25", "GENE_OR_GENE_PRODUCT", 35, 39], ["CD69", "GENE_OR_GENE_PRODUCT", 44, 48], ["Tregs", "CELL", 105, 110], ["Tregs", "CELL", 167, 172], ["cells", "CELL", 179, 184], ["CD25", "PROTEIN", 35, 39], ["CD69", "PROTEIN", 44, 48], ["Tregs", "CELL_TYPE", 105, 110], ["Tregs", "CELL_TYPE", 167, 172], ["CD25", "TEST", 35, 39], ["CD69", "TEST", 44, 48], ["Tregs", "PROBLEM", 105, 110], ["levels of both molecules", "PROBLEM", 112, 136], ["Tregs", "OBSERVATION", 105, 110], ["Tregs", "OBSERVATION", 167, 172]]], ["These results suggest that the initial activation of M133 Tconv was not affected by the presence of Tregs, perhaps because of the lag in Treg relative to Tconv activation, shown in Figure 3 .", [["Tregs", "ANATOMY", 100, 105], ["Treg", "ANATOMY", 137, 141], ["M133", "GENE_OR_GENE_PRODUCT", 53, 57], ["Tconv", "GENE_OR_GENE_PRODUCT", 58, 63], ["Tregs", "CELL", 100, 105], ["Treg", "CELL", 137, 141], ["Tconv", "GENE_OR_GENE_PRODUCT", 154, 159], ["M133 Tconv", "PROTEIN", 53, 63], ["Tregs", "CELL_TYPE", 100, 105], ["Treg", "CELL_TYPE", 137, 141], ["Tconv", "PROTEIN", 154, 159], ["the lag", "PROBLEM", 126, 133], ["Tregs", "OBSERVATION", 100, 105]]], ["However, as M133 Tregs became activated and proliferated, they functioned to downregulate both molecules on Tconv.", [["Tregs", "ANATOMY", 17, 22], ["M133", "CHEMICAL", 12, 16], ["Tregs", "CELL", 17, 22], ["Tconv", "GENE_OR_GENE_PRODUCT", 108, 113], ["Tregs", "CELL_TYPE", 17, 22], ["Tconv", "PROTEIN", 108, 113]]], ["Of note, CD69 levels were lower on M133 Tregs than on M133 Tconv in mice that received both types of cells, while, as expected, CD25 levels were higher on M133 Tregs ( Figure 6B , blue bars).Author SummaryM133 Tregs inhibited M133 Tconv proliferation in the DCLN at days 4 and 5 p.i., when cells were examined directly ex vivo.", [["M133 Tregs", "ANATOMY", 35, 45], ["cells", "ANATOMY", 101, 106], ["M133 Tregs", "ANATOMY", 155, 165], ["Tregs", "ANATOMY", 210, 215], ["DCLN", "ANATOMY", 258, 262], ["cells", "ANATOMY", 290, 295], ["SummaryM133", "CHEMICAL", 198, 209], ["SummaryM133", "CHEMICAL", 198, 209], ["CD69", "GENE_OR_GENE_PRODUCT", 9, 13], ["M133 Tregs", "CELL", 35, 45], ["Tconv", "GENE_OR_GENE_PRODUCT", 59, 64], ["mice", "ORGANISM", 68, 72], ["cells", "CELL", 101, 106], ["CD25", "GENE_OR_GENE_PRODUCT", 128, 132], ["M133 Tregs", "CELL", 155, 165], ["Tregs", "CELL", 210, 215], ["M133 Tconv", "CELL", 226, 236], ["DCLN", "CANCER", 258, 262], ["cells", "CELL", 290, 295], ["CD69", "PROTEIN", 9, 13], ["M133 Tregs", "CELL_TYPE", 35, 45], ["CD25", "PROTEIN", 128, 132], ["M133 Tregs", "CELL_TYPE", 155, 165], ["Tregs", "CELL_TYPE", 210, 215], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["CD69 levels", "TEST", 9, 20], ["CD25 levels", "TEST", 128, 139], ["Tregs", "PROBLEM", 210, 215], ["Tconv proliferation", "PROBLEM", 231, 250], ["proliferation", "OBSERVATION_MODIFIER", 237, 250]]], ["The effect of Tregs on proliferation is most likely even greater than shown in the figure because a limitation of this assay is that dye dilution cannot be detected beyond 9 divisions.", [["Tregs", "ANATOMY", 14, 19], ["Tregs", "CELL", 14, 19], ["dye", "SIMPLE_CHEMICAL", 133, 136], ["Tregs", "CELL_TYPE", 14, 19], ["Tregs on proliferation", "PROBLEM", 14, 36], ["this assay", "TEST", 114, 124], ["dye dilution", "TREATMENT", 133, 145], ["Tregs", "OBSERVATION", 14, 19], ["most likely", "UNCERTAINTY", 40, 51]]], ["Remarkably, at day 3 p.i., Tconv that had undergone more divisions were detected in the presence of Tregs, resulting in a higher expansion index (EI) ( Figure 6C ).", [["Tregs", "ANATOMY", 100, 105], ["Tconv", "GENE_OR_GENE_PRODUCT", 27, 32], ["Tregs", "CELL", 100, 105], ["Tconv", "PROTEIN", 27, 32], ["Tregs", "CELL_TYPE", 100, 105], ["a higher expansion index", "PROBLEM", 120, 144], ["Tregs", "OBSERVATION", 100, 105], ["higher", "OBSERVATION_MODIFIER", 122, 128], ["expansion", "OBSERVATION_MODIFIER", 129, 138], ["index", "OBSERVATION_MODIFIER", 139, 144]]], ["Of note, only the EI in the DCLN at day 3 p.i. is shown because the EI cannot be calculated when there are too few cells in the parent generation (DCLN and spleen at days 4 and 5 p.i.) or too few proliferated cells (spleen at day 3 in the presence of M133 Tregs).", [["DCLN", "ANATOMY", 28, 32], ["cells", "ANATOMY", 115, 120], ["DCLN", "ANATOMY", 147, 151], ["spleen", "ANATOMY", 156, 162], ["cells", "ANATOMY", 209, 214], ["spleen", "ANATOMY", 216, 222], ["M133 Tregs", "ANATOMY", 251, 261], ["DCLN", "CANCER", 28, 32], ["cells", "CELL", 115, 120], ["DCLN", "CANCER", 147, 151], ["spleen", "ORGAN", 156, 162], ["cells", "CELL", 209, 214], ["spleen", "ORGAN", 216, 222], ["M133 Tregs", "CELL", 251, 261], ["proliferated cells", "CELL_TYPE", 196, 214], ["M133 Tregs", "CELL_TYPE", 251, 261], ["too few cells", "PROBLEM", 107, 120], ["too few proliferated cells", "PROBLEM", 188, 214], ["spleen", "ANATOMY", 156, 162], ["few", "OBSERVATION_MODIFIER", 192, 195], ["proliferated cells", "OBSERVATION", 196, 214], ["spleen", "ANATOMY", 216, 222]]], ["Further, Tconv numbers in the DCLN decreased from day 4 to day 5 when transferred alone, indicating significant cell egress, while numbers of these cells continued to increase in the presence of M133 Tregs (Fig. 5B) .", [["DCLN", "ANATOMY", 30, 34], ["cell", "ANATOMY", 112, 116], ["cells", "ANATOMY", 148, 153], ["M133 Tregs", "ANATOMY", 195, 205], ["Tconv", "GENE_OR_GENE_PRODUCT", 9, 14], ["DCLN", "CANCER", 30, 34], ["cell", "CELL", 112, 116], ["cells", "CELL", 148, 153], ["M133 Tregs", "CELL", 195, 205], ["Tconv", "PROTEIN", 9, 14], ["M133 Tregs", "CELL_TYPE", 195, 205], ["significant cell egress", "PROBLEM", 100, 123], ["these cells", "PROBLEM", 142, 153], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["cell egress", "OBSERVATION", 112, 123]]], ["These results, in conjunction with decreased Tconv numbers in the spleen and brain at all times in the presence of M133 Tregs ( Figure 5B and 6C), suggest that Tregs inhibited egress from the DCLN in addition to effects on proliferation.", [["spleen", "ANATOMY", 66, 72], ["brain", "ANATOMY", 77, 82], ["M133 Tregs", "ANATOMY", 115, 125], ["Tregs", "ANATOMY", 160, 165], ["DCLN", "ANATOMY", 192, 196], ["Tconv", "GENE_OR_GENE_PRODUCT", 45, 50], ["spleen", "ORGAN", 66, 72], ["brain", "ORGAN", 77, 82], ["M133 Tregs", "CELL", 115, 125], ["Figure 5B", "GENE_OR_GENE_PRODUCT", 128, 137], ["Tregs", "CELL", 160, 165], ["DCLN", "CANCER", 192, 196], ["Tconv", "PROTEIN", 45, 50], ["M133 Tregs", "CELL_TYPE", 115, 125], ["Tregs", "CELL_TYPE", 160, 165], ["decreased Tconv numbers in the spleen and brain", "PROBLEM", 35, 82], ["Figure 5B", "TEST", 128, 137], ["Tregs inhibited egress", "PROBLEM", 160, 182], ["the DCLN", "TREATMENT", 188, 196], ["proliferation", "PROBLEM", 223, 236], ["spleen", "ANATOMY", 66, 72], ["brain", "ANATOMY", 77, 82], ["Tregs", "OBSERVATION", 160, 165], ["proliferation", "OBSERVATION", 223, 236]]], ["Of note, decreased Tconv numbers could reflect increased levels of apoptosis, but the fraction of Tconv apoptosis was the same in the presence or absence of transferred M133 Tregs in the DCLN at day 4 ( Figure 6D ).", [["Tregs", "ANATOMY", 174, 179], ["DCLN", "ANATOMY", 187, 191], ["M133", "CHEMICAL", 169, 173], ["M133", "CHEMICAL", 169, 173], ["Tconv", "GENE_OR_GENE_PRODUCT", 19, 24], ["Tconv", "GENE_OR_GENE_PRODUCT", 98, 103], ["Tregs", "CELL", 174, 179], ["Tconv", "PROTEIN", 19, 24], ["M133", "CELL_LINE", 169, 173], ["Tregs", "CELL_TYPE", 174, 179], ["decreased Tconv numbers", "PROBLEM", 9, 32], ["increased levels of apoptosis", "PROBLEM", 47, 76], ["Tconv apoptosis", "PROBLEM", 98, 113], ["Tregs", "TREATMENT", 174, 179], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["levels", "OBSERVATION_MODIFIER", 57, 63], ["apoptosis", "OBSERVATION", 67, 76], ["Tconv apoptosis", "OBSERVATION", 98, 113]]], ["In addition, levels of CXCR3 on Tconv in the DCLN were much lower at day 4 when Tregs were co-transferred ( Figure 6E ).", [["DCLN", "ANATOMY", 45, 49], ["Tregs", "ANATOMY", 80, 85], ["CXCR3", "GENE_OR_GENE_PRODUCT", 23, 28], ["Tconv", "GENE_OR_GENE_PRODUCT", 32, 37], ["DCLN", "CANCER", 45, 49], ["Tregs", "CELL", 80, 85], ["CXCR3", "PROTEIN", 23, 28], ["Tconv", "PROTEIN", 32, 37], ["Tregs", "CELL_TYPE", 80, 85], ["CXCR3", "TEST", 23, 28], ["Tconv", "TEST", 32, 37], ["the DCLN", "TEST", 41, 49]]], ["Since T cell entry into sites of inflammation depends in part on CXCR3 expression, this decreased expression contributed to decreased numbers in the brain and perhaps also in the spleen.", [["T cell", "ANATOMY", 6, 12], ["sites", "ANATOMY", 24, 29], ["brain", "ANATOMY", 149, 154], ["spleen", "ANATOMY", 179, 185], ["inflammation", "DISEASE", 33, 45], ["T cell", "CELL", 6, 12], ["CXCR3", "GENE_OR_GENE_PRODUCT", 65, 70], ["brain", "ORGAN", 149, 154], ["spleen", "ORGAN", 179, 185], ["CXCR3", "PROTEIN", 65, 70], ["inflammation", "PROBLEM", 33, 45], ["this decreased expression", "PROBLEM", 83, 108], ["decreased numbers in the brain", "PROBLEM", 124, 154], ["inflammation", "OBSERVATION", 33, 45], ["decreased", "OBSERVATION_MODIFIER", 124, 133], ["numbers", "OBSERVATION", 134, 141], ["brain", "ANATOMY", 149, 154], ["spleen", "ANATOMY", 179, 185]]], ["CXCR3 transcription is regulated by T-bet [26] ; consistent with this, T-bet expression in Tconv was less elevated in the presence of transferred Tregs ( Figure 6E ).", [["Tregs", "ANATOMY", 146, 151], ["CXCR3", "GENE_OR_GENE_PRODUCT", 0, 5], ["T-bet", "GENE_OR_GENE_PRODUCT", 36, 41], ["T-bet", "GENE_OR_GENE_PRODUCT", 71, 76], ["Tconv", "GENE_OR_GENE_PRODUCT", 91, 96], ["Tregs", "CELL", 146, 151], ["CXCR3", "PROTEIN", 0, 5], ["Tconv", "PROTEIN", 91, 96], ["Tregs", "CELL_TYPE", 146, 151], ["CXCR3 transcription", "TEST", 0, 19], ["less elevated", "PROBLEM", 101, 114]]], ["Thus, in the DCLN, M133 Tconv accumulation was determined by a balance of opposing effects on migration and proliferation, while in the spleen and brain, both effects contributed to decreased numbers of Tconv.", [["DCLN", "ANATOMY", 13, 17], ["spleen", "ANATOMY", 136, 142], ["brain", "ANATOMY", 147, 152], ["DCLN", "CANCER", 13, 17], ["Tconv", "GENE_OR_GENE_PRODUCT", 24, 29], ["spleen", "ORGAN", 136, 142], ["brain", "ORGAN", 147, 152], ["Tconv", "GENE_OR_GENE_PRODUCT", 203, 208], ["Tconv", "PROTEIN", 203, 208], ["proliferation", "PROBLEM", 108, 121], ["decreased numbers of Tconv", "PROBLEM", 182, 208], ["migration", "OBSERVATION_MODIFIER", 94, 103], ["proliferation", "OBSERVATION_MODIFIER", 108, 121], ["spleen", "ANATOMY", 136, 142], ["brain", "ANATOMY", 147, 152], ["decreased", "OBSERVATION_MODIFIER", 182, 191], ["numbers", "OBSERVATION_MODIFIER", 192, 199]]], ["Notably, CXCR3 and T-bet levels on M133 Tregs and M133 Tconv were similar when these cells were co-transferred ( Figure 6E , blue bars).Differential kinetics of T-bet and cytokine expression by M133 Tconv and Tregs in DCLNM133-specific Tregs in the infected brain express T-bet and several cytokines (IFN-c, TNF and IL-10) [12] .", [["M133 Tregs", "ANATOMY", 35, 45], ["cells", "ANATOMY", 85, 90], ["Tregs", "ANATOMY", 209, 214], ["Tregs", "ANATOMY", 236, 241], ["brain", "ANATOMY", 258, 263], ["CXCR3", "GENE_OR_GENE_PRODUCT", 9, 14], ["T-bet", "GENE_OR_GENE_PRODUCT", 19, 24], ["M133 Tregs", "CELL", 35, 45], ["M133 Tconv", "GENE_OR_GENE_PRODUCT", 50, 60], ["cells", "CELL", 85, 90], ["T-bet", "GENE_OR_GENE_PRODUCT", 161, 166], ["M133", "CELL", 194, 198], ["Tconv", "GENE_OR_GENE_PRODUCT", 199, 204], ["Tregs", "CELL", 209, 214], ["DCLNM133", "GENE_OR_GENE_PRODUCT", 218, 226], ["Tregs", "CELL", 236, 241], ["brain", "ORGAN", 258, 263], ["T-bet", "GENE_OR_GENE_PRODUCT", 272, 277], ["IFN-c", "GENE_OR_GENE_PRODUCT", 301, 306], ["TNF", "GENE_OR_GENE_PRODUCT", 308, 311], ["IL-10", "GENE_OR_GENE_PRODUCT", 316, 321], ["CXCR3", "PROTEIN", 9, 14], ["M133 Tregs", "CELL_LINE", 35, 45], ["M133 Tconv", "PROTEIN", 50, 60], ["cytokine", "PROTEIN", 171, 179], ["M133 Tconv", "CELL_LINE", 194, 204], ["Tregs", "CELL_TYPE", 209, 214], ["DCLNM133-specific Tregs", "CELL_LINE", 218, 241], ["T-bet", "PROTEIN", 272, 277], ["cytokines", "PROTEIN", 290, 299], ["IFN", "PROTEIN", 301, 304], ["TNF", "PROTEIN", 308, 311], ["CXCR3", "TEST", 9, 14], ["T", "TEST", 19, 20], ["bet levels", "TEST", 21, 31], ["M133", "TEST", 35, 39], ["Tregs", "TEST", 40, 45], ["M133 Tconv", "TEST", 50, 60], ["these cells", "TEST", 79, 90], ["T", "TEST", 161, 162], ["cytokine expression", "TEST", 171, 190], ["Tregs", "TEST", 209, 214], ["DCLNM133", "TEST", 218, 226], ["several cytokines", "TEST", 282, 299], ["IFN-c, TNF and IL", "TREATMENT", 301, 318], ["infected brain", "ANATOMY", 249, 263]]], ["We next sought to determine whether this differentiation to a Th1 phenotype occurred after Tregs had entered the brain, or earlier in the DCLN.", [["Tregs", "ANATOMY", 91, 96], ["brain", "ANATOMY", 113, 118], ["DCLN", "ANATOMY", 138, 142], ["Tregs", "CELL", 91, 96], ["brain", "ORGAN", 113, 118], ["DCLN", "CANCER", 138, 142], ["Tregs", "CELL_TYPE", 91, 96], ["a Th1 phenotype", "PROBLEM", 60, 75], ["brain", "ANATOMY", 113, 118]]], ["We transferred either M133 Tconv or Treg into mice prior to rJ2.2 infection and measured T-bet and cytokine expression in the DCLN at day 3.5 p.i.", [["Treg", "ANATOMY", 36, 40], ["DCLN", "ANATOMY", 126, 130], ["infection", "DISEASE", 66, 75], ["Tconv", "GENE_OR_GENE_PRODUCT", 27, 32], ["Treg", "CELL", 36, 40], ["mice", "ORGANISM", 46, 50], ["T-bet", "GENE_OR_GENE_PRODUCT", 89, 94], ["DCLN", "CANCER", 126, 130], ["M133 Tconv", "PROTEIN", 22, 32], ["Treg", "CELL_TYPE", 36, 40], ["cytokine", "PROTEIN", 99, 107], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["rJ2.2 infection", "PROBLEM", 60, 75], ["T-bet and cytokine expression", "TREATMENT", 89, 118], ["infection", "OBSERVATION", 66, 75]]], ["T-bet was expressed by both types of cells at this early time post infection, after either one (Tconv) or three (Treg) cell divisions.", [["cells", "ANATOMY", 37, 42], ["Treg", "ANATOMY", 113, 117], ["cell", "ANATOMY", 119, 123], ["infection", "DISEASE", 67, 76], ["T-bet", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 37, 42], ["Treg", "CELL", 113, 117], ["cell", "CELL", 119, 123], ["T-bet", "PROTEIN", 0, 5], ["infection", "PROBLEM", 67, 76], ["infection", "OBSERVATION", 67, 76]]], ["Further, IFN-c and IL-10 were expressed by both M133 Tconv and Tregs in the DCLN after direct ex vivo stimulation with M133 peptide.", [["M133 Tconv", "ANATOMY", 48, 58], ["Tregs", "ANATOMY", 63, 68], ["DCLN", "ANATOMY", 76, 80], ["IFN-c", "GENE_OR_GENE_PRODUCT", 9, 14], ["IL-10", "GENE_OR_GENE_PRODUCT", 19, 24], ["M133 Tconv", "CELL", 48, 58], ["Tregs", "CELL", 63, 68], ["DCLN", "CANCER", 76, 80], ["M133 peptide", "SIMPLE_CHEMICAL", 119, 131], ["IFN-c and IL-10", "PROTEIN", 9, 24], ["M133 Tconv", "CELL_LINE", 48, 58], ["Tregs", "CELL_TYPE", 63, 68], ["DCLN", "CELL_TYPE", 76, 80], ["IFN", "TEST", 9, 12], ["direct ex vivo stimulation", "TREATMENT", 87, 113], ["M133 peptide", "TREATMENT", 119, 131]]], ["Tregs required more cell divisions to express IFN-c than Tconv but conversely, IL-10 expression by Tregs occurred after fewer cell divisions than Tconv.", [["Tregs", "ANATOMY", 0, 5], ["cell", "ANATOMY", 20, 24], ["Tregs", "ANATOMY", 99, 104], ["cell", "ANATOMY", 126, 130], ["Tregs", "CELL", 0, 5], ["cell", "CELL", 20, 24], ["IFN-c", "GENE_OR_GENE_PRODUCT", 46, 51], ["Tconv", "GENE_OR_GENE_PRODUCT", 57, 62], ["IL-10", "GENE_OR_GENE_PRODUCT", 79, 84], ["Tregs", "CELL", 99, 104], ["cell", "CELL", 126, 130], ["Tregs", "CELL_TYPE", 0, 5], ["IFN", "PROTEIN", 46, 49], ["Tconv", "PROTEIN", 57, 62], ["IL", "PROTEIN", 79, 81], ["Tregs", "CELL_TYPE", 99, 104], ["Tconv", "PROTEIN", 146, 151], ["more cell divisions", "TREATMENT", 15, 34], ["more cell", "OBSERVATION_MODIFIER", 15, 24]]], ["Thus, Treg ability to express cytokines did not require entry into the infected brain, but rather the milieu in the draining DCLN was sufficient to trigger differentiation.", [["Treg", "ANATOMY", 6, 10], ["brain", "ANATOMY", 80, 85], ["DCLN", "ANATOMY", 125, 129], ["Treg", "CELL", 6, 10], ["brain", "ORGAN", 80, 85], ["DCLN", "CANCER", 125, 129], ["cytokines", "PROTEIN", 30, 39], ["entry into the infected brain", "PROBLEM", 56, 85], ["the draining DCLN", "TREATMENT", 112, 129], ["infected", "OBSERVATION", 71, 79], ["brain", "ANATOMY", 80, 85], ["draining", "OBSERVATION", 116, 124]]], ["These cells then migrated to the infected brain, already competent for cytokine expression.Differential kinetics of T-bet and cytokine expression by M133 Tconv and Tregs in DCLNTransferred M133 Tregs enhance survival and diminish the M133 Tconv immune response in the infected brainDifferential kinetics of T-bet and cytokine expression by M133 Tconv and Tregs in DCLNTo examine the effects of transferred M133 Tregs on clinical disease, we transferred 10 5 M133 Tregs (in the absence of M133 Tconv), bulk Tregs or bulk Tconv (control group) to infected mice one day prior to rJ2.2 infection.", [["cells", "ANATOMY", 6, 11], ["brain", "ANATOMY", 42, 47], ["Tregs", "ANATOMY", 164, 169], ["Tregs", "ANATOMY", 194, 199], ["Tregs", "ANATOMY", 355, 360], ["M133 Tregs", "ANATOMY", 406, 416], ["Tregs", "ANATOMY", 463, 468], ["Tregs", "ANATOMY", 506, 511], ["infection", "DISEASE", 582, 591], ["cells", "CELL", 6, 11], ["brain", "ORGAN", 42, 47], ["T-bet", "GENE_OR_GENE_PRODUCT", 116, 121], ["M133 Tconv", "CELL", 149, 159], ["Tregs", "CELL", 164, 169], ["Tregs", "CELL", 194, 199], ["Tconv", "GENE_OR_GENE_PRODUCT", 239, 244], ["T-bet", "GENE_OR_GENE_PRODUCT", 307, 312], ["M133", "CELL", 340, 344], ["Tconv", "GENE_OR_GENE_PRODUCT", 345, 350], ["Tregs", "CELL", 355, 360], ["DCLNTo", "CELL", 364, 370], ["M133 Tregs", "CELL", 406, 416], ["M133 Tregs", "CELL", 458, 468], ["Tconv", "GENE_OR_GENE_PRODUCT", 493, 498], ["Tregs", "CELL", 506, 511], ["Tconv", "GENE_OR_GENE_PRODUCT", 520, 525], ["mice", "ORGANISM", 554, 558], ["cytokine", "PROTEIN", 71, 79], ["cytokine", "PROTEIN", 126, 134], ["M133 Tconv", "PROTEIN", 149, 159], ["Tregs", "CELL_TYPE", 164, 169], ["DCLNTransferred M133", "CELL_LINE", 173, 193], ["Tregs", "CELL_TYPE", 194, 199], ["cytokine", "PROTEIN", 317, 325], ["M133 Tconv", "CELL_LINE", 340, 350], ["Tregs", "CELL_TYPE", 355, 360], ["DCLNTo", "CELL_LINE", 364, 370], ["M133 Tregs", "CELL_LINE", 406, 416], ["M133 Tregs", "CELL_TYPE", 458, 468], ["M133 Tconv", "PROTEIN", 488, 498], ["bulk Tregs", "CELL_TYPE", 501, 511], ["mice", "SPECIES", 554, 558], ["mice", "SPECIES", 554, 558], ["These cells", "PROBLEM", 0, 11], ["the infected brain", "PROBLEM", 29, 47], ["T-bet and cytokine expression", "TREATMENT", 116, 145], ["Tregs enhance survival", "TREATMENT", 194, 216], ["T-bet and cytokine expression", "TREATMENT", 307, 336], ["clinical disease", "PROBLEM", 420, 436], ["bulk Tconv (control group", "TREATMENT", 515, 540], ["rJ2.2 infection", "PROBLEM", 576, 591], ["infected", "OBSERVATION", 33, 41], ["brain", "ANATOMY", 42, 47], ["cytokine expression", "OBSERVATION", 71, 90], ["infected", "OBSERVATION_MODIFIER", 268, 276], ["infection", "OBSERVATION", 582, 591]]], ["Consistent with priming in the DCLN, numbers of M133 Tregs increased dramatically from day 0 to day 3 p.i. in the DCLN but not the spleen.", [["DCLN", "ANATOMY", 31, 35], ["M133", "ANATOMY", 48, 52], ["Tregs", "ANATOMY", 53, 58], ["DCLN", "ANATOMY", 114, 118], ["spleen", "ANATOMY", 131, 137], ["M133", "CHEMICAL", 48, 52], ["DCLN", "CANCER", 31, 35], ["Tregs", "CELL", 53, 58], ["DCLN", "CANCER", 114, 118], ["spleen", "ORGAN", 131, 137], ["Tregs", "CELL_TYPE", 53, 58], ["M133", "SPECIES", 48, 52], ["Tregs", "PROBLEM", 53, 58], ["spleen", "ANATOMY", 131, 137]]], ["M133 Tregs were first detected in the brain at day 3, peaked at day 7 in both the brain and DCLN and then gradually declined in both organs as the infection resolved ( Figure 8A ).", [["Tregs", "ANATOMY", 5, 10], ["brain", "ANATOMY", 38, 43], ["brain", "ANATOMY", 82, 87], ["DCLN", "ANATOMY", 92, 96], ["organs", "ANATOMY", 133, 139], ["M133", "CHEMICAL", 0, 4], ["infection", "DISEASE", 147, 156], ["M133", "CHEMICAL", 0, 4], ["Tregs", "CELL", 5, 10], ["brain", "ORGAN", 38, 43], ["brain", "ORGAN", 82, 87], ["DCLN", "CANCER", 92, 96], ["organs", "ORGAN", 133, 139], ["M133", "CELL_LINE", 0, 4], ["Tregs", "CELL_TYPE", 5, 10], ["M133", "SPECIES", 0, 4], ["Tregs", "TEST", 5, 10], ["the infection", "PROBLEM", 143, 156], ["brain", "ANATOMY", 38, 43], ["brain", "ANATOMY", 82, 87], ["organs", "ANATOMY", 133, 139], ["infection", "OBSERVATION", 147, 156]]], ["Transferred M133 Tregs, but not bulk Tregs improved survival and diminished weight loss ( Figure 8 , B and C) without affecting virus clearance (Figure 8D ).", [["M133 Tregs", "ANATOMY", 12, 22], ["Tregs", "ANATOMY", 37, 42], ["weight loss", "DISEASE", 76, 87], ["M133 Tregs", "CELL", 12, 22], ["Tregs", "CELL", 37, 42], ["M133 Tregs", "CELL_LINE", 12, 22], ["bulk Tregs", "CELL_TYPE", 32, 42], ["diminished weight loss", "PROBLEM", 65, 87], ["Figure", "TEST", 90, 96], ["affecting virus clearance", "PROBLEM", 118, 143], ["diminished", "OBSERVATION_MODIFIER", 65, 75]]], ["M133 Tregs decreased the frequencies of M133-specific CD4 T cells in the brain ( Figure 8E ).", [["Tregs", "ANATOMY", 5, 10], ["CD4 T cells", "ANATOMY", 54, 65], ["brain", "ANATOMY", 73, 78], ["M133", "CHEMICAL", 0, 4], ["M133", "CHEMICAL", 0, 4], ["Tregs", "CELL", 5, 10], ["M133", "GENE_OR_GENE_PRODUCT", 40, 44], ["CD4 T", "GENE_OR_GENE_PRODUCT", 54, 59], ["brain", "ORGAN", 73, 78], ["M133", "CELL_LINE", 0, 4], ["Tregs", "CELL_TYPE", 5, 10], ["M133", "PROTEIN", 40, 44], ["CD4 T cells", "CELL_TYPE", 54, 65], ["M133", "SPECIES", 0, 4], ["Tregs", "PROBLEM", 5, 10], ["the frequencies", "TEST", 21, 36], ["M133", "TEST", 40, 44], ["CD4 T cells", "OBSERVATION", 54, 65], ["brain", "ANATOMY", 73, 78]]], ["In addition, transferred M133 Tregs inhibited the effector function of these cells, manifested by reduced IFN-c expression per cell ( Figure 8F) .", [["M133 Tregs", "ANATOMY", 25, 35], ["cells", "ANATOMY", 77, 82], ["cell", "ANATOMY", 127, 131], ["M133 Tregs", "CELL", 25, 35], ["cells", "CELL", 77, 82], ["IFN-c", "GENE_OR_GENE_PRODUCT", 106, 111], ["cell", "CELL", 127, 131], ["M133 Tregs", "CELL_LINE", 25, 35], ["IFN", "PROTEIN", 106, 109], ["reduced IFN", "PROBLEM", 98, 109]]], ["The transferred Tregs also diminished the frequency of CD4 T cells recognizing the subdominant CD4 T cell epitope (epitope S358) but did not change the CD8 T cell response to the immunodominant S510 and subdominant S598 epitopes ( Figure 8E ).Differential kinetics of T-bet and cytokine expression by M133 Tconv and Tregs in DCLNAs expected, most of these transferred M133 Tregs expressed IL-10 or IL-10 and IFN-c after direct ex vivo peptide stimulation ( Figure 8G ).", [["Tregs", "ANATOMY", 16, 21], ["CD4 T cells", "ANATOMY", 55, 66], ["CD4 T cell", "ANATOMY", 95, 105], ["CD8 T cell", "ANATOMY", 152, 162], ["Tregs", "ANATOMY", 316, 321], ["DCLNAs", "ANATOMY", 325, 331], ["M133 Tregs", "ANATOMY", 368, 378], ["Tregs", "CELL", 16, 21], ["CD4 T cells", "CELL", 55, 66], ["CD4 T cell epitope", "GENE_OR_GENE_PRODUCT", 95, 113], ["CD8 T cell", "CELL", 152, 162], ["T-bet", "GENE_OR_GENE_PRODUCT", 268, 273], ["M133", "CELL", 301, 305], ["Tconv", "GENE_OR_GENE_PRODUCT", 306, 311], ["Tregs", "CELL", 316, 321], ["DCLNAs", "CELL", 325, 331], ["M133 Tregs", "CELL", 368, 378], ["IL-10", "GENE_OR_GENE_PRODUCT", 389, 394], ["IL-10", "GENE_OR_GENE_PRODUCT", 398, 403], ["IFN-c", "GENE_OR_GENE_PRODUCT", 408, 413], ["Tregs", "CELL_TYPE", 16, 21], ["CD4 T cells", "CELL_TYPE", 55, 66], ["CD4 T cell epitope", "PROTEIN", 95, 113], ["epitope S358", "PROTEIN", 115, 127], ["CD8", "PROTEIN", 152, 155], ["immunodominant S510", "PROTEIN", 179, 198], ["subdominant S598 epitopes", "PROTEIN", 203, 228], ["cytokine", "PROTEIN", 278, 286], ["M133 Tconv", "CELL_LINE", 301, 311], ["Tregs", "CELL_TYPE", 316, 321], ["DCLNAs", "CELL_TYPE", 325, 331], ["M133 Tregs", "CELL_LINE", 368, 378], ["IL-10", "PROTEIN", 389, 394], ["IL-10", "PROTEIN", 398, 403], ["IFN-c", "PROTEIN", 408, 413], ["CD4 T cells", "PROBLEM", 55, 66], ["the immunodominant S510", "TEST", 175, 198], ["T-bet and cytokine expression", "TREATMENT", 268, 297], ["Tregs in DCLNAs", "TREATMENT", 316, 331], ["IL", "TEST", 389, 391], ["IFN", "TREATMENT", 408, 411], ["direct ex vivo peptide stimulation", "TREATMENT", 420, 454], ["diminished", "OBSERVATION_MODIFIER", 27, 37], ["subdominant", "OBSERVATION_MODIFIER", 83, 94], ["CD4 T cell epitope", "OBSERVATION", 95, 113]]], ["IFN-c was expressed at lower levels per Treg than per effector CD4 T cell (compare Figure 8, F and G) .", [["Treg", "ANATOMY", 40, 44], ["CD4 T cell", "ANATOMY", 63, 73], ["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["Treg", "CELL", 40, 44], ["CD4 T cell", "CELL", 63, 73], ["IFN-c", "PROTEIN", 0, 5], ["Treg", "CELL_TYPE", 40, 44], ["effector CD4 T cell", "CELL_TYPE", 54, 73], ["Figure", "TEST", 83, 89]]], ["Of note, IFN-c + M133 Tregs expressed IL-10 at higher levels than those not expressing IFN-c ( Figure 8G ) perhaps reflecting the expression of IFN-c only after cells had extensively proliferated and were presumably highly activated (Figure 7) .Differential kinetics of T-bet and cytokine expression by M133 Tconv and Tregs in DCLNTo provide further support for the notion that M133 Tregs suppressed immune function in the CNS in addition to the DCLN, we assessed microglia activation after infection by measuring levels of MHC class II.", [["Tregs", "ANATOMY", 22, 27], ["cells", "ANATOMY", 161, 166], ["Tregs", "ANATOMY", 318, 323], ["Tregs", "ANATOMY", 383, 388], ["CNS", "ANATOMY", 423, 426], ["DCLN", "ANATOMY", 446, 450], ["microglia", "ANATOMY", 464, 473], ["M133", "CHEMICAL", 378, 382], ["infection", "DISEASE", 491, 500], ["M133", "CHEMICAL", 378, 382], ["IFN", "GENE_OR_GENE_PRODUCT", 9, 12], ["Tregs", "CELL", 22, 27], ["IL-10", "GENE_OR_GENE_PRODUCT", 38, 43], ["IFN-c", "GENE_OR_GENE_PRODUCT", 87, 92], ["IFN-c", "GENE_OR_GENE_PRODUCT", 144, 149], ["cells", "CELL", 161, 166], ["T-bet", "GENE_OR_GENE_PRODUCT", 270, 275], ["M133 Tconv", "GENE_OR_GENE_PRODUCT", 303, 313], ["Tregs", "CELL", 318, 323], ["Tregs", "CELL", 383, 388], ["CNS", "ANATOMICAL_SYSTEM", 423, 426], ["DCLN", "CANCER", 446, 450], ["microglia", "CELL", 464, 473], ["MHC class II", "GENE_OR_GENE_PRODUCT", 524, 536], ["IFN", "PROTEIN", 9, 12], ["M133", "PROTEIN", 17, 21], ["Tregs", "CELL_TYPE", 22, 27], ["IL-10", "PROTEIN", 38, 43], ["IFN-c", "PROTEIN", 87, 92], ["IFN", "PROTEIN", 144, 147], ["cytokine", "PROTEIN", 280, 288], ["M133 Tconv", "PROTEIN", 303, 313], ["Tregs", "CELL_TYPE", 318, 323], ["DCLNTo", "CELL_LINE", 327, 333], ["Tregs", "CELL_TYPE", 383, 388], ["DCLN", "PROTEIN", 446, 450], ["microglia", "CELL_TYPE", 464, 473], ["MHC class II", "PROTEIN", 524, 536], ["IL", "TEST", 38, 40], ["IFN", "PROBLEM", 144, 147], ["T-bet and cytokine expression", "TREATMENT", 270, 299], ["further support", "TREATMENT", 342, 357], ["the DCLN", "TREATMENT", 442, 450], ["infection", "PROBLEM", 491, 500], ["IL", "OBSERVATION_MODIFIER", 38, 40], ["CNS", "ANATOMY", 423, 426]]], ["Transfer of M133 Tregs resulted in decreased activation of microglia, as shown by diminished expression of MHC class II ( Figure 8H ) at day 7 p.i.", [["M133 Tregs", "ANATOMY", 12, 22], ["microglia", "ANATOMY", 59, 68], ["M133 Tregs", "CELL", 12, 22], ["microglia", "CELL", 59, 68], ["MHC class II", "GENE_OR_GENE_PRODUCT", 107, 119], ["Figure 8H", "GENE_OR_GENE_PRODUCT", 122, 131], ["M133 Tregs", "CELL_LINE", 12, 22], ["microglia", "CELL_TYPE", 59, 68], ["MHC class II", "PROTEIN", 107, 119], ["Figure 8H", "PROTEIN", 122, 131], ["decreased activation of microglia", "PROBLEM", 35, 68], ["decreased", "OBSERVATION_MODIFIER", 35, 44]]], ["Overall, these data indicate that M133 Tregs functioned in both the draining lymph nodes and site of infection, to diminish the effects of pathogenic CD4 T cells.Differential kinetics of T-bet and cytokine expression by M133 Tconv and Tregs in DCLNTo further buttress the conclusion that M133 Tregs preferentially suppressed the M133 Tconv response, we performed an in vitro suppression assay (Figure 9 ).", [["M133 Tregs", "ANATOMY", 34, 44], ["lymph nodes", "ANATOMY", 77, 88], ["site", "ANATOMY", 93, 97], ["CD4 T cells", "ANATOMY", 150, 161], ["Tregs", "ANATOMY", 235, 240], ["Tregs", "ANATOMY", 293, 298], ["infection", "DISEASE", 101, 110], ["M133", "CHEMICAL", 288, 292], ["M133", "CHEMICAL", 288, 292], ["M133 Tregs", "CELL", 34, 44], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 77, 88], ["CD4 T cells", "CELL", 150, 161], ["T-bet", "GENE_OR_GENE_PRODUCT", 187, 192], ["M133 Tconv", "GENE_OR_GENE_PRODUCT", 220, 230], ["Tregs", "CELL", 235, 240], ["M133", "CELL", 288, 292], ["Tregs", "CELL", 293, 298], ["Tconv", "GENE_OR_GENE_PRODUCT", 334, 339], ["M133 Tregs", "CELL_LINE", 34, 44], ["pathogenic CD4 T cells", "CELL_TYPE", 139, 161], ["cytokine", "PROTEIN", 197, 205], ["M133 Tconv", "PROTEIN", 220, 230], ["Tregs", "CELL_TYPE", 235, 240], ["Tregs", "CELL_TYPE", 293, 298], ["Tconv", "PROTEIN", 334, 339], ["infection", "PROBLEM", 101, 110], ["pathogenic CD4 T cells", "PROBLEM", 139, 161], ["T-bet and cytokine expression", "TREATMENT", 187, 216], ["Tregs", "TREATMENT", 235, 240], ["draining", "OBSERVATION_MODIFIER", 68, 76], ["lymph nodes", "OBSERVATION", 77, 88], ["infection", "OBSERVATION", 101, 110], ["pathogenic", "OBSERVATION_MODIFIER", 139, 149], ["CD4 T cells", "OBSERVATION", 150, 161]]], ["Because S358 and S510 TCR Tg mice were not available, we obtained CD4 and CD8 T cells from infected mice and labeled them with Violet.", [["CD4", "ANATOMY", 66, 69], ["CD8 T cells", "ANATOMY", 74, 85], ["TCR", "CHEMICAL", 22, 25], ["Violet", "CHEMICAL", 127, 133], ["S510 TCR", "GENE_OR_GENE_PRODUCT", 17, 25], ["mice", "ORGANISM", 29, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 66, 69], ["CD8", "GENE_OR_GENE_PRODUCT", 74, 77], ["mice", "ORGANISM", 100, 104], ["TCR", "PROTEIN", 22, 25], ["CD4 and CD8 T cells", "CELL_TYPE", 66, 85], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 100, 104], ["CD4", "TEST", 66, 69], ["Violet", "TREATMENT", 127, 133]]], ["Since these cells had been activated in vivo, M133 Tregs, isolated from uninfected M133 TCR Tg mice were therefore pre-activated in vitro with anti-CD3 and anti-CD28 antibodies.", [["cells", "ANATOMY", 12, 17], ["M133 Tregs", "ANATOMY", 46, 56], ["TCR", "CHEMICAL", 88, 91], ["cells", "CELL", 12, 17], ["M133 Tregs", "CELL", 46, 56], ["Tg mice", "ORGANISM", 92, 99], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 143, 151], ["anti-CD28 antibodies", "GENE_OR_GENE_PRODUCT", 156, 176], ["M133 Tregs", "CELL_TYPE", 46, 56], ["M133 TCR", "CELL_LINE", 83, 91], ["anti-CD3", "PROTEIN", 143, 151], ["anti-CD28 antibodies", "PROTEIN", 156, 176], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["Tregs", "TEST", 51, 56], ["anti-CD3", "TREATMENT", 143, 151], ["anti-CD28 antibodies", "TREATMENT", 156, 176]]], ["In all cases, M133 peptide was included in the in vitro suppression assay to activate M133 Tregs.", [["M133 Tregs", "ANATOMY", 86, 96], ["M133 peptide", "SIMPLE_CHEMICAL", 14, 26], ["M133 Tregs", "CELL", 86, 96], ["M133 Tregs", "CELL_LINE", 86, 96]]], ["Consequently, in order to distinguish proliferation of M133 and S358 CD4 or S510 CD8 T cells, the latter cells were obtained from mice infected with virus lacking expression of the M133 epitope (rJ2.2.M Y135Q ).", [["M133", "ANATOMY", 55, 59], ["S358 CD4", "ANATOMY", 64, 72], ["S510 CD8 T cells", "ANATOMY", 76, 92], ["cells", "ANATOMY", 105, 110], ["M133", "CELL", 55, 59], ["S358 CD4", "CELL", 64, 72], ["cells", "CELL", 105, 110], ["mice", "ORGANISM", 130, 134], ["M133 and S358 CD4", "CELL_LINE", 55, 72], ["S510 CD8 T cells", "CELL_LINE", 76, 92], ["M133 epitope", "PROTEIN", 181, 193], ["J2.2", "PROTEIN", 196, 200], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 130, 134], ["proliferation", "TEST", 38, 51], ["M133", "TEST", 55, 59], ["CD4", "TEST", 69, 72], ["the latter cells", "TEST", 94, 110], ["virus", "PROBLEM", 149, 154]]], ["As shown in Figure 9B and C, M133 Tregs preferentially suppressed the proliferation of M133 Tconv.", [["Tregs", "ANATOMY", 34, 39], ["Tregs", "CELL", 34, 39], ["Tregs", "CELL_TYPE", 34, 39], ["M133 Tconv", "PROTEIN", 87, 97], ["proliferation", "OBSERVATION_MODIFIER", 70, 83]]], ["In agreement with the results shown in Figure 8E and our previous results [27] , M133 Tregs inhibited the proliferation of S358-specific CD4 T cells more potently than that of S510-specific CD8 T cells.DiscussionTregs specific for epitopes present at sites of autoimmune inflammation diminish disease more effectively than bulk Treg populations [28] .", [["Tregs", "ANATOMY", 86, 91], ["S358-specific CD4 T cells", "ANATOMY", 123, 148], ["S510", "ANATOMY", 176, 180], ["CD8 T cells", "ANATOMY", 190, 201], ["sites", "ANATOMY", 251, 256], ["Treg", "ANATOMY", 328, 332], ["autoimmune inflammation", "DISEASE", 260, 283], ["Tregs", "CELL", 86, 91], ["S358", "CELL", 123, 127], ["CD4 T cells", "CELL", 137, 148], ["S510", "GENE_OR_GENE_PRODUCT", 176, 180], ["CD8 T cells", "CELL", 190, 201], ["Tregs", "CELL_TYPE", 86, 91], ["S358-specific CD4 T cells", "CELL_LINE", 123, 148], ["S510", "PROTEIN", 176, 180], ["CD8 T cells", "CELL_TYPE", 190, 201], ["epitopes", "PROTEIN", 231, 239], ["bulk Treg populations", "CELL_TYPE", 323, 344], ["Tregs", "PROBLEM", 86, 91], ["the proliferation", "TEST", 102, 119], ["S358", "TEST", 123, 127], ["S510", "TEST", 176, 180], ["epitopes", "PROBLEM", 231, 239], ["autoimmune inflammation diminish disease", "PROBLEM", 260, 300], ["proliferation", "OBSERVATION_MODIFIER", 106, 119], ["CD8 T cells", "OBSERVATION", 190, 201], ["autoimmune", "OBSERVATION_MODIFIER", 260, 270], ["inflammation", "OBSERVATION", 271, 283]]], ["Here we extend these results to mice with coronavirus-induced encephalitis and show that Tregs specific for a virus-specific CD4 T cell epitope are highly activated and protective.", [["Tregs", "ANATOMY", 89, 94], ["CD4 T cell", "ANATOMY", 125, 135], ["encephalitis", "DISEASE", 62, 74], ["mice", "ORGANISM", 32, 36], ["coronavirus", "ORGANISM", 42, 53], ["Tregs", "CELL", 89, 94], ["CD4", "GENE_OR_GENE_PRODUCT", 125, 128], ["Tregs", "CELL_TYPE", 89, 94], ["CD4 T cell epitope", "PROTEIN", 125, 143], ["mice", "SPECIES", 32, 36], ["coronavirus", "SPECIES", 42, 53], ["mice", "SPECIES", 32, 36], ["coronavirus-induced encephalitis", "PROBLEM", 42, 74], ["a virus", "PROBLEM", 108, 115], ["specific CD4 T cell epitope", "TREATMENT", 116, 143], ["encephalitis", "OBSERVATION", 62, 74]]], ["M133 Tregs proliferate, express cytokines, particularly the immunosuppressive cytokine IL-10, and suppress M133 Tconv proliferation in the DCLN.", [["Tregs", "ANATOMY", 5, 10], ["DCLN", "ANATOMY", 139, 143], ["M133", "CHEMICAL", 0, 4], ["M133", "CHEMICAL", 0, 4], ["Tregs", "CELL", 5, 10], ["IL-10", "GENE_OR_GENE_PRODUCT", 87, 92], ["M133 Tconv", "CELL", 107, 117], ["DCLN", "CANCER", 139, 143], ["M133", "CELL_LINE", 0, 4], ["Tregs", "CELL_TYPE", 5, 10], ["cytokines", "PROTEIN", 32, 41], ["immunosuppressive cytokine IL-10", "PROTEIN", 60, 92], ["M133", "SPECIES", 0, 4], ["Tregs proliferate", "PROBLEM", 5, 22], ["cytokines", "PROBLEM", 32, 41], ["the immunosuppressive cytokine IL", "TREATMENT", 56, 89]]], ["Further, they inhibit Tconv migration from the site of priming, the DCLN.", [["DCLN", "ANATOMY", 68, 72], ["Tconv", "GENE_OR_GENE_PRODUCT", 22, 27], ["DCLN", "CANCER", 68, 72], ["Tconv", "PROTEIN", 22, 27], ["DCLN", "DNA", 68, 72]]], ["After transfer to rJ2.2infected mice, M133 Tregs increase survival and decrease weight loss when compared to bulk populations of Tregs and decrease numbers and effector function of virus-specific CD4 T cells in the brain.", [["Tregs", "ANATOMY", 43, 48], ["Tregs", "ANATOMY", 129, 134], ["CD4 T cells", "ANATOMY", 196, 207], ["brain", "ANATOMY", 215, 220], ["M133", "CHEMICAL", 38, 42], ["weight loss", "DISEASE", 80, 91], ["mice", "ORGANISM", 32, 36], ["M133", "CELL", 38, 42], ["Tregs", "CELL", 43, 48], ["Tregs", "CELL", 129, 134], ["CD4 T cells", "CELL", 196, 207], ["brain", "ORGAN", 215, 220], ["Tregs", "CELL_TYPE", 43, 48], ["Tregs", "CELL_TYPE", 129, 134], ["CD4 T cells", "CELL_TYPE", 196, 207], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["M133", "SPECIES", 38, 42], ["decrease weight loss", "PROBLEM", 71, 91], ["Tregs", "PROBLEM", 129, 134], ["decrease numbers", "PROBLEM", 139, 155], ["effector function of virus", "PROBLEM", 160, 186], ["decrease", "OBSERVATION_MODIFIER", 71, 79], ["weight loss", "OBSERVATION", 80, 91], ["decrease", "OBSERVATION_MODIFIER", 139, 147], ["CD4 T cells", "OBSERVATION", 196, 207], ["brain", "ANATOMY", 215, 220]]], ["Many of these effects reflect Treg function in the DCLN, but additionally, microglia activation in the brain was diminished after M133 Treg transfer.", [["Treg", "ANATOMY", 30, 34], ["DCLN", "ANATOMY", 51, 55], ["microglia", "ANATOMY", 75, 84], ["brain", "ANATOMY", 103, 108], ["M133 Treg", "ANATOMY", 130, 139], ["Treg", "CELL", 30, 34], ["DCLN", "CANCER", 51, 55], ["microglia", "CELL", 75, 84], ["brain", "ORGAN", 103, 108], ["M133 Treg", "CELL", 130, 139], ["microglia", "CELL_TYPE", 75, 84], ["brain", "ANATOMY", 103, 108], ["diminished", "OBSERVATION_MODIFIER", 113, 123]]], ["We showed previously that large numbers of bulk Tregs could tamper the immune response in the infected brain, by causing a dimunition in total numbers of infiltrating cells, without affecting the cellular composition [7] .", [["Tregs", "ANATOMY", 48, 53], ["brain", "ANATOMY", 103, 108], ["infiltrating cells", "ANATOMY", 154, 172], ["cellular", "ANATOMY", 196, 204], ["Tregs", "CELL", 48, 53], ["brain", "ORGAN", 103, 108], ["cells", "CELL", 167, 172], ["cellular", "CELL", 196, 204], ["bulk Tregs", "CELL_TYPE", 43, 53], ["infiltrating cells", "CELL_TYPE", 154, 172], ["bulk Tregs", "PROBLEM", 43, 53], ["the immune response in the infected brain", "PROBLEM", 67, 108], ["infiltrating cells", "PROBLEM", 154, 172], ["large", "OBSERVATION_MODIFIER", 26, 31], ["numbers", "OBSERVATION_MODIFIER", 32, 39], ["bulk Tregs", "OBSERVATION", 43, 53], ["immune response", "OBSERVATION", 71, 86], ["infected", "OBSERVATION", 94, 102], ["brain", "ANATOMY", 103, 108], ["total", "OBSERVATION_MODIFIER", 137, 142], ["numbers", "OBSERVATION_MODIFIER", 143, 150], ["infiltrating cells", "OBSERVATION", 154, 172], ["without", "UNCERTAINTY", 174, 181], ["cellular", "OBSERVATION_MODIFIER", 196, 204], ["composition", "OBSERVATION_MODIFIER", 205, 216]]], ["However, the use of virus epitope-specific Tregs allowed for a targeted immune response with effects primarily on T cells responding to the same epitope, which are pathogenic in this case.", [["Tregs", "ANATOMY", 43, 48], ["T cells", "ANATOMY", 114, 121], ["Tregs", "CELL", 43, 48], ["T cells", "CELL", 114, 121], ["Tregs", "CELL_TYPE", 43, 48], ["T cells", "CELL_TYPE", 114, 121], ["virus epitope", "TREATMENT", 20, 33], ["Tregs", "TREATMENT", 43, 48], ["T cells", "TREATMENT", 114, 121]]], ["It should be noted that treatment with pathogen-specific Tregs is not always beneficial.", [["Tregs", "CELL", 57, 62], ["Tregs", "CELL_TYPE", 57, 62], ["pathogen-specific Tregs", "TREATMENT", 39, 62]]], ["In mice infected with Mtb, adoptive transfer of pathogen epitope-specific Tregs resulted in delayed effector CD4 and CD8 T cell responses to non-cognate Mtb epitopes in the draining lymph nodes and lungs and subsequent increased bacterial load [19] .DiscussionVirus-specific Tregs were primed in the same draining lymph nodes as effector T cells, but the kinetics of proliferation and cytokine production were different.", [["Tregs", "ANATOMY", 74, 79], ["effector CD4", "ANATOMY", 100, 112], ["CD8 T cell", "ANATOMY", 117, 127], ["lymph nodes", "ANATOMY", 182, 193], ["lungs", "ANATOMY", 198, 203], ["Tregs", "ANATOMY", 275, 280], ["lymph nodes", "ANATOMY", 314, 325], ["effector T cells", "ANATOMY", 329, 345], ["mice", "ORGANISM", 3, 7], ["Tregs", "CELL", 74, 79], ["CD4", "GENE_OR_GENE_PRODUCT", 109, 112], ["CD8", "GENE_OR_GENE_PRODUCT", 117, 120], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 182, 193], ["lungs", "ORGAN", 198, 203], ["Tregs", "CELL", 275, 280], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 314, 325], ["effector T cells", "CELL", 329, 345], ["pathogen epitope", "PROTEIN", 48, 64], ["Tregs", "CELL_TYPE", 74, 79], ["CD4", "PROTEIN", 109, 112], ["Mtb epitopes", "PROTEIN", 153, 165], ["Tregs", "CELL_TYPE", 275, 280], ["effector T cells", "CELL_TYPE", 329, 345], ["cytokine", "PROTEIN", 385, 393], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["Mtb", "PROBLEM", 22, 25], ["pathogen epitope", "TREATMENT", 48, 64], ["Tregs", "PROBLEM", 74, 79], ["delayed effector CD4", "PROBLEM", 92, 112], ["non-cognate Mtb epitopes", "PROBLEM", 141, 165], ["subsequent increased bacterial load", "PROBLEM", 208, 243], ["DiscussionVirus", "TEST", 250, 265], ["Tregs", "TREATMENT", 275, 280], ["effector T cells", "PROBLEM", 329, 345], ["proliferation", "PROBLEM", 367, 380], ["cytokine production", "PROBLEM", 385, 404], ["infected", "OBSERVATION_MODIFIER", 8, 16], ["Mtb", "OBSERVATION", 22, 25], ["delayed", "OBSERVATION_MODIFIER", 92, 99], ["effector CD4", "OBSERVATION", 100, 112], ["draining", "ANATOMY_MODIFIER", 173, 181], ["lymph nodes", "OBSERVATION", 182, 193], ["lungs", "ANATOMY", 198, 203], ["increased", "OBSERVATION_MODIFIER", 219, 228], ["bacterial load", "OBSERVATION", 229, 243], ["lymph nodes", "OBSERVATION", 314, 325], ["proliferation", "OBSERVATION_MODIFIER", 367, 380], ["cytokine production", "OBSERVATION", 385, 404]]], ["The onset of Treg proliferation lagged by approximately one day, possibly because Treg proliferation was dependent upon IL-2 production by Tconv in the DCLN.", [["Treg", "ANATOMY", 13, 17], ["Treg", "ANATOMY", 82, 86], ["DCLN", "ANATOMY", 152, 156], ["Treg", "CELL", 13, 17], ["Treg", "CELL", 82, 86], ["IL-2", "GENE_OR_GENE_PRODUCT", 120, 124], ["Tconv", "GENE_OR_GENE_PRODUCT", 139, 144], ["DCLN", "CANCER", 152, 156], ["Treg", "CELL_TYPE", 13, 17], ["IL", "PROTEIN", 120, 122], ["Tconv", "PROTEIN", 139, 144], ["Treg proliferation", "PROBLEM", 13, 31], ["Treg proliferation", "PROBLEM", 82, 100], ["Treg proliferation", "OBSERVATION", 13, 31], ["possibly because", "UNCERTAINTY", 65, 81], ["Treg proliferation", "OBSERVATION", 82, 100]]], ["This lag resulted in a lack of suppression of initial Tconv activation.", [["Tconv", "GENE_OR_GENE_PRODUCT", 54, 59], ["Tconv", "PROTEIN", 54, 59], ["initial Tconv activation", "PROBLEM", 46, 70]]], ["However, even by 1-2 divisions, Tconv downregulated CD69 and CD25 expression in the presence of M133 Tregs (Figure 6B) , suggesting decreased activation compared to mice that received only M133 Tconv.", [["M133 Tregs", "ANATOMY", 96, 106], ["Tconv", "GENE_OR_GENE_PRODUCT", 32, 37], ["CD69", "GENE_OR_GENE_PRODUCT", 52, 56], ["CD25", "GENE_OR_GENE_PRODUCT", 61, 65], ["M133 Tregs", "CELL", 96, 106], ["mice", "ORGANISM", 165, 169], ["CD69", "PROTEIN", 52, 56], ["CD25", "PROTEIN", 61, 65], ["M133 Tregs", "CELL_TYPE", 96, 106], ["M133 Tconv", "PROTEIN", 189, 199], ["mice", "SPECIES", 165, 169], ["mice", "SPECIES", 165, 169], ["CD69", "TEST", 52, 56], ["decreased activation", "PROBLEM", 132, 152], ["CD25 expression", "OBSERVATION", 61, 76], ["decreased activation", "OBSERVATION", 132, 152]]], ["Notably, even after Treg proliferation began, the M133 Tconv/Treg ratio continued to increase in the DCLN and CLN, the sites of priming, but not the spleen or ILN ( Figure 3C ), suggesting preferential retention or proliferation and perhaps, recruitment of Tconv.", [["Treg", "ANATOMY", 20, 24], ["Treg", "ANATOMY", 61, 65], ["DCLN", "ANATOMY", 101, 105], ["CLN", "ANATOMY", 110, 113], ["sites", "ANATOMY", 119, 124], ["spleen", "ANATOMY", 149, 155], ["Treg", "CELL", 20, 24], ["Tconv", "GENE_OR_GENE_PRODUCT", 55, 60], ["Treg", "GENE_OR_GENE_PRODUCT", 61, 65], ["DCLN", "CANCER", 101, 105], ["CLN", "CANCER", 110, 113], ["spleen", "ORGAN", 149, 155], ["Tconv", "GENE_OR_GENE_PRODUCT", 257, 262], ["Tconv", "PROTEIN", 55, 60], ["Tconv", "PROTEIN", 257, 262], ["Treg proliferation", "PROBLEM", 20, 38], ["the M133 Tconv/Treg ratio", "TEST", 46, 71], ["preferential retention", "PROBLEM", 189, 211], ["proliferation", "PROBLEM", 215, 228], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["spleen", "ANATOMY", 149, 155], ["ILN", "ANATOMY", 159, 162], ["suggesting", "UNCERTAINTY", 178, 188], ["preferential retention", "OBSERVATION", 189, 211], ["proliferation", "OBSERVATION", 215, 228]]], ["Preferential M133-specific effector CD4 T cell expansion also occurs in the natural infection because the ratio of M133-specific Tregs/T effector cells in the na\u00efve precursor pool is 0.15 but this decreases to 0.02 in the infected brain [12] .DiscussionIt is noteworthy that M133 Tconv proliferation appeared to increase in the DCLN at day 3 p.i. in the presence of cotransferred M133 Tregs.", [["CD4 T cell", "ANATOMY", 36, 46], ["Tregs/T effector cells", "ANATOMY", 129, 151], ["na\u00efve precursor pool", "ANATOMY", 159, 179], ["brain", "ANATOMY", 231, 236], ["DCLN", "ANATOMY", 328, 332], ["M133 Tregs", "ANATOMY", 380, 390], ["infection", "DISEASE", 84, 93], ["M133", "GENE_OR_GENE_PRODUCT", 13, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 36, 39], ["M133", "GENE_OR_GENE_PRODUCT", 115, 119], ["Tregs", "CELL", 129, 134], ["T effector cells", "CELL", 135, 151], ["brain", "ORGAN", 231, 236], ["M133 Tconv", "CELL", 275, 285], ["DCLN", "CANCER", 328, 332], ["M133 Tregs", "CELL", 380, 390], ["M133", "PROTEIN", 13, 17], ["CD4", "PROTEIN", 36, 39], ["M133", "PROTEIN", 115, 119], ["Tregs", "CELL_TYPE", 129, 134], ["T effector cells", "CELL_TYPE", 135, 151], ["cotransferred M133 Tregs", "CELL_LINE", 366, 390], ["Preferential M133", "TEST", 0, 17], ["the natural infection", "PROBLEM", 72, 93], ["the ratio", "TEST", 102, 111], ["M133", "TEST", 115, 119], ["cell expansion", "OBSERVATION", 42, 56], ["natural", "OBSERVATION_MODIFIER", 76, 83], ["infection", "OBSERVATION", 84, 93], ["infected", "OBSERVATION", 222, 230], ["brain", "ANATOMY", 231, 236], ["increase", "OBSERVATION_MODIFIER", 312, 320]]], ["However, rather than enhancing proliferation at this time, we postulate that Tregs actually function to inhibit Tconv egress from the DCLN, resulting in the retention of proliferated M133 T conv.", [["Tregs", "ANATOMY", 77, 82], ["DCLN", "ANATOMY", 134, 138], ["Tregs", "CELL", 77, 82], ["Tconv", "GENE_OR_GENE_PRODUCT", 112, 117], ["DCLN", "GENE_OR_GENE_PRODUCT", 134, 138], ["M133 T conv", "GENE_OR_GENE_PRODUCT", 183, 194], ["Tregs", "CELL_TYPE", 77, 82], ["Tconv", "PROTEIN", 112, 117], ["M133 T conv", "CELL_LINE", 183, 194], ["enhancing proliferation", "PROBLEM", 21, 44], ["enhancing", "OBSERVATION_MODIFIER", 21, 30], ["proliferation", "OBSERVATION", 31, 44], ["retention", "OBSERVATION_MODIFIER", 157, 166]]], ["Consistent with this, fewer M133 Tconv were detected in the spleen at this time point after cotransfer ( Figure 5B) .", [["spleen", "ANATOMY", 60, 66], ["Tconv", "GENE_OR_GENE_PRODUCT", 33, 38], ["spleen", "ORGAN", 60, 66], ["M133 Tconv", "PROTEIN", 28, 38], ["spleen", "ANATOMY", 60, 66]]], ["These results are similar to those obtained from FTY720-treated mice (Figure 4) , which showed that when T cell egress was blocked, proliferating cells accumulated in the draining lymph nodes but were not detected in distal lymphoid tissues.", [["T cell", "ANATOMY", 105, 111], ["cells", "ANATOMY", 146, 151], ["lymph nodes", "ANATOMY", 180, 191], ["distal lymphoid tissues", "ANATOMY", 217, 240], ["FTY720", "CHEMICAL", 49, 55], ["FTY720", "CHEMICAL", 49, 55], ["FTY720", "SIMPLE_CHEMICAL", 49, 55], ["mice", "ORGANISM", 64, 68], ["T cell", "CELL", 105, 111], ["cells", "CELL", 146, 151], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 180, 191], ["distal lymphoid tissues", "TISSUE", 217, 240], ["proliferating cells", "CELL_TYPE", 132, 151], ["mice", "SPECIES", 64, 68], ["T cell egress", "PROBLEM", 105, 118], ["proliferating cells", "PROBLEM", 132, 151], ["the draining lymph nodes", "PROBLEM", 167, 191], ["proliferating cells", "OBSERVATION", 132, 151], ["draining", "OBSERVATION_MODIFIER", 171, 179], ["lymph nodes", "OBSERVATION", 180, 191], ["not detected", "UNCERTAINTY", 201, 213], ["distal", "ANATOMY_MODIFIER", 217, 223], ["lymphoid tissues", "OBSERVATION", 224, 240]]], ["Tconv activation in the DCLN was also diminished in the presence of transferred M133 Tregs ( Figure 6B ).", [["DCLN", "ANATOMY", 24, 28], ["M133 Tregs", "ANATOMY", 80, 90], ["Tconv", "GENE_OR_GENE_PRODUCT", 0, 5], ["DCLN", "CANCER", 24, 28], ["M133 Tregs", "CELL", 80, 90], ["Tconv", "PROTEIN", 0, 5], ["DCLN", "DNA", 24, 28], ["M133 Tregs", "CELL_LINE", 80, 90], ["diminished", "OBSERVATION_MODIFIER", 38, 48]]], ["Tregs use a multitude of mechanisms to suppress Tconv and dendritic cell function, including the production of IL-10 [1, 29] .", [["Tregs", "ANATOMY", 0, 5], ["dendritic cell", "ANATOMY", 58, 72], ["Tregs", "CELL", 0, 5], ["Tconv", "GENE_OR_GENE_PRODUCT", 48, 53], ["dendritic cell", "CELL", 58, 72], ["IL-10", "GENE_OR_GENE_PRODUCT", 111, 116], ["Tregs", "CELL_TYPE", 0, 5], ["IL", "PROTEIN", 111, 113], ["dendritic cell function", "OBSERVATION", 58, 81]]], ["IL-10 was expressed by M133 Tregs within 4 divisions and likely contributed to the suppression of Tconv proliferation in the DCLN (Figure 7) .", [["M133", "ANATOMY", 23, 27], ["Tregs", "ANATOMY", 28, 33], ["DCLN", "ANATOMY", 125, 129], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["M133", "CELL", 23, 27], ["Tregs", "CELL", 28, 33], ["Tconv", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL-10", "PROTEIN", 0, 5], ["Tregs", "CELL_TYPE", 28, 33], ["Tconv", "PROTEIN", 98, 103], ["M133", "SPECIES", 23, 27], ["Tconv proliferation", "PROBLEM", 98, 117], ["likely contributed to", "UNCERTAINTY", 57, 78], ["Tconv proliferation", "OBSERVATION", 98, 117]]], ["Collectively, these results suggest that the relative numbers of virus-specific Tconv in the DCLN, spleen and brain of mice that received M133 Tregs, compared to those did not, reflect a complicated interplay between Treg effects on Tconv activation, proliferation and migration.DiscussionIn contrast to these results, Tregs were required for optimal migration of inflammatory cells including dendritic cells to the site of infection in mice infected with genital HSV, lymphocytic choriomeningitis virus or respiratory syncytial virus.", [["DCLN", "ANATOMY", 93, 97], ["spleen", "ANATOMY", 99, 105], ["brain", "ANATOMY", 110, 115], ["M133 Tregs", "ANATOMY", 138, 148], ["Treg", "ANATOMY", 217, 221], ["Tregs", "ANATOMY", 319, 324], ["inflammatory cells", "ANATOMY", 364, 382], ["dendritic cells", "ANATOMY", 393, 408], ["site", "ANATOMY", 416, 420], ["infection", "DISEASE", 424, 433], ["genital HSV, lymphocytic choriomeningitis virus", "DISEASE", 456, 503], ["respiratory syncytial virus", "DISEASE", 507, 534], ["Tconv", "GENE_OR_GENE_PRODUCT", 80, 85], ["DCLN", "CANCER", 93, 97], ["spleen", "ORGAN", 99, 105], ["brain", "ORGAN", 110, 115], ["mice", "ORGANISM", 119, 123], ["M133 Tregs", "CELL", 138, 148], ["Treg", "CELL", 217, 221], ["Tconv", "GENE_OR_GENE_PRODUCT", 233, 238], ["Tregs", "CELL", 319, 324], ["inflammatory cells", "CELL", 364, 382], ["dendritic cells", "CELL", 393, 408], ["mice", "ORGANISM", 437, 441], ["genital HSV", "ORGANISM", 456, 467], ["lymphocytic choriomeningitis virus", "ORGANISM", 469, 503], ["respiratory syncytial virus", "ORGANISM", 507, 534], ["Tconv", "PROTEIN", 80, 85], ["M133 Tregs", "CELL_TYPE", 138, 148], ["Tregs", "CELL_TYPE", 319, 324], ["inflammatory cells", "CELL_TYPE", 364, 382], ["dendritic cells", "CELL_TYPE", 393, 408], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 437, 441], ["lymphocytic choriomeningitis virus", "SPECIES", 469, 503], ["respiratory syncytial virus", "SPECIES", 507, 534], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 437, 441], ["HSV", "SPECIES", 464, 467], ["lymphocytic choriomeningitis virus", "SPECIES", 469, 503], ["respiratory syncytial virus", "SPECIES", 507, 534], ["virus", "TEST", 65, 70], ["Tconv activation", "TREATMENT", 233, 249], ["proliferation", "PROBLEM", 251, 264], ["Tregs", "TREATMENT", 319, 324], ["inflammatory cells", "PROBLEM", 364, 382], ["dendritic cells", "PROBLEM", 393, 408], ["infection", "PROBLEM", 424, 433], ["genital HSV", "PROBLEM", 456, 467], ["lymphocytic choriomeningitis virus", "PROBLEM", 469, 503], ["respiratory syncytial virus", "PROBLEM", 507, 534], ["virus", "OBSERVATION", 65, 70], ["spleen", "ANATOMY", 99, 105], ["brain", "ANATOMY", 110, 115], ["complicated", "OBSERVATION", 187, 198], ["Treg", "OBSERVATION", 217, 221], ["proliferation", "OBSERVATION_MODIFIER", 251, 264], ["migration", "OBSERVATION_MODIFIER", 269, 278], ["inflammatory cells", "OBSERVATION", 364, 382], ["dendritic cells", "OBSERVATION", 393, 408], ["infection", "OBSERVATION", 424, 433], ["genital HSV", "ANATOMY", 456, 467], ["lymphocytic choriomeningitis", "OBSERVATION", 469, 497], ["respiratory syncytial virus", "OBSERVATION", 507, 534]]], ["In their absence, virus clearance was delayed and survival decreased [2, 3] .", [["virus clearance", "PROBLEM", 18, 33]]], ["In these studies, Tregs were depleted prior to infection, a time when very few Tregs are virus-specific [12, 15] .", [["Tregs", "ANATOMY", 18, 23], ["Tregs", "ANATOMY", 79, 84], ["infection", "DISEASE", 47, 56], ["Tregs", "CELL", 18, 23], ["Tregs", "CELL", 79, 84], ["Tregs", "CELL_TYPE", 18, 23], ["Tregs", "CELL_TYPE", 79, 84], ["these studies", "TEST", 3, 16], ["infection", "PROBLEM", 47, 56], ["infection", "OBSERVATION", 47, 56]]], ["Together, the results from these studies and the present one suggest that non virus-specific Tregs are important for initial egress from lymphoid tissue to sites of inflammation, but virus-specific Tregs, which would be induced later in the infection, function to inhibit migration of virus-specific T cells to the infected site.DiscussionM133 Tregs also decreased the numbers of co-transferred M133 Tconv in the infected brain ( Figure 5B ).", [["Tregs", "ANATOMY", 93, 98], ["lymphoid tissue", "ANATOMY", 137, 152], ["sites", "ANATOMY", 156, 161], ["Tregs", "ANATOMY", 198, 203], ["T cells", "ANATOMY", 300, 307], ["site", "ANATOMY", 324, 328], ["Tregs", "ANATOMY", 344, 349], ["brain", "ANATOMY", 422, 427], ["inflammation", "DISEASE", 165, 177], ["infection", "DISEASE", 241, 250], ["DiscussionM133", "CHEMICAL", 329, 343], ["non virus", "ORGANISM", 74, 83], ["Tregs", "CELL", 93, 98], ["lymphoid tissue", "TISSUE", 137, 152], ["Tregs", "CELL", 198, 203], ["T cells", "CELL", 300, 307], ["Tregs", "CELL", 344, 349], ["M133 Tconv", "GENE_OR_GENE_PRODUCT", 395, 405], ["brain", "ORGAN", 422, 427], ["Tregs", "CELL_TYPE", 93, 98], ["Tregs", "CELL_TYPE", 198, 203], ["virus-specific T cells", "CELL_TYPE", 285, 307], ["Tregs", "CELL_TYPE", 344, 349], ["M133 Tconv", "PROTEIN", 395, 405], ["these studies", "TEST", 27, 40], ["non virus", "PROBLEM", 74, 83], ["initial egress from lymphoid tissue", "PROBLEM", 117, 152], ["inflammation", "PROBLEM", 165, 177], ["virus", "PROBLEM", 183, 188], ["the infection", "PROBLEM", 237, 250], ["virus", "PROBLEM", 285, 290], ["lymphoid tissue", "OBSERVATION", 137, 152], ["inflammation", "OBSERVATION", 165, 177], ["infection", "OBSERVATION", 241, 250], ["infected", "OBSERVATION", 315, 323], ["decreased", "OBSERVATION_MODIFIER", 355, 364], ["numbers", "OBSERVATION_MODIFIER", 369, 376], ["infected brain", "ANATOMY", 413, 427]]], ["M133 Tregs, if transferred alone, suppressed the endogenous M133 and, to a lesser extent, S358-specific CD4 T cell responses ( Figure 8E ).", [["Tregs", "ANATOMY", 5, 10], ["CD4 T cell", "ANATOMY", 104, 114], ["M133", "CHEMICAL", 0, 4], ["M133", "CHEMICAL", 0, 4], ["Tregs", "CELL", 5, 10], ["M133", "GENE_OR_GENE_PRODUCT", 60, 64], ["S358", "GENE_OR_GENE_PRODUCT", 90, 94], ["M133", "CELL_LINE", 0, 4], ["Tregs", "CELL_TYPE", 5, 10], ["endogenous M133", "PROTEIN", 49, 64], ["S358", "PROTEIN", 90, 94], ["CD4", "PROTEIN", 104, 107], ["M133", "SPECIES", 0, 4], ["lesser extent", "OBSERVATION_MODIFIER", 75, 88]]], ["Similar results were obtained when the suppressive ability of M133 Tregs was examined in vitro ( Figure 9 ).", [["M133 Tregs", "ANATOMY", 62, 72], ["M133 Tregs", "CELL", 62, 72], ["M133 Tregs", "CELL_LINE", 62, 72]]], ["Preferential suppression of the M133 Tconv compared to the S358 Tconv response may reflect antigen competition between endogenous M133 Tconv and transferred M133 Tregs.", [["M133 Tregs", "ANATOMY", 157, 167], ["M133", "GENE_OR_GENE_PRODUCT", 32, 36], ["S358 Tconv", "GENE_OR_GENE_PRODUCT", 59, 69], ["Tconv", "GENE_OR_GENE_PRODUCT", 135, 140], ["M133 Tregs", "CELL", 157, 167], ["M133 Tconv", "PROTEIN", 32, 42], ["Tconv", "PROTEIN", 64, 69], ["M133 Tconv", "PROTEIN", 130, 140], ["M133 Tregs", "CELL_LINE", 157, 167]]], ["This suppressive effect was not generalized since the number and frequency of cells responding to CD8 T cell epitopes S510 and S598 in mice were not changed by the presence of M133 Tregs ( Figure 8E ) and the proliferation of S510-specific CD8 T cells in vitro was less inhibited by M133 Tregs (Figure 9 ).", [["cells", "ANATOMY", 78, 83], ["CD8", "ANATOMY", 98, 101], ["T cell", "ANATOMY", 102, 108], ["M133 Tregs", "ANATOMY", 176, 186], ["S510-specific CD8 T cells", "ANATOMY", 226, 251], ["M133 Tregs", "ANATOMY", 283, 293], ["cells", "CELL", 78, 83], ["CD8", "GENE_OR_GENE_PRODUCT", 98, 101], ["T cell", "CELL", 102, 108], ["S598", "GENE_OR_GENE_PRODUCT", 127, 131], ["mice", "ORGANISM", 135, 139], ["M133 Tregs", "CELL", 176, 186], ["S510", "CELL", 226, 230], ["CD8", "GENE_OR_GENE_PRODUCT", 240, 243], ["M133 Tregs", "CELL", 283, 293], ["CD8", "PROTEIN", 98, 101], ["T cell epitopes", "PROTEIN", 102, 117], ["S510", "PROTEIN", 118, 122], ["S598", "PROTEIN", 127, 131], ["M133 Tregs", "CELL_TYPE", 176, 186], ["S510-specific CD8 T cells", "CELL_LINE", 226, 251], ["M133 Tregs", "CELL_TYPE", 283, 293], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["T cell epitopes", "TEST", 102, 117], ["the proliferation", "TEST", 205, 222], ["S510", "TEST", 226, 230]]], ["This lack of effect on CD8 T cell responses in the brain may explain why virus clearance is not changed in the presence of M133 Tregs ( Figure 8D) ; virus clearance is largely CD8 T cell dependent [20] .", [["CD8 T cell", "ANATOMY", 23, 33], ["brain", "ANATOMY", 51, 56], ["M133 Tregs", "ANATOMY", 123, 133], ["CD8 T cell", "ANATOMY", 176, 186], ["CD8 T cell", "CELL", 23, 33], ["brain", "ORGAN", 51, 56], ["M133 Tregs", "CELL", 123, 133], ["CD8", "GENE_OR_GENE_PRODUCT", 176, 179], ["CD8", "PROTEIN", 23, 26], ["M133 Tregs", "CELL_TYPE", 123, 133], ["CD8", "PROTEIN", 176, 179], ["CD8 T cell responses in the brain", "PROBLEM", 23, 56], ["virus clearance", "PROBLEM", 73, 88], ["virus clearance", "TEST", 149, 164], ["brain", "ANATOMY", 51, 56], ["may explain", "UNCERTAINTY", 57, 68]]], ["The diminished numbers of M133-specific Tconv reflected decreased proliferation in the DCLN, but also likely resulted from decreased expression of CXCR3 on M133 Tconv when M133 Tregs were co-transferred ( Figure 6E ).", [["DCLN", "ANATOMY", 87, 91], ["M133 Tregs", "ANATOMY", 172, 182], ["M133", "GENE_OR_GENE_PRODUCT", 26, 30], ["Tconv", "GENE_OR_GENE_PRODUCT", 40, 45], ["DCLN", "CANCER", 87, 91], ["CXCR3", "GENE_OR_GENE_PRODUCT", 147, 152], ["M133 Tregs", "CELL", 172, 182], ["M133", "PROTEIN", 26, 30], ["Tconv", "PROTEIN", 40, 45], ["CXCR3", "PROTEIN", 147, 152], ["M133 Tconv", "PROTEIN", 156, 166], ["M133 Tregs", "CELL_LINE", 172, 182], ["The diminished numbers", "PROBLEM", 0, 22], ["M133", "TEST", 26, 30], ["decreased proliferation in the DCLN", "PROBLEM", 56, 91], ["CXCR3", "TEST", 147, 152], ["diminished", "OBSERVATION_MODIFIER", 4, 14], ["numbers", "OBSERVATION_MODIFIER", 15, 22], ["decreased", "OBSERVATION_MODIFIER", 56, 65], ["proliferation", "OBSERVATION", 66, 79], ["decreased", "OBSERVATION_MODIFIER", 123, 132]]], ["Treg-mediated downregulation of CXCR3 expression on Tconv in draining lymph nodes was also observed in mice with autoimmune diabetes [30] .", [["lymph nodes", "ANATOMY", 70, 81], ["autoimmune diabetes", "DISEASE", 113, 132], ["Treg", "CELL", 0, 4], ["CXCR3", "GENE_OR_GENE_PRODUCT", 32, 37], ["Tconv", "GENE_OR_GENE_PRODUCT", 52, 57], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 70, 81], ["mice", "ORGANISM", 103, 107], ["CXCR3", "PROTEIN", 32, 37], ["Tconv", "PROTEIN", 52, 57], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 103, 107], ["CXCR3 expression", "PROBLEM", 32, 48], ["draining lymph nodes", "PROBLEM", 61, 81], ["autoimmune diabetes", "PROBLEM", 113, 132], ["draining", "OBSERVATION_MODIFIER", 61, 69], ["lymph nodes", "OBSERVATION", 70, 81]]], ["Further, transfer of M133 Tregs resulted in decreased expression of MHC class II on microglia, which potentially diminished their ability to activate T cells ( Figure 8I ).", [["M133 Tregs", "ANATOMY", 21, 31], ["microglia", "ANATOMY", 84, 93], ["T cells", "ANATOMY", 150, 157], ["M133 Tregs", "CELL", 21, 31], ["MHC class II", "GENE_OR_GENE_PRODUCT", 68, 80], ["microglia", "CELL", 84, 93], ["T cells", "CELL", 150, 157], ["M133 Tregs", "CELL_LINE", 21, 31], ["MHC class II", "PROTEIN", 68, 80], ["microglia", "CELL_TYPE", 84, 93], ["T cells", "CELL_TYPE", 150, 157]]], ["In addition, M133 Tregs entered the brain at earlier times than M133 Tconv ( Figure 3D ).", [["M133 Tregs", "ANATOMY", 13, 23], ["brain", "ANATOMY", 36, 41], ["M133 Tregs", "CELL", 13, 23], ["brain", "ORGAN", 36, 41], ["M133 Tregs", "CELL_LINE", 13, 23], ["brain", "ANATOMY", 36, 41]]], ["Together, these results suggest that Tregs directly suppressed microglia activation, but it is also possible that decreased numbers of Tconv in the brain contributed to lower microglial MHC class II expression.DiscussionTregs in the infected brain expressed IFN-c, albeit at lower levels on a per cell basis when compared to Tconv (Figure 8 , F and G).", [["Tregs", "ANATOMY", 37, 42], ["microglia", "ANATOMY", 63, 72], ["brain", "ANATOMY", 148, 153], ["Tregs", "ANATOMY", 220, 225], ["brain", "ANATOMY", 242, 247], ["cell", "ANATOMY", 297, 301], ["Tregs", "CELL", 37, 42], ["microglia", "CELL", 63, 72], ["Tconv", "GENE_OR_GENE_PRODUCT", 135, 140], ["brain", "ORGAN", 148, 153], ["MHC class II", "GENE_OR_GENE_PRODUCT", 186, 198], ["Tregs", "CELL", 220, 225], ["brain", "ORGAN", 242, 247], ["IFN-c", "GENE_OR_GENE_PRODUCT", 258, 263], ["cell", "CELL", 297, 301], ["Tregs", "CELL_TYPE", 37, 42], ["microglia", "CELL_TYPE", 63, 72], ["Tconv", "PROTEIN", 135, 140], ["MHC class II", "PROTEIN", 186, 198], ["Tregs", "CELL_TYPE", 220, 225], ["IFN-c", "PROTEIN", 258, 263], ["Tconv", "PROTEIN", 325, 330], ["Tregs directly suppressed microglia activation", "PROBLEM", 37, 83], ["decreased numbers of Tconv in the brain", "PROBLEM", 114, 153], ["suppressed", "OBSERVATION_MODIFIER", 52, 62], ["microglia activation", "OBSERVATION", 63, 83], ["decreased", "OBSERVATION_MODIFIER", 114, 123], ["numbers", "OBSERVATION_MODIFIER", 124, 131], ["brain", "ANATOMY", 148, 153], ["lower", "ANATOMY_MODIFIER", 169, 174], ["microglial MHC", "OBSERVATION", 175, 189], ["brain", "ANATOMY", 242, 247]]], ["We and others have shown that the expression of IFN-c does not abrogate the immunosuppressive functions of Tregs in vitro or in mice and is even required for optimal activity in some settings [12, 27, 31, 32] .", [["Tregs", "ANATOMY", 107, 112], ["IFN-c", "GENE_OR_GENE_PRODUCT", 48, 53], ["Tregs", "CELL", 107, 112], ["mice", "ORGANISM", 128, 132], ["IFN-c", "PROTEIN", 48, 53], ["Tregs", "CELL_TYPE", 107, 112], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 128, 132], ["Tregs in vitro", "TREATMENT", 107, 121]]], ["However, Treg-expressed IFN-c may contribute to the inflammatory milieu, although whether this is physiologically significant will require further work.", [["Treg", "ANATOMY", 9, 13], ["Treg", "CELL", 9, 13], ["IFN-c", "GENE_OR_GENE_PRODUCT", 24, 29], ["Treg", "CELL_TYPE", 9, 13], ["IFN-c", "PROTEIN", 24, 29], ["the inflammatory milieu", "PROBLEM", 48, 71], ["inflammatory", "OBSERVATION", 52, 64]]], ["It is also notable that while Tregs in the brains of rJ2.2-infected mice expressed IFN-c, IFN-c expression by Tregs has not been detected in the lungs or draining lymph nodes of mice infected with Mtb or influenza A virus [10, 13] .", [["Tregs", "ANATOMY", 30, 35], ["brains", "ANATOMY", 43, 49], ["Tregs", "ANATOMY", 110, 115], ["lungs", "ANATOMY", 145, 150], ["lymph nodes", "ANATOMY", 163, 174], ["Tregs", "CELL", 30, 35], ["brains", "ORGAN", 43, 49], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 53, 58], ["mice", "ORGANISM", 68, 72], ["IFN-c", "GENE_OR_GENE_PRODUCT", 83, 88], ["IFN-c", "GENE_OR_GENE_PRODUCT", 90, 95], ["Tregs", "CELL", 110, 115], ["lungs", "ORGAN", 145, 150], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 163, 174], ["mice", "ORGANISM", 178, 182], ["Mtb", "GENE_OR_GENE_PRODUCT", 197, 200], ["influenza A virus", "ORGANISM", 204, 221], ["Tregs", "CELL_TYPE", 30, 35], ["IFN", "PROTEIN", 83, 86], ["IFN", "PROTEIN", 90, 93], ["Tregs", "CELL_TYPE", 110, 115], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 178, 182], ["influenza A virus", "SPECIES", 204, 221], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 178, 182], ["influenza A virus", "SPECIES", 204, 221], ["draining lymph nodes", "PROBLEM", 154, 174], ["Mtb", "PROBLEM", 197, 200], ["influenza A virus", "PROBLEM", 204, 221], ["lungs", "ANATOMY", 145, 150], ["draining", "OBSERVATION_MODIFIER", 154, 162], ["lymph nodes", "OBSERVATION", 163, 174]]], ["Although M133 Tregs ameliorated clinical disease in rJ2.2-infected mice, their immunosuppressive efficacy in the inflamed brain may have been suboptimal.", [["M133", "ANATOMY", 9, 13], ["Tregs", "ANATOMY", 14, 19], ["brain", "ANATOMY", 122, 127], ["M133", "CHEMICAL", 9, 13], ["M133", "CHEMICAL", 9, 13], ["M133", "CELL", 9, 13], ["Tregs", "CELL", 14, 19], ["rJ2.2", "ORGANISM", 52, 57], ["mice", "ORGANISM", 67, 71], ["brain", "ORGAN", 122, 127], ["M133", "CELL_LINE", 9, 13], ["Tregs", "CELL_TYPE", 14, 19], ["mice", "SPECIES", 67, 71], ["M133", "SPECIES", 9, 13], ["mice", "SPECIES", 67, 71], ["Tregs ameliorated clinical disease in rJ2.2", "PROBLEM", 14, 57], ["infected mice", "PROBLEM", 58, 71], ["infected mice", "OBSERVATION_MODIFIER", 58, 71], ["immunosuppressive efficacy", "OBSERVATION", 79, 105], ["inflamed", "ANATOMY_MODIFIER", 113, 121], ["brain", "ANATOMY", 122, 127]]], ["In mice with experimental autoimmune encephalomyelitis, myelin-specific Tregs were detected in the brain and spinal cord, but their function was inhibited by TNF and IL-6 [33] ; these two cytokines are expressed in the rJ2.2-infected CNS [20, 34] .DiscussionTransfer of M133 compared to bulk Tregs resulted in improved outcomes (Figure 8 , B and C) because these cells, unlike bulk Tregs, underwent proliferation, entered the infected brain at even earlier times than M133 Tconv ( Figure 3D) , and decreased the number of pathogenic M133-specific CD4 T cells at this site ( Figure 8E) .", [["myelin", "ANATOMY", 56, 62], ["Tregs", "ANATOMY", 72, 77], ["brain", "ANATOMY", 99, 104], ["spinal cord", "ANATOMY", 109, 120], ["CNS", "ANATOMY", 234, 237], ["Tregs", "ANATOMY", 292, 297], ["cells", "ANATOMY", 363, 368], ["Tregs", "ANATOMY", 382, 387], ["brain", "ANATOMY", 435, 440], ["CD4 T cells", "ANATOMY", 547, 558], ["autoimmune encephalomyelitis", "DISEASE", 26, 54], ["M133", "CHEMICAL", 270, 274], ["mice", "ORGANISM", 3, 7], ["myelin", "GENE_OR_GENE_PRODUCT", 56, 62], ["Tregs", "CELL", 72, 77], ["brain", "ORGAN", 99, 104], ["spinal cord", "ORGAN", 109, 120], ["TNF", "GENE_OR_GENE_PRODUCT", 158, 161], ["IL-6", "GENE_OR_GENE_PRODUCT", 166, 170], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 219, 224], ["CNS", "ANATOMICAL_SYSTEM", 234, 237], ["Tregs", "CELL", 292, 297], ["cells", "CELL", 363, 368], ["Tregs", "CELL", 382, 387], ["brain", "ORGAN", 435, 440], ["M133", "GENE_OR_GENE_PRODUCT", 533, 537], ["CD4 T cells", "CELL", 547, 558], ["Tregs", "CELL_TYPE", 72, 77], ["TNF", "PROTEIN", 158, 161], ["cytokines", "PROTEIN", 188, 197], ["M133", "CELL_LINE", 270, 274], ["bulk Tregs", "CELL_TYPE", 287, 297], ["Tregs", "CELL_TYPE", 382, 387], ["M133", "PROTEIN", 533, 537], ["CD4 T cells", "CELL_TYPE", 547, 558], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["experimental autoimmune encephalomyelitis", "PROBLEM", 13, 54], ["myelin", "PROBLEM", 56, 62], ["TNF", "TEST", 158, 161], ["IL", "TEST", 166, 168], ["these two cytokines", "TEST", 178, 197], ["Figure", "TEST", 329, 335], ["these cells", "PROBLEM", 357, 368], ["proliferation", "PROBLEM", 399, 412], ["the infected brain", "PROBLEM", 422, 440], ["autoimmune encephalomyelitis", "OBSERVATION", 26, 54], ["brain", "ANATOMY", 99, 104], ["spinal cord", "ANATOMY", 109, 120], ["bulk Tregs", "OBSERVATION", 377, 387], ["proliferation", "OBSERVATION", 399, 412], ["infected", "OBSERVATION", 426, 434], ["brain", "ANATOMY", 435, 440], ["decreased", "OBSERVATION_MODIFIER", 498, 507]]], ["Further, the majority of M133-specific Tregs, whether endogenous or transferred, expressed IL-10 in both the DCLN and brain [12] (Figure 7 and 8G) .", [["Tregs", "ANATOMY", 39, 44], ["DCLN", "ANATOMY", 109, 113], ["brain", "ANATOMY", 118, 123], ["M133", "GENE_OR_GENE_PRODUCT", 25, 29], ["Tregs", "CELL", 39, 44], ["IL-10", "GENE_OR_GENE_PRODUCT", 91, 96], ["DCLN", "CANCER", 109, 113], ["brain", "ORGAN", 118, 123], ["M133-specific Tregs", "CELL_LINE", 25, 44], ["IL-10", "PROTEIN", 91, 96], ["M133", "TEST", 25, 29], ["IL", "TEST", 91, 93], ["brain", "ANATOMY", 118, 123]]], ["These results suggest a potential role for virus epitope-specific Tregs as a therapeutic option in encephalitis and perhaps in other infections.", [["Tregs", "ANATOMY", 66, 71], ["encephalitis", "DISEASE", 99, 111], ["infections", "DISEASE", 133, 143], ["Tregs", "CELL", 66, 71], ["Tregs", "CELL_TYPE", 66, 71], ["virus epitope", "TREATMENT", 43, 56], ["Tregs", "TREATMENT", 66, 71], ["a therapeutic option", "TREATMENT", 75, 95], ["encephalitis", "PROBLEM", 99, 111], ["other infections", "PROBLEM", 127, 143], ["encephalitis", "OBSERVATION", 99, 111], ["infections", "OBSERVATION", 133, 143]]], ["Compared to bulk Tregs, virus epitope-specific Tregs would have the advantage of specifically diminishing numbers and function of pathogenic CD4 T cells responding to the same epitope without generally suppressing the anti-virus T cell response.", [["Tregs", "ANATOMY", 47, 52], ["CD4 T cells", "ANATOMY", 141, 152], ["anti-virus T cell", "ANATOMY", 218, 235], ["Tregs", "CELL", 17, 22], ["Tregs", "CELL", 47, 52], ["CD4 T cells", "CELL", 141, 152], ["anti-virus T cell", "CELL", 218, 235], ["Tregs", "CELL_TYPE", 17, 22], ["virus epitope", "PROTEIN", 24, 37], ["Tregs", "CELL_TYPE", 47, 52], ["pathogenic CD4 T cells", "CELL_TYPE", 130, 152], ["bulk Tregs", "TEST", 12, 22], ["virus epitope", "TEST", 24, 37], ["Tregs", "TREATMENT", 47, 52], ["diminishing numbers", "PROBLEM", 94, 113], ["pathogenic CD4 T cells", "PROBLEM", 130, 152], ["pathogenic CD4", "OBSERVATION", 130, 144]]], ["Thus far, Tregs have been used clinically in patients with autoimmune disease and transplantation (e.g., [35, 36] , but our results suggest a possible role in viral infections.MiceSpecific pathogen-free 6 week old C57BL/6 (B6) and Thy1.1 and CD45.1 congenic mice were purchased from the National Cancer Institute.", [["Tregs", "ANATOMY", 10, 15], ["autoimmune disease", "DISEASE", 59, 77], ["viral infections", "DISEASE", 159, 175], ["Cancer", "DISEASE", 296, 302], ["Tregs", "CELL", 10, 15], ["patients", "ORGANISM", 45, 53], ["C57BL/6 (B6)", "ORGANISM", 214, 226], ["Thy1.1", "CELL", 231, 237], ["CD45.1 congenic mice", "ORGANISM", 242, 262], ["Tregs", "CELL_TYPE", 10, 15], ["patients", "SPECIES", 45, 53], ["mice", "SPECIES", 258, 262], ["mice", "SPECIES", 258, 262], ["Tregs", "TREATMENT", 10, 15], ["autoimmune disease", "PROBLEM", 59, 77], ["transplantation", "TREATMENT", 82, 97], ["viral infections", "PROBLEM", 159, 175], ["MiceSpecific pathogen", "TEST", 176, 197], ["viral infections", "OBSERVATION", 159, 175], ["Cancer", "OBSERVATION", 296, 302]]], ["Mice transgenic for the expression of an M133specific public T cell receptor (M133 Tg mice) were developed as previously described [23] .", [["T cell", "ANATOMY", 61, 67], ["Mice", "ORGANISM", 0, 4], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 61, 76], ["M133 Tg mice", "ORGANISM", 78, 90], ["M133specific public T cell receptor", "PROTEIN", 41, 76], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["an M133specific public T cell receptor", "TREATMENT", 38, 76]]], ["Foxp3 gfp (B6.Cg-FOXP3 tm2tch /J) mice, in which eGFP is expressed behind an IRES element, were purchased from Jackson Laboratories.", [["Foxp3", "GENE_OR_GENE_PRODUCT", 0, 5], ["gfp", "GENE_OR_GENE_PRODUCT", 6, 9], ["B6.Cg", "GENE_OR_GENE_PRODUCT", 11, 16], ["FOXP3", "GENE_OR_GENE_PRODUCT", 17, 22], ["eGFP", "GENE_OR_GENE_PRODUCT", 49, 53], ["Foxp3 gfp", "DNA", 0, 9], ["B6.Cg", "PROTEIN", 11, 16], ["FOXP3", "PROTEIN", 17, 22], ["eGFP", "DNA", 49, 53], ["IRES element", "DNA", 77, 89], ["mice", "SPECIES", 34, 38], ["Foxp3 gfp", "TEST", 0, 9], ["B6.Cg", "TEST", 11, 16], ["IRES element", "OBSERVATION", 77, 89]]], ["Male mice were used in all experiments.", [["mice", "ORGANISM", 5, 9], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 5, 9]]], ["Mice were maintained in the animal care facility at the University of Iowa.Virus infectionA neuroattenuated variant of the JHMV strain of MHV, rJ2.2 (a recombinant version of the J2.2-V-1 virus) [37] and a mutated rJ2.2 (rJ2.2.M Y135Q ) in which the M133 epitope was engineered to abolish binding to the I-A b antigen [38] , were propagated in mouse 17Cl-1 cells and titered on HeLa-MHVR cells [39] .", [["17Cl-1 cells", "ANATOMY", 350, 362], ["HeLa-MHVR cells", "ANATOMY", 378, 393], ["Mice", "ORGANISM", 0, 4], ["Virus", "ORGANISM", 75, 80], ["JHMV strain", "ORGANISM", 123, 134], ["MHV", "ORGANISM", 138, 141], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 143, 148], ["J2.2-V-1 virus", "ORGANISM", 179, 193], ["I-A b antigen", "GENE_OR_GENE_PRODUCT", 304, 317], ["mouse", "ORGANISM", 344, 349], ["17Cl-1 cells", "CELL", 350, 362], ["HeLa-MHVR cells", "CELL", 378, 393], ["rJ2.2", "PROTEIN", 143, 148], ["mutated rJ2.2", "PROTEIN", 206, 219], ["M133 epitope", "PROTEIN", 250, 262], ["mouse 17Cl-1 cells", "CELL_LINE", 344, 362], ["HeLa", "CELL_LINE", 378, 382], ["MHVR cells", "CELL_LINE", 383, 393], ["Mice", "SPECIES", 0, 4], ["-1 virus", "SPECIES", 185, 193], ["mouse", "SPECIES", 344, 349], ["MHV", "SPECIES", 138, 141], ["mouse", "SPECIES", 344, 349], ["Virus infectionA", "PROBLEM", 75, 91], ["the JHMV strain of MHV", "PROBLEM", 119, 141], ["a mutated rJ2.2", "TEST", 204, 219], ["A b antigen", "TEST", 306, 317], ["HeLa", "TEST", 378, 382], ["MHV", "OBSERVATION_MODIFIER", 138, 141]]], ["6-7week-old mice were inoculated intracerebrally with 600 PFU rJ2.2 or 2,000 PFU rJ2.2.MY135Q in 30 ml DMEM.", [["MY135Q", "CHEMICAL", 87, 93], ["mice", "ORGANISM", 12, 16], ["MY135Q", "PROTEIN", 87, 93], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16]]], ["After viral inoculation, mice were examined and weighed daily.Antibodies and flow cytometryThe following antibodies and streptavidin, purchased from BD Biosciences, eBiosciences and BioLegend, were used in this study:Isolation of mononuclear cells from brainsBrains harvested after PBS perfusion were dispersed and digested with 1 mg/ml collagenase D (Roche) and 0.1 mg/ml DNase I (Roche) at 37uC for 30 min.", [["mononuclear cells", "ANATOMY", 230, 247], ["brains", "ANATOMY", 253, 259], ["Brains", "ANATOMY", 259, 265], ["mice", "ORGANISM", 25, 29], ["streptavidin", "GENE_OR_GENE_PRODUCT", 120, 132], ["mononuclear cells", "CELL", 230, 247], ["brains", "ORGAN", 253, 259], ["collagenase D", "SIMPLE_CHEMICAL", 337, 350], ["DNase I", "GENE_OR_GENE_PRODUCT", 373, 380], ["antibodies", "PROTEIN", 105, 115], ["streptavidin", "PROTEIN", 120, 132], ["BD Biosciences", "PROTEIN", 149, 163], ["BioLegend", "PROTEIN", 182, 191], ["mononuclear cells", "CELL_TYPE", 230, 247], ["DNase I", "PROTEIN", 373, 380], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["viral inoculation", "TREATMENT", 6, 23], ["Antibodies", "TEST", 62, 72], ["flow cytometry", "TEST", 77, 91], ["streptavidin", "TREATMENT", 120, 132], ["BD Biosciences", "TEST", 149, 163], ["eBiosciences", "TEST", 165, 177], ["BioLegend", "TREATMENT", 182, 191], ["this study", "TEST", 206, 216], ["mononuclear cells", "PROBLEM", 230, 247], ["PBS perfusion", "TEST", 282, 295], ["collagenase D (Roche)", "TREATMENT", 337, 358], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["inoculation", "OBSERVATION", 12, 23], ["flow cytometry", "OBSERVATION", 77, 91], ["mononuclear cells", "OBSERVATION", 230, 247], ["brains", "ANATOMY", 253, 259]]], ["Dissociated brain was passed through a 70-mm cell strainer, followed by Percoll gradient (70/ 37%) centrifugation.", [["brain", "ANATOMY", 12, 17], ["cell", "ANATOMY", 45, 49], ["brain", "ORGAN", 12, 17], ["cell", "CELL", 45, 49], ["a 70-mm cell strainer", "TREATMENT", 37, 58], ["Percoll gradient", "TEST", 72, 88], ["brain", "ANATOMY", 12, 17]]], ["Mononuclear cells were collected from the interphase, washed, and resuspended in culture medium for further analysis.Blood MHC class II tetramer stainingPeripheral blood was collected from the orbital sinus of WT-Foxp3 gfp or M133 Tg-Foxp3 gfp mice using heparinized Natelson blood collecting tubes (Fisher Scientific, Pittsburgh, PA).", [["Mononuclear cells", "ANATOMY", 0, 17], ["interphase", "ANATOMY", 42, 52], ["Blood", "ANATOMY", 117, 122], ["Peripheral blood", "ANATOMY", 153, 169], ["orbital sinus", "ANATOMY", 193, 206], ["blood", "ANATOMY", 276, 281], ["Mononuclear cells", "CELL", 0, 17], ["interphase", "CELLULAR_COMPONENT", 42, 52], ["Blood", "ORGANISM_SUBSTANCE", 117, 122], ["MHC class II tetramer", "GENE_OR_GENE_PRODUCT", 123, 144], ["Peripheral blood", "ORGANISM_SUBSTANCE", 153, 169], ["orbital sinus", "MULTI-TISSUE_STRUCTURE", 193, 206], ["Foxp3", "GENE_OR_GENE_PRODUCT", 213, 218], ["gfp", "GENE_OR_GENE_PRODUCT", 219, 222], ["Foxp3", "GENE_OR_GENE_PRODUCT", 234, 239], ["blood", "ORGANISM_SUBSTANCE", 276, 281], ["Mononuclear cells", "CELL_TYPE", 0, 17], ["Blood MHC class II tetramer", "PROTEIN", 117, 144], ["Foxp3 gfp", "DNA", 213, 222], ["Foxp3", "PROTEIN", 234, 239], ["mice", "SPECIES", 244, 248], ["mice", "SPECIES", 244, 248], ["Mononuclear cells", "PROBLEM", 0, 17], ["further analysis", "TEST", 100, 116], ["Peripheral blood", "TEST", 153, 169], ["WT", "TEST", 210, 212], ["Foxp3 gfp", "TEST", 213, 222], ["M133", "TEST", 226, 230], ["Tg", "TEST", 231, 233], ["heparinized Natelson blood collecting tubes", "TREATMENT", 255, 298], ["Peripheral", "ANATOMY_MODIFIER", 153, 163], ["blood", "ANATOMY", 164, 169], ["orbital sinus", "ANATOMY", 193, 206]]], ["100 ml blood were incubated with equal volumes of RP10 media containing 5U heparin and 1.6 mg PE-conjugated I-A b /M133 tetramers (obtained from the NIH/NIAID MHC Tetramer Core Facility, Atlanta, GA) for 1 hour at 37uC.", [["blood", "ANATOMY", 7, 12], ["heparin", "CHEMICAL", 75, 82], ["PE", "CHEMICAL", 94, 96], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["5U heparin", "SIMPLE_CHEMICAL", 72, 82], ["M133 tetramers", "SIMPLE_CHEMICAL", 115, 129], ["MHC", "PROTEIN", 159, 162], ["RP10 media", "TREATMENT", 50, 60], ["5U heparin", "TREATMENT", 72, 82]]], ["Cells were then stained with anti-CD4-PerCP-Cy5.5 at 4uC, and red blood cells were removed with ACK lysing buffer.Intracellular cytokine and transcription factor stainingTo detect IFN-c and IL-10 production by antigen-specific CD4 effector T cells (Tconv) and Tregs, mononuclear cells isolated from the LN or brain were stimulated with 5 mM peptides M133 or S358 (CD4 T cells) or 1 mM S510 (CD8 T cells) (Bio-synthesis, Inc, Lewiston, TX) in complete RPMI 1640 medium for 6 h at 37uC, in the presence of 1 ml/ml Golgiplug (BD) and antigenpresenting cells (CHB3 cells, B cell line, H-2D b , I-A b ).", [["Cells", "ANATOMY", 0, 5], ["red blood cells", "ANATOMY", 62, 77], ["Intracellular", "ANATOMY", 114, 127], ["CD4 effector T cells", "ANATOMY", 227, 247], ["Tconv", "ANATOMY", 249, 254], ["Tregs", "ANATOMY", 260, 265], ["mononuclear cells", "ANATOMY", 267, 284], ["LN", "ANATOMY", 303, 305], ["brain", "ANATOMY", 309, 314], ["CD4 T cells", "ANATOMY", 364, 375], ["CD8 T cells", "ANATOMY", 391, 402], ["cells", "ANATOMY", 549, 554], ["CHB3 cells", "ANATOMY", 556, 566], ["B cell line", "ANATOMY", 568, 579], ["Cells", "CELL", 0, 5], ["anti-CD4", "GENE_OR_GENE_PRODUCT", 29, 37], ["PerCP-Cy5.5", "SIMPLE_CHEMICAL", 38, 49], ["4uC", "SIMPLE_CHEMICAL", 53, 56], ["red blood cells", "CELL", 62, 77], ["ACK", "ORGANISM_SUBSTANCE", 96, 99], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["IFN-c", "GENE_OR_GENE_PRODUCT", 180, 185], ["IL-10", "GENE_OR_GENE_PRODUCT", 190, 195], ["antigen", "GENE_OR_GENE_PRODUCT", 210, 217], ["CD4", "GENE_OR_GENE_PRODUCT", 227, 230], ["T cells", "CELL", 240, 247], ["Tconv", "CELL", 249, 254], ["Tregs", "CELL", 260, 265], ["mononuclear cells", "CELL", 267, 284], ["LN", "MULTI-TISSUE_STRUCTURE", 303, 305], ["brain", "ORGAN", 309, 314], ["S358", "CELL", 358, 362], ["CD4 T cells", "CELL", 364, 375], ["CD8 T cells", "CELL", 391, 402], ["cells", "CELL", 549, 554], ["CHB3 cells", "CELL", 556, 566], ["B cell line", "CELL", 568, 579], ["H-2D b", "CELL", 581, 587], ["anti-CD4", "PROTEIN", 29, 37], ["PerCP", "PROTEIN", 38, 43], ["red blood cells", "CELL_TYPE", 62, 77], ["cytokine", "PROTEIN", 128, 136], ["transcription factor", "PROTEIN", 141, 161], ["IFN", "PROTEIN", 180, 183], ["CD4 effector T cells", "CELL_TYPE", 227, 247], ["Tconv", "CELL_TYPE", 249, 254], ["Tregs", "CELL_TYPE", 260, 265], ["mononuclear cells", "CELL_TYPE", 267, 284], ["CD4 T cells", "CELL_TYPE", 364, 375], ["CD8 T cells", "CELL_TYPE", 391, 402], ["antigenpresenting cells", "CELL_TYPE", 531, 554], ["CHB3 cells", "CELL_LINE", 556, 566], ["B cell line", "CELL_LINE", 568, 579], ["H-2D b", "CELL_LINE", 581, 587], ["I-A b", "CELL_LINE", 590, 595], ["anti-CD4", "TEST", 29, 37], ["PerCP", "TEST", 38, 43], ["Cy", "TEST", 44, 46], ["red blood cells", "TEST", 62, 77], ["ACK lysing buffer", "TREATMENT", 96, 113], ["Intracellular cytokine", "TEST", 114, 136], ["transcription factor staining", "TEST", 141, 170], ["IFN", "TEST", 180, 183], ["IL", "TEST", 190, 192], ["antigen", "TEST", 210, 217], ["Tconv", "TEST", 249, 254], ["Tregs", "TEST", 260, 265], ["mononuclear cells", "TEST", 267, 284], ["5 mM peptides M133", "TEST", 336, 354], ["CD4 T cells", "TEST", 364, 375], ["mM S510", "TEST", 382, 389], ["CD8 T cells", "TEST", 391, 402], ["Bio-synthesis", "TEST", 405, 418], ["TX", "TREATMENT", 435, 437], ["antigenpresenting cells", "PROBLEM", 531, 554], ["CHB3 cells", "TEST", 556, 566], ["B cell line", "TEST", 568, 579], ["H", "TEST", 581, 582], ["Tregs", "ANATOMY", 260, 265], ["mononuclear cells", "OBSERVATION", 267, 284], ["LN", "ANATOMY", 303, 305], ["brain", "ANATOMY", 309, 314]]], ["The rJ2.2specific epitopes encompass residues 133-147 of the transmembrane (M) protein and residues 358-372 and 510-518 of the surface (S) glycoprotein [40, 41] .", [["transmembrane", "ANATOMY", 61, 74], ["surface", "ANATOMY", 127, 134], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 4, 9], ["transmembrane", "CELLULAR_COMPONENT", 61, 74], ["rJ2.2specific epitopes", "PROTEIN", 4, 26], ["transmembrane (M) protein", "PROTEIN", 61, 86], ["surface (S) glycoprotein", "PROTEIN", 127, 151], ["the transmembrane (M) protein", "TEST", 57, 86], ["residues", "TEST", 91, 99]]], ["Intracellular expression of IFN-c and IL-10 was assayed.", [["Intracellular", "ANATOMY", 0, 13], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["IFN-c", "GENE_OR_GENE_PRODUCT", 28, 33], ["IL-10", "GENE_OR_GENE_PRODUCT", 38, 43], ["IFN-c and IL-10", "PROTEIN", 28, 43], ["IFN", "TEST", 28, 31], ["IL", "TEST", 38, 40]]], ["A Foxp3 Staining Buffer Set (eBioscience) was used for Foxp3 or T-bet staining or when cells were analyzed for Foxp3 and cytokine expression simultaneously; otherwise, BD Cytofix/Cytoperm and Perm/Wash buffers (BD Biosciences) were used in intracellular cytokine staining assays.Adoptive transferFor all adoptive transfers, lymphocytes were prepared from spleens and lymph nodes of donor mice.", [["cells", "ANATOMY", 87, 92], ["intracellular", "ANATOMY", 240, 253], ["lymphocytes", "ANATOMY", 324, 335], ["spleens", "ANATOMY", 355, 362], ["lymph nodes", "ANATOMY", 367, 378], ["Foxp3", "GENE_OR_GENE_PRODUCT", 2, 7], ["Foxp3", "GENE_OR_GENE_PRODUCT", 55, 60], ["T-bet", "GENE_OR_GENE_PRODUCT", 64, 69], ["cells", "CELL", 87, 92], ["Foxp3", "GENE_OR_GENE_PRODUCT", 111, 116], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 240, 253], ["lymphocytes", "CELL", 324, 335], ["spleens", "ORGAN", 355, 362], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 367, 378], ["mice", "ORGANISM", 388, 392], ["Foxp3", "PROTEIN", 2, 7], ["Foxp3", "PROTEIN", 55, 60], ["Foxp3", "PROTEIN", 111, 116], ["cytokine", "PROTEIN", 121, 129], ["cytokine", "PROTEIN", 254, 262], ["lymphocytes", "CELL_TYPE", 324, 335], ["mice", "SPECIES", 388, 392], ["mice", "SPECIES", 388, 392], ["A Foxp3 Staining Buffer Set (eBioscience)", "TREATMENT", 0, 41], ["Foxp3", "PROBLEM", 55, 60], ["T-bet staining", "TREATMENT", 64, 78], ["Foxp3 and cytokine expression", "TREATMENT", 111, 140], ["BD Cytofix", "TREATMENT", 168, 178], ["Cytoperm", "TREATMENT", 179, 187], ["Perm/Wash buffers", "TREATMENT", 192, 209], ["BD Biosciences", "TREATMENT", 211, 225], ["intracellular cytokine staining assays", "TEST", 240, 278], ["lymph nodes of donor mice", "TREATMENT", 367, 392], ["spleens", "ANATOMY", 355, 362], ["lymph nodes", "OBSERVATION", 367, 378]]], ["For transfer of bulk Tconv and Tregs, cells were purified from Foxp3 gfp /Thy1.1 or Foxp3 gfp /CD45.1 mice.", [["Tregs", "ANATOMY", 31, 36], ["cells", "ANATOMY", 38, 43], ["Tconv", "GENE_OR_GENE_PRODUCT", 21, 26], ["Tregs", "CELL", 31, 36], ["cells", "CELL", 38, 43], ["Foxp3", "GENE_OR_GENE_PRODUCT", 63, 68], ["gfp", "GENE_OR_GENE_PRODUCT", 69, 72], ["Thy1.1", "GENE_OR_GENE_PRODUCT", 74, 80], ["Foxp3", "GENE_OR_GENE_PRODUCT", 84, 89], ["gfp", "GENE_OR_GENE_PRODUCT", 90, 93], ["CD45.1", "GENE_OR_GENE_PRODUCT", 95, 101], ["Tconv", "PROTEIN", 21, 26], ["Tregs", "CELL_TYPE", 31, 36], ["Foxp3", "PROTEIN", 63, 68], ["Foxp3 gfp", "DNA", 84, 93], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 102, 106], ["Foxp3 gfp", "TEST", 63, 72], ["Foxp3 gfp", "TEST", 84, 93]]], ["For transfer of M133 Tconv and Tregs, donor M133 TCR Tg/Foxp3 gfp mice were generated by crossing M133 TCR Tg mice with Foxp3 gfp or Foxp3 gfp /Thy1.1 mice.", [["Tregs", "ANATOMY", 31, 36], ["Tconv", "GENE_OR_GENE_PRODUCT", 21, 26], ["Tregs", "CELL", 31, 36], ["TCR", "GENE_OR_GENE_PRODUCT", 49, 52], ["Foxp3", "GENE_OR_GENE_PRODUCT", 56, 61], ["TCR", "GENE_OR_GENE_PRODUCT", 103, 106], ["mice", "ORGANISM", 110, 114], ["Foxp3", "GENE_OR_GENE_PRODUCT", 120, 125], ["gfp", "GENE_OR_GENE_PRODUCT", 126, 129], ["Foxp3", "GENE_OR_GENE_PRODUCT", 133, 138], ["M133 Tconv", "CELL_LINE", 16, 26], ["Tregs", "CELL_TYPE", 31, 36], ["Foxp3", "PROTEIN", 56, 61], ["TCR", "PROTEIN", 103, 106], ["Foxp3 gfp", "DNA", 120, 129], ["Foxp3 gfp", "DNA", 133, 142], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 151, 155], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 110, 114], ["Foxp3 gfp", "TREATMENT", 120, 129]]], ["CD4 + T cells were negatively selected using a CD4 T Cell Isolation Kit II (containing a biotinylated antibody cocktail) and an AutoMACS (Miltenyi Biotech).", [["CD4 + T cells", "ANATOMY", 0, 13], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["CD4 T Cell Isolation Kit II", "PROTEIN", 47, 74], ["biotinylated antibody cocktail", "PROTEIN", 89, 119], ["AutoMACS", "PROTEIN", 128, 136], ["Miltenyi Biotech", "PROTEIN", 138, 154], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 6, 13], ["a CD4 T Cell Isolation Kit II", "TREATMENT", 45, 74], ["a biotinylated antibody cocktail", "TREATMENT", 87, 119], ["an AutoMACS (Miltenyi Biotech", "TREATMENT", 125, 154]]], ["Enriched CD4 T cells were further labeled with anti-mouse CD8-APC, B220-APC and streptavidin-APC.", [["CD4 T cells", "ANATOMY", 9, 20], ["CD4 T cells", "CELL", 9, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["APC", "GENE_OR_GENE_PRODUCT", 62, 65], ["B220", "GENE_OR_GENE_PRODUCT", 67, 71], ["APC", "GENE_OR_GENE_PRODUCT", 72, 75], ["streptavidin-APC", "GENE_OR_GENE_PRODUCT", 80, 96], ["CD4 T cells", "CELL_TYPE", 9, 20], ["anti-mouse CD8", "PROTEIN", 47, 61], ["APC", "PROTEIN", 62, 65], ["B220", "PROTEIN", 67, 71], ["APC", "PROTEIN", 72, 75], ["streptavidin", "PROTEIN", 80, 92], ["APC", "CELL_TYPE", 93, 96], ["Enriched CD4 T cells", "TEST", 0, 20], ["anti-mouse CD8", "TEST", 47, 61], ["APC", "TEST", 62, 65], ["B220", "TEST", 67, 71], ["APC", "TEST", 72, 75], ["streptavidin", "TREATMENT", 80, 92], ["APC", "PROBLEM", 93, 96]]], ["Tconvs (APC 2 GFP 2 ) or Tregs (APC 2 GFP hi ) were then sorted twice using yield mode followed by purity mode on a FACSDiva or FACSAria (BD).", [["Tregs", "ANATOMY", 25, 30], ["APC 2 GFP 2", "GENE_OR_GENE_PRODUCT", 8, 19], ["Tconvs", "PROTEIN", 0, 6], ["Tregs", "CELL_TYPE", 25, 30], ["APC 2 GFP hi", "CELL_LINE", 32, 44], ["Tconvs", "TEST", 0, 6], ["APC", "TEST", 8, 11], ["GFP", "TEST", 14, 17], ["Tregs", "PROBLEM", 25, 30], ["APC", "TEST", 32, 35]]], ["Cell purities were typically 99.4%-99.7%.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell purities", "TEST", 0, 13]]], ["Cells were then labeled with 3 mM CFSE (Invitrogen) or Violet dye (CellTrace Violet Cell Proliferation Kit, Invitrogen).", [["Cells", "ANATOMY", 0, 5], ["Cell", "ANATOMY", 84, 88], ["CFSE", "CHEMICAL", 34, 38], ["CFSE", "CHEMICAL", 34, 38], ["Violet", "CHEMICAL", 55, 61], ["Cells", "CELL", 0, 5], ["CFSE", "SIMPLE_CHEMICAL", 34, 38], ["Invitrogen", "SIMPLE_CHEMICAL", 40, 50], ["Violet dye", "SIMPLE_CHEMICAL", 55, 65], ["Cells", "TEST", 0, 5], ["3 mM CFSE (Invitrogen)", "TREATMENT", 29, 51], ["Violet dye", "TREATMENT", 55, 65], ["CellTrace Violet Cell Proliferation Kit", "TREATMENT", 67, 106]]], ["Because about 50% and 97% of Tregs and Tconvs in M133 TCR Tg/Foxp3 gfp mice were M133-specific ( Figure 1A) , Tregs and Tconvs were mixed at a 2:1 ratio (1.5610 5 and 7.5610 4 ) in most co-transfer experiments to achieve a 1:1 ratio of M133 Tregs to Tconv.", [["Tregs", "ANATOMY", 29, 34], ["Tregs", "ANATOMY", 110, 115], ["Tregs", "CELL", 29, 34], ["Tconvs", "GENE_OR_GENE_PRODUCT", 39, 45], ["TCR", "GENE_OR_GENE_PRODUCT", 54, 57], ["Foxp3", "GENE_OR_GENE_PRODUCT", 61, 66], ["Tregs", "CELL", 110, 115], ["Tconvs", "GENE_OR_GENE_PRODUCT", 120, 126], ["M133 Tregs", "CELL", 236, 246], ["Tconv", "GENE_OR_GENE_PRODUCT", 250, 255], ["Tregs", "CELL_TYPE", 29, 34], ["Tconvs", "PROTEIN", 39, 45], ["Foxp3", "PROTEIN", 61, 66], ["M133", "PROTEIN", 81, 85], ["Tregs", "CELL_TYPE", 110, 115], ["M133 Tregs", "CELL_TYPE", 236, 246], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["Tregs", "TEST", 29, 34], ["Tconvs", "TEST", 39, 45], ["TCR", "TEST", 54, 57], ["Tg", "TEST", 58, 60], ["Foxp3 gfp mice", "TEST", 61, 75], ["M133", "TEST", 81, 85], ["Tregs", "TEST", 110, 115], ["Tconvs", "TEST", 120, 126]]], ["Cells were transferred to 6-7 week congenic B6 mice 24 hours prior to rJ2.2 infection.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 76, 85], ["Cells", "CELL", 0, 5], ["B6 mice", "ORGANISM", 44, 51], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["rJ2.2 infection", "PROBLEM", 70, 85], ["infection", "OBSERVATION", 76, 85]]], ["The expansion index (fold-expansion of the overall culture) was obtained using FlowJo software, proliferation platform (Tree Star).Adoptive transferIn some experiments, recipient mice were treated intraperitoneally with 80 mg FTY720 (Cayman Chemical, Ann Arbor, MI) 0.5 hour prior to infection and once a day thereafter.Adoptive transferIn vitro suppression assay B6 (Thy1.2) mice were infected with rJ2.2 or rJ2.2.M Y135Q at day -8.", [["FTY720", "CHEMICAL", 226, 232], ["infection", "DISEASE", 284, 293], ["FTY720", "CHEMICAL", 226, 232], ["mice", "ORGANISM", 179, 183], ["FTY720", "SIMPLE_CHEMICAL", 226, 232], ["Cayman", "SIMPLE_CHEMICAL", 234, 240], ["mice", "ORGANISM", 376, 380], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 400, 405], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 376, 380], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 376, 380], ["The expansion index", "TEST", 0, 19], ["the overall culture", "TEST", 39, 58], ["FlowJo software", "TEST", 79, 94], ["Ann Arbor, MI)", "TREATMENT", 251, 265], ["infection", "PROBLEM", 284, 293], ["Adoptive transferIn vitro suppression", "TREATMENT", 320, 357], ["expansion", "OBSERVATION_MODIFIER", 4, 13], ["index", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 284, 293]]], ["To obtain responder cells, CD4 and CD8 T cells were sorted from the brains of rJ2.2-infected (M133-specific CD4) or of rJ2.2.M Y135Q -infected (S358-specific CD4 and S510-specific CD8) mice at day 0.", [["cells", "ANATOMY", 20, 25], ["CD4", "ANATOMY", 27, 30], ["CD8 T cells", "ANATOMY", 35, 46], ["brains", "ANATOMY", 68, 74], ["M133", "ANATOMY", 94, 98], ["CD4", "ANATOMY", 158, 161], ["cells", "CELL", 20, 25], ["CD4", "CELL", 27, 30], ["CD8", "GENE_OR_GENE_PRODUCT", 35, 38], ["brains", "ORGAN", 68, 74], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 78, 83], ["M133", "CELL", 94, 98], ["CD4", "GENE_OR_GENE_PRODUCT", 108, 111], ["Y135Q", "GENE_OR_GENE_PRODUCT", 127, 132], ["S358", "CELL", 144, 148], ["CD4", "GENE_OR_GENE_PRODUCT", 158, 161], ["S510", "GENE_OR_GENE_PRODUCT", 166, 170], ["CD8", "GENE_OR_GENE_PRODUCT", 180, 183], ["responder cells", "CELL_TYPE", 10, 25], ["CD4 and CD8 T cells", "CELL_TYPE", 27, 46], ["CD4", "PROTEIN", 108, 111], ["CD4", "PROTEIN", 158, 161], ["S510", "PROTEIN", 166, 170], ["CD8", "PROTEIN", 180, 183], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 185, 189], ["responder cells", "TEST", 10, 25], ["CD4", "TEST", 27, 30], ["CD8 T cells", "TEST", 35, 46], ["rJ2.2", "TEST", 78, 83], ["M133", "TEST", 94, 98], ["rJ2", "TEST", 119, 122], ["CD4", "TEST", 158, 161], ["S510", "TEST", 166, 170], ["infected", "OBSERVATION", 84, 92]]], ["At day -1, M133 Tregs were sorted from na\u00efve M133 TCR Tg/Foxp3 gfp /Thy1.1 mice as described above, stimulated with coated anti-CD3 mAb+anti-CD28 mAb (5 mg/ ml each) for 24 hours and washed thoroughly before use.", [["M133 Tregs", "ANATOMY", 11, 21], ["M133 Tregs", "CELL", 11, 21], ["TCR", "GENE_OR_GENE_PRODUCT", 50, 53], ["Foxp3", "GENE_OR_GENE_PRODUCT", 57, 62], ["CD3", "GENE_OR_GENE_PRODUCT", 128, 131], ["CD28", "GENE_OR_GENE_PRODUCT", 141, 145], ["M133 Tregs", "CELL_LINE", 11, 21], ["Foxp3", "PROTEIN", 57, 62], ["anti", "PROTEIN", 123, 127], ["CD3 mAb", "PROTEIN", 128, 135], ["anti", "PROTEIN", 136, 140], ["CD28 mAb", "PROTEIN", 141, 149], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["Tregs", "TEST", 16, 21], ["na\u00efve", "TEST", 39, 44], ["coated anti-CD3 mAb", "TREATMENT", 116, 135], ["anti-CD28 mAb", "TREATMENT", 136, 149]]], ["To set up the suppression assay ( Figure 9A) , 5610 4 Violet-labeled (2 mM) responders were co-cultured with 2.5610 5 irradiated CHB3 cells (2000 rad) and the indicated number of M133 Tregs per well, in the presence of 5 mM M133 peptide (for M133-specific CD4) or 5 mM S358+5 mM M133 peptide (for S358-specific CD4) or 1 mM S510+5 mM M133 peptide (for S510-specific CD8), in a 96-well round bottom plate.", [["CHB3 cells", "ANATOMY", 129, 139], ["Tregs", "ANATOMY", 184, 189], ["Violet", "CHEMICAL", 54, 60], ["CHB3 cells", "CELL", 129, 139], ["M133 Tregs", "CELL", 179, 189], ["CD4", "GENE_OR_GENE_PRODUCT", 256, 259], ["S358", "SIMPLE_CHEMICAL", 297, 301], ["CD4", "GENE_OR_GENE_PRODUCT", 311, 314], ["M133 peptide", "SIMPLE_CHEMICAL", 334, 346], ["CD8", "GENE_OR_GENE_PRODUCT", 366, 369], ["CHB3 cells", "CELL_LINE", 129, 139], ["M133 Tregs", "CELL_LINE", 179, 189], ["M133", "PROTEIN", 242, 246], ["CD4", "PROTEIN", 256, 259], ["S358", "PROTEIN", 297, 301], ["CD4", "PROTEIN", 311, 314], ["S510", "PROTEIN", 352, 356], ["CD8", "PROTEIN", 366, 369], ["M133", "TEST", 242, 246], ["peptide", "TEST", 284, 291], ["S358", "TEST", 297, 301], ["M133 peptide", "TEST", 334, 346], ["S510", "TEST", 352, 356], ["bottom plate", "OBSERVATION", 391, 403]]], ["After 66 hours, cells were harvested and stained with anti-Thy1.2 and anti-CD4 or anti-CD8 antibodies.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["anti-Thy1.2", "SIMPLE_CHEMICAL", 54, 65], ["anti-CD4", "GENE_OR_GENE_PRODUCT", 70, 78], ["anti-CD8 antibodies", "SIMPLE_CHEMICAL", 82, 101], ["anti-Thy1.2", "PROTEIN", 54, 65], ["anti-CD4", "PROTEIN", 70, 78], ["anti-CD8 antibodies", "PROTEIN", 82, 101], ["anti-Thy", "TEST", 54, 62], ["anti-CD4", "TREATMENT", 70, 78], ["anti-CD8 antibodies", "TREATMENT", 82, 101]]], ["CD4 or CD8 responders were analyzed for Violet dye dilution by flow cytometry.", [["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 7, 10], ["Violet dye", "SIMPLE_CHEMICAL", 40, 50], ["CD4", "PROTEIN", 0, 3], ["CD8", "PROTEIN", 7, 10], ["CD4", "TEST", 0, 3], ["CD8 responders", "TEST", 7, 21], ["Violet dye dilution", "TEST", 40, 59], ["flow cytometry", "TEST", 63, 77], ["flow cytometry", "OBSERVATION", 63, 77]]], ["The Division Index (DI, the average number of cell divisions) was obtained using FlowJo software (Tree Star, Inc.).", [["cell", "ANATOMY", 46, 50], ["cell", "CELL", 46, 50], ["The Division Index", "TEST", 0, 18], ["Division", "OBSERVATION_MODIFIER", 4, 12], ["Index", "OBSERVATION_MODIFIER", 13, 18]]], ["The percentage of suppression by Tregs was calculated as follows: % suppression = 100% x [12(DI of responders plus Tregs/DI of responders only)].Statistical analysisData are expressed as mean 6 SEM.", [["Tregs", "ANATOMY", 33, 38], ["Tregs", "ANATOMY", 115, 120], ["Tregs", "CELL", 33, 38], ["Tregs", "CELL", 115, 120], ["Tregs", "CELL_TYPE", 33, 38], ["Tregs", "CELL_TYPE", 115, 120], ["Tregs/DI of responders", "TREATMENT", 115, 137], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Two-tailed, unpaired Student t tests were used to analyze differences in mean values between groups in most experiments.", [["Student t tests", "TEST", 21, 36]]], ["Log-rank (Mantel-Cox) tests were used to analyze differences in survival.", [["Mantel-Cox) tests", "TEST", 10, 27]]], ["P values,0.05 were considered significant.", [["P values", "TEST", 0, 8]]], ["This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.", [["This study", "TEST", 0, 10]]]], "86431a5391ad8d12589fe686d0486cf2a0e912f0": [["IntroductionThe liver flukes, Fasciola hepatica and Fasciola gigantica are the causative agents of fasciolosis, a foodborne zoonotic disease affecting grazing animals and humans worldwide [1] .", [["liver flukes", "ANATOMY", 16, 28], ["liver flukes", "DISEASE", 16, 28], ["Fasciola hepatica", "DISEASE", 30, 47], ["Fasciola gigantica", "DISEASE", 52, 70], ["fasciolosis", "DISEASE", 99, 110], ["zoonotic disease", "DISEASE", 124, 140], ["liver", "ORGAN", 16, 21], ["flukes", "ORGANISM", 22, 28], ["Fasciola hepatica", "ORGANISM", 30, 47], ["Fasciola gigantica", "ORGANISM", 52, 70], ["humans", "ORGANISM", 171, 177], ["Fasciola hepatica", "SPECIES", 30, 47], ["Fasciola gigantica", "SPECIES", 52, 70], ["humans", "SPECIES", 171, 177], ["Fasciola hepatica", "SPECIES", 30, 47], ["Fasciola gigantica", "SPECIES", 52, 70], ["humans", "SPECIES", 171, 177], ["The liver flukes", "PROBLEM", 12, 28], ["Fasciola hepatica", "PROBLEM", 30, 47], ["Fasciola gigantica", "PROBLEM", 52, 70], ["fasciolosis", "PROBLEM", 99, 110], ["a foodborne zoonotic disease", "PROBLEM", 112, 140], ["liver", "ANATOMY", 16, 21], ["flukes", "OBSERVATION", 22, 28], ["Fasciola", "OBSERVATION_MODIFIER", 30, 38], ["hepatica", "ANATOMY", 39, 47], ["Fasciola gigantica", "OBSERVATION", 52, 70], ["fasciolosis", "OBSERVATION", 99, 110]]], ["Liver fluke causes economic losses of over US$ 3 billion worldwide per annum to livestock via mortality, reduction in host fecundity, susceptibility to other infections, decrease in meat, milk and wool production and condemnation of livers [1] .", [["Liver fluke", "ANATOMY", 0, 11], ["meat", "ANATOMY", 182, 186], ["milk", "ANATOMY", 188, 192], ["livers", "ANATOMY", 233, 239], ["Liver fluke", "DISEASE", 0, 11], ["infections", "DISEASE", 158, 168], ["Liver", "ORGAN", 0, 5], ["fluke", "ORGANISM", 6, 11], ["meat", "ORGANISM_SUBDIVISION", 182, 186], ["milk", "ORGANISM_SUBSTANCE", 188, 192], ["livers", "ORGAN", 233, 239], ["Liver fluke", "PROBLEM", 0, 11], ["host fecundity", "PROBLEM", 118, 132], ["other infections", "PROBLEM", 152, 168], ["fluke", "OBSERVATION", 6, 11], ["host fecundity", "OBSERVATION", 118, 132], ["livers", "ANATOMY", 233, 239]]], ["The disease is increasing in livestock worldwide with contributing factors such as climate change (warmer winters and wetter summers supporting larger intermediate mud snail host populations); fragmented disease management (only treating sheep not cattle and limiting veterinary interaction); encouragement of wet-lands; livestock movement; and/or failure/ resistance of chemical control treatments in the absence of commercial vaccines [1, 2] .", [["sheep", "SPECIES", 238, 243], ["cattle", "SPECIES", 248, 254], ["sheep", "SPECIES", 238, 243], ["cattle", "SPECIES", 248, 254], ["The disease", "PROBLEM", 0, 11], ["larger intermediate mud snail host populations", "TREATMENT", 144, 190], ["fragmented disease management", "TREATMENT", 193, 222], ["chemical control treatments", "TREATMENT", 371, 398], ["commercial vaccines", "TREATMENT", 417, 436], ["disease", "OBSERVATION", 4, 11], ["increasing", "OBSERVATION_MODIFIER", 15, 25], ["fragmented", "OBSERVATION_MODIFIER", 193, 203], ["disease", "OBSERVATION", 204, 211]]], ["Fasciolosis is also a re-emerging human disease with estimates of between 2.4 and 17 million people infected worldwide [3] .", [["Fasciolosis", "DISEASE", 0, 11], ["human", "ORGANISM", 34, 39], ["people", "ORGANISM", 93, 99], ["human", "SPECIES", 34, 39], ["people", "SPECIES", 93, 99], ["human", "SPECIES", 34, 39], ["Fasciolosis", "PROBLEM", 0, 11], ["a re-emerging human disease", "PROBLEM", 20, 47]]], ["In response, the World Health Organisation have added fasciolosis to the preventative chemotherapy concept [4] .IntroductionThere are currently no commercial vaccines and triclabendazole (TCBZ) is the most important fasciolicide, as the only drug with significant efficacy against adult worms and juveniles [5] .", [["worms", "ANATOMY", 287, 292], ["triclabendazole", "CHEMICAL", 171, 186], ["TCBZ", "CHEMICAL", 188, 192], ["fasciolicide", "CHEMICAL", 216, 228], ["triclabendazole", "CHEMICAL", 171, 186], ["TCBZ", "CHEMICAL", 188, 192], ["fasciolicide", "CHEMICAL", 216, 228], ["triclabendazole", "SIMPLE_CHEMICAL", 171, 186], ["TCBZ", "SIMPLE_CHEMICAL", 188, 192], ["fasciolicide", "SIMPLE_CHEMICAL", 216, 228], ["worms", "SPECIES", 287, 292], ["fasciolosis", "PROBLEM", 54, 65], ["the preventative chemotherapy concept", "TREATMENT", 69, 106], ["commercial vaccines", "TREATMENT", 147, 166], ["triclabendazole (TCBZ)", "TREATMENT", 171, 193], ["adult worms", "PROBLEM", 281, 292]]], ["Evidence from developed countries where TCBZ has been used widely exposes the reliance on this drug as an Achilles heel of liver fluke chemotherapeutic control, with well-established evidence of drug-resistance [5] .", [["liver fluke", "ANATOMY", 123, 134], ["TCBZ", "CHEMICAL", 40, 44], ["TCBZ", "CHEMICAL", 40, 44], ["TCBZ", "SIMPLE_CHEMICAL", 40, 44], ["Achilles heel", "ORGANISM", 106, 119], ["liver", "ORGAN", 123, 128], ["TCBZ", "TREATMENT", 40, 44], ["this drug", "TREATMENT", 90, 99], ["liver fluke chemotherapeutic control", "TREATMENT", 123, 159], ["drug-resistance", "PROBLEM", 195, 210], ["Achilles", "ANATOMY", 106, 114], ["liver", "ANATOMY", 123, 128], ["fluke", "OBSERVATION", 129, 134]]], ["Therefore, TCBZ does not offer a long-term sustainable option for livestock farmers worldwide.", [["TCBZ", "CHEMICAL", 11, 15], ["TCBZ", "CHEMICAL", 11, 15], ["TCBZ", "SIMPLE_CHEMICAL", 11, 15], ["a long-term sustainable option", "TREATMENT", 31, 61]]], ["The need for a liver fluke vaccine is further underscored by the fact that the costs associated with anthelmintic intervention for fluke control make short-lived chemotherapy an unsustainable option in developing countries.", [["liver fluke", "ANATOMY", 15, 26], ["liver fluke", "DISEASE", 15, 26], ["liver", "ORGAN", 15, 20], ["fluke", "ORGANISM", 21, 26], ["a liver fluke vaccine", "TREATMENT", 13, 34], ["anthelmintic intervention", "TREATMENT", 101, 126], ["fluke control", "TREATMENT", 131, 144], ["short-lived chemotherapy", "TREATMENT", 150, 174], ["liver", "ANATOMY", 15, 20], ["fluke", "OBSERVATION", 21, 26]]], ["Protein superfamily studies in liver fluke have provided a number of leading vaccine candidates.", [["liver fluke", "ANATOMY", 31, 42], ["liver fluke", "DISEASE", 31, 42], ["liver fluke", "CANCER", 31, 42], ["Protein superfamily studies", "TEST", 0, 27], ["leading vaccine candidates", "TREATMENT", 69, 95], ["liver", "ANATOMY", 31, 36]]], ["High quality one-gene based vaccine discovery research has identified several vaccine candidates from protein superfamilies that provide significant, but often variable protection rates in challenge animal trials against liver fluke.IntroductionFor example, Mu class Glutathione transferase (GSTs) have been widely investigated as vaccine candidates for fasciolosis [6] [7] [8] [9] .", [["liver fluke", "ANATOMY", 221, 232], ["liver fluke", "DISEASE", 221, 232], ["fasciolosis", "DISEASE", 354, 365], ["Glutathione", "CHEMICAL", 267, 278], ["liver", "ORGAN", 221, 226], ["fluke", "ORGANISM", 227, 232], ["Mu class Glutathione transferase", "GENE_OR_GENE_PRODUCT", 258, 290], ["GSTs", "GENE_OR_GENE_PRODUCT", 292, 296], ["fasciolosis [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 354, 381], ["protein superfamilies", "PROTEIN", 102, 123], ["Mu class Glutathione transferase", "PROTEIN", 258, 290], ["GSTs", "PROTEIN", 292, 296], ["several vaccine candidates", "TREATMENT", 70, 96], ["protein superfamilies", "TREATMENT", 102, 123], ["liver fluke", "PROBLEM", 221, 232], ["Mu class Glutathione transferase (GSTs)", "TREATMENT", 258, 297], ["fasciolosis", "PROBLEM", 354, 365], ["liver", "ANATOMY", 221, 226], ["fluke", "OBSERVATION", 227, 232]]], ["The Mu class GSTs have established roles in general Phase II detoxification of xenobiotic and endogenously derived toxins in F. hepatica within the host bile environment [10] .", [["bile", "ANATOMY", 153, 157], ["Mu class GSTs", "GENE_OR_GENE_PRODUCT", 4, 17], ["F. hepatica", "ORGANISM", 125, 136], ["bile", "MULTI-TISSUE_STRUCTURE", 153, 157], ["Mu class GSTs", "PROTEIN", 4, 17], ["F. hepatica", "SPECIES", 125, 136], ["F. hepatica", "SPECIES", 125, 136], ["hepatica", "ANATOMY", 128, 136], ["bile", "ANATOMY", 153, 157]]], ["The general detoxification role is supported by GSTs contributing to 4% of the total soluble protein in F. hepatica, with a widespread tissue distribution.", [["tissue", "ANATOMY", 135, 141], ["GSTs", "GENE_OR_GENE_PRODUCT", 48, 52], ["F. hepatica", "ORGANISM", 104, 115], ["tissue", "TISSUE", 135, 141], ["GSTs", "PROTEIN", 48, 52], ["soluble protein", "PROTEIN", 85, 100], ["F. hepatica", "SPECIES", 104, 115], ["F. hepatica", "SPECIES", 104, 115], ["hepatica", "ANATOMY", 107, 115], ["widespread", "OBSERVATION_MODIFIER", 124, 134], ["tissue", "OBSERVATION", 135, 141], ["distribution", "OBSERVATION_MODIFIER", 142, 154]]], ["Proteomics and EST sequencing approaches have now delineated what members of the GST family are expressed in F. hepatica and two new classes of GST, Sigma and Omega, have been uncovered [11] .", [["GST", "GENE_OR_GENE_PRODUCT", 81, 84], ["F. hepatica", "ORGANISM", 109, 120], ["GST", "GENE_OR_GENE_PRODUCT", 144, 147], ["Sigma", "GENE_OR_GENE_PRODUCT", 149, 154], ["Omega", "GENE_OR_GENE_PRODUCT", 159, 164], ["GST family", "PROTEIN", 81, 91], ["GST", "PROTEIN", 144, 147], ["Omega", "PROTEIN", 159, 164], ["F. hepatica", "SPECIES", 109, 120], ["F. hepatica", "SPECIES", 109, 120], ["Proteomics", "TEST", 0, 10], ["EST sequencing approaches", "TREATMENT", 15, 40], ["hepatica", "ANATOMY", 112, 120]]], ["In the related trematode, Schistosoma mansoni, the Sigma class GST (Sm28) has generally shown more robust protection in vaccine trials against schistosome infection [12] , than the F. hepatica Mu GSTs against F. hepatica infection.IntroductionSigma class GSTs, unlike Mu Class GSTs, have been characterized as GSH-dependent hematopoietic prostaglandin synthases responsible for the production of prostaglandins in both mammals and parasitic worms [13] [14] [15] [16] [17] [18] .", [["Schistosoma mansoni", "DISEASE", 26, 45], ["schistosome infection", "DISEASE", 143, 164], ["F. hepatica infection", "DISEASE", 209, 230], ["GSH", "CHEMICAL", 310, 313], ["prostaglandin", "CHEMICAL", 338, 351], ["prostaglandins", "CHEMICAL", 396, 410], ["[13] [14] [15] [16] [17]", "CHEMICAL", 447, 471], ["GSH", "CHEMICAL", 310, 313], ["prostaglandin", "CHEMICAL", 338, 351], ["prostaglandins", "CHEMICAL", 396, 410], ["trematode", "ORGANISM", 15, 24], ["Schistosoma mansoni", "ORGANISM", 26, 45], ["Sigma class GST", "GENE_OR_GENE_PRODUCT", 51, 66], ["Sm28", "GENE_OR_GENE_PRODUCT", 68, 72], ["schistosome", "ORGANISM", 143, 154], ["F. hepatica", "ORGANISM", 181, 192], ["Mu GSTs", "ORGANISM", 193, 200], ["F. hepatica", "ORGANISM", 209, 220], ["IntroductionSigma class GSTs", "GENE_OR_GENE_PRODUCT", 231, 259], ["Mu Class GSTs", "GENE_OR_GENE_PRODUCT", 268, 281], ["GSH", "SIMPLE_CHEMICAL", 310, 313], ["hematopoietic prostaglandin synthases", "GENE_OR_GENE_PRODUCT", 324, 361], ["prostaglandins", "SIMPLE_CHEMICAL", 396, 410], ["[13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 447, 476], ["Sigma class GST", "PROTEIN", 51, 66], ["Sm28", "PROTEIN", 68, 72], ["F. hepatica Mu GSTs", "PROTEIN", 181, 200], ["IntroductionSigma class GSTs", "PROTEIN", 231, 259], ["Mu Class GSTs", "PROTEIN", 268, 281], ["GSH-dependent hematopoietic prostaglandin synthases", "PROTEIN", 310, 361], ["Schistosoma mansoni", "SPECIES", 26, 45], ["F. hepatica", "SPECIES", 181, 192], ["F. hepatica", "SPECIES", 209, 220], ["worms", "SPECIES", 441, 446], ["Schistosoma mansoni", "SPECIES", 26, 45], ["F. hepatica", "SPECIES", 181, 192], ["F. hepatica", "SPECIES", 209, 220], ["vaccine trials", "TREATMENT", 120, 134], ["schistosome infection", "PROBLEM", 143, 164], ["hepatica infection", "PROBLEM", 212, 230], ["GSH", "TEST", 310, 313], ["dependent hematopoietic prostaglandin synthases", "TREATMENT", 314, 361], ["the production of prostaglandins", "PROBLEM", 378, 410], ["parasitic worms", "PROBLEM", 431, 446], ["trematode", "OBSERVATION_MODIFIER", 15, 24], ["Schistosoma mansoni", "OBSERVATION", 26, 45], ["more robust", "OBSERVATION_MODIFIER", 94, 105], ["hepatica", "ANATOMY", 184, 192], ["hepatica", "ANATOMY", 212, 220], ["infection", "OBSERVATION", 221, 230]]], ["Prostaglandins have been extensively studied in mammals and are shown to be involved in a range of physiological and pathological responses [19] [20] [21] [22] [23] .", [["Prostaglandins", "CHEMICAL", 0, 14], ["Prostaglandins", "GENE_OR_GENE_PRODUCT", 0, 14], ["[19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 140, 164], ["Prostaglandins", "TREATMENT", 0, 14]]], ["Parasite-produced prostaglandins may be involved in parasite development and reproduction as well as the modulation of host immunity, allergy and inflammation during establishment and maintenance of a host infection [16, [24] [25] [26] [27] [28] ].", [["parasite", "ANATOMY", 52, 60], ["prostaglandins", "CHEMICAL", 18, 32], ["allergy", "DISEASE", 134, 141], ["inflammation", "DISEASE", 146, 158], ["infection", "DISEASE", 206, 215], ["prostaglandins", "CHEMICAL", 18, 32], ["[16, [24] [25] [26] [27] [28] ].", "CHEMICAL", 216, 248], ["Parasite", "CELL", 0, 8], ["prostaglandins", "SIMPLE_CHEMICAL", 18, 32], ["[24] [25] [26] [27] [28] ].", "SIMPLE_CHEMICAL", 221, 248], ["prostaglandins", "TREATMENT", 18, 32], ["allergy", "PROBLEM", 134, 141], ["inflammation", "PROBLEM", 146, 158], ["a host infection", "PROBLEM", 199, 215], ["inflammation", "OBSERVATION", 146, 158]]], ["The host protection success of Sigma GST based vaccinations in schistosomiasis may therefore be related to neutralising specific functions in host-parasite interplay, such as prostaglandin synthase activity.IntroductionIn this manuscript we follow four work pathways to functionally characterise the newly identified Sigma GST from F. hepatica.", [["schistosomiasis", "DISEASE", 63, 78], ["prostaglandin", "CHEMICAL", 175, 188], ["F. hepatica", "DISEASE", 332, 343], ["prostaglandin", "CHEMICAL", 175, 188], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 31, 40], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 175, 197], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 317, 326], ["F. hepatica", "ORGANISM", 332, 343], ["Sigma GST", "PROTEIN", 31, 40], ["prostaglandin synthase", "PROTEIN", 175, 197], ["Sigma GST", "PROTEIN", 317, 326], ["F. hepatica", "SPECIES", 332, 343], ["F. hepatica", "SPECIES", 332, 343], ["The host protection", "TREATMENT", 0, 19], ["Sigma GST based vaccinations", "TREATMENT", 31, 59], ["schistosomiasis", "PROBLEM", 63, 78], ["prostaglandin synthase activity", "TREATMENT", 175, 206], ["hepatica", "ANATOMY", 335, 343]]], ["1) We confirm its designation as a Sigma class GST using substrate profiling, 2) we assess prostaglandin synthase activity and its effect on host immune cells, 3) we localise the Sigma GST within adult fluke and between ontogenic stages and 4) assess its potential as a vaccine candidate.Sequence analysisGST proteins representative of recognised GST superfamily classes were obtained from European Bioinformatics Institute Interpro database (http://www.ebi.ac.uk/ interpro/), and from non-redundant databases at NCBI (http://www.ncbi.nlm.nih. gov/).", [["immune cells", "ANATOMY", 146, 158], ["adult fluke", "ANATOMY", 196, 207], ["prostaglandin", "CHEMICAL", 91, 104], ["prostaglandin", "CHEMICAL", 91, 104], ["GST", "GENE_OR_GENE_PRODUCT", 47, 50], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 91, 113], ["host immune cells", "CELL", 141, 158], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 179, 188], ["adult fluke", "ORGAN", 196, 207], ["GST", "GENE_OR_GENE_PRODUCT", 347, 350], ["Sigma class GST", "PROTEIN", 35, 50], ["prostaglandin synthase", "PROTEIN", 91, 113], ["host immune cells", "CELL_TYPE", 141, 158], ["Sigma GST", "PROTEIN", 179, 188], ["analysisGST proteins", "PROTEIN", 297, 317], ["GST superfamily classes", "PROTEIN", 347, 370], ["substrate profiling", "TEST", 57, 76], ["prostaglandin synthase activity", "TREATMENT", 91, 122], ["host immune cells", "TREATMENT", 141, 158], ["Sequence analysisGST proteins", "TEST", 288, 317]]], ["A mammalian and a helminth or invertebrate GST sequence were selected for each GST class where available.", [["GST", "GENE_OR_GENE_PRODUCT", 43, 46], ["GST", "GENE_OR_GENE_PRODUCT", 79, 82], ["mammalian and a helminth or invertebrate GST sequence", "DNA", 2, 55], ["GST class", "PROTEIN", 79, 88], ["invertebrate GST sequence", "TEST", 30, 55]]], ["[30] and sequence identity matrices produced from multiple alignments.", [["sequence identity matrices", "TEST", 9, 35], ["multiple alignments", "OBSERVATION", 50, 69]]], ["Phylogenetic bootstrap neighbour-joining trees were produced as PHYLIP output files in ClustalX Version 1.83 [31] according to the neighbour-joining method of Saitou and Nei [32] .", [["Phylogenetic bootstrap neighbour", "TREATMENT", 0, 32]]], ["ClustalX default settings for alignments were accepted using the GONNET protein weight matrices with PHYLIP tree format files viewed within TREEVIEW [33] .Sequence analysisRecombinant Fasciola hepatica glutathione transferase Sigma class (rFhGST-S1) production Full-length cDNA for FhGST-S1 was available in the form of an expressed sequence tag (EST) clone Fhep24h03, details of which can be obtained from the previously published Sigma class GST [11] and is identical to the submitted GenBank accession No.", [["glutathione", "CHEMICAL", 202, 213], ["glutathione", "CHEMICAL", 202, 213], ["Fasciola hepatica", "ORGANISM", 184, 201], ["glutathione transferase Sigma class", "GENE_OR_GENE_PRODUCT", 202, 237], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 239, 248], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 282, 290], ["Sigma class GST", "GENE_OR_GENE_PRODUCT", 432, 447], ["GONNET protein weight matrices", "DNA", 65, 95], ["Fasciola hepatica glutathione transferase Sigma class (rFhGST-S1) production Full-length cDNA", "DNA", 184, 277], ["FhGST", "PROTEIN", 282, 287], ["S1", "DNA", 288, 290], ["expressed sequence tag (EST) clone Fhep24h03", "DNA", 323, 367], ["Sigma class GST", "PROTEIN", 432, 447], ["Fasciola hepatica", "SPECIES", 184, 201], ["Fasciola hepatica", "SPECIES", 184, 201], ["the GONNET protein weight matrices", "TREATMENT", 61, 95], ["Sequence analysisRecombinant Fasciola hepatica glutathione transferase", "TEST", 155, 225], ["Sigma class", "TEST", 226, 237], ["rFhGST", "TEST", 239, 245], ["FhGST", "TEST", 282, 287], ["GenBank accession", "OBSERVATION", 487, 504]]], ["DQ974116.1 (NCBI http://www.ncbi.nlm.nih.gov/).Sequence analysisFhGST-S1 was amplified via PCR using the following primer pair: rFhGST-S1 forward primer, 59 GGAATTCCATATGGA-CAAACAGCATTTCAAGTT 39;rFhGST-S1 reverse primer, 59 ATAAGAATGCGGCCGCCTAGAATGGAGTTTTTGCAC-GTTTTTT 39.", [["analysisFhGST-S1", "GENE_OR_GENE_PRODUCT", 56, 72], ["analysisFhGST-S1", "DNA", 56, 72], ["primer pair", "DNA", 115, 126], ["rFhGST", "DNA", 128, 134], ["rFhGST-S1 reverse primer", "DNA", 195, 219], ["GTTTTTT 39", "DNA", 261, 271], ["Sequence analysisFhGST", "TEST", 47, 69], ["PCR", "TEST", 91, 94], ["rFhGST", "TEST", 128, 134], ["GGAATTCCATATGGA-", "TEST", 157, 173], ["CAAACAGCATTTCAAGTT", "TEST", 173, 191], ["rFhGST", "TEST", 195, 201], ["ATAAGAATGCGGCCGCCTAGAATGGAGTTTTTGCAC", "TEST", 224, 260]]], ["Restriction enzyme sites (in bold type and underlined) for NdeI (forward primer) and NotI (reverse primer) were included so that the entire ORF could be directionally cloned into the pET23a (Novagen) vector.", [["NdeI", "GENE_OR_GENE_PRODUCT", 59, 63], ["NotI", "GENE_OR_GENE_PRODUCT", 85, 89], ["pET23a", "GENE_OR_GENE_PRODUCT", 183, 189], ["Novagen", "GENE_OR_GENE_PRODUCT", 191, 198], ["Restriction enzyme sites", "DNA", 0, 24], ["NdeI (forward primer", "DNA", 59, 79], ["NotI", "DNA", 85, 89], ["reverse primer", "DNA", 91, 105], ["ORF", "DNA", 140, 143], ["pET23a (Novagen) vector", "DNA", 183, 206], ["Restriction enzyme sites", "PROBLEM", 0, 24], ["NdeI", "PROBLEM", 59, 63], ["the entire ORF", "PROBLEM", 129, 143], ["the pET23a (Novagen) vector", "TREATMENT", 179, 206], ["sites", "OBSERVATION_MODIFIER", 19, 24]]], ["Recombinant protein was produced in Escherichia coli BL21(DE3) cells (Novagen).Sequence analysisProtein purification of rFhGST-S1 and native F. hepatica GSTs rFhGST-S1 protein was purified according to the glutathione affinity chromatography method of Simons and Vander Jagt [34] from transformed E. coli cytosol following protein expression.", [["DE3) cells", "ANATOMY", 58, 68], ["cytosol", "ANATOMY", 305, 312], ["glutathione", "CHEMICAL", 206, 217], ["glutathione", "CHEMICAL", 206, 217], ["Escherichia coli", "ORGANISM", 36, 52], ["BL21", "ORGANISM", 53, 57], ["DE3) cells", "CELL", 58, 68], ["Novagen", "GENE_OR_GENE_PRODUCT", 70, 77], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 120, 129], ["F. hepatica", "ORGANISM", 141, 152], ["GSTs", "ORGANISM", 153, 157], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 158, 167], ["glutathione", "SIMPLE_CHEMICAL", 206, 217], ["E. coli", "ORGANISM", 297, 304], ["cytosol", "ORGANISM_SUBSTANCE", 305, 312], ["Recombinant protein", "PROTEIN", 0, 19], ["Escherichia coli BL21(DE3) cells", "CELL_LINE", 36, 68], ["rFhGST", "PROTEIN", 120, 126], ["S1", "PROTEIN", 127, 129], ["native F. hepatica GSTs", "PROTEIN", 134, 157], ["rFhGST", "PROTEIN", 158, 164], ["S1 protein", "PROTEIN", 165, 175], ["Escherichia coli BL21", "SPECIES", 36, 57], ["F. hepatica", "SPECIES", 141, 152], ["E. coli", "SPECIES", 297, 304], ["Escherichia coli BL21", "SPECIES", 36, 57], ["DE3", "SPECIES", 58, 61], ["F. hepatica", "SPECIES", 141, 152], ["E. coli", "SPECIES", 297, 304], ["Recombinant protein", "TEST", 0, 19], ["Escherichia coli BL21(DE3) cells (Novagen", "TREATMENT", 36, 77], ["Sequence analysisProtein purification", "TEST", 79, 116], ["rFhGST", "TEST", 120, 126], ["native F. hepatica GSTs rFhGST", "TEST", 134, 164], ["S1 protein", "TEST", 165, 175], ["the glutathione affinity chromatography", "TEST", 202, 241], ["Simons", "TEST", 252, 258], ["Vander Jagt", "TEST", 263, 274], ["transformed E. coli cytosol", "TREATMENT", 285, 312], ["Escherichia coli BL21", "OBSERVATION", 36, 57], ["hepatica", "ANATOMY", 144, 152], ["protein expression", "OBSERVATION", 323, 341]]], ["Native GSTs were purified from F. hepatica soluble cytosolic supernatants as previously described [11] .", [["cytosolic supernatants", "ANATOMY", 51, 73], ["GSTs", "GENE_OR_GENE_PRODUCT", 7, 11], ["F. hepatica", "ORGANISM", 31, 42], ["GSTs", "PROTEIN", 7, 11], ["F. hepatica", "SPECIES", 31, 42], ["F. hepatica", "SPECIES", 31, 42], ["Native GSTs", "PROBLEM", 0, 11], ["hepatica soluble cytosolic supernatants", "TREATMENT", 34, 73], ["hepatica", "ANATOMY", 34, 42]]], ["Purity of rFhGST-S1 was assessed by electrospray ionisation (ESI) mass spectrometry, sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 2DE according to LaCourse et al. [35] .Substrate profiling of Sigma GSTA range of model and natural substrates (see Table 1 for details) were used to profile the Sigma GST.", [["sodium dodecyl sulphate", "CHEMICAL", 85, 108], ["sodium dodecyl sulphate polyacrylamide", "CHEMICAL", 85, 123], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 10, 19], ["sodium dodecyl sulphate polyacrylamide", "SIMPLE_CHEMICAL", 85, 123], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 321, 330], ["rFhGST", "PROTEIN", 10, 16], ["Sigma GST", "PROTEIN", 321, 330], ["mass spectrometry", "TEST", 66, 83], ["sodium dodecyl sulphate polyacrylamide gel electrophoresis", "TREATMENT", 85, 143], ["S1", "ANATOMY", 17, 19], ["Sigma GSTA", "OBSERVATION_MODIFIER", 221, 231]]], ["A number of ligands were also assessed for their ability to inhibit GST activity with 1-chloro-2, 4-dinitrobenzene (CDNB) as the second substrate [36] .", [["1-chloro-2, 4-dinitrobenzene", "CHEMICAL", 86, 114], ["CDNB", "CHEMICAL", 116, 120], ["1-chloro-2, 4-dinitrobenzene", "CHEMICAL", 86, 114], ["CDNB", "CHEMICAL", 116, 120], ["GST", "GENE_OR_GENE_PRODUCT", 68, 71], ["1-chloro-2, 4-dinitrobenzene", "SIMPLE_CHEMICAL", 86, 114], ["CDNB", "SIMPLE_CHEMICAL", 116, 120], ["GST", "PROTEIN", 68, 71], ["GST activity", "TEST", 68, 80]]], ["Values were reported as the concentration of inhibitor required to bring GST specific activity to 50% of its original activity (IC50).", [["GST", "GENE_OR_GENE_PRODUCT", 73, 76], ["GST", "PROTEIN", 73, 76], ["Values", "TEST", 0, 6], ["the concentration of inhibitor", "TREATMENT", 24, 54]]], ["At least six different inhibitor concentrations were used in each IC50 determination in triplicate.", [["different inhibitor concentrations", "TREATMENT", 13, 47], ["IC50 determination", "TEST", 66, 84]]], ["Inhibitors were pre-incubated for 5 minutes prior to starting reactions.", [["Inhibitors", "TREATMENT", 0, 10]]], ["IC50 values were estimated graphically [37] .Substrate profiling of Sigma GSTProstaglandin synthase activity was assessed via an adapted method based upon those of Sommer et al. [26] and Meyer et al. [16, 38] , with extraction modifications based upon Schmidt et al. [39] .", [["Sigma GSTProstaglandin synthase", "GENE_OR_GENE_PRODUCT", 68, 99], ["Sigma GSTProstaglandin synthase", "PROTEIN", 68, 99], ["IC50 values", "TEST", 0, 11], ["Sigma GSTProstaglandin synthase activity", "TREATMENT", 68, 108], ["extraction modifications", "TREATMENT", 216, 240], ["Sigma GSTProstaglandin", "OBSERVATION", 68, 90]]], ["In brief, reactions were performed in glass vials in 2 mM sodium phosphate buffer, pH 7.4, containing 10 mM glutathione,Author SummaryCombating neglected parasitic diseases is of paramount importance to improve the health of human populations and/or their domestic animals.", [["sodium phosphate", "CHEMICAL", 58, 74], ["glutathione", "CHEMICAL", 108, 119], ["parasitic diseases", "DISEASE", 154, 172], ["sodium phosphate", "CHEMICAL", 58, 74], ["glutathione", "CHEMICAL", 108, 119], ["sodium phosphate buffer", "SIMPLE_CHEMICAL", 58, 81], ["glutathione", "SIMPLE_CHEMICAL", 108, 119], ["human", "ORGANISM", 225, 230], ["human", "SPECIES", 225, 230], ["human", "SPECIES", 225, 230], ["2 mM sodium phosphate buffer", "TREATMENT", 53, 81], ["pH", "TEST", 83, 85], ["parasitic diseases", "PROBLEM", 154, 172], ["parasitic diseases", "OBSERVATION", 154, 172]]], ["Uncovering key roles in host-parasite interactions may support the vaccine potential portfolio of a parasite protein.", [["parasite protein", "PROTEIN", 100, 116], ["a parasite protein", "TREATMENT", 98, 116]]], ["Fasciola hepatica causes global disease in humans and their livestock but no commercial vaccines are available.", [["Fasciola hepatica", "DISEASE", 0, 17], ["Fasciola hepatica", "ORGANISM", 0, 17], ["humans", "ORGANISM", 43, 49], ["Fasciola hepatica", "SPECIES", 0, 17], ["humans", "SPECIES", 43, 49], ["Fasciola hepatica", "SPECIES", 0, 17], ["humans", "SPECIES", 43, 49], ["Fasciola hepatica", "PROBLEM", 0, 17], ["global disease in humans", "PROBLEM", 25, 49], ["commercial vaccines", "TREATMENT", 77, 96], ["hepatica", "ANATOMY", 9, 17], ["global", "OBSERVATION_MODIFIER", 25, 31], ["disease", "OBSERVATION", 32, 39]]], ["Members of the Sigma class glutathione transferase (GST) family have long been highlighted as vaccine candidates towards parasitic flatworms.", [["glutathione", "CHEMICAL", 27, 38], ["parasitic flatworms", "DISEASE", 121, 140], ["glutathione", "CHEMICAL", 27, 38], ["Sigma class glutathione transferase", "GENE_OR_GENE_PRODUCT", 15, 50], ["GST", "GENE_OR_GENE_PRODUCT", 52, 55], ["Sigma class glutathione transferase (GST) family", "PROTEIN", 15, 63], ["parasitic flatworms", "PROBLEM", 121, 140]]], ["To this end, a Sigma class GST is currently undergoing phase II clinical trials to protect against infection from the schistosomes.", [["infection", "DISEASE", 99, 108], ["GST", "GENE_OR_GENE_PRODUCT", 27, 30], ["Sigma class GST", "PROTEIN", 15, 30], ["phase II clinical trials", "TREATMENT", 55, 79], ["infection", "PROBLEM", 99, 108], ["the schistosomes", "PROBLEM", 114, 130], ["infection", "OBSERVATION", 99, 108]]], ["In this study we characterise the protein from F. hepatica following four work pathways that 1) confirm its designation as a Sigma class GST using substrate profiling, 2) assess prostaglandin synthase activity and its effect on host immune cells, 3) localise the Sigma GST within adult fluke and between ontogenic stages and 4) measure its potential as a vaccine candidate.", [["immune cells", "ANATOMY", 233, 245], ["adult fluke", "ANATOMY", 280, 291], ["prostaglandin", "CHEMICAL", 178, 191], ["prostaglandin", "CHEMICAL", 178, 191], ["F. hepatica", "ORGANISM", 47, 58], ["Sigma class GST", "GENE_OR_GENE_PRODUCT", 125, 140], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 178, 200], ["host immune cells", "CELL", 228, 245], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 263, 272], ["adult fluke", "ORGAN", 280, 291], ["Sigma class GST", "PROTEIN", 125, 140], ["prostaglandin synthase", "PROTEIN", 178, 200], ["host immune cells", "CELL_TYPE", 228, 245], ["Sigma GST", "PROTEIN", 263, 272], ["F. hepatica", "SPECIES", 47, 58], ["F. hepatica", "SPECIES", 47, 58], ["this study", "TEST", 3, 13], ["substrate profiling", "TEST", 147, 166], ["prostaglandin synthase activity", "TREATMENT", 178, 209], ["host immune cells", "TREATMENT", 228, 245], ["the Sigma GST", "TEST", 259, 272]]], ["The work presented here shows F. hepatica Sigma class GST to have key host-parasite roles and we suggest, warrants further investigation for inclusion into vaccine formulations.", [["F. hepatica", "ORGANISM", 30, 41], ["Sigma class GST", "GENE_OR_GENE_PRODUCT", 42, 57], ["F. hepatica Sigma class GST", "PROTEIN", 30, 57], ["F. hepatica", "SPECIES", 30, 41], ["F. hepatica", "SPECIES", 30, 41], ["further investigation", "TEST", 115, 136], ["inclusion into vaccine formulations", "TREATMENT", 141, 176]]], ["Recombinant FhGST-S1 shows activity towards a broad range of model and natural GST substrates with a similar enzymatic profile to the Schistosomiasis vaccine trialist (Sm28GST -P09792). rFhGST-S1 also displays high glutathione-dependent lipid peroxidase activity compared to both Sm28GST and Sj26GST (Q26513) [47] .", [["Schistosomiasis", "DISEASE", 134, 149], ["Sm28GST -P09792", "CHEMICAL", 168, 183], ["glutathione", "CHEMICAL", 215, 226], ["glutathione", "CHEMICAL", 215, 226], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 12, 20], ["GST", "GENE_OR_GENE_PRODUCT", 79, 82], ["Sm28GST -P09792", "CELL", 168, 183], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 186, 195], ["glutathione", "SIMPLE_CHEMICAL", 215, 226], ["peroxidase", "GENE_OR_GENE_PRODUCT", 243, 253], ["FhGST", "PROTEIN", 12, 17], ["S1", "PROTEIN", 18, 20], ["rFhGST", "PROTEIN", 186, 192], ["S1", "PROTEIN", 193, 195], ["lipid peroxidase", "PROTEIN", 237, 253], ["Recombinant FhGST", "TEST", 0, 17], ["natural GST substrates", "PROBLEM", 71, 93], ["the Schistosomiasis vaccine trialist", "TREATMENT", 130, 166], ["rFhGST", "TEST", 186, 192], ["high glutathione-dependent lipid peroxidase activity", "PROBLEM", 210, 262], ["Schistosomiasis", "OBSERVATION", 134, 149], ["S1", "ANATOMY", 193, 195], ["high glutathione", "OBSERVATION", 210, 226], ["dependent", "OBSERVATION_MODIFIER", 227, 236], ["lipid", "OBSERVATION", 237, 242], ["peroxidase activity", "OBSERVATION", 243, 262]]], ["Reasonably high GSH-dependent lipid peroxidase activity has also been seen in a 'weak affinity' fraction following chromatofocusing of GSH transferase activity that failed to bind GSH-sepharose [10] .", [["GSH", "CHEMICAL", 16, 19], ["GSH", "CHEMICAL", 135, 138], ["GSH", "CHEMICAL", 180, 183], ["GSH", "CHEMICAL", 16, 19], ["GSH", "CHEMICAL", 135, 138], ["GSH", "CHEMICAL", 180, 183], ["GSH", "SIMPLE_CHEMICAL", 16, 19], ["peroxidase", "GENE_OR_GENE_PRODUCT", 36, 46], ["GSH transferase", "GENE_OR_GENE_PRODUCT", 135, 150], ["GSH", "SIMPLE_CHEMICAL", 180, 183], ["lipid peroxidase", "PROTEIN", 30, 46], ["GSH transferase", "PROTEIN", 135, 150], ["dependent lipid peroxidase activity", "PROBLEM", 20, 55], ["a 'weak affinity' fraction", "PROBLEM", 78, 104], ["GSH transferase activity", "PROBLEM", 135, 159], ["high GSH", "OBSERVATION", 11, 19]]], ["ND -Not determined.Author Summary**Data taken from Walker et al. [47] . doi:10.1371/journal.pntd.0001666.t001Author SummarySigma Class Glutathione Transferase of F. hepatica www.plosntds.org 50 mM NaCl, 0.5 mM tryptophan, 1 mM hematin, 1 U COX-1 enzyme, 100 mM arachidonic acid (All Sigma, UK.", [["NaCl", "CHEMICAL", 197, 201], ["tryptophan", "CHEMICAL", 210, 220], ["hematin", "CHEMICAL", 227, 234], ["arachidonic acid", "CHEMICAL", 261, 277], ["Glutathione", "CHEMICAL", 135, 146], ["NaCl", "CHEMICAL", 197, 201], ["tryptophan", "CHEMICAL", 210, 220], ["hematin", "CHEMICAL", 227, 234], ["arachidonic acid", "CHEMICAL", 261, 277], ["Glutathione", "GENE_OR_GENE_PRODUCT", 135, 146], ["F. hepatica", "ORGANISM", 162, 173], ["tryptophan", "SIMPLE_CHEMICAL", 210, 220], ["hematin", "SIMPLE_CHEMICAL", 227, 234], ["COX-1", "GENE_OR_GENE_PRODUCT", 240, 245], ["arachidonic acid", "SIMPLE_CHEMICAL", 261, 277], ["F. hepatica", "SPECIES", 162, 173], ["F. hepatica", "SPECIES", 162, 173], ["ND", "PROBLEM", 0, 2], ["NaCl", "TEST", 197, 201], ["tryptophan", "TEST", 210, 220], ["COX", "TEST", 240, 243], ["enzyme", "TEST", 246, 252], ["mM arachidonic acid", "TEST", 258, 277], ["hepatica", "ANATOMY", 165, 173]]], ["COX-1 [C0733]) and rFhGST-S1 at final concentration ranges of 0.1-100.0 mg/ml.", [["COX-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 19, 28], ["COX", "PROTEIN", 0, 3], ["rFhGST", "PROTEIN", 19, 25], ["COX", "TEST", 0, 3], ["rFhGST", "TEST", 19, 25]]], ["Negative control reactions lacking either GST or COX-1 were also prepared.", [["GST", "GENE_OR_GENE_PRODUCT", 42, 45], ["COX-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["GST", "PROTEIN", 42, 45], ["COX-1", "PROTEIN", 49, 54], ["COX", "TEST", 49, 52]]], ["Reactions were incubated for 5-10 min in a water bath at 37uC.", [["a water bath", "TREATMENT", 41, 53]]], ["This was followed by 4 minutes incubation at 25uC in a shaking water bath.", [["25uC", "CHEMICAL", 45, 49], ["a shaking water bath", "TREATMENT", 53, 73]]], ["Prostaglandins were extracted by adding 860 mL of ice-cold ethyl acetate.", [["ice-cold ethyl acetate", "CHEMICAL", 50, 72], ["ethyl acetate", "CHEMICAL", 59, 72], ["Prostaglandins", "SIMPLE_CHEMICAL", 0, 14], ["ethyl acetate", "SIMPLE_CHEMICAL", 59, 72], ["Prostaglandins", "TREATMENT", 0, 14], ["ice-cold ethyl acetate", "TREATMENT", 50, 72]]], ["The upper ethyl acetate layer was retained and solvent was evaporated under a nitrogen stream at 45uC.", [["ethyl acetate", "CHEMICAL", 10, 23], ["ethyl acetate", "CHEMICAL", 10, 23], ["nitrogen", "CHEMICAL", 78, 86], ["The upper ethyl acetate layer", "TREATMENT", 0, 29], ["a nitrogen stream", "TREATMENT", 76, 93], ["upper", "ANATOMY_MODIFIER", 4, 9]]], ["The remaining residue was reconstituted in 50 ml of methanol/water/fomic acid (25:75:0,1) mix at pH 2.8 and stored at 280uC until ready for mass spectrometry analysis.", [["fomic acid", "CHEMICAL", 67, 77], ["methanol", "CHEMICAL", 52, 60], ["fomic acid", "CHEMICAL", 67, 77], ["methanol", "SIMPLE_CHEMICAL", 52, 60], ["water", "SIMPLE_CHEMICAL", 61, 66], ["fomic acid", "SIMPLE_CHEMICAL", 67, 77], ["methanol/water/fomic acid", "TREATMENT", 52, 77], ["pH", "TEST", 97, 99], ["mass spectrometry analysis", "TEST", 140, 166]]], ["Standards of prostaglandins D2, E2 and F2a (Cayman, Ltd) were also prepared in methanol/water/ formic acid mix for analysis.Prostaglandin detectionThe nano LC-MS analyses were performed using a Waters Q-Tof micro mass spectrometer (Waters) coupled to a LC-Packings Ultimate nano LC system (Dionex).", [["prostaglandins", "CHEMICAL", 13, 27], ["E2", "CHEMICAL", 32, 34], ["formic acid", "CHEMICAL", 95, 106], ["Prostaglandin", "CHEMICAL", 124, 137], ["prostaglandins D2, E2 and F2a", "CHEMICAL", 13, 42], ["methanol", "CHEMICAL", 79, 87], ["formic acid", "CHEMICAL", 95, 106], ["Prostaglandin", "CHEMICAL", 124, 137], ["prostaglandins D2", "SIMPLE_CHEMICAL", 13, 30], ["E2", "SIMPLE_CHEMICAL", 32, 34], ["F2a", "SIMPLE_CHEMICAL", 39, 42], ["Cayman", "SIMPLE_CHEMICAL", 44, 50], ["Ltd", "GENE_OR_GENE_PRODUCT", 52, 55], ["methanol", "SIMPLE_CHEMICAL", 79, 87], ["water", "SIMPLE_CHEMICAL", 88, 93], ["formic acid", "SIMPLE_CHEMICAL", 95, 106], ["Prostaglandin", "SIMPLE_CHEMICAL", 124, 137], ["prostaglandins D2", "TREATMENT", 13, 30], ["E2 and F2a (Cayman", "TREATMENT", 32, 50], ["methanol/water/ formic acid mix", "TREATMENT", 79, 110], ["Prostaglandin detection", "TEST", 124, 147], ["The nano LC-MS analyses", "TEST", 147, 170], ["a Waters Q-Tof micro mass spectrometer", "TREATMENT", 192, 230], ["a LC-Packings Ultimate nano LC system", "TREATMENT", 251, 288]]], ["The pre-column used was a LC Packings C18 PepMap 100 and the nano LC column used was a LC Packings 15 cm PepMap 100 C18 (both Dionex).", [["PepMap 100 C18", "CHEMICAL", 105, 119], ["The pre-column", "TREATMENT", 0, 14], ["a LC Packings C18 PepMap", "TREATMENT", 24, 48], ["the nano LC column", "TREATMENT", 57, 75], ["a LC Packings", "TREATMENT", 85, 98]]], ["Samples were loaded on the pre-column with mobile phase A (25% methanol with 0.1% formic acid added).", [["Samples", "ANATOMY", 0, 7], ["formic acid", "CHEMICAL", 82, 93], ["methanol", "CHEMICAL", 63, 71], ["formic acid", "CHEMICAL", 82, 93], ["methanol", "SIMPLE_CHEMICAL", 63, 71], ["formic acid", "SIMPLE_CHEMICAL", 82, 93], ["Samples", "TEST", 0, 7], ["mobile phase A (25% methanol", "TREATMENT", 43, 71], ["0.1% formic acid", "TREATMENT", 77, 93]]], ["Loading flow rate was 0.03 ml/min for 6 min.", [["Loading flow rate", "TREATMENT", 0, 17]]], ["The samples were eluted on to the nano LC column using mobile phases B (60% acetonitrile) and C (100% methanol).", [["samples", "ANATOMY", 4, 11], ["acetonitrile", "CHEMICAL", 76, 88], ["methanol", "CHEMICAL", 102, 110], ["C", "SIMPLE_CHEMICAL", 94, 95], ["methanol", "SIMPLE_CHEMICAL", 102, 110], ["The samples", "TEST", 0, 11], ["mobile phases B (60% acetonitrile)", "TREATMENT", 55, 89], ["C (100% methanol", "TREATMENT", 94, 110]]], ["A typical gradient profile was 100% B to 100% C in 10 min (flow rate of 0.2 ml/min) with the column held at 100% C for 1 hour.", [["A typical gradient profile", "TEST", 0, 26], ["flow rate", "TEST", 59, 68], ["the column", "TREATMENT", 89, 99], ["gradient", "OBSERVATION_MODIFIER", 10, 18]]], ["The mass spectrometer was operated in the negative ion nano electrospray mode with a source temperature of 80uC and capillary voltage 2.8 kV.", [["capillary", "ANATOMY", 116, 125], ["capillary", "TISSUE", 116, 125], ["The mass spectrometer", "PROBLEM", 0, 21], ["a source temperature", "TEST", 83, 103], ["capillary voltage", "TEST", 116, 133], ["mass", "OBSERVATION", 4, 8]]], ["The scan range was 40 to 400 Da for 1.5 s.Prostaglandin detectionLiver fluke extract and excretory/secretory (ES) product preparation F. hepatica adults were collected, cultured in vitro for 4 h and the ES products collected and prepared as previously described [40] .", [["ES", "ANATOMY", 110, 112], ["Prostaglandin detectionLiver fluke extract", "CHEMICAL", 42, 84], ["Prostaglandin", "CHEMICAL", 42, 55], ["F. hepatica", "ORGANISM", 134, 145], ["adults", "ORGANISM", 146, 152], ["F. hepatica", "SPECIES", 134, 145], ["F. hepatica", "SPECIES", 134, 145], ["The scan range", "TEST", 0, 14], ["Prostaglandin detectionLiver fluke extract", "TEST", 42, 84], ["the ES products", "TREATMENT", 199, 214], ["hepatica", "ANATOMY", 137, 145]]], ["Newly excysted juveniles (NEJ) were excysted from metacercariea in vitro and cultured in Fasciola saline for 4 h post excystment as previously described [41] .", [["NEJ", "ANATOMY", 26, 29], ["NEJ", "CANCER", 26, 29], ["Fasciola saline", "ORGANISM", 89, 104], ["Newly excysted juveniles (NEJ)", "PROBLEM", 0, 30], ["vitro", "TREATMENT", 67, 72], ["Fasciola saline", "TREATMENT", 89, 104], ["juveniles", "OBSERVATION", 15, 24]]], ["F. hepatica (adult and NEJ) soluble fractions were obtained by homogenisation of frozen fluke at 4uC in a glass grinder in lysis buffer (20 mM KHPO 4 , pH 7.0, 0.1% Triton-X100 and a cocktail of protease inhibitors [Roche, Complete-Mini, EDTA-free]).", [["NEJ", "ANATOMY", 23, 26], ["4uC", "CHEMICAL", 97, 100], ["Triton-X100", "CHEMICAL", 165, 176], ["KHPO 4", "CHEMICAL", 143, 149], ["Triton-X100", "CHEMICAL", 165, 176], ["EDTA", "CHEMICAL", 238, 242], ["F. hepatica", "ORGANISM", 0, 11], ["NEJ", "CELL", 23, 26], ["4uC", "SIMPLE_CHEMICAL", 97, 100], ["Triton-X100", "SIMPLE_CHEMICAL", 165, 176], ["EDTA", "SIMPLE_CHEMICAL", 238, 242], ["F. hepatica", "SPECIES", 0, 11], ["F. hepatica", "SPECIES", 0, 11], ["adult and NEJ) soluble fractions", "TREATMENT", 13, 45], ["a glass grinder in lysis buffer", "TREATMENT", 104, 135], ["KHPO", "TEST", 143, 147], ["pH", "TEST", 152, 154], ["protease inhibitors", "TREATMENT", 195, 214], ["hepatica", "ANATOMY", 3, 11]]], ["Homogenates were centrifuged at 100,0006 g for 1 h at 4uC.", [["Homogenates", "ANATOMY", 0, 11], ["Homogenates", "ORGANISM_SUBSTANCE", 0, 11]]], ["Supernatants were considered as the soluble cytosolic fraction.", [["Supernatants", "ANATOMY", 0, 12], ["cytosolic", "ANATOMY", 44, 53], ["Supernatants", "CELL", 0, 12], ["the soluble cytosolic fraction", "TEST", 32, 62]]], ["Cytosolic protein extracts were treated and resolved by 2DE as described previously [11] .", [["Cytosolic", "ANATOMY", 0, 9], ["extracts", "ANATOMY", 18, 26], ["extracts", "ORGANISM_SUBSTANCE", 18, 26], ["Cytosolic protein extracts", "TEST", 0, 26]]], ["F. hepatica eggs were isolated, cultured and protein extracted as previously described [42] .Western blottingRecombinant F. hepatica Sigma GST (rFhGST-S1), and native F. hepatica S-hexylGSH-affinity purified GST samples (and human/rat recombinant PGD-synthase) were subjected to standard SDS-PAGE and 2DE, electro-transferred to membranes [43, 44] and western blotted with a polyclonal antibody (1:20,000 dilution) raised in rabbits to the recombinant F. hepatica Sigma GST by Lampire Biological Laboratories, USA.", [["eggs", "ANATOMY", 12, 16], ["samples", "ANATOMY", 212, 219], ["membranes", "ANATOMY", 329, 338], ["F. hepatica", "ORGANISM", 0, 11], ["eggs", "ORGANISM", 12, 16], ["F. hepatica", "ORGANISM", 121, 132], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 133, 142], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 144, 153], ["F. hepatica", "ORGANISM", 167, 178], ["GST", "GENE_OR_GENE_PRODUCT", 208, 211], ["human", "ORGANISM", 225, 230], ["rat", "ORGANISM", 231, 234], ["PGD-synthase", "GENE_OR_GENE_PRODUCT", 247, 259], ["membranes", "CELLULAR_COMPONENT", 329, 338], ["rabbits", "ORGANISM", 425, 432], ["F. hepatica", "ORGANISM", 452, 463], ["Sigma GST", "ORGANISM", 464, 473], ["Recombinant F. hepatica Sigma GST", "PROTEIN", 109, 142], ["rFhGST", "PROTEIN", 144, 150], ["S1", "PROTEIN", 151, 153], ["native F. hepatica S-hexylGSH-affinity purified GST samples", "PROTEIN", 160, 219], ["human/rat recombinant PGD-synthase", "PROTEIN", 225, 259], ["polyclonal antibody", "PROTEIN", 375, 394], ["recombinant F. hepatica Sigma GST", "PROTEIN", 440, 473], ["F. hepatica", "SPECIES", 0, 11], ["F. hepatica", "SPECIES", 121, 132], ["F. hepatica", "SPECIES", 167, 178], ["human", "SPECIES", 225, 230], ["rat", "SPECIES", 231, 234], ["rabbits", "SPECIES", 425, 432], ["F. hepatica", "SPECIES", 452, 463], ["F. hepatica", "SPECIES", 0, 11], ["F. hepatica", "SPECIES", 121, 132], ["F. hepatica", "SPECIES", 167, 178], ["human", "SPECIES", 225, 230], ["rat", "SPECIES", 231, 234], ["rabbits", "SPECIES", 425, 432], ["F. hepatica", "SPECIES", 452, 463], ["F. hepatica eggs", "TEST", 0, 16], ["protein", "TEST", 45, 52], ["hepatica Sigma GST", "TEST", 124, 142], ["rFhGST", "TEST", 144, 150], ["hexylGSH", "TEST", 181, 189], ["GST samples", "TEST", 208, 219], ["human/rat recombinant PGD-synthase", "TREATMENT", 225, 259], ["a polyclonal antibody", "TEST", 373, 394], ["hepatica", "ANATOMY", 3, 11], ["hepatica", "ANATOMY", 124, 132], ["hepatica", "ANATOMY", 170, 178], ["hepatica", "ANATOMY", 455, 463]]], ["Membranes were also probed with Mu class GST antibody (represented by the anti-Schistosoma japonicum GST26 Mu class antibody [1:1,000 dilution] and an anti-rat PGD-synthase antibody [1:1,000 dilution], Pharmacia-Biotech 27-4577).", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["Mu class GST", "GENE_OR_GENE_PRODUCT", 32, 44], ["anti-Schistosoma japonicum", "ORGANISM", 74, 100], ["Mu class antibody", "GENE_OR_GENE_PRODUCT", 107, 124], ["anti-rat PGD-synthase", "GENE_OR_GENE_PRODUCT", 151, 172], ["Mu class GST antibody", "PROTEIN", 32, 53], ["anti-Schistosoma japonicum GST26 Mu class antibody", "PROTEIN", 74, 124], ["anti-rat PGD-synthase antibody", "PROTEIN", 151, 181], ["anti-Schistosoma japonicum", "SPECIES", 74, 100], ["anti-Schistosoma japonicum", "SPECIES", 74, 100], ["Mu class GST antibody", "TEST", 32, 53], ["the anti-Schistosoma japonicum", "TEST", 70, 100], ["an anti-rat PGD", "TEST", 148, 163], ["synthase antibody", "TEST", 164, 181], ["Pharmacia", "TEST", 202, 211]]], ["F. hepatica eggs, NEJs (somatic and ES preparations) and adults (somatic and ES preparations) were subjected to SDS-PAGE and also electro-transferred as described above and probed with the polyclonal antibody raised in rabbits to the recombinant F. hepatica Sigma GST.", [["eggs", "ANATOMY", 12, 16], ["NEJs", "ANATOMY", 18, 22], ["somatic", "ANATOMY", 24, 31], ["ES preparations", "ANATOMY", 36, 51], ["ES", "ANATOMY", 77, 79], ["F. hepatica", "ORGANISM", 0, 11], ["eggs", "ORGANISM", 12, 16], ["NEJs", "CELL", 18, 22], ["rabbits", "ORGANISM", 219, 226], ["F. hepatica", "ORGANISM", 246, 257], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 258, 267], ["polyclonal antibody", "PROTEIN", 189, 208], ["recombinant F. hepatica Sigma GST", "PROTEIN", 234, 267], ["F. hepatica", "SPECIES", 0, 11], ["rabbits", "SPECIES", 219, 226], ["F. hepatica", "SPECIES", 246, 257], ["F. hepatica", "SPECIES", 0, 11], ["rabbits", "SPECIES", 219, 226], ["F. hepatica", "SPECIES", 246, 257], ["the polyclonal antibody", "PROBLEM", 185, 208], ["hepatica", "ANATOMY", 3, 11], ["hepatica", "ANATOMY", 249, 257]]], ["All western blots were developed as described previously [11] .Western blottingImmunolocalisation studies F. hepatica Sigma class GST (FhGST-S1) was detected by immunohistology in tissue sections of whole adult F. hepatica extracted from bile ducts of sheep liver and also in situ from sections of liver.Western blottingStaining for FhGST-S1 was performed on formalin-fixed and paraffin-embedded tissue sections according to the method described previously [45] .", [["tissue sections", "ANATOMY", 180, 195], ["bile ducts", "ANATOMY", 238, 248], ["liver", "ANATOMY", 258, 263], ["sections", "ANATOMY", 286, 294], ["liver", "ANATOMY", 298, 303], ["tissue sections", "ANATOMY", 396, 411], ["formalin", "CHEMICAL", 359, 367], ["paraffin", "CHEMICAL", 378, 386], ["F. hepatica", "ORGANISM", 106, 117], ["Sigma class GST", "GENE_OR_GENE_PRODUCT", 118, 133], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 135, 143], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 180, 195], ["F. hepatica", "ORGANISM", 211, 222], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 238, 248], ["sheep", "ORGANISM", 252, 257], ["liver", "ORGAN", 258, 263], ["liver", "ORGAN", 298, 303], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 333, 341], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 396, 411], ["F. hepatica Sigma class GST", "PROTEIN", 106, 133], ["FhGST", "PROTEIN", 135, 140], ["S1", "PROTEIN", 141, 143], ["FhGST", "PROTEIN", 333, 338], ["S1", "PROTEIN", 339, 341], ["F. hepatica", "SPECIES", 106, 117], ["F. hepatica", "SPECIES", 211, 222], ["sheep", "SPECIES", 252, 257], ["F. hepatica", "SPECIES", 106, 117], ["F. hepatica", "SPECIES", 211, 222], ["sheep", "SPECIES", 252, 257], ["All western blots", "PROBLEM", 0, 17], ["Immunolocalisation studies", "TEST", 79, 105], ["bile ducts of sheep liver", "PROBLEM", 238, 263], ["FhGST", "TEST", 333, 338], ["formalin-fixed and paraffin-embedded tissue sections", "TREATMENT", 359, 411], ["hepatica", "ANATOMY", 109, 117], ["hepatica", "ANATOMY", 214, 222], ["bile ducts", "ANATOMY", 238, 248], ["sheep", "ANATOMY_MODIFIER", 252, 257], ["liver", "ANATOMY", 258, 263], ["liver", "ANATOMY", 298, 303], ["S1", "ANATOMY", 339, 341]]], ["Sections were washed in Tris-buffered saline (TBS; 0.1 M Tris-HCl with 0.9% NaCl [pH 7.2]), treated with 0.05% (w/v) protease (type XXIV, bacterial: Sigma) in TBS for 5 min at 37uC for antigen retrieval, before three further 5 min washes in ice-cold TBS.", [["Tris-HCl", "CHEMICAL", 57, 65], ["NaCl", "CHEMICAL", 76, 80], ["Tris", "CHEMICAL", 24, 28], ["Tris-HCl", "CHEMICAL", 57, 65], ["NaCl", "CHEMICAL", 76, 80], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 24, 44], ["Tris-HCl", "SIMPLE_CHEMICAL", 57, 65], ["protease", "PROTEIN", 117, 125], ["buffered saline (TBS", "TREATMENT", 29, 49], ["Tris", "TEST", 57, 61], ["pH", "TEST", 82, 84], ["w/v) protease (type XXIV", "TREATMENT", 112, 136], ["antigen retrieval", "TREATMENT", 185, 202]]], ["Following TBS washes, sections were incubated for 10 min in 50% (v/v) swine serum in TBS followed by incubation for 15-18 h at 4uC in rFhGST-S1 polyclonal antibody (diluted at 1:500 in 20% swine serum in TBS).", [["sections", "ANATOMY", 22, 30], ["serum", "ANATOMY", 76, 81], ["serum", "ANATOMY", 195, 200], ["swine", "ORGANISM", 70, 75], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["swine", "ORGANISM", 189, 194], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["rFhGST", "PROTEIN", 134, 140], ["S1 polyclonal antibody", "PROTEIN", 141, 163], ["swine", "SPECIES", 70, 75], ["swine", "SPECIES", 189, 194], ["swine", "SPECIES", 70, 75], ["swine", "SPECIES", 189, 194], ["TBS washes", "TREATMENT", 10, 20], ["swine serum in TBS", "PROBLEM", 70, 88], ["rFhGST", "TEST", 134, 140], ["S1 polyclonal antibody", "TEST", 141, 163], ["serum in TBS", "TEST", 195, 207]]], ["Sections were again washed in TBS before further incubation at ambient temperature (approximately 20uC+/23uC) with anti-rabbit peroxidise anti-peroxidase (PAP; diluted at 1:100 in 20% swine serum in TBS).", [["serum", "ANATOMY", 190, 195], ["anti-rabbit peroxidise anti-peroxidase", "SIMPLE_CHEMICAL", 115, 153], ["PAP", "SIMPLE_CHEMICAL", 155, 158], ["swine", "ORGANISM", 184, 189], ["serum", "ORGANISM_SUBSTANCE", 190, 195], ["anti-rabbit peroxidise anti-peroxidase", "PROTEIN", 115, 153], ["PAP", "PROTEIN", 155, 158], ["anti-rabbit", "SPECIES", 115, 126], ["swine", "SPECIES", 184, 189], ["anti-rabbit", "SPECIES", 115, 126], ["swine", "SPECIES", 184, 189], ["ambient temperature", "TEST", 63, 82], ["anti-rabbit peroxidise anti-peroxidase (PAP", "TREATMENT", 115, 158]]], ["Following washes with TBS, sections were incubated, with stirring, for 10 min, with 3,3-diaminobenzidine tetrahydrochloride (DAB; Fluka, Buchs, Switzerland) with 0.01% v/v hydrogen peroxide in 0.1 M imidazole buffer pH 7.1, before counterstaining with Papanicolaou's hematoxylin for 30 s.", [["sections", "ANATOMY", 27, 35], ["3,3-diaminobenzidine tetrahydrochloride", "CHEMICAL", 84, 123], ["DAB", "CHEMICAL", 125, 128], ["M imidazole", "CHEMICAL", 197, 208], ["3,3-diaminobenzidine tetrahydrochloride", "CHEMICAL", 84, 123], ["DAB", "CHEMICAL", 125, 128], ["Fluka", "CHEMICAL", 130, 135], ["hydrogen peroxide", "CHEMICAL", 172, 189], ["imidazole", "CHEMICAL", 199, 208], ["hematoxylin", "CHEMICAL", 267, 278], ["3,3-diaminobenzidine tetrahydrochloride", "SIMPLE_CHEMICAL", 84, 123], ["DAB", "SIMPLE_CHEMICAL", 125, 128], ["Fluka", "SIMPLE_CHEMICAL", 130, 135], ["Buchs", "SIMPLE_CHEMICAL", 137, 142], ["v/v hydrogen peroxide", "SIMPLE_CHEMICAL", 168, 189], ["Papanicolaou", "SIMPLE_CHEMICAL", 252, 264], ["hematoxylin", "SIMPLE_CHEMICAL", 267, 278], ["diaminobenzidine tetrahydrochloride", "TREATMENT", 88, 123], ["0.01% v/v hydrogen peroxide", "TREATMENT", 162, 189], ["imidazole buffer pH", "TREATMENT", 199, 218], ["Papanicolaou's hematoxylin", "TREATMENT", 252, 278]]], ["Sections were then rinsed, dehydrated in alcohol, cleared in xylene, and mounted.", [["alcohol", "CHEMICAL", 41, 48], ["alcohol", "CHEMICAL", 41, 48], ["xylene", "CHEMICAL", 61, 67], ["alcohol", "SIMPLE_CHEMICAL", 41, 48], ["xylene", "SIMPLE_CHEMICAL", 61, 67]]], ["Consecutive sections from each tissue were used as negative controls in which the rFhGST-S1 polyclonal antibody was replaced by TBS.Induction of prostaglandin from dendritic cellsAnimals.", [["sections", "ANATOMY", 12, 20], ["tissue", "ANATOMY", 31, 37], ["dendritic cells", "ANATOMY", 164, 179], ["prostaglandin", "CHEMICAL", 145, 158], ["prostaglandin", "CHEMICAL", 145, 158], ["tissue", "TISSUE", 31, 37], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 82, 91], ["prostaglandin", "SIMPLE_CHEMICAL", 145, 158], ["dendritic cells", "CELL", 164, 179], ["rFhGST", "PROTEIN", 82, 88], ["S1 polyclonal antibody", "PROTEIN", 89, 111], ["TBS", "PROTEIN", 128, 131], ["dendritic cells", "CELL_TYPE", 164, 179], ["Consecutive sections from each tissue", "TEST", 0, 37], ["the rFhGST-S1 polyclonal antibody", "TEST", 78, 111], ["TBS", "TEST", 128, 131], ["Induction of prostaglandin", "TREATMENT", 132, 158], ["dendritic cells", "PROBLEM", 164, 179], ["dendritic cells", "OBSERVATION", 164, 179]]], ["C57BL/6 mice were purchased from Harlan Ltd (UK) and TLR4KO (on a C57BL/6 background) bone marrow cells were a gift from Professor Padraic Fallon (Trinity College Dublin, Ireland).", [["bone marrow cells", "ANATOMY", 86, 103], ["C57BL/6 mice", "ORGANISM", 0, 12], ["Harlan Ltd", "ORGANISM", 33, 43], ["UK", "GENE_OR_GENE_PRODUCT", 45, 47], ["TLR4KO", "GENE_OR_GENE_PRODUCT", 53, 59], ["C57BL/6 background", "ORGANISM", 66, 84], ["bone marrow cells", "CELL", 86, 103], ["bone marrow cells", "CELL_TYPE", 86, 103], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["TLR4KO", "TEST", 53, 59], ["a C57BL/6 background)", "TREATMENT", 64, 85], ["bone marrow cells", "PROBLEM", 86, 103], ["bone marrow", "ANATOMY", 86, 97]]], ["All mice were maintained according to the Irish Department of Children and Health.Induction of prostaglandin from dendritic cellsCell culturing and cytokine analysis.", [["dendritic cells", "ANATOMY", 114, 129], ["Cell", "ANATOMY", 129, 133], ["prostaglandin", "CHEMICAL", 95, 108], ["prostaglandin", "CHEMICAL", 95, 108], ["mice", "ORGANISM", 4, 8], ["prostaglandin", "SIMPLE_CHEMICAL", 95, 108], ["dendritic cells", "CELL", 114, 129], ["Cell", "CELL", 129, 133], ["dendritic cells", "CELL_TYPE", 114, 129], ["cytokine", "PROTEIN", 148, 156], ["mice", "SPECIES", 4, 8], ["Children", "SPECIES", 62, 70], ["mice", "SPECIES", 4, 8], ["Induction of prostaglandin", "TREATMENT", 82, 108], ["dendritic cells", "PROBLEM", 114, 129], ["Cell culturing", "TEST", 129, 143], ["cytokine analysis", "TEST", 148, 165], ["dendritic cells", "OBSERVATION", 114, 129]]], ["Bone marrowderived immature dendritic cells (DCs) were prepared by culturing bone marrow cells isolated from the femurs and tibia of C57BL/6j and TLR4 2/2 mice in complete RPMI 1640 (cRPMI; 5% [v/v] heat inactivated Fetal Calf Serum [FCS] [30 mins at 60uC], 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 50 mM 2-mercaptoethanol) with recombinant mouse GM-CSF (20 ng/ml; R&D Systems), at 37uC.", [["Bone", "ANATOMY", 0, 4], ["dendritic cells", "ANATOMY", 28, 43], ["DCs", "ANATOMY", 45, 48], ["bone marrow cells", "ANATOMY", 77, 94], ["femurs", "ANATOMY", 113, 119], ["tibia", "ANATOMY", 124, 129], ["RPMI 1640", "CHEMICAL", 172, 181], ["penicillin", "CHEMICAL", 267, 277], ["streptomycin", "CHEMICAL", 289, 301], ["L-glutamine", "CHEMICAL", 308, 319], ["2-mercaptoethanol", "CHEMICAL", 330, 347], ["GM", "CHEMICAL", 372, 374], ["penicillin", "CHEMICAL", 267, 277], ["streptomycin", "CHEMICAL", 289, 301], ["L-glutamine", "CHEMICAL", 308, 319], ["2-mercaptoethanol", "CHEMICAL", 330, 347], ["Bone", "TISSUE", 0, 4], ["dendritic cells", "CELL", 28, 43], ["DCs", "CELL", 45, 48], ["bone marrow cells", "CELL", 77, 94], ["femurs", "ORGAN", 113, 119], ["tibia", "ORGANISM_SUBDIVISION", 124, 129], ["C57BL/6j", "ORGANISM", 133, 141], ["TLR4", "GENE_OR_GENE_PRODUCT", 146, 150], ["mice", "ORGANISM", 155, 159], ["Serum", "ORGANISM_SUBSTANCE", 227, 232], ["penicillin", "SIMPLE_CHEMICAL", 267, 277], ["streptomycin", "SIMPLE_CHEMICAL", 289, 301], ["L-glutamine", "SIMPLE_CHEMICAL", 308, 319], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 330, 347], ["mouse", "ORGANISM", 366, 371], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 372, 378], ["Bone marrowderived immature dendritic cells", "CELL_TYPE", 0, 43], ["DCs", "CELL_TYPE", 45, 48], ["bone marrow cells", "CELL_TYPE", 77, 94], ["TLR4", "PROTEIN", 146, 150], ["CSF", "PROTEIN", 375, 378], ["mice", "SPECIES", 155, 159], ["mouse", "SPECIES", 366, 371], ["mice", "SPECIES", 155, 159], ["mouse", "SPECIES", 366, 371], ["Bone marrowderived immature dendritic cells", "PROBLEM", 0, 43], ["culturing bone marrow cells", "TEST", 67, 94], ["cRPMI", "TEST", 183, 188], ["v", "TEST", 196, 197], ["heat", "TEST", 199, 203], ["Fetal Calf Serum", "TEST", 216, 232], ["FCS", "TEST", 234, 237], ["penicillin", "TREATMENT", 267, 277], ["streptomycin", "TREATMENT", 289, 301], ["2 mM L-glutamine", "TREATMENT", 303, 319], ["mercaptoethanol", "TREATMENT", 332, 347], ["recombinant mouse GM-CSF", "TREATMENT", 354, 378], ["dendritic cells", "OBSERVATION", 28, 43], ["femurs", "ANATOMY", 113, 119], ["tibia", "ANATOMY", 124, 129]]], ["On days 3 and 6 of culture, fresh medium with GM-CSF (20 ng/ml) was added to the cells.", [["cells", "ANATOMY", 81, 86], ["GM", "CHEMICAL", 46, 48], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 46, 52], ["cells", "CELL", 81, 86], ["CSF", "PROTEIN", 49, 52], ["culture", "TEST", 19, 26], ["GM-CSF", "TREATMENT", 46, 52]]], ["On day 8, cells were harvested, counted and stained with CD11c (Caltag Laboratories) for analysis by flow cytometry to determine purity (.90%).", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["CD11c", "GENE_OR_GENE_PRODUCT", 57, 62], ["CD11c", "PROTEIN", 57, 62], ["Caltag Laboratories", "PROTEIN", 64, 83], ["analysis", "TEST", 89, 97], ["flow cytometry", "TEST", 101, 115], ["purity", "TEST", 129, 135]]], ["J774 cells and RAW264.7, murine macrophage cell lines were cultured in cRPMI 1640 medium containing 10% (v/v) FCS.", [["J774 cells", "ANATOMY", 0, 10], ["RAW264.7", "ANATOMY", 15, 23], ["macrophage cell lines", "ANATOMY", 32, 53], ["J774 cells", "CELL", 0, 10], ["RAW264.7", "CELL", 15, 23], ["murine", "ORGANISM", 25, 31], ["macrophage cell lines", "CELL", 32, 53], ["J774 cells", "CELL_LINE", 0, 10], ["RAW264.7", "CELL_LINE", 15, 23], ["murine macrophage cell lines", "CELL_LINE", 25, 53], ["murine", "SPECIES", 25, 31], ["J774 cells", "TEST", 0, 10], ["murine macrophage cell lines", "TEST", 25, 53], ["cRPMI", "TEST", 71, 76], ["FCS", "TEST", 110, 113], ["macrophage cell lines", "OBSERVATION", 32, 53]]], ["All cells were used to conduct experiments when they reached ,90% confluence.Induction of prostaglandin from dendritic cellsFor all experiments, cells were seeded into 24-well plates (Nunc) at 10 6 /ml in complete RPMI 1640 except for DCs where GM-CSF (5 ng/ml) was also added.", [["cells", "ANATOMY", 4, 9], ["dendritic cells", "ANATOMY", 109, 124], ["cells", "ANATOMY", 145, 150], ["DCs", "ANATOMY", 235, 238], ["prostaglandin", "CHEMICAL", 90, 103], ["GM", "CHEMICAL", 245, 247], ["prostaglandin", "CHEMICAL", 90, 103], ["cells", "CELL", 4, 9], ["prostaglandin", "SIMPLE_CHEMICAL", 90, 103], ["dendritic cells", "CELL", 109, 124], ["cells", "CELL", 145, 150], ["DCs", "CELL", 235, 238], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 245, 251], ["dendritic cells", "CELL_TYPE", 109, 124], ["DCs", "CELL_TYPE", 235, 238], ["CSF", "PROTEIN", 248, 251], ["All cells", "TREATMENT", 0, 9], ["Induction of prostaglandin", "TREATMENT", 77, 103], ["dendritic cells", "PROBLEM", 109, 124], ["CSF", "TEST", 248, 251], ["dendritic cells", "OBSERVATION", 109, 124]]], ["Cells were treated with medium only, rFhGST-S1 (10 mg) or LPS (Alexa; 100 ng/ml) for 18 h.", [["Cells", "ANATOMY", 0, 5], ["rFhGST-S1", "CHEMICAL", 37, 46], ["LPS", "CHEMICAL", 58, 61], ["Cells", "CELL", 0, 5], ["rFhGST-S1", "SIMPLE_CHEMICAL", 37, 46], ["LPS", "SIMPLE_CHEMICAL", 58, 61], ["Alexa", "SIMPLE_CHEMICAL", 63, 68], ["rFhGST-S1", "TREATMENT", 37, 46], ["LPS (Alexa", "TREATMENT", 58, 68]]], ["Levels of total prostaglandin (PG), prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2) were measured using the Cayman competitive EIA.", [["prostaglandin", "CHEMICAL", 16, 29], ["PG", "CHEMICAL", 31, 33], ["prostaglandin E2", "CHEMICAL", 36, 52], ["PGE2", "CHEMICAL", 54, 58], ["prostaglandin D2", "CHEMICAL", 64, 80], ["PGD2", "CHEMICAL", 82, 86], ["prostaglandin", "CHEMICAL", 16, 29], ["prostaglandin E2", "CHEMICAL", 36, 52], ["PGE2", "CHEMICAL", 54, 58], ["prostaglandin D2", "CHEMICAL", 64, 80], ["PGD2", "CHEMICAL", 82, 86], ["prostaglandin", "SIMPLE_CHEMICAL", 16, 29], ["PG", "SIMPLE_CHEMICAL", 31, 33], ["prostaglandin E2", "SIMPLE_CHEMICAL", 36, 52], ["PGE2", "SIMPLE_CHEMICAL", 54, 58], ["prostaglandin D2", "SIMPLE_CHEMICAL", 64, 80], ["PGD2", "SIMPLE_CHEMICAL", 82, 86], ["Cayman", "SIMPLE_CHEMICAL", 112, 118], ["Levels", "TEST", 0, 6], ["total prostaglandin (PG)", "TREATMENT", 10, 34], ["prostaglandin E2 (PGE2)", "TREATMENT", 36, 59], ["prostaglandin D2 (PGD2)", "TREATMENT", 64, 87]]], ["The values were calculated using free data analysis software available at www.caymanchem.com/analysis/ eia.", [["The values", "TEST", 0, 10], ["free data analysis", "TEST", 33, 51], ["eia", "TEST", 103, 106]]], ["Data are presented as the mean 6 SEM following subtraction Sigma Class Glutathione Transferase of F. hepatica www.plosntds.org of medium controls and are representative of two separate experiments.", [["Glutathione", "CHEMICAL", 71, 82], ["Glutathione", "CHEMICAL", 71, 82], ["Glutathione", "SIMPLE_CHEMICAL", 71, 82], ["F. hepatica", "ORGANISM", 98, 109], ["F. hepatica", "SPECIES", 98, 109], ["F. hepatica", "SPECIES", 98, 109], ["hepatica", "ANATOMY", 101, 109], ["medium controls", "OBSERVATION_MODIFIER", 130, 145]]], ["Prior to experimentation, rFhGST-S1 was assessed for endotoxin (i.e. LPS) contamination using the Pyrogene endotoxin detection system (Cambrex).Vaccination StrategyExperimental design.", [["endotoxin", "CHEMICAL", 53, 62], ["LPS", "CHEMICAL", 69, 72], ["Pyrogene", "CHEMICAL", 98, 106], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 26, 35], ["endotoxin", "SIMPLE_CHEMICAL", 53, 62], ["LPS", "SIMPLE_CHEMICAL", 69, 72], ["Pyrogene", "SIMPLE_CHEMICAL", 98, 106], ["rFhGST", "PROTEIN", 26, 32], ["experimentation", "TEST", 9, 24], ["rFhGST", "TEST", 26, 32], ["endotoxin", "PROBLEM", 53, 62], ["the Pyrogene endotoxin detection system", "TREATMENT", 94, 133], ["S1", "ANATOMY", 33, 35]]], ["Nineteen 5-month old, Malague\u00f1a breed goats were used for a vaccine trial.", [["goats", "ORGANISM", 38, 43], ["goats", "SPECIES", 38, 43], ["goats", "SPECIES", 38, 43], ["Malague\u00f1a breed goats", "TREATMENT", 22, 43], ["a vaccine trial", "TREATMENT", 58, 73]]], ["The animals were free of parasitic and infectious diseases as indicated by fecal analysis and absence of clinical signs.", [["parasitic and infectious diseases", "DISEASE", 25, 58], ["animals", "ORGANISM", 4, 11], ["fecal", "ORGANISM_SUBSTANCE", 75, 80], ["parasitic and infectious diseases", "PROBLEM", 25, 58], ["fecal analysis", "TEST", 75, 89], ["clinical signs", "PROBLEM", 105, 119], ["infectious", "OBSERVATION", 39, 49]]], ["Group 1 (n = 10) were immunized with two subcutaneous injections of 100 mg of rFhGST-S1 in 1 ml of Quil A in 1 ml of PBS each injection separated by 4 weeks.", [["subcutaneous", "ANATOMY", 41, 53], ["rFhGST-S1", "CHEMICAL", 78, 87], ["Quil A", "CHEMICAL", 99, 105], ["Quil A", "CHEMICAL", 99, 105], ["two subcutaneous injections", "TREATMENT", 37, 64], ["rFhGST", "TREATMENT", 78, 84], ["Quil A", "TREATMENT", 99, 105], ["PBS each injection", "TREATMENT", 117, 135]]], ["Group 2 (n = 9) served as an infected control and was immunized at the same time with 1 ml of Quil A in 1 ml of PBS.", [["Quil A", "CHEMICAL", 94, 100], ["Quil A", "CHEMICAL", 94, 100], ["Quil A", "SIMPLE_CHEMICAL", 94, 100], ["an infected control", "TREATMENT", 26, 45], ["Quil A", "TREATMENT", 94, 100], ["PBS", "TREATMENT", 112, 115], ["infected", "OBSERVATION", 29, 37]]], ["Twelve weeks after the first immunization, animals were orally infected with 100 F. hepatica metacercariae of bovine origin.", [["animals", "ORGANISM", 43, 50], ["F. hepatica metacercariae", "ORGANISM", 81, 106], ["bovine", "ORGANISM", 110, 116], ["F. hepatica", "SPECIES", 81, 92], ["bovine", "SPECIES", 110, 116], ["F. hepatica", "SPECIES", 81, 92], ["the first immunization", "TREATMENT", 19, 41], ["hepatica", "ANATOMY", 84, 92], ["metacercariae", "OBSERVATION", 93, 106], ["bovine origin", "OBSERVATION", 110, 123]]], ["Three animals from each group were killed at 7, 8 and 9 days post-infection to study hepatic changes and host response during the early stages post-infection; the remaining animals (7 and 6 goats per group) were killed 15 weeks after infection to study fluke burdens, fecal egg counts and hepatic lesions.", [["hepatic", "ANATOMY", 85, 92], ["fluke", "ANATOMY", 253, 258], ["egg", "ANATOMY", 274, 277], ["hepatic lesions", "ANATOMY", 289, 304], ["infection", "DISEASE", 234, 243], ["hepatic lesions", "DISEASE", 289, 304], ["hepatic", "ORGAN", 85, 92], ["goats", "ORGANISM", 190, 195], ["fluke", "ORGANISM", 253, 258], ["fecal", "ORGANISM_SUBSTANCE", 268, 273], ["egg", "ORGANISM_SUBSTANCE", 274, 277], ["hepatic lesions", "PATHOLOGICAL_FORMATION", 289, 304], ["goats", "SPECIES", 190, 195], ["goats", "SPECIES", 190, 195], ["study hepatic changes", "PROBLEM", 79, 100], ["host response", "PROBLEM", 105, 118], ["infection", "PROBLEM", 234, 243], ["study fluke burdens", "TEST", 247, 266], ["fecal egg counts", "TEST", 268, 284], ["hepatic lesions", "PROBLEM", 289, 304], ["hepatic", "ANATOMY", 85, 92], ["host response", "OBSERVATION", 105, 118], ["fecal egg counts", "OBSERVATION", 268, 284], ["hepatic", "ANATOMY", 289, 296], ["lesions", "OBSERVATION", 297, 304]]], ["All goats were sacrificed by intravenous injection of thiobarbital.", [["intravenous", "ANATOMY", 29, 40], ["thiobarbital", "CHEMICAL", 54, 66], ["thiobarbital", "CHEMICAL", 54, 66], ["goats", "ORGANISM", 4, 9], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 40], ["thiobarbital", "SIMPLE_CHEMICAL", 54, 66], ["goats", "SPECIES", 4, 9], ["goats", "SPECIES", 4, 9], ["thiobarbital", "TREATMENT", 54, 66]]], ["The experiment was approved by the Bioethical Committee of the University of Cordoba (N. 7119) and it was carried out according to European (86/609/CEE) and Spanish (RD 223/1988) directives for animal experimentation.Vaccination StrategyFluke burdens and morphometrics.", [["Vaccination", "TREATMENT", 217, 228]]], ["At necropsy, gallbladders and bile ducts were opened and flukes recovered.", [["gallbladders", "ANATOMY", 13, 25], ["bile ducts", "ANATOMY", 30, 40], ["flukes", "ANATOMY", 57, 63], ["gallbladders", "MULTI-TISSUE_STRUCTURE", 13, 25], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 30, 40], ["flukes", "PROBLEM", 57, 63], ["gallbladders", "ANATOMY", 13, 25], ["bile ducts", "ANATOMY", 30, 40], ["flukes", "OBSERVATION_MODIFIER", 57, 63], ["recovered", "OBSERVATION_MODIFIER", 64, 73]]], ["Llivers were cut (,1 cm pieces) and washed in hot water to collect the remaining flukes.", [["Llivers", "ANATOMY", 0, 7], ["flukes", "ANATOMY", 81, 87], ["flukes", "ORGAN", 81, 87], ["flukes", "OBSERVATION", 81, 87]]], ["Flukes were counted, measured and weighed.Vaccination StrategyFecal egg counts.", [["egg", "ANATOMY", 68, 71], ["Vaccination StrategyFecal egg counts", "TEST", 42, 78]]], ["Sedimentation techniques at 12 and 13 weeks after infection using four grams of feces were conducted to give eggs per gram (EPG).Vaccination StrategyPathological assessment.", [["infection", "DISEASE", 50, 59], ["feces", "ORGANISM", 80, 85], ["Sedimentation techniques", "TEST", 0, 24], ["infection", "PROBLEM", 50, 59], ["four grams of feces", "TREATMENT", 66, 85], ["Pathological assessment", "TEST", 149, 172]]], ["At necropsy livers were photographed by the visceral and diaphragmatic aspects for gross pathology evaluation as described previously [46] .", [["livers", "ANATOMY", 12, 18], ["visceral", "ANATOMY", 44, 52], ["livers", "ORGAN", 12, 18], ["visceral", "TISSUE", 44, 52], ["diaphragmatic", "ORGAN", 57, 70], ["gross pathology evaluation", "TEST", 83, 109], ["livers", "ANATOMY", 12, 18], ["visceral", "ANATOMY", 44, 52], ["diaphragmatic", "ANATOMY", 57, 70]]], ["Gross hepatic lesions were scored as: absent [2] ; mild [+] (less than 10% of hepatic surface affected); moderate [++] (10-25% of hepatic surface affected); severe [+++] (25-50% of hepatic surface affected) and very severe [++++] (more than 50% of hepatic surface affected).", [["hepatic lesions", "ANATOMY", 6, 21], ["hepatic surface", "ANATOMY", 78, 93], ["hepatic surface", "ANATOMY", 130, 145], ["hepatic surface", "ANATOMY", 181, 196], ["hepatic surface", "ANATOMY", 248, 263], ["Gross hepatic lesions", "CANCER", 0, 21], ["hepatic surface", "MULTI-TISSUE_STRUCTURE", 248, 263], ["Gross hepatic lesions", "PROBLEM", 0, 21], ["hepatic surface", "TEST", 181, 196], ["very severe [++++]", "PROBLEM", 211, 229], ["hepatic", "ANATOMY", 6, 13], ["lesions", "OBSERVATION", 14, 21], ["mild", "OBSERVATION_MODIFIER", 51, 55], ["hepatic", "ANATOMY", 78, 85], ["surface", "ANATOMY_MODIFIER", 86, 93], ["moderate", "OBSERVATION_MODIFIER", 105, 113], ["hepatic", "ANATOMY", 130, 137], ["surface", "ANATOMY_MODIFIER", 138, 145], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["hepatic", "ANATOMY", 181, 188], ["surface", "ANATOMY_MODIFIER", 189, 196], ["very", "OBSERVATION_MODIFIER", 211, 215], ["severe", "OBSERVATION_MODIFIER", 216, 222], ["hepatic", "ANATOMY", 248, 255], ["surface", "ANATOMY_MODIFIER", 256, 263]]], ["Tissue samples were collected from the left (6 samples) and right (2 samples) hepatic lobes, fixed in 10% buffered formalin and embedded in paraffin wax.", [["Tissue samples", "ANATOMY", 0, 14], ["left", "ANATOMY", 39, 43], ["samples", "ANATOMY", 47, 54], ["samples", "ANATOMY", 69, 76], ["hepatic lobes", "ANATOMY", 78, 91], ["formalin", "CHEMICAL", 115, 123], ["formalin", "CHEMICAL", 115, 123], ["paraffin", "CHEMICAL", 140, 148], ["Tissue samples", "CANCER", 0, 14], ["hepatic lobes", "MULTI-TISSUE_STRUCTURE", 78, 91], ["formalin", "SIMPLE_CHEMICAL", 115, 123], ["Tissue samples", "TEST", 0, 14], ["left", "ANATOMY_MODIFIER", 39, 43], ["right", "ANATOMY_MODIFIER", 60, 65], ["hepatic", "ANATOMY", 78, 85], ["lobes", "ANATOMY_MODIFIER", 86, 91], ["paraffin wax", "OBSERVATION", 140, 152]]], ["Tissue sections (4 mm) were stained with haematoxylin and eosin (HE) for the histopathological study.Vaccination StrategySpecific IgG response.", [["Tissue sections", "ANATOMY", 0, 15], ["haematoxylin", "CHEMICAL", 41, 53], ["eosin", "CHEMICAL", 58, 63], ["Tissue sections", "MULTI-TISSUE_STRUCTURE", 0, 15], ["haematoxylin", "SIMPLE_CHEMICAL", 41, 53], ["eosin", "SIMPLE_CHEMICAL", 58, 63], ["IgG", "PROTEIN", 130, 133], ["Tissue sections", "TEST", 0, 15], ["haematoxylin", "TEST", 41, 53], ["eosin", "TEST", 58, 63], ["the histopathological study", "TEST", 73, 100]]], ["Specific IgG anti-rFhGST-S1were measured using the ELISA method as described previously [46] .", [["IgG", "GENE_OR_GENE_PRODUCT", 9, 12], ["IgG anti-rFhGST", "PROTEIN", 9, 24], ["S1were", "PROTEIN", 25, 31], ["Specific IgG anti-rFhGST", "TEST", 0, 24], ["the ELISA method", "TEST", 47, 63]]], ["A total of 10 mg/ml of rFhGST-S1 was used to coat microtitre plates, 100 ml/well of goat sera diluted in blocking buffer and rabbit antigoat IgG peroxidase conjugated (whole molecule -Sigma) diluted in blocking buffer at 1:10000.", [["sera", "ANATOMY", 89, 93], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 23, 32], ["goat", "ORGANISM", 84, 88], ["sera", "ORGANISM_SUBSTANCE", 89, 93], ["rabbit", "ORGANISM", 125, 131], ["rFhGST", "PROTEIN", 23, 29], ["S1", "PROTEIN", 30, 32], ["rabbit antigoat IgG peroxidase", "PROTEIN", 125, 155], ["goat", "SPECIES", 84, 88], ["rabbit", "SPECIES", 125, 131], ["goat", "SPECIES", 84, 88], ["rabbit", "SPECIES", 125, 131], ["rFhGST-S1", "TREATMENT", 23, 32], ["coat microtitre plates", "TREATMENT", 45, 67], ["goat sera", "TREATMENT", 84, 93], ["blocking buffer", "TREATMENT", 105, 120], ["rabbit antigoat IgG peroxidase", "TREATMENT", 125, 155], ["blocking buffer", "TREATMENT", 202, 217]]], ["Serum pools were from ten experimentally infected goats and ten uninfected goats as positive and negative controls, respectively.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["goats", "ORGANISM", 50, 55], ["goats", "ORGANISM", 75, 80], ["goats", "SPECIES", 50, 55], ["goats", "SPECIES", 75, 80], ["goats", "SPECIES", 50, 55], ["goats", "SPECIES", 75, 80], ["Serum pools", "TEST", 0, 11]]], ["All samples were analysed in duplicate.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["Results were expressed as antibody titre (Log10).Expression, purification and characterisation of rFhGST-S1Aligning Sigma class GSTs of trematodes shows the extent of identity and similarity across this class of GSTs ( Figure S1 ).", [["rFhGST-S1Aligning Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 98, 132], ["GSTs", "GENE_OR_GENE_PRODUCT", 212, 216], ["rFhGST", "PROTEIN", 98, 104], ["S1Aligning Sigma class GSTs", "PROTEIN", 105, 132], ["GSTs", "PROTEIN", 212, 216], ["Figure S1", "PROTEIN", 219, 228], ["antibody titre", "TEST", 26, 40], ["rFhGST", "TEST", 98, 104], ["trematodes", "OBSERVATION", 136, 146], ["extent", "OBSERVATION_MODIFIER", 157, 163]]], ["An amino acid sequence comparison of FhGST-S1 with other trematode GSTs places FhGST-S1 into the Sigma class of GSTs, with identities averaging approximately 45%.", [["amino acid", "CHEMICAL", 3, 13], ["amino acid", "CHEMICAL", 3, 13], ["amino acid", "AMINO_ACID", 3, 13], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 37, 45], ["trematode GSTs", "GENE_OR_GENE_PRODUCT", 57, 71], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 79, 87], ["GSTs", "GENE_OR_GENE_PRODUCT", 112, 116], ["FhGST", "PROTEIN", 37, 42], ["S1", "PROTEIN", 43, 45], ["trematode GSTs", "PROTEIN", 57, 71], ["FhGST", "PROTEIN", 79, 84], ["S1", "PROTEIN", 85, 87], ["GSTs", "PROTEIN", 112, 116], ["An amino acid sequence", "TEST", 0, 22], ["FhGST", "TEST", 37, 42], ["other trematode GSTs", "TEST", 51, 71], ["identities", "TEST", 123, 133], ["trematode GSTs", "OBSERVATION", 57, 71]]], ["Comparison with the most closely matching mammalian GSTs shows sequence identities averaging only approximately 28% (Table S1 ).", [["mammalian GSTs", "GENE_OR_GENE_PRODUCT", 42, 56], ["mammalian GSTs", "PROTEIN", 42, 56], ["sequence identities", "TEST", 63, 82]]], ["Despite phylogenetic neighbour-joining trees place mammalian and trematode GSTs within the same broad Sigma class ( Figure S1 ) there remains a distinct separation of the trematode and mammalian clusters.Expression, purification and characterisation of rFhGST-S1Full sequence length recombinant F. hepatica Sigma Class GST (rFhGST-S1) was shown to be purified to a high level from transformed E. coli cytosol following expression yielding 57.3 mg of rFhGST-S1 from a 1 litre culture of BL21 (DE3) cells.", [["cytosol", "ANATOMY", 401, 408], ["DE3) cells", "ANATOMY", 492, 502], ["GSTs", "GENE_OR_GENE_PRODUCT", 75, 79], ["rFhGST", "GENE_OR_GENE_PRODUCT", 253, 259], ["F. hepatica", "ORGANISM", 295, 306], ["Sigma Class GST", "GENE_OR_GENE_PRODUCT", 307, 322], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 324, 333], ["E. coli", "ORGANISM", 393, 400], ["cytosol", "ORGANISM_SUBSTANCE", 401, 408], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 450, 459], ["BL21", "CELL", 486, 490], ["DE3) cells", "CELL", 492, 502], ["mammalian and trematode GSTs", "PROTEIN", 51, 79], ["rFhGST", "PROTEIN", 253, 259], ["S1Full sequence length recombinant F. hepatica Sigma Class GST", "PROTEIN", 260, 322], ["rFhGST", "PROTEIN", 324, 330], ["S1", "PROTEIN", 331, 333], ["rFhGST", "PROTEIN", 450, 456], ["S1", "PROTEIN", 457, 459], ["BL21 (DE3) cells", "CELL_LINE", 486, 502], ["F. hepatica", "SPECIES", 295, 306], ["E. coli", "SPECIES", 393, 400], ["F. hepatica", "SPECIES", 295, 306], ["E. coli", "SPECIES", 393, 400], ["BL21", "SPECIES", 486, 490], ["trematode GSTs", "PROBLEM", 65, 79], ["rFhGST", "TEST", 253, 259], ["a high level", "PROBLEM", 363, 375], ["transformed E. coli cytosol", "PROBLEM", 381, 408], ["rFhGST", "TEST", 450, 456], ["a 1 litre culture", "TEST", 465, 482], ["trematode GSTs", "OBSERVATION", 65, 79], ["distinct", "OBSERVATION_MODIFIER", 144, 152], ["separation", "OBSERVATION", 153, 163], ["trematode", "OBSERVATION", 171, 180], ["mammalian clusters", "OBSERVATION", 185, 203], ["hepatica", "ANATOMY", 298, 306]]], ["Purity was judged by the presence of a single band upon SDS-PAGE at the estimated size and a dominating single peak via ESI MS at the precise calculated theoretical mass for the complete protein sequence (Figure 1 ).", [["protein sequence", "PROTEIN", 187, 203], ["a single band upon SDS", "PROBLEM", 37, 59], ["the precise calculated theoretical mass", "PROBLEM", 130, 169], ["the complete protein sequence", "TEST", 174, 203], ["size", "OBSERVATION_MODIFIER", 82, 86], ["mass", "OBSERVATION", 165, 169]]], ["Analysing this fraction by 2D SDS-PAGE revealed a single protein resolving into 3 protein spots.", [["2D SDS", "TEST", 27, 33], ["a single protein", "PROBLEM", 48, 64], ["3 protein spots", "PROBLEM", 80, 95], ["protein spots", "OBSERVATION", 82, 95]]], ["Western blotting of the 2DE profile with anti-rFhGST-S1 antibody confirmed all 3 resolved protein spots as rFhGST-S1 (2DE and western blot data not shown).", [["anti-rFhGST-S1", "GENE_OR_GENE_PRODUCT", 41, 55], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 107, 116], ["anti-rFhGST", "PROTEIN", 41, 52], ["S1 antibody", "PROTEIN", 53, 64], ["rFhGST", "PROTEIN", 107, 113], ["S1", "PROTEIN", 114, 116], ["the 2DE profile", "TEST", 20, 35], ["anti-rFhGST-S1 antibody", "TEST", 41, 64], ["protein spots", "TEST", 90, 103], ["rFhGST", "TEST", 107, 113], ["2DE", "TEST", 118, 121], ["western blot data", "TEST", 126, 143]]], ["No recognition was seen probing the 3 spots with an anti-Mu class antibody.Expression, purification and characterisation of rFhGST-S1rFhGST-S1 was produced as an active protein, displaying significant enzymic activity towards the model GST substrate 1chloro-2,4-dinitrobenzene (CDNB) and a range of substrates commonly used to characterise GSTs (Table 1) .", [["1chloro-2,4-dinitrobenzene", "CHEMICAL", 250, 276], ["CDNB", "CHEMICAL", 278, 282], ["1chloro-2,4-dinitrobenzene", "CHEMICAL", 250, 276], ["CDNB", "CHEMICAL", 278, 282], ["rFhGST-S1rFhGST-S1", "GENE_OR_GENE_PRODUCT", 124, 142], ["GST", "GENE_OR_GENE_PRODUCT", 236, 239], ["1chloro-2,4-dinitrobenzene", "SIMPLE_CHEMICAL", 250, 276], ["CDNB", "SIMPLE_CHEMICAL", 278, 282], ["GSTs", "GENE_OR_GENE_PRODUCT", 340, 344], ["anti-Mu class antibody", "PROTEIN", 52, 74], ["rFhGST", "PROTEIN", 124, 130], ["S1rFhGST", "PROTEIN", 131, 139], ["S1", "PROTEIN", 140, 142], ["GSTs", "PROTEIN", 340, 344], ["an anti-Mu class antibody", "TREATMENT", 49, 74], ["rFhGST", "TEST", 124, 130], ["an active protein", "PROBLEM", 159, 176], ["significant enzymic activity", "PROBLEM", 189, 217], ["1chloro", "TEST", 250, 257], ["a range of substrates", "TREATMENT", 288, 309]]], ["F. hepatica GST is very similar in terms of its enzymatic profile to the GST of S. Sigma Class Glutathione Transferase of F. hepatica www.plosntds.org japonicum currently undergoing clinical vaccine trials.", [["Glutathione", "CHEMICAL", 95, 106], ["F. hepatica", "ORGANISM", 0, 11], ["GST", "GENE_OR_GENE_PRODUCT", 12, 15], ["GST", "GENE_OR_GENE_PRODUCT", 73, 76], ["Glutathione Transferase", "GENE_OR_GENE_PRODUCT", 95, 118], ["F. hepatica", "ORGANISM", 122, 133], ["org japonicum", "ORGANISM", 147, 160], ["F. hepatica GST", "PROTEIN", 0, 15], ["GST", "PROTEIN", 73, 76], ["S. Sigma Class Glutathione Transferase", "PROTEIN", 80, 118], ["F. hepatica", "SPECIES", 0, 11], ["F. hepatica", "SPECIES", 122, 133], ["org japonicum", "SPECIES", 147, 160], ["F. hepatica", "SPECIES", 0, 11], ["F. hepatica", "SPECIES", 122, 133], ["org japonicum", "SPECIES", 147, 160], ["F. hepatica GST", "TEST", 0, 15], ["org japonicum", "PROBLEM", 147, 160], ["clinical vaccine trials", "TREATMENT", 182, 205], ["hepatica", "ANATOMY", 3, 11], ["very", "OBSERVATION_MODIFIER", 19, 23], ["similar", "OBSERVATION_MODIFIER", 24, 31], ["hepatica", "ANATOMY", 125, 133]]], ["FhGST-S1 also displays higher glutathione-dependent lipid peroxidase activity compared to both Sm28GST and Sj26GST [47] .", [["glutathione", "CHEMICAL", 30, 41], ["glutathione", "CHEMICAL", 30, 41], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 0, 8], ["glutathione", "SIMPLE_CHEMICAL", 30, 41], ["peroxidase", "GENE_OR_GENE_PRODUCT", 58, 68], ["Sm28GST", "GENE_OR_GENE_PRODUCT", 95, 102], ["FhGST", "PROTEIN", 0, 5], ["S1", "PROTEIN", 6, 8], ["lipid peroxidase", "PROTEIN", 52, 68], ["Sm28GST", "PROTEIN", 95, 102], ["FhGST", "TEST", 0, 5], ["higher glutathione-dependent lipid peroxidase activity", "PROBLEM", 23, 77], ["higher glutathione", "OBSERVATION", 23, 41], ["dependent", "OBSERVATION_MODIFIER", 42, 51], ["lipid", "OBSERVATION", 52, 57], ["peroxidase activity", "OBSERVATION", 58, 77]]], ["Interestingly, ligand inhibition studies on rFhGST-S1 showed the enzymic activity of rFhGST-S1 with CDNB was inhibited by the major pro-active form of the main liver fluke drug Triclabendazole.", [["liver fluke", "ANATOMY", 160, 171], ["CDNB", "CHEMICAL", 100, 104], ["Triclabendazole", "CHEMICAL", 177, 192], ["CDNB", "CHEMICAL", 100, 104], ["Triclabendazole", "CHEMICAL", 177, 192], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 44, 53], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 85, 94], ["CDNB", "SIMPLE_CHEMICAL", 100, 104], ["liver", "ORGAN", 160, 165], ["Triclabendazole", "SIMPLE_CHEMICAL", 177, 192], ["rFhGST", "PROTEIN", 44, 50], ["rFhGST", "PROTEIN", 85, 91], ["ligand inhibition studies", "TEST", 15, 40], ["rFhGST", "TEST", 44, 50], ["the enzymic activity of rFhGST", "PROBLEM", 61, 91], ["CDNB", "TEST", 100, 104], ["Triclabendazole", "TREATMENT", 177, 192], ["main", "ANATOMY_MODIFIER", 155, 159], ["liver", "ANATOMY", 160, 165], ["fluke drug Triclabendazole", "OBSERVATION", 166, 192]]], ["The sulphoxide derivative (TCBZ SO) gave an IC50 (50% enzyme inhibition) of 5765 mM (5 replicates).", [["sulphoxide", "CHEMICAL", 4, 14], ["TCBZ SO", "CHEMICAL", 27, 34], ["sulphoxide", "CHEMICAL", 4, 14], ["TCBZ SO", "CHEMICAL", 27, 34], ["sulphoxide derivative", "SIMPLE_CHEMICAL", 4, 25], ["TCBZ SO", "SIMPLE_CHEMICAL", 27, 34], ["The sulphoxide derivative (TCBZ SO", "TREATMENT", 0, 34], ["an IC50 (50% enzyme inhibition", "TREATMENT", 41, 71]]], ["Bile acids, potentially natural ligands for liver fluke tegumental associated proteins in the host bile environment, were also assessed for activity inhibition.", [["Bile", "ANATOMY", 0, 4], ["liver", "ANATOMY", 44, 49], ["tegumental", "ANATOMY", 56, 66], ["bile", "ANATOMY", 99, 103], ["Bile acids", "CHEMICAL", 0, 10], ["Bile acids", "CHEMICAL", 0, 10], ["Bile acids", "SIMPLE_CHEMICAL", 0, 10], ["liver", "ORGAN", 44, 49], ["bile", "MULTI-TISSUE_STRUCTURE", 99, 103], ["liver fluke tegumental associated proteins", "PROTEIN", 44, 86], ["Bile acids", "TEST", 0, 10], ["liver fluke", "PROBLEM", 44, 55], ["activity inhibition", "TREATMENT", 140, 159], ["acids", "OBSERVATION", 5, 10], ["natural ligands", "OBSERVATION", 24, 39], ["liver", "ANATOMY", 44, 49], ["fluke", "OBSERVATION", 50, 55], ["proteins", "OBSERVATION", 78, 86], ["bile", "ANATOMY", 99, 103]]], ["The rFhGST-S1 interacted with all three bile acids tested using five replicate assays: Cholic acid (IC50 302673 mM); Deoxycholic acid (IC50 223621 mM) and Chenodeoxycholic acid (IC50 6469 mM) .Expression, purification and characterisation of rFhGST-S1Previous studies on the Sigma class GSTs from both mammals and helminth parasites have revealed a capacity to synthesise Prostaglandin D2 (PGD2) and PGE2.", [["Cholic acid", "CHEMICAL", 87, 98], ["Deoxycholic acid", "CHEMICAL", 117, 133], ["Chenodeoxycholic acid", "CHEMICAL", 155, 176], ["Prostaglandin D2", "CHEMICAL", 372, 388], ["PGD2", "CHEMICAL", 390, 394], ["PGE2", "CHEMICAL", 400, 404], ["bile acids", "CHEMICAL", 40, 50], ["Cholic acid", "CHEMICAL", 87, 98], ["Deoxycholic acid", "CHEMICAL", 117, 133], ["Chenodeoxycholic acid", "CHEMICAL", 155, 176], ["Prostaglandin D2", "CHEMICAL", 372, 388], ["PGD2", "CHEMICAL", 390, 394], ["PGE2", "CHEMICAL", 400, 404], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 4, 13], ["bile acids", "SIMPLE_CHEMICAL", 40, 50], ["Cholic acid", "SIMPLE_CHEMICAL", 87, 98], ["Deoxycholic acid", "SIMPLE_CHEMICAL", 117, 133], ["Chenodeoxycholic acid", "SIMPLE_CHEMICAL", 155, 176], ["rFhGST", "GENE_OR_GENE_PRODUCT", 242, 248], ["Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 275, 291], ["Prostaglandin D2", "GENE_OR_GENE_PRODUCT", 372, 388], ["PGD2", "SIMPLE_CHEMICAL", 390, 394], ["PGE2", "SIMPLE_CHEMICAL", 400, 404], ["rFhGST", "PROTEIN", 4, 10], ["S1", "PROTEIN", 11, 13], ["rFhGST", "PROTEIN", 242, 248], ["Sigma class GSTs", "PROTEIN", 275, 291], ["The rFhGST", "TEST", 0, 10], ["all three bile acids", "TEST", 30, 50], ["Cholic acid", "TEST", 87, 98], ["IC50", "TEST", 100, 104], ["Deoxycholic acid", "TEST", 117, 133], ["IC50", "TEST", 135, 139], ["Chenodeoxycholic acid (IC50", "TREATMENT", 155, 182], ["rFhGST", "TEST", 242, 248], ["helminth parasites", "TEST", 314, 332], ["Prostaglandin D2 (PGD2)", "TREATMENT", 372, 395], ["PGE2", "TREATMENT", 400, 404]]], ["Since prostaglandin synthase activity may be a conserved role of Sigma class GSTs, we also tested the ability of rFhGST-S1 to synthesise prostaglandin eicosanoids using a coupled assay with COX-1.", [["prostaglandin", "CHEMICAL", 6, 19], ["prostaglandin eicosanoids", "CHEMICAL", 137, 162], ["prostaglandin", "CHEMICAL", 6, 19], ["prostaglandin eicosanoids", "CHEMICAL", 137, 162], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 6, 28], ["Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 65, 81], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 113, 122], ["prostaglandin eicosanoids", "SIMPLE_CHEMICAL", 137, 162], ["COX-1", "GENE_OR_GENE_PRODUCT", 190, 195], ["prostaglandin synthase", "PROTEIN", 6, 28], ["Sigma class GSTs", "PROTEIN", 65, 81], ["rFhGST", "PROTEIN", 113, 119], ["S1", "PROTEIN", 120, 122], ["COX-1", "PROTEIN", 190, 195], ["prostaglandin synthase activity", "TREATMENT", 6, 37], ["rFhGST", "TEST", 113, 119], ["synthesise prostaglandin eicosanoids", "TREATMENT", 126, 162], ["a coupled assay", "TEST", 169, 184], ["COX", "TEST", 190, 193]]], ["COX-1 catalyses the conversion of arachidonic acid to the H2 form before the prostaglandin isomer is converted to either the D or E form.", [["arachidonic acid", "CHEMICAL", 34, 50], ["prostaglandin isomer", "CHEMICAL", 77, 97], ["arachidonic acid", "CHEMICAL", 34, 50], ["H2", "CHEMICAL", 58, 60], ["prostaglandin", "CHEMICAL", 77, 90], ["COX-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["arachidonic acid", "SIMPLE_CHEMICAL", 34, 50], ["prostaglandin isomer", "SIMPLE_CHEMICAL", 77, 97], ["D", "SIMPLE_CHEMICAL", 125, 126], ["COX-1", "PROTEIN", 0, 5], ["D or E form", "PROTEIN", 125, 136], ["COX", "TEST", 0, 3], ["arachidonic acid", "TREATMENT", 34, 50], ["the prostaglandin isomer", "TREATMENT", 73, 97]]], ["Nano-LC/MS analysis enabled us to detect the presence of both PGD2 and PGE2 in the assay mixture with the PGD2 form being the more abundant of the two prostanoids ( Figure 2 ).", [["PGD2", "CHEMICAL", 62, 66], ["PGE2", "CHEMICAL", 71, 75], ["PGD2", "CHEMICAL", 106, 110], ["PGD2", "CHEMICAL", 62, 66], ["PGE2", "CHEMICAL", 71, 75], ["prostanoids", "CHEMICAL", 151, 162], ["PGD2", "SIMPLE_CHEMICAL", 62, 66], ["PGE2", "SIMPLE_CHEMICAL", 71, 75], ["PGD2", "SIMPLE_CHEMICAL", 106, 110], ["LC/MS analysis", "TEST", 5, 19], ["both PGD2 and PGE2 in the assay mixture", "TEST", 57, 96]]], ["While some PGE2 in the mixture could have arisen from rapid degradation of the unstable PGH2, nano-LC-MS was unable to detect either PGD2 or PGE2 in negative control reactions lacking either COX-1 or GST.", [["PGE2", "CHEMICAL", 11, 15], ["PGH2", "CHEMICAL", 88, 92], ["PGD2", "CHEMICAL", 133, 137], ["PGE2", "CHEMICAL", 141, 145], ["PGE2", "CHEMICAL", 11, 15], ["PGH2", "CHEMICAL", 88, 92], ["PGD2", "CHEMICAL", 133, 137], ["PGE2", "CHEMICAL", 141, 145], ["PGE2", "SIMPLE_CHEMICAL", 11, 15], ["PGH2", "SIMPLE_CHEMICAL", 88, 92], ["PGD2", "SIMPLE_CHEMICAL", 133, 137], ["PGE2", "SIMPLE_CHEMICAL", 141, 145], ["COX-1", "GENE_OR_GENE_PRODUCT", 191, 196], ["GST", "GENE_OR_GENE_PRODUCT", 200, 203], ["COX-1", "PROTEIN", 191, 196], ["GST", "PROTEIN", 200, 203], ["some PGE2 in the mixture", "PROBLEM", 6, 30], ["the unstable PGH2", "PROBLEM", 75, 92], ["PGD2", "PROBLEM", 133, 137], ["PGE2 in negative control reactions", "PROBLEM", 141, 175], ["COX", "TEST", 191, 194], ["PGE2", "OBSERVATION", 11, 15], ["rapid", "OBSERVATION_MODIFIER", 54, 59]]], ["The rFhGST-S1 catalyses PGD2 formation in a concentration-dependent manner as previously described for rOvGST-1 [26] .", [["PGD2", "CHEMICAL", 24, 28], ["PGD2", "CHEMICAL", 24, 28], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 4, 13], ["PGD2", "SIMPLE_CHEMICAL", 24, 28], ["rOvGST-1", "GENE_OR_GENE_PRODUCT", 103, 111], ["rFhGST", "PROTEIN", 4, 10], ["S1", "PROTEIN", 11, 13], ["rOvGST", "PROTEIN", 103, 109], ["The rFhGST", "TEST", 0, 10], ["rOvGST", "TEST", 103, 109], ["S1", "ANATOMY", 11, 13], ["PGD2 formation", "OBSERVATION", 24, 38]]], ["PGD2 was also detected in coupled assays with rFhGST-S1 and COX-1 using an Enzyme Immno Assay (EIA) detection kit (Cayman) and showed similar results (results not shown).Tissue localisation of Sigma GSTFhGST-S1 was first identified in adult liver fluke in S-hexyl-GSH affinity isolated fractions of cytosol [11] .", [["Tissue", "ANATOMY", 170, 176], ["liver fluke", "ANATOMY", 241, 252], ["cytosol", "ANATOMY", 299, 306], ["PGD2", "CHEMICAL", 0, 4], ["S-hexyl-GSH", "CHEMICAL", 256, 267], ["PGD2", "CHEMICAL", 0, 4], ["S-hexyl-GSH", "CHEMICAL", 256, 267], ["PGD2", "SIMPLE_CHEMICAL", 0, 4], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 46, 55], ["COX-1", "GENE_OR_GENE_PRODUCT", 60, 65], ["Tissue", "TISSUE", 170, 176], ["Sigma GSTFhGST-S1", "GENE_OR_GENE_PRODUCT", 193, 210], ["liver", "ORGAN", 241, 246], ["fluke", "ORGANISM_SUBSTANCE", 247, 252], ["S-hexyl-GSH", "SIMPLE_CHEMICAL", 256, 267], ["cytosol", "ORGANISM_SUBSTANCE", 299, 306], ["rFhGST", "PROTEIN", 46, 52], ["S1", "PROTEIN", 53, 55], ["COX-1", "PROTEIN", 60, 65], ["Sigma GSTFhGST", "PROTEIN", 193, 207], ["S1", "PROTEIN", 208, 210], ["PGD2", "TEST", 0, 4], ["rFhGST", "TEST", 46, 52], ["COX", "TEST", 60, 63], ["an Enzyme Immno Assay", "TEST", 72, 93], ["Tissue localisation", "TEST", 170, 189], ["S-hexyl", "TEST", 256, 263], ["cytosol", "TEST", 299, 306], ["Sigma GSTFhGST", "OBSERVATION", 193, 207], ["S1", "ANATOMY", 208, 210], ["liver", "ANATOMY", 241, 246]]], ["Western blots confirmed the presence of FhGST-S1 in NEJs and adult flukes and further enabled us to identify the Sigma GST in relative abundance in egg extracts, suggesting that it may play a metabolic role in embryogenesis/reproduction (Figure 3) .", [["NEJs", "ANATOMY", 52, 56], ["adult flukes", "ANATOMY", 61, 73], ["egg extracts", "ANATOMY", 148, 160], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 40, 48], ["NEJs", "PATHOLOGICAL_FORMATION", 52, 56], ["adult flukes", "ORGAN", 61, 73], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 113, 122], ["egg extracts", "ORGANISM_SUBSTANCE", 148, 160], ["FhGST", "PROTEIN", 40, 45], ["S1", "PROTEIN", 46, 48], ["NEJs", "CELL_TYPE", 52, 56], ["Sigma GST", "PROTEIN", 113, 122], ["Western blots", "TEST", 0, 13], ["FhGST-S1 in NEJs", "PROBLEM", 40, 56], ["adult flukes", "PROBLEM", 61, 73], ["S1", "ANATOMY", 46, 48], ["NEJs", "ANATOMY", 52, 56]]], ["Western blot analyses demonstrate that FhGST-S1 is consistently expressed during the course of in vitro parasite embryonation (days 1-9, only data for days 2, 7 and 9 shown in Figure 3 ).", [["FhGST-S1", "GENE_OR_GENE_PRODUCT", 39, 47], ["FhGST", "PROTEIN", 39, 44], ["S1", "PROTEIN", 45, 47], ["Western blot analyses", "TEST", 0, 21]]], ["In contrast, immunoblot analysis of freshly voided (day 0) eggs reveals that expression of the Sigma class GST is greatly reduced at the time of voiding from the host (Figure 3) .", [["Sigma class GST", "GENE_OR_GENE_PRODUCT", 95, 110], ["Sigma class GST", "PROTEIN", 95, 110], ["immunoblot analysis", "TEST", 13, 32], ["the Sigma class GST", "PROBLEM", 91, 110], ["greatly", "OBSERVATION_MODIFIER", 114, 121], ["reduced", "OBSERVATION_MODIFIER", 122, 129]]], ["However, immunolocalisation studies of adult parasites revealed an abundance of FhGST-S1 in the vitelline cells and eggs, emphasising the likely importance of this enzyme in egg formation and development.", [["vitelline cells", "ANATOMY", 96, 111], ["eggs", "ANATOMY", 116, 120], ["egg", "ANATOMY", 174, 177], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 80, 88], ["vitelline cells", "CELL", 96, 111], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 116, 120], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 174, 177], ["FhGST", "PROTEIN", 80, 85], ["S1", "PROTEIN", 86, 88], ["vitelline cells", "CELL_TYPE", 96, 111], ["immunolocalisation studies", "TEST", 9, 35], ["adult parasites", "PROBLEM", 39, 54], ["FhGST", "TEST", 80, 85], ["this enzyme", "TEST", 159, 170], ["vitelline cells", "ANATOMY", 96, 111]]], ["Some staining was also found in the parasite parenchyma and tegument, also suggesting a role at the hostparasite interface ( Figure 4) .", [["parenchyma", "ANATOMY", 45, 55], ["tegument", "ANATOMY", 60, 68], ["parasite parenchyma", "MULTI-TISSUE_STRUCTURE", 36, 55], ["tegument", "ORGANISM_SUBSTANCE", 60, 68], ["Some staining", "PROBLEM", 0, 13], ["staining", "OBSERVATION", 5, 13], ["parasite", "OBSERVATION", 36, 44], ["parenchyma", "ANATOMY_MODIFIER", 45, 55], ["tegument", "ANATOMY", 60, 68]]], ["Indeed, FhGST-S1 was detected in ES products of adult fluke cultured in vitro ( Figure 3 ) suggesting that the protein could, in principle, come into contact with the host immune system as it is released from the tegument during tegumental turnover and sloughing of the fluke body surface.", [["ES", "ANATOMY", 33, 35], ["adult fluke", "ANATOMY", 48, 59], ["immune system", "ANATOMY", 172, 185], ["tegument", "ANATOMY", 213, 221], ["tegumental", "ANATOMY", 229, 239], ["fluke body surface", "ANATOMY", 270, 288], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 8, 16], ["ES products", "CELL", 33, 44], ["adult fluke", "CELL", 48, 59], ["tegument", "CELLULAR_COMPONENT", 213, 221], ["tegumental", "CELLULAR_COMPONENT", 229, 239], ["body surface", "CELLULAR_COMPONENT", 276, 288], ["FhGST", "PROTEIN", 8, 13], ["S1", "PROTEIN", 14, 16], ["adult fluke", "PROBLEM", 48, 59], ["the protein", "PROBLEM", 107, 118], ["tegumental turnover", "PROBLEM", 229, 248], ["S1", "ANATOMY", 14, 16], ["sloughing", "OBSERVATION", 253, 262], ["fluke body", "OBSERVATION", 270, 280]]], ["Detection of prostaglandin synthase activity of rFhGST-S1 via a mass spectrometry approach.", [["prostaglandin", "CHEMICAL", 13, 26], ["prostaglandin", "CHEMICAL", 13, 26], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 13, 35], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 48, 57], ["prostaglandin synthase", "PROTEIN", 13, 35], ["rFhGST", "PROTEIN", 48, 54], ["S1", "PROTEIN", 55, 57], ["prostaglandin synthase activity of rFhGST", "PROBLEM", 13, 54], ["a mass spectrometry approach", "TREATMENT", 62, 90], ["prostaglandin synthase activity", "OBSERVATION", 13, 44], ["S1", "ANATOMY", 55, 57], ["mass", "OBSERVATION", 64, 68]]], ["A coupled assay with rFhGST-S1 and COX-1 catalyses the conversion of arachidonic acid to the H2 form before the prostaglandin isomer is converted to either the D or E form.", [["arachidonic acid", "CHEMICAL", 69, 85], ["prostaglandin isomer", "CHEMICAL", 112, 132], ["arachidonic acid", "CHEMICAL", 69, 85], ["H2", "CHEMICAL", 93, 95], ["prostaglandin", "CHEMICAL", 112, 125], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 21, 30], ["COX-1", "GENE_OR_GENE_PRODUCT", 35, 40], ["arachidonic acid", "SIMPLE_CHEMICAL", 69, 85], ["prostaglandin isomer", "SIMPLE_CHEMICAL", 112, 132], ["D", "SIMPLE_CHEMICAL", 160, 161], ["rFhGST", "PROTEIN", 21, 27], ["S1", "PROTEIN", 28, 30], ["COX-1", "PROTEIN", 35, 40], ["D or E form", "PROTEIN", 160, 171], ["A coupled assay", "TEST", 0, 15], ["rFhGST", "TEST", 21, 27], ["COX", "TEST", 35, 38], ["arachidonic acid", "TREATMENT", 69, 85], ["the prostaglandin isomer", "TREATMENT", 108, 132]]], ["Nano-LC/MS analysis allowed detection of both PGD2 (A) and PGE2 (B) in the assay mixture with the PGD2 form being the more abundant of the two prostanoids (C).", [["PGD2", "CHEMICAL", 46, 50], ["PGE2", "CHEMICAL", 59, 63], ["PGD2", "CHEMICAL", 98, 102], ["PGE2 (B)", "CHEMICAL", 59, 67], ["prostanoids", "CHEMICAL", 143, 154], ["PGD2", "SIMPLE_CHEMICAL", 46, 50], ["A", "SIMPLE_CHEMICAL", 52, 53], ["PGE2", "SIMPLE_CHEMICAL", 59, 63], ["B", "SIMPLE_CHEMICAL", 65, 66], ["PGD2", "SIMPLE_CHEMICAL", 98, 102], ["prostanoids", "SIMPLE_CHEMICAL", 143, 154], ["C", "SIMPLE_CHEMICAL", 156, 157], ["MS analysis", "TEST", 8, 19], ["both PGD2 (A) and PGE2 (B) in the assay mixture", "TEST", 41, 88]]], ["Boxed figures above peaks show the fragmentation ions specific to detection of PGD2 (a) and PGE2 (b) according to the method of Schmidt et al. [39] . doi:10.1371/journal.pntd.0001666.g002Tissue localisation of Sigma GSTSigma Class Glutathione Transferase of F. hepatica www.plosntds.org Influence of rFhGST-S1 on prostaglandin synthesis in host immune cells rFhGST-S1 exhibited prostaglandin synthase activity producing PGE2 and PGD2.", [["immune cells", "ANATOMY", 345, 357], ["PGD2", "CHEMICAL", 79, 83], ["PGE2", "CHEMICAL", 92, 96], ["Glutathione", "CHEMICAL", 231, 242], ["prostaglandin", "CHEMICAL", 313, 326], ["prostaglandin", "CHEMICAL", 378, 391], ["PGE2", "CHEMICAL", 420, 424], ["PGD2", "CHEMICAL", 429, 433], ["PGD2", "CHEMICAL", 79, 83], ["PGE2", "CHEMICAL", 92, 96], ["Glutathione", "CHEMICAL", 231, 242], ["prostaglandin", "CHEMICAL", 313, 326], ["prostaglandin", "CHEMICAL", 378, 391], ["PGE2", "CHEMICAL", 420, 424], ["PGD2", "CHEMICAL", 429, 433], ["PGD2", "SIMPLE_CHEMICAL", 79, 83], ["PGE2", "SIMPLE_CHEMICAL", 92, 96], ["Glutathione", "GENE_OR_GENE_PRODUCT", 231, 242], ["F. hepatica", "ORGANISM", 258, 269], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 300, 309], ["prostaglandin", "SIMPLE_CHEMICAL", 313, 326], ["host immune cells", "CELL", 340, 357], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 358, 367], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 378, 400], ["PGE2", "SIMPLE_CHEMICAL", 420, 424], ["PGD2", "SIMPLE_CHEMICAL", 429, 433], ["Sigma GSTSigma Class Glutathione Transferase", "PROTEIN", 210, 254], ["rFhGST", "PROTEIN", 300, 306], ["host immune cells", "CELL_TYPE", 340, 357], ["rFhGST", "PROTEIN", 358, 364], ["S1", "PROTEIN", 365, 367], ["prostaglandin synthase", "PROTEIN", 378, 400], ["F. hepatica", "SPECIES", 258, 269], ["F. hepatica www.plosntds.org", "SPECIES", 258, 286], ["the fragmentation ions", "PROBLEM", 31, 53], ["PGD2 (a) and PGE2 (b)", "TREATMENT", 79, 100], ["rFhGST", "TEST", 300, 306], ["prostaglandin synthesis", "TREATMENT", 313, 336], ["rFhGST", "TEST", 358, 364], ["prostaglandin synthase activity", "TREATMENT", 378, 409], ["PGD2", "PROBLEM", 429, 433], ["fragmentation", "OBSERVATION", 35, 48], ["hepatica", "ANATOMY", 261, 269], ["S1", "ANATOMY", 307, 309]]], ["In addition, it has been shown previously that rFhGST-S1 activates DCs in vitro [48] .", [["DCs", "ANATOMY", 67, 70], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 47, 56], ["DCs", "CELL", 67, 70], ["rFhGST", "PROTEIN", 47, 53], ["S1", "PROTEIN", 54, 56], ["DCs", "CELL_TYPE", 67, 70]]], ["Therefore, an attempt to determine if rFhGST-S1 could induce the secretion of total prostaglandin, PGE2 and PGD2 from DCs was performed.", [["DCs", "ANATOMY", 118, 121], ["prostaglandin", "CHEMICAL", 84, 97], ["PGE2", "CHEMICAL", 99, 103], ["PGD2", "CHEMICAL", 108, 112], ["prostaglandin", "CHEMICAL", 84, 97], ["PGE2", "CHEMICAL", 99, 103], ["PGD2", "CHEMICAL", 108, 112], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 38, 47], ["prostaglandin", "SIMPLE_CHEMICAL", 84, 97], ["PGE2", "SIMPLE_CHEMICAL", 99, 103], ["PGD2", "SIMPLE_CHEMICAL", 108, 112], ["DCs", "CELL", 118, 121], ["rFhGST", "PROTEIN", 38, 44], ["DCs", "CELL_TYPE", 118, 121], ["rFhGST", "TEST", 38, 44], ["total prostaglandin", "TREATMENT", 78, 97], ["PGE2", "TREATMENT", 99, 103], ["PGD2", "TREATMENT", 108, 112], ["DCs", "TEST", 118, 121]]], ["Prior to experimentation, endotoxin levels in rFhGST-S1 were assessed and were similar to that of the media alone.", [["endotoxin", "CHEMICAL", 26, 35], ["endotoxin", "SIMPLE_CHEMICAL", 26, 35], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 46, 55], ["endotoxin", "PROTEIN", 26, 35], ["rFhGST", "PROTEIN", 46, 52], ["experimentation", "TEST", 9, 24], ["endotoxin levels", "TEST", 26, 42], ["rFhGST", "TEST", 46, 52], ["S1", "ANATOMY", 53, 55]]], ["Both of which were below the lower limit of detection (,0.01 EU/ml).", [["lower limit", "OBSERVATION_MODIFIER", 29, 40]]], ["When examining prostaglandin induction DCs stimulated with rFhGST-S1 secreted total prostaglandin and PGE2 (DC (WT); Figure 5 ) but not PGD2 (data not shown).", [["DCs", "ANATOMY", 39, 42], ["prostaglandin", "CHEMICAL", 15, 28], ["prostaglandin", "CHEMICAL", 84, 97], ["PGE2", "CHEMICAL", 102, 106], ["PGD2", "CHEMICAL", 136, 140], ["prostaglandin", "CHEMICAL", 15, 28], ["prostaglandin", "CHEMICAL", 84, 97], ["PGE2", "CHEMICAL", 102, 106], ["DC (WT)", "CHEMICAL", 108, 115], ["PGD2", "CHEMICAL", 136, 140], ["prostaglandin", "SIMPLE_CHEMICAL", 15, 28], ["DCs", "CELL", 39, 42], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 59, 68], ["prostaglandin", "SIMPLE_CHEMICAL", 84, 97], ["PGE2", "SIMPLE_CHEMICAL", 102, 106], ["PGD2", "SIMPLE_CHEMICAL", 136, 140], ["DCs", "CELL_TYPE", 39, 42], ["rFhGST", "PROTEIN", 59, 65], ["S1", "PROTEIN", 66, 68], ["DC", "CELL_TYPE", 108, 110], ["prostaglandin induction", "TREATMENT", 15, 38], ["rFhGST", "TEST", 59, 65], ["S1 secreted total prostaglandin", "TREATMENT", 66, 97], ["PGE2 (DC (WT)", "TREATMENT", 102, 115], ["PGD2", "PROBLEM", 136, 140]]], ["Since it has been previously determined that the activation of DCs by rFhGST-S1 was dependent upon TLR4 [48] we repeated the experiment in DCs from TLR4KO mice and in keeping with previous findings demonstrated that the secretion of total prostaglandin and PGE2 by rFhGST-S1 was significantly reduced in the absence of the TLR4 receptor (DC (TLR4KO); Figure 5 ). rFhGST-S1 was then further assessed for its potential to induce prostaglandin secretion from macrophages by exposing two macrophage cell lines with rFhGST-S1.", [["DCs", "ANATOMY", 63, 66], ["DCs", "ANATOMY", 139, 142], ["macrophages", "ANATOMY", 456, 467], ["macrophage cell lines", "ANATOMY", 484, 505], ["prostaglandin", "CHEMICAL", 239, 252], ["PGE2", "CHEMICAL", 257, 261], ["prostaglandin", "CHEMICAL", 427, 440], ["prostaglandin", "CHEMICAL", 239, 252], ["PGE2", "CHEMICAL", 257, 261], ["prostaglandin", "CHEMICAL", 427, 440], ["DCs", "CELL", 63, 66], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 70, 79], ["TLR4", "GENE_OR_GENE_PRODUCT", 99, 103], ["DCs", "CELL", 139, 142], ["TLR4KO mice", "ORGANISM", 148, 159], ["prostaglandin", "SIMPLE_CHEMICAL", 239, 252], ["PGE2", "SIMPLE_CHEMICAL", 257, 261], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 265, 274], ["TLR4 receptor", "GENE_OR_GENE_PRODUCT", 323, 336], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 363, 372], ["prostaglandin", "SIMPLE_CHEMICAL", 427, 440], ["macrophages", "CELL", 456, 467], ["macrophage cell lines", "CELL", 484, 505], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 511, 520], ["DCs", "CELL_TYPE", 63, 66], ["rFhGST", "PROTEIN", 70, 76], ["S1", "PROTEIN", 77, 79], ["TLR4", "PROTEIN", 99, 103], ["DCs", "CELL_TYPE", 139, 142], ["rFhGST", "PROTEIN", 265, 271], ["TLR4 receptor", "PROTEIN", 323, 336], ["DC", "CELL_TYPE", 338, 340], ["TLR4KO", "PROTEIN", 342, 348], ["rFhGST", "PROTEIN", 363, 369], ["S1", "PROTEIN", 370, 372], ["macrophages", "CELL_TYPE", 456, 467], ["macrophage cell lines", "CELL_LINE", 484, 505], ["rFhGST", "PROTEIN", 511, 517], ["S1", "PROTEIN", 518, 520], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 155, 159], ["total prostaglandin", "TREATMENT", 233, 252], ["PGE2", "TEST", 257, 261], ["rFhGST", "TEST", 363, 369], ["prostaglandin secretion from macrophages", "PROBLEM", 427, 467], ["two macrophage cell lines", "TREATMENT", 480, 505], ["reduced", "OBSERVATION_MODIFIER", 293, 300], ["S1", "ANATOMY", 370, 372], ["macrophage cell lines", "OBSERVATION", 484, 505], ["S1", "ANATOMY", 518, 520]]], ["After 18 hours the levels of total prostaglandin, PGE2 and PGD2 were measured.", [["prostaglandin", "CHEMICAL", 35, 48], ["PGE2", "CHEMICAL", 50, 54], ["PGD2", "CHEMICAL", 59, 63], ["prostaglandin", "CHEMICAL", 35, 48], ["PGE2", "CHEMICAL", 50, 54], ["PGD2", "CHEMICAL", 59, 63], ["prostaglandin", "SIMPLE_CHEMICAL", 35, 48], ["PGE2", "SIMPLE_CHEMICAL", 50, 54], ["PGD2", "SIMPLE_CHEMICAL", 59, 63], ["total prostaglandin", "TREATMENT", 29, 48], ["PGE2", "TEST", 50, 54], ["PGD2", "TEST", 59, 63]]], ["In this assay, both macrophage cells lines stimulated with rFhGST-S1 secreted total prostaglandin, PGE2 and PGD2 ( Figure 6 ).", [["macrophage cells lines", "ANATOMY", 20, 42], ["prostaglandin", "CHEMICAL", 84, 97], ["PGE2", "CHEMICAL", 99, 103], ["PGD2", "CHEMICAL", 108, 112], ["prostaglandin", "CHEMICAL", 84, 97], ["PGE2", "CHEMICAL", 99, 103], ["PGD2", "CHEMICAL", 108, 112], ["macrophage cells lines", "CELL", 20, 42], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 59, 68], ["prostaglandin", "SIMPLE_CHEMICAL", 84, 97], ["PGE2", "SIMPLE_CHEMICAL", 99, 103], ["PGD2", "SIMPLE_CHEMICAL", 108, 112], ["macrophage cells lines", "CELL_LINE", 20, 42], ["rFhGST", "PROTEIN", 59, 65], ["S1", "PROTEIN", 66, 68], ["this assay", "TEST", 3, 13], ["both macrophage cells lines", "TREATMENT", 15, 42], ["rFhGST", "TEST", 59, 65], ["S1 secreted total prostaglandin", "TREATMENT", 66, 97], ["PGE2 and PGD2", "TREATMENT", 99, 112], ["macrophage cells lines", "OBSERVATION", 20, 42]]], ["However, the levels secreted by J744 cell line were higher when compared to the amount secreted by RAW264.7 cell line.", [["J744 cell line", "ANATOMY", 32, 46], ["RAW264.7 cell line", "ANATOMY", 99, 117], ["J744 cell line", "CELL", 32, 46], ["RAW264.7 cell line", "CELL", 99, 117], ["J744 cell line", "CELL_LINE", 32, 46], ["RAW264.7 cell line", "CELL_LINE", 99, 117], ["J744 cell line", "TREATMENT", 32, 46], ["cell line", "OBSERVATION", 37, 46], ["RAW264.7 cell line", "OBSERVATION", 99, 117]]], ["In these experiments we included medium only as a negative control and LPS as a positive control.", [["LPS", "CHEMICAL", 71, 74], ["LPS", "SIMPLE_CHEMICAL", 71, 74], ["LPS", "TREATMENT", 71, 74], ["a positive control", "TREATMENT", 78, 96]]], ["In all experiments the levels of prostaglandin in response to rFhGST-S1 was comparable to the levels secreted in responses to LPS.Tissue localisation of Sigma GSTAssessment of goat vaccinations with rFhGST-S1 challenged with F. hepatica Following the completion of the vaccine trial, liver fluke were recovered and the livers scored.", [["Tissue", "ANATOMY", 130, 136], ["liver fluke", "ANATOMY", 284, 295], ["livers", "ANATOMY", 319, 325], ["prostaglandin", "CHEMICAL", 33, 46], ["LPS", "CHEMICAL", 126, 129], ["F. hepatica", "DISEASE", 225, 236], ["liver fluke", "DISEASE", 284, 295], ["prostaglandin", "CHEMICAL", 33, 46], ["prostaglandin", "SIMPLE_CHEMICAL", 33, 46], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 62, 71], ["LPS", "SIMPLE_CHEMICAL", 126, 129], ["Tissue", "TISSUE", 130, 136], ["goat", "ORGANISM", 176, 180], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 199, 208], ["F. hepatica", "ORGANISM", 225, 236], ["liver fluke", "ORGAN", 284, 295], ["livers", "ORGAN", 319, 325], ["rFhGST", "PROTEIN", 62, 68], ["rFhGST", "PROTEIN", 199, 205], ["goat", "SPECIES", 176, 180], ["F. hepatica", "SPECIES", 225, 236], ["goat", "SPECIES", 176, 180], ["F. hepatica", "SPECIES", 225, 236], ["prostaglandin", "TREATMENT", 33, 46], ["rFhGST", "TEST", 62, 68], ["LPS", "TEST", 126, 129], ["goat vaccinations", "TREATMENT", 176, 193], ["the vaccine trial", "TREATMENT", 265, 282], ["Sigma GSTAssessment", "OBSERVATION", 153, 172], ["hepatica", "ANATOMY", 228, 236], ["liver", "ANATOMY", 284, 289], ["livers", "ANATOMY", 319, 325]]], ["When assessing fluke burdens, length, weight and fecal egg counts, no significant differences between rFhGST-S1 immunised and Quil A immunised groups were observed.", [["fluke", "ANATOMY", 15, 20], ["fecal egg", "ANATOMY", 49, 58], ["fluke", "ORGANISM", 15, 20], ["fecal", "ORGANISM_SUBSTANCE", 49, 54], ["egg", "ORGANISM_SUBSTANCE", 55, 58], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 102, 111], ["Quil A immunised", "ORGANISM", 126, 142], ["rFhGST", "PROTEIN", 102, 108], ["length", "TEST", 30, 36], ["weight", "TEST", 38, 44], ["fecal egg counts", "TEST", 49, 65], ["significant differences", "PROBLEM", 70, 93], ["rFhGST", "TEST", 102, 108], ["Quil A immunised groups", "TREATMENT", 126, 149], ["fecal egg", "ANATOMY", 49, 58], ["no", "UNCERTAINTY", 67, 69], ["significant", "OBSERVATION_MODIFIER", 70, 81]]], ["Despite this lack of significance, at 7-9 days post-infection (dpi) the number of gross hepatic lesions appeared reduced in rFhGST-S1 immunised groups compared to the Quil A control group.", [["hepatic lesions", "ANATOMY", 88, 103], ["hepatic lesions", "DISEASE", 88, 103], ["gross", "PATHOLOGICAL_FORMATION", 82, 87], ["hepatic lesions", "PATHOLOGICAL_FORMATION", 88, 103], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 124, 133], ["rFhGST", "PROTEIN", 124, 130], ["gross hepatic lesions", "PROBLEM", 82, 103], ["gross", "OBSERVATION_MODIFIER", 82, 87], ["hepatic", "ANATOMY", 88, 95], ["lesions", "OBSERVATION", 96, 103], ["reduced", "OBSERVATION_MODIFIER", 113, 120]]], ["At 15 weeks post-infection (wpi), a similar outcome is observed.", [["infection", "DISEASE", 17, 26], ["post-infection (wpi", "PROBLEM", 12, 31], ["infection", "OBSERVATION", 17, 26]]], ["Liver hepatic lesion scoring appeared to show reductions in the severity of damage occurred in the rFhGST-S1 immunised group compared to the Quil A only group, despite no significant differences in the aforementioned morphometric data.Tissue localisation of Sigma GSTMicroscopically, at 7-9 dpi animals from the Quil A group showed tortuous necrotic tracts surrounded by a scarce inflammatory infiltration with occasional eosinophils ( Figure 7A ).", [["Liver hepatic lesion", "ANATOMY", 0, 20], ["Tissue", "ANATOMY", 235, 241], ["tortuous necrotic tracts", "ANATOMY", 332, 356], ["eosinophils", "ANATOMY", 422, 433], ["necrotic", "DISEASE", 341, 349], ["Liver hepatic", "MULTI-TISSUE_STRUCTURE", 0, 13], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 99, 108], ["Tissue", "TISSUE", 235, 241], ["necrotic tracts", "PATHOLOGICAL_FORMATION", 341, 356], ["eosinophils", "CELL", 422, 433], ["eosinophils", "CELL_TYPE", 422, 433], ["Liver hepatic lesion", "PROBLEM", 0, 20], ["damage", "PROBLEM", 76, 82], ["Sigma GSTMicroscopically", "TEST", 258, 282], ["tortuous necrotic tracts", "PROBLEM", 332, 356], ["a scarce inflammatory infiltration", "PROBLEM", 371, 405], ["occasional eosinophils", "PROBLEM", 411, 433], ["hepatic", "ANATOMY", 6, 13], ["lesion", "OBSERVATION", 14, 20], ["reductions", "OBSERVATION_MODIFIER", 46, 56], ["severity", "OBSERVATION_MODIFIER", 64, 72], ["damage", "OBSERVATION", 76, 82], ["Sigma GSTMicroscopically", "OBSERVATION", 258, 282], ["tortuous", "OBSERVATION_MODIFIER", 332, 340], ["necrotic", "OBSERVATION", 341, 349], ["scarce", "OBSERVATION_MODIFIER", 373, 379], ["inflammatory", "OBSERVATION_MODIFIER", 380, 392], ["infiltration", "OBSERVATION", 393, 405], ["occasional", "OBSERVATION_MODIFIER", 411, 421], ["eosinophils", "OBSERVATION", 422, 433]]], ["Older necrotic areas were surrounded by macrophages, epithelioid cells and multinucleate giant cells and lymphocytes.", [["necrotic areas", "ANATOMY", 6, 20], ["macrophages", "ANATOMY", 40, 51], ["epithelioid cells", "ANATOMY", 53, 70], ["multinucleate giant cells", "ANATOMY", 75, 100], ["lymphocytes", "ANATOMY", 105, 116], ["necrotic", "DISEASE", 6, 14], ["necrotic areas", "PATHOLOGICAL_FORMATION", 6, 20], ["macrophages", "CELL", 40, 51], ["epithelioid cells", "CELL", 53, 70], ["multinucleate giant cells", "CELL", 75, 100], ["lymphocytes", "CELL", 105, 116], ["macrophages", "CELL_TYPE", 40, 51], ["epithelioid cells", "CELL_TYPE", 53, 70], ["multinucleate giant cells", "CELL_TYPE", 75, 100], ["lymphocytes", "CELL_TYPE", 105, 116], ["Older necrotic areas", "PROBLEM", 0, 20], ["macrophages", "PROBLEM", 40, 51], ["epithelioid cells", "PROBLEM", 53, 70], ["multinucleate giant cells", "PROBLEM", 75, 100], ["lymphocytes", "PROBLEM", 105, 116], ["necrotic", "OBSERVATION_MODIFIER", 6, 14], ["macrophages", "ANATOMY", 40, 51], ["epithelioid cells", "OBSERVATION", 53, 70], ["multinucleate giant cells", "OBSERVATION", 75, 100], ["lymphocytes", "ANATOMY", 105, 116]]], ["Some migrating larvae were found in the liver parenchyma without inflammatory infiltrate associated to them.", [["liver parenchyma", "ANATOMY", 40, 56], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 40, 56], ["Some migrating larvae", "PROBLEM", 0, 21], ["inflammatory infiltrate", "PROBLEM", 65, 88], ["migrating", "OBSERVATION_MODIFIER", 5, 14], ["larvae", "OBSERVATION", 15, 21], ["liver", "ANATOMY", 40, 45], ["parenchyma", "ANATOMY_MODIFIER", 46, 56], ["without", "UNCERTAINTY", 57, 64], ["inflammatory", "OBSERVATION_MODIFIER", 65, 77], ["infiltrate", "OBSERVATION", 78, 88]]], ["In goats immunised with rFhGST-S1 smaller necrotic areas associated to a heavy infiltration of eosinophils ( Figure 7B ) were seen.", [["necrotic areas", "ANATOMY", 42, 56], ["eosinophils", "ANATOMY", 95, 106], ["necrotic", "DISEASE", 42, 50], ["goats", "ORGANISM", 3, 8], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 24, 33], ["necrotic areas", "PATHOLOGICAL_FORMATION", 42, 56], ["eosinophils", "CELL", 95, 106], ["rFhGST", "PROTEIN", 24, 30], ["eosinophils", "CELL_TYPE", 95, 106], ["goats", "SPECIES", 3, 8], ["goats", "SPECIES", 3, 8], ["rFhGST", "PROBLEM", 24, 30], ["S1 smaller necrotic areas", "PROBLEM", 31, 56], ["a heavy infiltration of eosinophils", "PROBLEM", 71, 106], ["smaller", "OBSERVATION_MODIFIER", 34, 41], ["necrotic", "OBSERVATION_MODIFIER", 42, 50], ["areas", "OBSERVATION", 51, 56], ["heavy", "OBSERVATION_MODIFIER", 73, 78], ["infiltration", "OBSERVATION", 79, 91], ["eosinophils", "OBSERVATION", 95, 106]]], ["Unlike the Quil A immunised group, all migrating larvae found were surrounded by a heavy infiltration of eosinophils.Tissue localisation of Sigma GSTA significant increase of IgG anti-rFhGST-S1 was observed two weeks after vaccination with a strong increase after the second injection at week 4 in immunised animals ( Figure 8 ).", [["eosinophils", "ANATOMY", 105, 116], ["Tissue", "ANATOMY", 117, 123], ["Quil A immunised", "ORGANISM", 11, 27], ["larvae", "ORGANISM", 49, 55], ["eosinophils", "CELL", 105, 116], ["Tissue", "TISSUE", 117, 123], ["Sigma GSTA", "SIMPLE_CHEMICAL", 140, 150], ["IgG anti-rFhGST-S1", "GENE_OR_GENE_PRODUCT", 175, 193], ["eosinophils", "CELL_TYPE", 105, 116], ["Sigma GSTA", "PROTEIN", 140, 150], ["IgG", "PROTEIN", 175, 178], ["anti-rFhGST", "PROTEIN", 179, 190], ["S1", "PROTEIN", 191, 193], ["a heavy infiltration of eosinophils", "PROBLEM", 81, 116], ["Tissue localisation", "TEST", 117, 136], ["Sigma GSTA", "TEST", 140, 150], ["IgG anti-rFhGST-S1", "PROBLEM", 175, 193], ["vaccination", "TREATMENT", 223, 234], ["the second injection", "TREATMENT", 264, 284], ["heavy", "OBSERVATION_MODIFIER", 83, 88], ["infiltration", "OBSERVATION", 89, 101], ["eosinophils", "OBSERVATION", 105, 116], ["Sigma GSTA", "OBSERVATION_MODIFIER", 140, 150], ["significant", "OBSERVATION_MODIFIER", 151, 162], ["increase", "OBSERVATION_MODIFIER", 163, 171], ["IgG anti-rFhGST", "OBSERVATION", 175, 190], ["strong", "OBSERVATION_MODIFIER", 242, 248], ["increase", "OBSERVATION_MODIFIER", 249, 257]]], ["The Quil A control group did not show any specific IgG response until 2 weeks after infection.", [["infection", "DISEASE", 84, 93], ["IgG", "GENE_OR_GENE_PRODUCT", 51, 54], ["IgG", "PROTEIN", 51, 54], ["infection", "PROBLEM", 84, 93], ["infection", "OBSERVATION", 84, 93]]], ["Specific IgG titres increased during infection in both groups, but they were consistently higher in the immunised group throughout the duration of the the experiment.DiscussionPrevious studies have highlighted the importance of parasite GSTs, including Sigma class GSTs, in host-parasite interactions and as potential vaccination candidates.", [["infection", "DISEASE", 37, 46], ["IgG", "GENE_OR_GENE_PRODUCT", 9, 12], ["GSTs", "GENE_OR_GENE_PRODUCT", 237, 241], ["Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 253, 269], ["IgG", "PROTEIN", 9, 12], ["parasite GSTs", "PROTEIN", 228, 241], ["Sigma class GSTs", "PROTEIN", 253, 269], ["Specific IgG titres", "TEST", 0, 19], ["infection", "PROBLEM", 37, 46], ["DiscussionPrevious studies", "TEST", 166, 192], ["IgG titres", "OBSERVATION", 9, 19], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["infection", "OBSERVATION", 37, 46], ["consistently", "OBSERVATION_MODIFIER", 77, 89], ["higher", "OBSERVATION_MODIFIER", 90, 96]]], ["With this in mind, we have studied the relatively newly identified Sigma class GST from F. hepatica to both enhance our understanding of this important enzyme in Fasciola and the Sigma class of GSTs as a whole.DiscussionAlignments and phylogenetics classified FhGST-S1 alongside trematode and mammalian Sigma class GSTs, yet there remains a Sigma Class Glutathione Transferase of F. hepatica www.plosntds.org distinct divide between the parasites and their hosts, a phenomenon also observed for the recently reclassified 'Nu' class of GSTs from nematodes [49] .", [["Glutathione", "CHEMICAL", 353, 364], ["Glutathione", "CHEMICAL", 353, 364], ["Sigma class GST", "GENE_OR_GENE_PRODUCT", 67, 82], ["F. hepatica", "ORGANISM", 88, 99], ["Fasciola", "ORGANISM", 162, 170], ["GSTs", "GENE_OR_GENE_PRODUCT", 194, 198], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 260, 268], ["Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 303, 319], ["Glutathione", "GENE_OR_GENE_PRODUCT", 353, 364], ["F. hepatica", "ORGANISM", 380, 391], ["GSTs", "GENE_OR_GENE_PRODUCT", 535, 539], ["Sigma class GST", "PROTEIN", 67, 82], ["GSTs", "PROTEIN", 194, 198], ["FhGST", "PROTEIN", 260, 265], ["trematode and mammalian Sigma class GSTs", "PROTEIN", 279, 319], ["Sigma Class Glutathione Transferase", "PROTEIN", 341, 376], ["GSTs", "PROTEIN", 535, 539], ["F. hepatica", "SPECIES", 88, 99], ["F. hepatica", "SPECIES", 380, 391], ["F. hepatica", "SPECIES", 88, 99], ["F. hepatica", "SPECIES", 380, 391], ["DiscussionAlignments", "TEST", 210, 230], ["hepatica", "ANATOMY", 91, 99], ["hepatica", "ANATOMY", 383, 391]]], ["Therefore, it may be that trematode GSTs are sufficiently distinct to support a sub-classification within the broad Sigma class.", [["GSTs", "GENE_OR_GENE_PRODUCT", 36, 40], ["trematode GSTs", "PROTEIN", 26, 40], ["trematode GSTs", "PROBLEM", 26, 40]]], ["The distinction of FhGST-S1 from fasciolosis host Sigma class GSTs enhances its potential as a therapeutic target.DiscussionSubstrate activity profiling of rFhGST-S1 using model substrates showed the enzyme to have comparable activity to other trematode Sigma class GSTs such as Sm28GST [47] .", [["FhGST-S1", "GENE_OR_GENE_PRODUCT", 19, 27], ["Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 50, 66], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 156, 165], ["Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 254, 270], ["FhGST", "PROTEIN", 19, 24], ["S1", "PROTEIN", 25, 27], ["fasciolosis host Sigma class GSTs", "PROTEIN", 33, 66], ["rFhGST", "PROTEIN", 156, 162], ["S1", "PROTEIN", 163, 165], ["trematode Sigma class GSTs", "PROTEIN", 244, 270], ["FhGST", "TEST", 19, 24], ["rFhGST", "TEST", 156, 162], ["model substrates", "TEST", 172, 188], ["the enzyme", "PROBLEM", 196, 206], ["S1", "ANATOMY", 25, 27], ["fasciolosis", "OBSERVATION", 33, 44]]], ["However, rFhGST-S1 exhibits relatively high GSH-conjugating activity towards the potentially natural reactive aldehyde, 4-hydroxy-nonenal (4-HNE) toxin and high GSH-dependent peroxidase activity towards the tested lipid peroxides which includes the endogenous substrate linoleic acid hydroperoxide.", [["GSH", "CHEMICAL", 44, 47], ["aldehyde", "CHEMICAL", 110, 118], ["4-hydroxy-nonenal", "CHEMICAL", 120, 137], ["4-HNE", "CHEMICAL", 139, 144], ["GSH", "CHEMICAL", 161, 164], ["linoleic acid hydroperoxide", "CHEMICAL", 270, 297], ["GSH", "CHEMICAL", 44, 47], ["aldehyde", "CHEMICAL", 110, 118], ["4-hydroxy-nonenal", "CHEMICAL", 120, 137], ["4-HNE", "CHEMICAL", 139, 144], ["GSH", "CHEMICAL", 161, 164], ["peroxides", "CHEMICAL", 220, 229], ["linoleic acid hydroperoxide", "CHEMICAL", 270, 297], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 9, 18], ["GSH", "SIMPLE_CHEMICAL", 44, 47], ["aldehyde", "SIMPLE_CHEMICAL", 110, 118], ["4-hydroxy-nonenal", "SIMPLE_CHEMICAL", 120, 137], ["4-HNE) toxin", "SIMPLE_CHEMICAL", 139, 151], ["GSH", "SIMPLE_CHEMICAL", 161, 164], ["peroxidase", "SIMPLE_CHEMICAL", 175, 185], ["lipid peroxides", "SIMPLE_CHEMICAL", 214, 229], ["linoleic acid hydroperoxide", "SIMPLE_CHEMICAL", 270, 297], ["rFhGST", "PROTEIN", 9, 15], ["peroxidase", "PROTEIN", 175, 185], ["rFhGST", "TEST", 9, 15], ["relatively high GSH", "PROBLEM", 28, 47], ["hydroxy", "TEST", 122, 129], ["toxin", "TEST", 146, 151], ["high GSH-dependent peroxidase activity", "PROBLEM", 156, 194], ["the tested lipid peroxides", "TEST", 203, 229], ["the endogenous substrate linoleic acid hydroperoxide", "TREATMENT", 245, 297], ["high GSH", "OBSERVATION", 39, 47], ["conjugating activity", "OBSERVATION", 48, 68], ["reactive aldehyde", "OBSERVATION", 101, 118], ["peroxidase activity", "OBSERVATION", 175, 194]]], ["4-HNE is the major aldehydic end-product of lipid peroxidation that is involved in signalling of host immune cells leading to apoptosis of T-and Bcells [50] .DiscussionAssessing the inhibition of rFhGST-S1 activity with CDNB revealed that both bile acids and the flukicide TCBZ appear to bind to the enzyme.", [["immune cells", "ANATOMY", 102, 114], ["4-HNE", "CHEMICAL", 0, 5], ["CDNB", "CHEMICAL", 220, 224], ["bile acids", "CHEMICAL", 244, 254], ["TCBZ", "CHEMICAL", 273, 277], ["4-HNE", "CHEMICAL", 0, 5], ["CDNB", "CHEMICAL", 220, 224], ["bile acids", "CHEMICAL", 244, 254], ["TCBZ", "CHEMICAL", 273, 277], ["4-HNE", "SIMPLE_CHEMICAL", 0, 5], ["lipid", "SIMPLE_CHEMICAL", 44, 49], ["host immune cells", "CELL", 97, 114], ["T", "CELL", 139, 140], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 196, 205], ["CDNB", "SIMPLE_CHEMICAL", 220, 224], ["bile acids", "SIMPLE_CHEMICAL", 244, 254], ["flukicide", "SIMPLE_CHEMICAL", 263, 272], ["TCBZ", "SIMPLE_CHEMICAL", 273, 277], ["host immune cells", "CELL_TYPE", 97, 114], ["rFhGST", "PROTEIN", 196, 202], ["enzyme", "PROTEIN", 300, 306], ["lipid peroxidation", "PROBLEM", 44, 62], ["host immune cells", "PROBLEM", 97, 114], ["rFhGST", "TEST", 196, 202], ["CDNB", "TEST", 220, 224], ["both bile acids", "TEST", 239, 254], ["the flukicide TCBZ", "TREATMENT", 259, 277], ["the enzyme", "TEST", 296, 306], ["lipid peroxidation", "OBSERVATION", 44, 62], ["host immune cells", "OBSERVATION", 97, 114], ["bile acids", "ANATOMY", 244, 254]]], ["In particular, the interaction of the bile acid cholate with rFhGST-S1 is approximately ten fold higher than GSTs from the sheep intestinal cestode Moniezia expansa [51] .", [["bile acid cholate", "CHEMICAL", 38, 55], ["bile acid cholate", "CHEMICAL", 38, 55], ["bile acid", "SIMPLE_CHEMICAL", 38, 47], ["cholate", "SIMPLE_CHEMICAL", 48, 55], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 61, 70], ["GSTs", "GENE_OR_GENE_PRODUCT", 109, 113], ["sheep", "ORGANISM", 123, 128], ["intestinal", "ORGAN", 129, 139], ["rFhGST", "PROTEIN", 61, 67], ["S1", "PROTEIN", 68, 70], ["GSTs", "PROTEIN", 109, 113], ["sheep", "SPECIES", 123, 128], ["Moniezia expansa", "SPECIES", 148, 164], ["sheep", "SPECIES", 123, 128], ["Moniezia expansa", "SPECIES", 148, 164], ["the bile acid cholate", "TEST", 34, 55], ["bile", "ANATOMY", 38, 42], ["S1", "ANATOMY", 68, 70], ["approximately", "OBSERVATION_MODIFIER", 74, 87], ["ten fold", "OBSERVATION_MODIFIER", 88, 96], ["sheep", "ANATOMY_MODIFIER", 123, 128], ["intestinal", "ANATOMY", 129, 139], ["cestode Moniezia", "OBSERVATION", 140, 156]]], ["Host bile acids are known as triggers of physiological processes in trematodes including Fasciola sp.", [["bile", "ANATOMY", 5, 9], ["bile acids", "CHEMICAL", 5, 15], ["bile acids", "CHEMICAL", 5, 15], ["bile acids", "SIMPLE_CHEMICAL", 5, 15], ["Fasciola sp", "ORGANISM", 89, 100], ["Fasciola", "SPECIES", 89, 97], ["Host bile acids", "TEST", 0, 15], ["physiological processes in trematodes", "PROBLEM", 41, 78], ["Fasciola sp", "PROBLEM", 89, 100], ["bile", "ANATOMY", 5, 9], ["acids", "OBSERVATION", 10, 15], ["trematodes", "OBSERVATION", 68, 78], ["Fasciola sp", "OBSERVATION", 89, 100]]], ["Therefore, molecular interaction of bile acids with FhGST-S1 warrants further investigation especially, given that FhGST-S1 is localised to near the body surface of the fluke, where it could potentially bind cholate and other free bile acids found in abundance in host bile (cholate is found at approximately 100 mM in sheep bile) [54] .", [["body surface", "ANATOMY", 149, 161], ["fluke", "ANATOMY", 169, 174], ["bile", "ANATOMY", 269, 273], ["bile", "ANATOMY", 325, 329], ["bile acids", "CHEMICAL", 36, 46], ["cholate", "CHEMICAL", 208, 215], ["bile acids", "CHEMICAL", 231, 241], ["cholate", "CHEMICAL", 275, 282], ["bile acids", "CHEMICAL", 36, 46], ["cholate", "CHEMICAL", 208, 215], ["bile acids", "CHEMICAL", 231, 241], ["cholate", "CHEMICAL", 275, 282], ["bile acids", "SIMPLE_CHEMICAL", 36, 46], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 52, 60], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 115, 123], ["body surface", "CELLULAR_COMPONENT", 149, 161], ["fluke", "ORGAN", 169, 174], ["cholate", "SIMPLE_CHEMICAL", 208, 215], ["bile acids", "SIMPLE_CHEMICAL", 231, 241], ["bile", "SIMPLE_CHEMICAL", 269, 273], ["cholate", "SIMPLE_CHEMICAL", 275, 282], ["bile", "MULTI-TISSUE_STRUCTURE", 325, 329], ["FhGST", "PROTEIN", 52, 57], ["S1", "PROTEIN", 58, 60], ["FhGST", "PROTEIN", 115, 120], ["S1", "PROTEIN", 121, 123], ["sheep", "SPECIES", 319, 324], ["sheep", "SPECIES", 319, 324], ["bile acids", "TEST", 36, 46], ["further investigation", "TEST", 70, 91], ["other free bile acids", "TEST", 220, 241], ["bile", "ANATOMY", 36, 40], ["body", "ANATOMY_MODIFIER", 149, 153], ["surface", "ANATOMY_MODIFIER", 154, 161], ["fluke", "ANATOMY", 169, 174], ["host", "ANATOMY_MODIFIER", 264, 268], ["bile", "ANATOMY", 269, 273]]], ["The hydroxy-TCBZ SO levels in the bile have been shown to be in excess of 100 mM [55] thus, the IC50 of 5765 mM for TCBZ SO suggests the abundant FhGST-S1 could be involved in TCBZ response in phase III sequestration based detoxification.", [["bile", "ANATOMY", 34, 38], ["hydroxy-TCBZ", "CHEMICAL", 4, 16], ["TCBZ", "CHEMICAL", 116, 120], ["TCBZ", "CHEMICAL", 176, 180], ["hydroxy-TCBZ SO", "CHEMICAL", 4, 19], ["TCBZ SO", "CHEMICAL", 116, 123], ["TCBZ", "CHEMICAL", 176, 180], ["hydroxy-TCBZ SO", "SIMPLE_CHEMICAL", 4, 19], ["bile", "MULTI-TISSUE_STRUCTURE", 34, 38], ["TCBZ SO", "SIMPLE_CHEMICAL", 116, 123], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 146, 154], ["TCBZ", "SIMPLE_CHEMICAL", 176, 180], ["FhGST", "PROTEIN", 146, 151], ["S1", "PROTEIN", 152, 154], ["The hydroxy-TCBZ SO levels", "TEST", 0, 26], ["the IC50", "TEST", 92, 100], ["TCBZ", "TEST", 116, 120], ["bile", "ANATOMY", 34, 38]]], ["This finding warrants further investigation to understand the role of FhGST-S1 in TCBZ action or detoxification.DiscussionSigma class GSTs from both parasites and mammals have been known to exhibit prostaglandin synthase activity.", [["TCBZ", "CHEMICAL", 82, 86], ["prostaglandin", "CHEMICAL", 198, 211], ["prostaglandin", "CHEMICAL", 198, 211], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 70, 78], ["TCBZ", "SIMPLE_CHEMICAL", 82, 86], ["DiscussionSigma class GSTs", "GENE_OR_GENE_PRODUCT", 112, 138], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 198, 220], ["FhGST", "PROTEIN", 70, 75], ["DiscussionSigma class GSTs", "PROTEIN", 112, 138], ["prostaglandin synthase", "PROTEIN", 198, 220], ["further investigation", "TEST", 22, 43], ["detoxification", "TREATMENT", 97, 111], ["prostaglandin synthase activity", "TREATMENT", 198, 229]]], ["To this end, the Sigma GST from F. hepatica shares a high sequence identity with recognised Sigma class GSTs with prostaglandin synthase activity, including rOvGST-1 from the filarial parasite, Onchocerca volvulus.", [["prostaglandin", "CHEMICAL", 114, 127], ["filarial parasite", "DISEASE", 175, 192], ["Onchocerca volvulus", "DISEASE", 194, 213], ["prostaglandin", "CHEMICAL", 114, 127], ["Sigma", "ORGANISM", 17, 22], ["GST", "GENE_OR_GENE_PRODUCT", 23, 26], ["F. hepatica", "ORGANISM", 32, 43], ["Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 92, 108], ["prostaglandin synthase", "GENE_OR_GENE_PRODUCT", 114, 136], ["rOvGST-1", "GENE_OR_GENE_PRODUCT", 157, 165], ["filarial parasite", "ORGANISM", 175, 192], ["Onchocerca volvulus", "ORGANISM", 194, 213], ["Sigma GST", "PROTEIN", 17, 26], ["Sigma class GSTs", "PROTEIN", 92, 108], ["prostaglandin synthase", "PROTEIN", 114, 136], ["rOvGST", "PROTEIN", 157, 163], ["F. hepatica", "SPECIES", 32, 43], ["Onchocerca volvulus", "SPECIES", 194, 213], ["F. hepatica", "SPECIES", 32, 43], ["Onchocerca volvulus", "SPECIES", 194, 213], ["the Sigma GST", "TEST", 13, 26], ["a high sequence identity", "PROBLEM", 51, 75], ["prostaglandin synthase activity", "TREATMENT", 114, 145], ["rOvGST", "TEST", 157, 163], ["the filarial parasite", "PROBLEM", 171, 192], ["Onchocerca volvulus", "PROBLEM", 194, 213], ["hepatica", "ANATOMY", 35, 43], ["filarial", "ANATOMY", 175, 183], ["parasite", "OBSERVATION", 184, 192], ["Onchocerca volvulus", "OBSERVATION", 194, 213]]], ["Using a coupled assay with COX-1 we have shown that rFhGST-S1 is capable of synthesizing both PGD 2 and PGE 2 , with PGD 2 being the predominant prostanoid.", [["PGE 2", "CHEMICAL", 104, 109], ["prostanoid", "CHEMICAL", 145, 155], ["COX-1", "GENE_OR_GENE_PRODUCT", 27, 32], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 52, 61], ["PGD 2", "GENE_OR_GENE_PRODUCT", 94, 99], ["PGE 2", "GENE_OR_GENE_PRODUCT", 104, 109], ["PGD 2", "GENE_OR_GENE_PRODUCT", 117, 122], ["prostanoid", "SIMPLE_CHEMICAL", 145, 155], ["COX", "PROTEIN", 27, 30], ["rFhGST", "PROTEIN", 52, 58], ["S1", "PROTEIN", 59, 61], ["a coupled assay with COX", "TEST", 6, 30], ["PGD 2", "PROBLEM", 117, 122], ["S1", "ANATOMY", 59, 61], ["predominant", "OBSERVATION_MODIFIER", 133, 144], ["prostanoid", "OBSERVATION", 145, 155]]], ["Parasite-derived eicosanoids, including prostaglandins, are known to be important in the establishment of parasitic infection and the survival and proliferation within the host.", [["prostaglandins", "CHEMICAL", 40, 54], ["parasitic infection", "DISEASE", 106, 125], ["prostaglandins", "CHEMICAL", 40, 54], ["prostaglandins", "SIMPLE_CHEMICAL", 40, 54], ["prostaglandins", "TREATMENT", 40, 54], ["parasitic infection", "PROBLEM", 106, 125], ["eicosanoids", "OBSERVATION_MODIFIER", 17, 28], ["parasitic", "OBSERVATION_MODIFIER", 106, 115], ["infection", "OBSERVATION", 116, 125]]], ["Therefore, eicosanoids produced by parasitic helminths may play a role in pathophysiological changes during helminth infections.", [["eicosanoids", "CHEMICAL", 11, 22], ["parasitic helminths", "DISEASE", 35, 54], ["helminth infections", "DISEASE", 108, 127], ["eicosanoids", "CHEMICAL", 11, 22], ["parasitic helminths", "PROBLEM", 35, 54], ["pathophysiological changes", "PROBLEM", 74, 100], ["helminth infections", "PROBLEM", 108, 127]]], ["For example, chronic fasciolosis is associated with fever and changes in liver biochemistry, both of which could be associated with parasite-derived eicosanoids thromboxane B2 (TXB2), PGI 2 , PGE 2 and leukotriene B4 (LTB 4 ), detected in the ES products and homogenates of adult F. hepatica worms [56] .", [["liver", "ANATOMY", 73, 78], ["ES products", "ANATOMY", 243, 254], ["homogenates", "ANATOMY", 259, 270], ["fasciolosis", "DISEASE", 21, 32], ["fever", "DISEASE", 52, 57], ["thromboxane", "CHEMICAL", 161, 172], ["TXB2", "CHEMICAL", 177, 181], ["leukotriene B4", "CHEMICAL", 202, 216], ["thromboxane B2", "CHEMICAL", 161, 175], ["PGE 2", "CHEMICAL", 192, 197], ["leukotriene B4", "CHEMICAL", 202, 216], ["liver", "ORGAN", 73, 78], ["thromboxane B2", "GENE_OR_GENE_PRODUCT", 161, 175], ["TXB2", "SIMPLE_CHEMICAL", 177, 181], ["PGI 2", "GENE_OR_GENE_PRODUCT", 184, 189], ["PGE 2", "GENE_OR_GENE_PRODUCT", 192, 197], ["leukotriene B4", "GENE_OR_GENE_PRODUCT", 202, 216], ["LTB 4", "GENE_OR_GENE_PRODUCT", 218, 223], ["F. hepatica", "ORGANISM", 280, 291], ["worms", "ORGANISM", 292, 297], ["F. hepatica", "SPECIES", 280, 291], ["worms", "SPECIES", 292, 297], ["F. hepatica", "SPECIES", 280, 291], ["chronic fasciolosis", "PROBLEM", 13, 32], ["fever", "PROBLEM", 52, 57], ["changes in liver biochemistry", "PROBLEM", 62, 91], ["parasite", "PROBLEM", 132, 140], ["eicosanoids thromboxane B2 (TXB2)", "TEST", 149, 182], ["PGI", "TEST", 184, 187], ["PGE", "TEST", 192, 195], ["leukotriene B4 (LTB", "TEST", 202, 221], ["chronic", "OBSERVATION_MODIFIER", 13, 20], ["fasciolosis", "OBSERVATION", 21, 32], ["fever", "OBSERVATION", 52, 57], ["liver", "ANATOMY", 73, 78], ["biochemistry", "OBSERVATION", 79, 91], ["hepatica", "ANATOMY", 283, 291]]], ["In addition, the migration of host epidermal Langerhans cells, which play a key part in immune defence mechanisms, has been shown to be inhibited by parasite-derived PGD 2 in the Schistosoma mansonimouse model of human infection, thus allowing schistosomes to manipulate the host immune system [57] .", [["epidermal Langerhans cells", "ANATOMY", 35, 61], ["infection", "DISEASE", 219, 228], ["epidermal Langerhans cells", "CELL", 35, 61], ["PGD 2", "GENE_OR_GENE_PRODUCT", 166, 171], ["Schistosoma mansonimouse", "ORGANISM", 179, 203], ["human", "ORGANISM", 213, 218], ["host epidermal Langerhans cells", "CELL_TYPE", 30, 61], ["Schistosoma mansonimouse", "SPECIES", 179, 203], ["human", "SPECIES", 213, 218], ["Schistosoma mansonimouse", "SPECIES", 179, 203], ["human", "SPECIES", 213, 218], ["host epidermal Langerhans cells", "TREATMENT", 30, 61], ["human infection", "PROBLEM", 213, 228], ["migration", "OBSERVATION_MODIFIER", 17, 26], ["host epidermal", "OBSERVATION", 30, 44], ["Langerhans cells", "OBSERVATION", 45, 61], ["infection", "OBSERVATION", 219, 228]]], ["Earlier studies have revealed the presence of eicosanoids produced by S. mansoni cercariae which could also play a role in establishment of infections through loss of the cercarial tail following penetration of the skin [58] .", [["tail", "ANATOMY", 181, 185], ["skin", "ANATOMY", 215, 219], ["eicosanoids", "CHEMICAL", 46, 57], ["S. mansoni cercariae", "DISEASE", 70, 90], ["infections", "DISEASE", 140, 150], ["S. mansoni cercariae", "ORGANISM", 70, 90], ["cercarial tail", "ORGANISM_SUBDIVISION", 171, 185], ["skin", "ORGAN", 215, 219], ["S. mansoni", "SPECIES", 70, 80], ["S. mansoni", "SPECIES", 70, 80], ["Earlier studies", "TEST", 0, 15], ["S. mansoni cercariae", "PROBLEM", 70, 90], ["infections through loss of the cercarial tail", "PROBLEM", 140, 185], ["eicosanoids", "OBSERVATION", 46, 57], ["mansoni cercariae", "OBSERVATION", 73, 90], ["infections", "OBSERVATION", 140, 150], ["cercarial tail", "ANATOMY", 171, 185], ["skin", "ANATOMY", 215, 219]]], ["It therefore seems likely that prostaglandins synthesised via FhGST-S1 will have a role in establishing the infection within the host.DiscussionIn general, prostaglandins and eicosanoids have potent biological activities in reproduction.", [["prostaglandins", "CHEMICAL", 31, 45], ["infection", "DISEASE", 108, 117], ["prostaglandins", "CHEMICAL", 156, 170], ["eicosanoids", "CHEMICAL", 175, 186], ["prostaglandins", "CHEMICAL", 31, 45], ["prostaglandins", "CHEMICAL", 156, 170], ["eicosanoids", "CHEMICAL", 175, 186], ["prostaglandins", "SIMPLE_CHEMICAL", 31, 45], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 62, 70], ["prostaglandins", "SIMPLE_CHEMICAL", 156, 170], ["eicosanoids", "SIMPLE_CHEMICAL", 175, 186], ["FhGST", "PROTEIN", 62, 67], ["S1", "PROTEIN", 68, 70], ["prostaglandins synthesised", "PROBLEM", 31, 57], ["the infection", "PROBLEM", 104, 117], ["prostaglandins and eicosanoids", "TREATMENT", 156, 186], ["seems likely", "UNCERTAINTY", 13, 25], ["infection", "OBSERVATION", 108, 117]]], ["For example in the zebrafish egg, high levels of PGE 2 were seen post fertilisation coupled with high PGD 2 synthase transcript levels during the early stages of egg Figure 4 .", [["egg", "ANATOMY", 29, 32], ["PGE", "CHEMICAL", 49, 52], ["PGE 2", "CHEMICAL", 49, 54], ["zebrafish", "ORGANISM", 19, 28], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 29, 32], ["PGE 2", "GENE_OR_GENE_PRODUCT", 49, 54], ["PGD 2 synthase", "GENE_OR_GENE_PRODUCT", 102, 116], ["PGE 2", "PROTEIN", 49, 54], ["PGD 2 synthase", "PROTEIN", 102, 116], ["zebrafish", "SPECIES", 19, 28], ["zebrafish", "SPECIES", 19, 28], ["high levels of PGE 2", "PROBLEM", 34, 54], ["high PGD 2 synthase transcript levels", "TREATMENT", 97, 134], ["zebrafish egg", "ANATOMY", 19, 32], ["high", "OBSERVATION_MODIFIER", 34, 38]]], ["Images of FhGST-S1 localisation within F. hepatica tissue.", [["tissue", "ANATOMY", 51, 57], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 10, 18], ["F. hepatica", "ORGANISM", 39, 50], ["tissue", "TISSUE", 51, 57], ["FhGST", "PROTEIN", 10, 15], ["F. hepatica", "SPECIES", 39, 50], ["F. hepatica", "SPECIES", 39, 50], ["Images", "TEST", 0, 6], ["FhGST", "TEST", 10, 15], ["hepatica tissue", "ANATOMY", 42, 57]]], ["A) Anti-F. hepatica FhGST-S1 immunohistochemical stain of a fluke in cross section within the host sheep liver bile duct.", [["fluke", "ANATOMY", 60, 65], ["liver bile duct", "ANATOMY", 105, 120], ["Anti-F. hepatica", "ORGANISM", 3, 19], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 20, 28], ["sheep", "ORGANISM", 99, 104], ["liver bile duct", "MULTI-TISSUE_STRUCTURE", 105, 120], ["sheep", "SPECIES", 99, 104], ["Anti-F. hepatica", "SPECIES", 3, 19], ["sheep", "SPECIES", 99, 104], ["A) Anti-F. hepatica FhGST", "TEST", 0, 25], ["immunohistochemical stain", "TEST", 29, 54], ["a fluke", "PROBLEM", 58, 65], ["hepatica", "ANATOMY", 11, 19], ["S1", "ANATOMY", 26, 28], ["immunohistochemical stain", "OBSERVATION", 29, 54], ["fluke", "OBSERVATION", 60, 65], ["host", "ANATOMY_MODIFIER", 94, 98], ["sheep", "ANATOMY_MODIFIER", 99, 104], ["liver", "ANATOMY", 105, 110], ["bile duct", "ANATOMY", 111, 120]]], ["Heavily stained eggs (E) are shown released from the fluke into the bile duct in the top left-hand corner.", [["eggs", "ANATOMY", 16, 20], ["fluke", "ANATOMY", 53, 58], ["bile duct", "ANATOMY", 68, 77], ["left-hand", "ANATOMY", 89, 98], ["eggs", "ORGANISM_SUBSTANCE", 16, 20], ["fluke", "ORGANISM", 53, 58], ["bile duct", "MULTI-TISSUE_STRUCTURE", 68, 77], ["fluke", "OBSERVATION", 53, 58], ["bile duct", "ANATOMY", 68, 77], ["top", "ANATOMY_MODIFIER", 85, 88], ["left", "ANATOMY_MODIFIER", 89, 93], ["hand", "ANATOMY", 94, 98], ["corner", "ANATOMY_MODIFIER", 99, 105]]], ["Brown stained areas show the presence of FhGST-S1 proteins.", [["FhGST-S1", "GENE_OR_GENE_PRODUCT", 41, 49], ["FhGST", "PROTEIN", 41, 46], ["S1 proteins", "PROTEIN", 47, 58], ["Brown stained areas", "PROBLEM", 0, 19], ["FhGST-S1 proteins", "PROBLEM", 41, 58], ["stained", "OBSERVATION", 6, 13]]], ["The lack of staining in the host liver (L) highlights the specificity of the antibody.", [["liver", "ANATOMY", 33, 38], ["liver", "ORGAN", 33, 38], ["staining in the host liver", "PROBLEM", 12, 38], ["staining", "OBSERVATION", 12, 20], ["host", "ANATOMY_MODIFIER", 28, 32], ["liver", "ANATOMY", 33, 38]]], ["Composite picture.", [["Composite picture", "PROBLEM", 0, 17]]], ["B) Enlarged region of A showing the intense anti-F. hepatica FhGST-S1staining in the voided eggs (E).", [["eggs", "ANATOMY", 92, 96], ["anti-F. hepatica", "ORGANISM", 44, 60], ["FhGST", "PROTEIN", 61, 66], ["anti-F. hepatica", "SPECIES", 44, 60], ["anti-F. hepatica", "SPECIES", 44, 60], ["Enlarged region of A", "PROBLEM", 3, 23], ["Enlarged", "OBSERVATION", 3, 11], ["intense", "OBSERVATION_MODIFIER", 36, 43], ["hepatica", "ANATOMY", 52, 60], ["voided eggs", "ANATOMY", 85, 96]]], ["The spines (S) present in the tegument (T) can be clearly distinguished by their lack of FhGST-S1 presence.", [["spines", "ANATOMY", 4, 10], ["tegument", "ANATOMY", 30, 38], ["spines", "MULTI-TISSUE_STRUCTURE", 4, 10], ["tegument", "CELLULAR_COMPONENT", 30, 38], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 89, 97], ["FhGST", "PROTEIN", 89, 94], ["S1", "PROTEIN", 95, 97], ["spines", "ANATOMY", 4, 10], ["tegument", "ANATOMY", 30, 38]]], ["C-E) Cross sections of a F. hepatica adult highlighting staining of FhGST-S1 in the parenchyma (P), musculature (M),the tegument (T), basal membrane (Bm) and most intensely in the vitelline cells (V) and developing eggs (DE) .", [["sections", "ANATOMY", 11, 19], ["parenchyma", "ANATOMY", 84, 94], ["musculature", "ANATOMY", 100, 111], ["tegument", "ANATOMY", 120, 128], ["basal membrane", "ANATOMY", 134, 148], ["vitelline cells", "ANATOMY", 180, 195], ["eggs", "ANATOMY", 215, 219], ["C-E", "GENE_OR_GENE_PRODUCT", 0, 3], ["F. hepatica", "ORGANISM", 25, 36], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 68, 76], ["parenchyma", "TISSUE", 84, 94], ["musculature", "TISSUE", 100, 111], ["tegument", "CELLULAR_COMPONENT", 120, 128], ["basal membrane", "CELLULAR_COMPONENT", 134, 148], ["vitelline cells", "CELL", 180, 195], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 215, 219], ["FhGST", "PROTEIN", 68, 73], ["S1", "PROTEIN", 74, 76], ["vitelline cells", "CELL_TYPE", 180, 195], ["F. hepatica", "SPECIES", 25, 36], ["F. hepatica", "SPECIES", 25, 36], ["hepatica", "ANATOMY", 28, 36], ["S1", "ANATOMY_MODIFIER", 74, 76], ["parenchyma", "ANATOMY", 84, 94], ["musculature", "ANATOMY", 100, 111], ["tegument", "ANATOMY", 120, 128], ["basal membrane", "ANATOMY", 134, 148], ["Bm", "ANATOMY", 150, 152], ["vitelline cells", "ANATOMY", 180, 195]]], ["No staining can be seen in the tegumental spines (S), testes (T) or the intestinal caecum (IC). doi:10.1371/journal.pntd.0001666.g004 Figure 5 . rFhGST-SI stimulates the production total prostaglandin and PGE2 from dendritic cells (DCs) in a TLR4 dependent manner.", [["tegumental spines", "ANATOMY", 31, 48], ["testes", "ANATOMY", 54, 60], ["intestinal caecum", "ANATOMY", 72, 89], ["dendritic cells", "ANATOMY", 215, 230], ["DCs", "ANATOMY", 232, 235], ["doi:10.1371/journal.pntd.0001666.g004", "CHEMICAL", 96, 133], ["prostaglandin", "CHEMICAL", 187, 200], ["PGE2", "CHEMICAL", 205, 209], ["prostaglandin", "CHEMICAL", 187, 200], ["PGE2", "CHEMICAL", 205, 209], ["tegumental spines", "CELLULAR_COMPONENT", 31, 48], ["testes", "ORGAN", 54, 60], ["intestinal caecum", "ORGAN", 72, 89], ["rFhGST-SI", "GENE_OR_GENE_PRODUCT", 145, 154], ["prostaglandin", "SIMPLE_CHEMICAL", 187, 200], ["PGE2", "SIMPLE_CHEMICAL", 205, 209], ["dendritic cells", "CELL", 215, 230], ["DCs", "CELL", 232, 235], ["TLR4", "GENE_OR_GENE_PRODUCT", 242, 246], ["rFhGST", "PROTEIN", 145, 151], ["dendritic cells", "CELL_TYPE", 215, 230], ["DCs", "CELL_TYPE", 232, 235], ["TLR4", "PROTEIN", 242, 246], ["staining", "PROBLEM", 3, 11], ["rFhGST", "TEST", 145, 151], ["the production total prostaglandin", "TREATMENT", 166, 200], ["PGE2", "TREATMENT", 205, 209], ["dendritic cells", "PROBLEM", 215, 230], ["staining", "OBSERVATION", 3, 11], ["can be seen", "UNCERTAINTY", 12, 23], ["tegumental spines", "ANATOMY", 31, 48], ["testes", "ANATOMY", 54, 60], ["intestinal caecum", "ANATOMY", 72, 89], ["dendritic cells", "OBSERVATION", 215, 230], ["TLR4 dependent", "OBSERVATION_MODIFIER", 242, 256]]], ["DCs derived from the bone marrow from C57BL/ 6j mice were cultured in vitro with medium, rFhGST-S1 (10 mg/ml) or LPS (100 ng/ml) for 18 hours, and the production of total prostaglandin, PGE2 and PGD2 (data for PGD2 not shown) released into supernatants determined by competitive EIA.", [["DCs", "ANATOMY", 0, 3], ["bone marrow", "ANATOMY", 21, 32], ["supernatants", "ANATOMY", 240, 252], ["rFhGST-S1", "CHEMICAL", 89, 98], ["LPS", "CHEMICAL", 113, 116], ["prostaglandin", "CHEMICAL", 171, 184], ["PGE2", "CHEMICAL", 186, 190], ["PGD2", "CHEMICAL", 195, 199], ["PGD2", "CHEMICAL", 210, 214], ["prostaglandin", "CHEMICAL", 171, 184], ["PGE2", "CHEMICAL", 186, 190], ["PGD2", "CHEMICAL", 195, 199], ["PGD2", "CHEMICAL", 210, 214], ["DCs", "CELL", 0, 3], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 21, 32], ["C57BL/ 6j mice", "ORGANISM", 38, 52], ["rFhGST-S1", "SIMPLE_CHEMICAL", 89, 98], ["LPS", "SIMPLE_CHEMICAL", 113, 116], ["prostaglandin", "SIMPLE_CHEMICAL", 171, 184], ["PGE2", "SIMPLE_CHEMICAL", 186, 190], ["PGD2", "SIMPLE_CHEMICAL", 195, 199], ["PGD2", "SIMPLE_CHEMICAL", 210, 214], ["DCs", "CELL_TYPE", 0, 3], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["the bone marrow", "TEST", 17, 32], ["C57BL/ 6j mice", "TREATMENT", 38, 52], ["LPS", "TREATMENT", 113, 116], ["total prostaglandin", "TREATMENT", 165, 184], ["PGE2", "TREATMENT", 186, 190], ["PGD2", "TREATMENT", 195, 199], ["PGD2", "TEST", 210, 214], ["bone marrow", "ANATOMY", 21, 32]]], ["Data are presented as the mean 6 SEM following subtraction of medium controls and are representative of two experiments.", [["subtraction of medium controls", "TREATMENT", 47, 77]]], ["WT -wild type; TLR4KO -Toll like receptor 4 knock out. doi:10.1371/journal.pntd.0001666.g005DiscussionSigma Class Glutathione Transferase of F. hepatica www.plosntds.org development concomitant with an exponential decrease of PGD 2 levels over the next 120 h post fertilisation [59] .", [["Glutathione", "CHEMICAL", 114, 125], ["TLR4KO -Toll like receptor 4", "GENE_OR_GENE_PRODUCT", 15, 43], ["Class Glutathione Transferase", "GENE_OR_GENE_PRODUCT", 108, 137], ["F. hepatica", "ORGANISM", 141, 152], ["PGD 2", "GENE_OR_GENE_PRODUCT", 226, 231], ["TLR4KO", "PROTEIN", 15, 21], ["Toll like receptor 4", "PROTEIN", 23, 43], ["Class Glutathione Transferase", "PROTEIN", 108, 137], ["PGD 2", "PROTEIN", 226, 231], ["F. hepatica", "SPECIES", 141, 152], ["F. hepatica", "SPECIES", 141, 152], ["WT", "TEST", 0, 2], ["TLR4KO", "TEST", 15, 21], ["an exponential decrease of PGD", "TREATMENT", 199, 229], ["hepatica", "ANATOMY", 144, 152]]], ["However, in F. hepatica, eggs in gravid adults are released in an immature state in the bile duct, where they pass to the external environment via the host's excretory system and complete embryogenesis ex-host.", [["eggs", "ANATOMY", 25, 29], ["bile duct", "ANATOMY", 88, 97], ["excretory system", "ANATOMY", 158, 174], ["F. hepatica", "DISEASE", 12, 23], ["F. hepatica", "ORGANISM", 12, 23], ["eggs", "ORGANISM_SUBSTANCE", 25, 29], ["bile duct", "MULTI-TISSUE_STRUCTURE", 88, 97], ["excretory system", "ANATOMICAL_SYSTEM", 158, 174], ["F. hepatica", "SPECIES", 12, 23], ["F. hepatica", "SPECIES", 12, 23], ["hepatica", "ANATOMY", 15, 23], ["immature state", "OBSERVATION", 66, 80], ["bile duct", "ANATOMY", 88, 97]]], ["Therefore, FhGST-S1 may have a secondary, or indeed primary, function in egg development and embyrogenesis.", [["egg", "ANATOMY", 73, 76], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 11, 19], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 73, 76], ["FhGST", "PROTEIN", 11, 16], ["S1", "PROTEIN", 17, 19], ["embyrogenesis", "PROBLEM", 93, 106], ["secondary", "OBSERVATION_MODIFIER", 31, 40]]], ["A role in egg development is further supported by proteomic studies of F. hepatica ontogenic stages which reveal the presence of FhGST-S1 in eggs ( [42] and the current study).DiscussionFhGST-S1 appears to be highly abundant in eggs with western blotting showing FhGST-S1 to be constitutively expressed, despite its association with a large spot consisting of multiple co-migrating proteins unresolved via 2DE (for association see [42] ).", [["egg", "ANATOMY", 10, 13], ["eggs", "ANATOMY", 228, 232], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 10, 13], ["F. hepatica", "ORGANISM", 71, 82], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 129, 137], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 141, 145], ["DiscussionFhGST-S1", "GENE_OR_GENE_PRODUCT", 176, 194], ["eggs", "ORGANISM_SUBSTANCE", 228, 232], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 263, 271], ["FhGST", "PROTEIN", 129, 134], ["S1", "PROTEIN", 135, 137], ["DiscussionFhGST", "PROTEIN", 176, 191], ["S1", "PROTEIN", 192, 194], ["FhGST", "PROTEIN", 263, 268], ["S1", "PROTEIN", 269, 271], ["co-migrating proteins", "PROTEIN", 369, 390], ["F. hepatica", "SPECIES", 71, 82], ["F. hepatica", "SPECIES", 71, 82], ["proteomic studies", "TEST", 50, 67], ["FhGST-S1 in eggs", "PROBLEM", 129, 145], ["the current study", "TEST", 157, 174], ["western blotting", "TEST", 238, 254], ["a large spot", "PROBLEM", 333, 345], ["multiple co-migrating proteins", "PROBLEM", 360, 390], ["hepatica", "ANATOMY", 74, 82]]], ["Immunolocalisation studies revealed that FhGST-S1 is closely associated with vitelline cells of mature adult worms.", [["vitelline cells", "ANATOMY", 77, 92], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 41, 49], ["vitelline cells", "CELL", 77, 92], ["worms", "DEVELOPING_ANATOMICAL_STRUCTURE", 109, 114], ["FhGST", "PROTEIN", 41, 46], ["S1", "PROTEIN", 47, 49], ["vitelline cells", "CELL_TYPE", 77, 92], ["worms", "SPECIES", 109, 114], ["Immunolocalisation studies", "TEST", 0, 26], ["FhGST-S1", "PROBLEM", 41, 49], ["vitelline cells", "PROBLEM", 77, 92], ["mature adult worms", "PROBLEM", 96, 114], ["vitelline cells", "OBSERVATION", 77, 92], ["mature", "OBSERVATION_MODIFIER", 96, 102], ["adult worms", "OBSERVATION", 103, 114]]], ["Given the importance of PGs in reproduction, we hypothesize that PG synthase activity exhibited by rFhGST-S1 contributes to developmental cues during egg formation.", [["egg", "ANATOMY", 150, 153], ["PG", "CHEMICAL", 65, 67], ["PGs", "GENE_OR_GENE_PRODUCT", 24, 27], ["PG synthase", "GENE_OR_GENE_PRODUCT", 65, 76], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 99, 108], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 150, 153], ["PG synthase", "PROTEIN", 65, 76], ["rFhGST", "PROTEIN", 99, 105], ["S1", "PROTEIN", 106, 108], ["PGs", "PROBLEM", 24, 27], ["PG synthase activity", "PROBLEM", 65, 85], ["developmental cues", "PROBLEM", 124, 142]]], ["Interestingly, no FhGST-S1 was seen in day 0, unembryonated, eggs by western blotting yet in situ immunlocalisation showed freshly voided eggs, equivalent to day 0 eggs, to contain copious amounts of FhGST-S1.", [["eggs", "ANATOMY", 61, 65], ["eggs", "ANATOMY", 138, 142], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 18, 26], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 200, 208], ["FhGST", "PROTEIN", 18, 23], ["S1", "PROTEIN", 24, 26], ["FhGST", "PROTEIN", 200, 205], ["S1", "PROTEIN", 206, 208], ["freshly voided eggs", "PROBLEM", 123, 142], ["no", "UNCERTAINTY", 15, 17], ["S1", "ANATOMY", 24, 26], ["voided eggs", "OBSERVATION", 131, 142], ["copious amounts", "OBSERVATION", 181, 196], ["S1", "ANATOMY", 206, 208]]], ["While it is most likely that FhGST-S1 is present in day 0 eggs, albeit at a reduced expression, the discrepancy seen between the two techniques is probably related to the antibody dilutions used for each method; in total a 40-fold difference in favour of immunolocalisation.DiscussionFhGST-S1 was also identified in both NEJs and adult worms using western blotting.", [["NEJs", "ANATOMY", 321, 325], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 29, 37], ["DiscussionFhGST-S1", "GENE_OR_GENE_PRODUCT", 274, 292], ["NEJs", "CANCER", 321, 325], ["FhGST", "PROTEIN", 29, 34], ["S1", "PROTEIN", 35, 37], ["DiscussionFhGST", "PROTEIN", 274, 289], ["S1", "PROTEIN", 290, 292], ["NEJs", "CELL_TYPE", 321, 325], ["worms", "SPECIES", 336, 341], ["a reduced expression", "PROBLEM", 74, 94], ["the antibody dilutions", "TREATMENT", 167, 189], ["immunolocalisation", "PROBLEM", 255, 273], ["most likely", "UNCERTAINTY", 12, 23], ["probably related to", "UNCERTAINTY", 147, 166], ["40-fold", "OBSERVATION_MODIFIER", 223, 230]]], ["This finding emphasises the multifunctionality of FhGST-S1, where in NEJs egg productions is not yet in process, suggesting its main function is in PG synthesis for host modulation or as a detoxification enzyme.", [["PG", "CHEMICAL", 148, 150], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 50, 58], ["NEJs", "GENE_OR_GENE_PRODUCT", 69, 73], ["PG", "SIMPLE_CHEMICAL", 148, 150], ["FhGST", "PROTEIN", 50, 55], ["S1", "PROTEIN", 56, 58], ["detoxification enzyme", "PROTEIN", 189, 210], ["a detoxification enzyme", "TEST", 187, 210], ["main", "OBSERVATION_MODIFIER", 128, 132]]], ["In the adult worm, FhGST-S1 could also be localised, to a smaller extent, in the parenchyma and tegument.", [["parenchyma", "ANATOMY", 81, 91], ["tegument", "ANATOMY", 96, 104], ["worm", "ORGAN", 13, 17], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 19, 27], ["parenchyma", "TISSUE", 81, 91], ["tegument", "CELLULAR_COMPONENT", 96, 104], ["FhGST", "PROTEIN", 19, 24], ["S1", "PROTEIN", 25, 27], ["adult", "OBSERVATION_MODIFIER", 7, 12], ["worm", "OBSERVATION", 13, 17], ["S1", "ANATOMY", 25, 27], ["could also be", "UNCERTAINTY", 28, 41], ["localised", "OBSERVATION", 42, 51], ["smaller", "OBSERVATION_MODIFIER", 58, 65], ["extent", "OBSERVATION_MODIFIER", 66, 72], ["parenchyma", "ANATOMY_MODIFIER", 81, 91], ["tegument", "ANATOMY_MODIFIER", 96, 104]]], ["Given the high activity of FhGST-S1 towards the toxic 4-HNE and to lipid hydroperoxides this suggests a detoxification role at the host-parasite interface.DiscussionWith near surface expression of FhGST-S1, in the parenchyma and tegument, there is the potential for this enzyme to be readily released into the host environment.", [["surface", "ANATOMY", 175, 182], ["parenchyma", "ANATOMY", 214, 224], ["tegument", "ANATOMY", 229, 237], ["4-HNE", "CHEMICAL", 54, 59], ["hydroperoxides", "CHEMICAL", 73, 87], ["4-HNE", "CHEMICAL", 54, 59], ["hydroperoxides", "CHEMICAL", 73, 87], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 27, 35], ["4-HNE", "SIMPLE_CHEMICAL", 54, 59], ["lipid hydroperoxides", "SIMPLE_CHEMICAL", 67, 87], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 197, 205], ["parenchyma", "TISSUE", 214, 224], ["tegument", "ORGANISM_SUBSTANCE", 229, 237], ["FhGST", "PROTEIN", 27, 32], ["S1", "PROTEIN", 33, 35], ["FhGST", "PROTEIN", 197, 202], ["S1", "PROTEIN", 203, 205], ["lipid hydroperoxides", "TEST", 67, 87], ["this enzyme", "PROBLEM", 266, 277], ["high activity", "OBSERVATION_MODIFIER", 10, 23], ["parasite interface", "OBSERVATION", 136, 154], ["S1", "ANATOMY", 203, 205], ["parenchyma", "ANATOMY", 214, 224]]], ["Indeed, we have identified FhGST-S1 in the ES products of adult worms.", [["ES", "ANATOMY", 43, 45], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 27, 35], ["ES products", "CELL", 43, 54], ["worms", "DEVELOPING_ANATOMICAL_STRUCTURE", 64, 69], ["FhGST", "PROTEIN", 27, 32], ["S1", "PROTEIN", 33, 35], ["worms", "SPECIES", 64, 69], ["FhGST", "TEST", 27, 32], ["adult worms", "PROBLEM", 58, 69], ["adult worms", "OBSERVATION", 58, 69]]], ["With this in mind, previous studies have highlighted the importance of parasite Sigma class GSTs in immunomodulation of the host immune response.", [["Sigma class GSTs", "GENE_OR_GENE_PRODUCT", 80, 96], ["parasite Sigma class GSTs", "PROTEIN", 71, 96], ["previous studies", "TEST", 19, 35], ["host immune response", "OBSERVATION", 124, 144]]], ["This includes our recent study implicating rFhGST-S1 in chronic inflammation through the activation of dendritic cells (DCs) [48] .", [["dendritic cells", "ANATOMY", 103, 118], ["DCs", "ANATOMY", 120, 123], ["inflammation", "DISEASE", 64, 76], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 43, 52], ["dendritic cells", "CELL", 103, 118], ["DCs", "CELL", 120, 123], ["rFhGST", "PROTEIN", 43, 49], ["S1", "PROTEIN", 50, 52], ["dendritic cells", "CELL_TYPE", 103, 118], ["DCs", "CELL_TYPE", 120, 123], ["our recent study", "TEST", 14, 30], ["rFhGST", "TEST", 43, 49], ["chronic inflammation", "PROBLEM", 56, 76], ["dendritic cells", "PROBLEM", 103, 118], ["S1", "ANATOMY", 50, 52], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["inflammation", "OBSERVATION", 64, 76], ["dendritic cells", "OBSERVATION", 103, 118]]], ["While active rFhGST-S1 was able to induce levels of IL-12p40 and IL-6 cytokines in DCs in a dose-dependent manner, the previously described F. hepatica Mu-class GSTs failed to induce any cytokine secretion.", [["DCs", "ANATOMY", 83, 86], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 13, 22], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 52, 60], ["IL-6", "GENE_OR_GENE_PRODUCT", 65, 69], ["DCs", "CELL", 83, 86], ["F. hepatica", "ORGANISM", 140, 151], ["Mu-class GSTs", "GENE_OR_GENE_PRODUCT", 152, 165], ["rFhGST", "PROTEIN", 13, 19], ["S1", "PROTEIN", 20, 22], ["IL-12p40 and IL-6 cytokines", "PROTEIN", 52, 79], ["DCs", "CELL_TYPE", 83, 86], ["F. hepatica Mu-class GSTs", "PROTEIN", 140, 165], ["cytokine", "PROTEIN", 187, 195], ["F. hepatica", "SPECIES", 140, 151], ["F. hepatica", "SPECIES", 140, 151], ["IL", "TEST", 52, 54], ["IL", "TEST", 65, 67], ["any cytokine secretion", "PROBLEM", 183, 205], ["hepatica", "ANATOMY", 143, 151]]], ["Since denatured rFhGST-S1 also failed to induce any cytokines in DCs, activation of DCs is likely related to the structure and activity of the enzyme.", [["DCs", "ANATOMY", 65, 68], ["DCs", "ANATOMY", 84, 87], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 16, 25], ["DCs", "CELL", 65, 68], ["DCs", "CELL", 84, 87], ["rFhGST", "PROTEIN", 16, 22], ["S1", "PROTEIN", 23, 25], ["cytokines", "PROTEIN", 52, 61], ["DCs", "CELL_TYPE", 65, 68], ["DCs", "CELL_TYPE", 84, 87], ["enzyme", "PROTEIN", 143, 149], ["DCs", "PROBLEM", 84, 87], ["the enzyme", "TEST", 139, 149]]], ["However, inhibition of nitric oxide production, involved in driving a Th2 immune response, may also be a contributing factor in skewing the host response to fasciolosis [60] .DiscussionF. hepatica infections are associated with a T-helper-cell type 2 (Th2) immune response dominating during the chronic phases of infection [61] , but pro-inflammatory responses are suppressed [62] .", [["nitric oxide", "CHEMICAL", 23, 35], ["fasciolosis", "DISEASE", 157, 168], ["hepatica infections", "DISEASE", 188, 207], ["infection", "DISEASE", 313, 322], ["nitric oxide", "CHEMICAL", 23, 35], ["nitric oxide", "SIMPLE_CHEMICAL", 23, 35], ["hepatica", "ORGANISM", 188, 196], ["T-helper-cell type 2", "GENE_OR_GENE_PRODUCT", 230, 250], ["Th2", "GENE_OR_GENE_PRODUCT", 252, 255], ["hepatica", "SPECIES", 188, 196], ["hepatica", "SPECIES", 188, 196], ["nitric oxide production", "TREATMENT", 23, 46], ["a contributing factor", "PROBLEM", 103, 124], ["fasciolosis", "PROBLEM", 157, 168], ["hepatica infections", "PROBLEM", 188, 207], ["immune response", "PROBLEM", 257, 272], ["infection", "PROBLEM", 313, 322], ["infections", "OBSERVATION", 197, 207], ["chronic phases", "OBSERVATION_MODIFIER", 295, 309], ["infection", "OBSERVATION", 313, 322]]], ["Suppression of allergic responses during chronic parasitic worm infections has a mutually beneficial effect on the parasites' proliferation and the hosts' survival.", [["allergic", "DISEASE", 15, 23], ["parasitic worm infections", "DISEASE", 49, 74], ["allergic responses", "PROBLEM", 15, 33], ["chronic parasitic worm infections", "PROBLEM", 41, 74], ["the parasites' proliferation", "PROBLEM", 111, 139], ["allergic", "OBSERVATION", 15, 23], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["parasitic worm infections", "OBSERVATION", 49, 74]]], ["Prostanoids, including PGD 2 , are important in mediating these allergic inflammatory responses.", [["Prostanoids", "DISEASE", 0, 11], ["allergic", "DISEASE", 64, 72], ["Prostanoids", "GENE_OR_GENE_PRODUCT", 0, 11], ["PGD 2", "GENE_OR_GENE_PRODUCT", 23, 28], ["PGD 2", "PROTEIN", 23, 28], ["PGD 2", "PROBLEM", 23, 28], ["these allergic inflammatory responses", "PROBLEM", 58, 95]]], ["While generally regarded as pro-inflammatory molecules, these important lipid molecules are also involved in mediating antiinflammatory responses [63] .", [["pro-inflammatory molecules", "PROTEIN", 28, 54], ["pro-inflammatory molecules", "PROBLEM", 28, 54]]], ["Helminth-derived molecules are thought to be involved in driving the Th2 response stereotypical of parasitic worm infections.", [["worm", "ANATOMY", 109, 113], ["parasitic worm infections", "DISEASE", 99, 124], ["Th2", "GENE_OR_GENE_PRODUCT", 69, 72], ["parasitic worm", "ORGANISM", 99, 113], ["parasitic worm infections", "PROBLEM", 99, 124], ["parasitic worm infections", "OBSERVATION", 99, 124]]], ["DC and macrophage cell cultures Figure 6 . rFhGST-SI stimulates the production PGE2 and PGD2 from the macrophage cell lines J774 and RAW264.7.", [["DC", "ANATOMY", 0, 2], ["macrophage cell cultures", "ANATOMY", 7, 31], ["macrophage cell lines J774", "ANATOMY", 102, 128], ["RAW264.7", "ANATOMY", 133, 141], ["PGE2", "CHEMICAL", 79, 83], ["PGD2", "CHEMICAL", 88, 92], ["PGE2", "CHEMICAL", 79, 83], ["PGD2", "CHEMICAL", 88, 92], ["DC", "CELL", 0, 2], ["macrophage cell cultures Figure 6", "CELL", 7, 40], ["rFhGST-SI", "GENE_OR_GENE_PRODUCT", 43, 52], ["PGE2", "SIMPLE_CHEMICAL", 79, 83], ["PGD2", "SIMPLE_CHEMICAL", 88, 92], ["macrophage cell lines J774", "CELL", 102, 128], ["RAW264.7", "CELL", 133, 141], ["DC", "CELL_TYPE", 0, 2], ["macrophage cell cultures", "CELL_LINE", 7, 31], ["rFhGST", "PROTEIN", 43, 49], ["macrophage cell lines", "CELL_LINE", 102, 123], ["J774", "CELL_LINE", 124, 128], ["RAW264.7", "CELL_LINE", 133, 141], ["macrophage cell cultures", "TEST", 7, 31], ["rFhGST", "TEST", 43, 49], ["the production PGE2", "TEST", 64, 83], ["PGD2", "TEST", 88, 92], ["macrophage cell", "OBSERVATION", 7, 22], ["macrophage cell lines", "OBSERVATION", 102, 123]]], ["J744 and RAW264.7 macrophage cell lines were cultured in vitro with medium, rFhGST-S1 (10 mg/ml) or LPS (100 ng/ml) for 18 hours, and the production of total prostaglandin, PGE2 and PGD2 released into supernatants determined by competitive EIA.", [["J744", "ANATOMY", 0, 4], ["RAW264.7 macrophage cell lines", "ANATOMY", 9, 39], ["supernatants", "ANATOMY", 201, 213], ["rFhGST-S1", "CHEMICAL", 76, 85], ["LPS", "CHEMICAL", 100, 103], ["prostaglandin", "CHEMICAL", 158, 171], ["PGE2", "CHEMICAL", 173, 177], ["PGD2", "CHEMICAL", 182, 186], ["prostaglandin", "CHEMICAL", 158, 171], ["PGE2", "CHEMICAL", 173, 177], ["PGD2", "CHEMICAL", 182, 186], ["J744", "CELL", 0, 4], ["RAW264.7 macrophage cell lines", "CELL", 9, 39], ["rFhGST-S1", "SIMPLE_CHEMICAL", 76, 85], ["LPS", "SIMPLE_CHEMICAL", 100, 103], ["prostaglandin", "SIMPLE_CHEMICAL", 158, 171], ["PGE2", "SIMPLE_CHEMICAL", 173, 177], ["PGD2", "SIMPLE_CHEMICAL", 182, 186], ["J744", "CELL_LINE", 0, 4], ["RAW264.7 macrophage cell lines", "CELL_LINE", 9, 39], ["macrophage cell lines", "TEST", 18, 39], ["rFhGST", "TEST", 76, 82], ["LPS", "TREATMENT", 100, 103], ["total prostaglandin", "TREATMENT", 152, 171], ["PGE2", "TREATMENT", 173, 177], ["PGD2", "TREATMENT", 182, 186], ["cell lines", "OBSERVATION", 29, 39]]], ["Data are presented as the mean 6 SEM following subtraction of medium controls and are representative of two experiments. doi:10.1371/journal.pntd.0001666.g006DiscussionSigma Class Glutathione Transferase of F. hepatica www.plosntds.org exposed to rFhGST-S1 showed elevated levels of Th2 cytokines after 24 h [48] .", [["Glutathione", "CHEMICAL", 180, 191], ["Class Glutathione Transferase", "GENE_OR_GENE_PRODUCT", 174, 203], ["F. hepatica", "ORGANISM", 207, 218], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 247, 256], ["Class Glutathione Transferase", "PROTEIN", 174, 203], ["rFhGST", "PROTEIN", 247, 253], ["Th2 cytokines", "PROTEIN", 283, 296], ["F. hepatica", "SPECIES", 207, 218], ["F. hepatica", "SPECIES", 207, 218], ["subtraction of medium controls", "TREATMENT", 47, 77], ["rFhGST", "TEST", 247, 253], ["elevated levels of Th2 cytokines", "PROBLEM", 264, 296], ["hepatica", "ANATOMY", 210, 218], ["elevated", "OBSERVATION", 264, 272]]], ["In this study, the effects of rFhGST-S1 exposure onprostanoid synthesis in host immune cells was investigated.", [["immune cells", "ANATOMY", 80, 92], ["rFhGST", "CHEMICAL", 30, 36], ["onprostanoid", "CHEMICAL", 49, 61], ["onprostanoid", "CHEMICAL", 49, 61], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 30, 39], ["onprostanoid", "SIMPLE_CHEMICAL", 49, 61], ["host immune cells", "CELL", 75, 92], ["rFhGST", "PROTEIN", 30, 36], ["host immune cells", "CELL_TYPE", 75, 92], ["this study", "TEST", 3, 13], ["rFhGST", "TEST", 30, 36], ["S1 exposure onprostanoid synthesis", "TREATMENT", 37, 71], ["host immune cells", "TREATMENT", 75, 92], ["host immune cells", "OBSERVATION", 75, 92]]], ["The results of which show the stimulation of PGD 2 and PGE 2 in both DCs and macrophage cell lines suggesting FhGST-S1 is one such helminth derived molecule capable of driving the Th2 response.DiscussionAs we have shown FhGST-S1 to have key roles in F. hepatica, both in NEJs and adult worms, coupled with the near surface expression and release of the enzyme via the ES products, we assessed the potential of FhGST-S1 to be used as a vaccine candidate.", [["DCs", "ANATOMY", 69, 72], ["macrophage cell lines", "ANATOMY", 77, 98], ["NEJs", "ANATOMY", 271, 275], ["surface", "ANATOMY", 315, 322], ["F. hepatica", "DISEASE", 250, 261], ["PGE 2", "CHEMICAL", 55, 60], ["PGD 2", "GENE_OR_GENE_PRODUCT", 45, 50], ["PGE 2", "GENE_OR_GENE_PRODUCT", 55, 60], ["DCs", "CELL", 69, 72], ["macrophage cell lines", "CELL", 77, 98], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 110, 118], ["Th2", "GENE_OR_GENE_PRODUCT", 180, 183], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 220, 228], ["F. hepatica", "ORGANISM", 250, 261], ["NEJs", "CANCER", 271, 275], ["adult worms", "ORGANISM", 280, 291], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 410, 418], ["PGD 2", "PROTEIN", 45, 50], ["PGE 2", "PROTEIN", 55, 60], ["DCs", "CELL_TYPE", 69, 72], ["macrophage cell lines", "CELL_LINE", 77, 98], ["FhGST", "PROTEIN", 110, 115], ["S1", "PROTEIN", 116, 118], ["FhGST", "PROTEIN", 220, 225], ["S1", "PROTEIN", 226, 228], ["enzyme", "PROTEIN", 353, 359], ["FhGST", "PROTEIN", 410, 415], ["S1", "PROTEIN", 416, 418], ["F. hepatica", "SPECIES", 250, 261], ["worms", "SPECIES", 286, 291], ["F. hepatica", "SPECIES", 250, 261], ["PGD", "TEST", 45, 48], ["PGE", "TREATMENT", 55, 58], ["macrophage cell lines", "TREATMENT", 77, 98], ["FhGST", "TEST", 110, 115], ["the enzyme", "TEST", 349, 359], ["FhGST-S1", "TREATMENT", 410, 418], ["macrophage cell lines", "OBSERVATION", 77, 98], ["hepatica", "ANATOMY", 253, 261]]], ["This was especially poignant given that the S. mansoni Sigma GST homologue (Sm28) is in phase II clinical trials [12] .", [["S. mansoni", "ORGANISM", 44, 54], ["Sigma GST", "GENE_OR_GENE_PRODUCT", 55, 64], ["Sm28", "GENE_OR_GENE_PRODUCT", 76, 80], ["S. mansoni Sigma GST homologue", "PROTEIN", 44, 74], ["Sm28", "PROTEIN", 76, 80], ["S. mansoni", "SPECIES", 44, 54], ["S. mansoni", "SPECIES", 44, 54]]], ["Unfortunately, the current goat based vaccine trial did not show any significant differences in fluke burdens between the rFhGST-S1 immunised and Quil A control group.", [["goat", "ORGANISM", 27, 31], ["fluke", "ORGAN", 96, 101], ["goat", "SPECIES", 27, 31], ["the current goat based vaccine trial", "TREATMENT", 15, 51], ["fluke burdens", "PROBLEM", 96, 109], ["fluke", "OBSERVATION", 96, 101]]], ["However, a high individual variability was recorded, particularly in the vaccinated group also reported in previous trials using goats vaccinated with alternative candidates such as cathepsin L1 [64] and Sm14 [65] .", [["goats", "ORGANISM", 129, 134], ["cathepsin L1", "GENE_OR_GENE_PRODUCT", 182, 194], ["cathepsin L1", "PROTEIN", 182, 194], ["goats", "SPECIES", 129, 134], ["goats", "SPECIES", 129, 134], ["a high individual variability", "PROBLEM", 9, 38], ["goats vaccinated", "TREATMENT", 129, 145], ["alternative candidates", "TREATMENT", 151, 173], ["cathepsin L1", "TEST", 182, 194]]], ["The vaccine trial shown here using a target species with an acceptable adjuvant may have been adversely affected by the strain of F. hepatica used to challenge goats.", [["F. hepatica", "DISEASE", 130, 141], ["F. hepatica", "ORGANISM", 130, 141], ["goats", "ORGANISM", 160, 165], ["F. hepatica", "SPECIES", 130, 141], ["goats", "SPECIES", 160, 165], ["F. hepatica", "SPECIES", 130, 141], ["goats", "SPECIES", 160, 165], ["The vaccine trial", "TREATMENT", 0, 17], ["a target species", "PROBLEM", 35, 51], ["an acceptable adjuvant", "TREATMENT", 57, 79], ["hepatica", "ANATOMY", 133, 141]]], ["Here we have shown an unusually high infectivity rate with the strain of F. hepatica used; which we have reported in a previous trial using goats [64] .", [["F. hepatica", "DISEASE", 73, 84], ["F. hepatica", "ORGANISM", 73, 84], ["goats", "ORGANISM", 140, 145], ["F. hepatica", "SPECIES", 73, 84], ["goats", "SPECIES", 140, 145], ["F. hepatica", "SPECIES", 73, 84], ["goats", "SPECIES", 140, 145], ["an unusually high infectivity rate", "PROBLEM", 19, 53], ["unusually", "OBSERVATION_MODIFIER", 22, 31], ["high", "OBSERVATION_MODIFIER", 32, 36], ["infectivity", "OBSERVATION", 37, 48], ["hepatica", "ANATOMY", 76, 84]]], ["Using an alternative strain of F. hepatica for experimental infections in this species has given normal infectivity rates ranging from 14% to 26.5% [65] .DiscussionIn the present trial it appeared that goats immunised with rFhGST-S1, despite no variations in fluke burdens or morphometrics, showed reduced gross hepatic lesions during early infection, up to day 9 post infection, which continued to week 15 post infection where liver scores for hepatic lesions appeared reduced for rFhGST-S1 immunised animals.", [["hepatic lesions", "ANATOMY", 312, 327], ["liver", "ANATOMY", 428, 433], ["hepatic lesions", "ANATOMY", 445, 460], ["F. hepatica", "DISEASE", 31, 42], ["infections", "DISEASE", 60, 70], ["hepatic lesions", "DISEASE", 312, 327], ["infection", "DISEASE", 341, 350], ["infection", "DISEASE", 369, 378], ["infection", "DISEASE", 412, 421], ["hepatic lesions", "DISEASE", 445, 460], ["F. hepatica", "ORGANISM", 31, 42], ["goats", "ORGANISM", 202, 207], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 223, 232], ["fluke", "ORGANISM_SUBDIVISION", 259, 264], ["hepatic lesions", "PATHOLOGICAL_FORMATION", 312, 327], ["liver", "ORGAN", 428, 433], ["hepatic lesions", "PATHOLOGICAL_FORMATION", 445, 460], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 482, 491], ["rFhGST", "PROTEIN", 223, 229], ["rFhGST", "PROTEIN", 482, 488], ["F. hepatica", "SPECIES", 31, 42], ["goats", "SPECIES", 202, 207], ["F. hepatica", "SPECIES", 31, 42], ["goats", "SPECIES", 202, 207], ["experimental infections in this species", "PROBLEM", 47, 86], ["variations in fluke burdens", "PROBLEM", 245, 272], ["morphometrics", "TEST", 276, 289], ["reduced gross hepatic lesions", "PROBLEM", 298, 327], ["early infection", "PROBLEM", 335, 350], ["infection", "PROBLEM", 369, 378], ["infection", "PROBLEM", 412, 421], ["liver scores", "TEST", 428, 440], ["hepatic lesions", "PROBLEM", 445, 460], ["rFhGST", "TEST", 482, 488], ["hepatica", "ANATOMY", 34, 42], ["infections", "OBSERVATION", 60, 70], ["infectivity", "OBSERVATION_MODIFIER", 104, 115], ["reduced", "OBSERVATION_MODIFIER", 298, 305], ["gross", "OBSERVATION_MODIFIER", 306, 311], ["hepatic", "ANATOMY", 312, 319], ["lesions", "OBSERVATION", 320, 327], ["early", "OBSERVATION_MODIFIER", 335, 340], ["infection", "OBSERVATION", 341, 350], ["infection", "OBSERVATION", 369, 378], ["infection", "OBSERVATION", 412, 421], ["liver", "ANATOMY", 428, 433], ["hepatic", "ANATOMY", 445, 452], ["lesions", "OBSERVATION", 453, 460]]], ["These results suggest that animals from the immunised group produced an early response to migrating larvae that has induced some partial protection from liver damage.", [["liver", "ANATOMY", 153, 158], ["liver damage", "DISEASE", 153, 165], ["liver", "ORGAN", 153, 158], ["migrating larvae", "TREATMENT", 90, 106], ["liver damage", "PROBLEM", 153, 165], ["partial", "OBSERVATION_MODIFIER", 129, 136], ["protection", "OBSERVATION", 137, 147], ["liver", "ANATOMY", 153, 158], ["damage", "OBSERVATION", 159, 165]]], ["The early and consistent specific IgG response found in the present work also agrees with the results obtained in a previous trial using na\u00efve FhGST [46] .", [["IgG", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgG", "PROTEIN", 34, 37], ["IgG response", "OBSERVATION", 34, 46]]], ["However, in both studies high levels of specific IgG did not induced a protective response reducing worm burdens.DiscussionA promising aspect of producing anti-helminth vaccines is developing multivalent vaccines.", [["worm", "ANATOMY", 100, 104], ["IgG", "GENE_OR_GENE_PRODUCT", 49, 52], ["worm", "ORGANISM_SUBDIVISION", 100, 104], ["IgG", "PROTEIN", 49, 52], ["specific IgG", "TEST", 40, 52], ["producing anti-helminth vaccines", "TREATMENT", 145, 177], ["multivalent vaccines", "TREATMENT", 192, 212]]], ["In many cases the greatest protection from challenge is by vaccinating with a combination of Fasciola antigens [66, 67] .", [["Fasciola", "ORGANISM", 93, 101], ["Fasciola antigens", "PROTEIN", 93, 110], ["Fasciola antigens", "TEST", 93, 110]]], ["Therefore, based on the immunisation with FhGST-S1 showing an early response reducing hepatica damage, could be considered for inclusion into a multivalent vaccine against Fasciolosis.", [["hepatica damage", "DISEASE", 86, 101], ["Fasciolosis", "DISEASE", 172, 183], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 42, 50], ["hepatica", "ORGANISM", 86, 94], ["FhGST", "PROTEIN", 42, 47], ["the immunisation", "TEST", 20, 36], ["FhGST", "TEST", 42, 47], ["hepatica damage", "PROBLEM", 86, 101], ["a multivalent vaccine", "TREATMENT", 142, 163], ["Fasciolosis", "PROBLEM", 172, 183], ["hepatica damage", "OBSERVATION", 86, 101]]], ["In addition, in light of our findings showing FhGST-S1 to be highly prominent in egg production and the egg itself, as with previous vaccination trials [67] , it will be important to investigate the ability of eggs voided from vaccinated animals to embryonate.", [["egg", "ANATOMY", 81, 84], ["egg", "ANATOMY", 104, 107], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 46, 54], ["egg", "ORGANISM_SUBDIVISION", 81, 84], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 104, 107], ["eggs", "ORGANISM", 210, 214], ["FhGST", "PROTEIN", 46, 51], ["S1", "PROTEIN", 52, 54], ["our findings", "TEST", 25, 37], ["FhGST-S1", "PROBLEM", 46, 54], ["previous vaccination trials", "TREATMENT", 124, 151], ["highly", "OBSERVATION_MODIFIER", 61, 67], ["prominent", "OBSERVATION", 68, 77], ["egg production", "OBSERVATION", 81, 95]]], ["The potential to reduce pasture contamination by inhibiting egg embryonation, combined with the www.plosntds.org demonstrated reduction in liver damage, warrants further exploration using rFhGST-S1 as a vaccine candidate.DiscussionIn summary, we have further promoted the concept that FhGST-S1 clearly demonstrates key host-parasite roles in synthesising PGs and stimulating PG release from host innate immune cells.", [["egg", "ANATOMY", 60, 63], ["liver", "ANATOMY", 139, 144], ["immune cells", "ANATOMY", 403, 415], ["plosntds", "CHEMICAL", 100, 108], ["liver damage", "DISEASE", 139, 151], ["PG", "CHEMICAL", 375, 377], ["egg", "ORGANISM", 60, 63], ["liver", "ORGAN", 139, 144], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 188, 197], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 285, 293], ["PGs", "GENE_OR_GENE_PRODUCT", 355, 358], ["PG", "GENE_OR_GENE_PRODUCT", 375, 377], ["innate immune cells", "CELL", 396, 415], ["rFhGST", "PROTEIN", 188, 194], ["FhGST", "PROTEIN", 285, 290], ["S1", "PROTEIN", 291, 293], ["host innate immune cells", "CELL_TYPE", 391, 415], ["pasture contamination", "PROBLEM", 24, 45], ["inhibiting egg embryonation", "PROBLEM", 49, 76], ["liver damage", "PROBLEM", 139, 151], ["further exploration", "TEST", 162, 181], ["synthesising PGs", "TREATMENT", 342, 358], ["stimulating PG release", "TREATMENT", 363, 385], ["reduction", "OBSERVATION_MODIFIER", 126, 135], ["liver", "ANATOMY", 139, 144], ["damage", "OBSERVATION", 145, 151]]], ["In addition we have shown FhGST-S1 to be a key protein for detoxification, which may well be involved in TCBZ response.", [["TCBZ", "CHEMICAL", 105, 109], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 26, 34], ["TCBZ", "SIMPLE_CHEMICAL", 105, 109], ["FhGST", "PROTEIN", 26, 31], ["S1", "PROTEIN", 32, 34], ["TCBZ", "PROTEIN", 105, 109]]], ["In line with current vaccine development theory we have shown FhGST-S1 to have multi-functional roles in the liver fluke physiology.", [["liver fluke", "ANATOMY", 109, 120], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 62, 70], ["liver fluke", "MULTI-TISSUE_STRUCTURE", 109, 120], ["FhGST", "PROTEIN", 62, 67], ["S1", "PROTEIN", 68, 70], ["current vaccine", "TREATMENT", 13, 28], ["the liver fluke physiology", "PROBLEM", 105, 131], ["liver", "ANATOMY", 109, 114], ["fluke", "OBSERVATION", 115, 120]]], ["Furthermore, we have shown FhGST-S1 to be expressed across ontogenic stages, localised to the fluke surface, and to the egg, both characteristics vital for vaccine development and success.", [["fluke surface", "ANATOMY", 94, 107], ["egg", "ANATOMY", 120, 123], ["FhGST-S1", "GENE_OR_GENE_PRODUCT", 27, 35], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 120, 123], ["FhGST", "PROTEIN", 27, 32], ["S1", "PROTEIN", 33, 35], ["vaccine development", "TREATMENT", 156, 175], ["fluke", "ANATOMY", 94, 99]]], ["Whilst no protection from fluke burden was seen in trials, the inclusion of rFhGST-S1 as a multivalent vaccine component should be investigated.", [["fluke", "ORGANISM", 26, 31], ["rFhGST-S1", "GENE_OR_GENE_PRODUCT", 76, 85], ["rFhGST", "PROTEIN", 76, 82], ["fluke burden", "PROBLEM", 26, 38], ["a multivalent vaccine component", "TREATMENT", 89, 120], ["fluke", "OBSERVATION_MODIFIER", 26, 31], ["burden", "OBSERVATION", 32, 38]]], ["This will be essential to improve any future vaccine formulation.", [["any future vaccine formulation", "TREATMENT", 34, 64]]], ["Figure S1 Multiple sequence alignment and neighbourjoining phylogenetic tree across seven species-independent classes of GSTs.", [["GSTs", "GENE_OR_GENE_PRODUCT", 121, 125], ["GSTs", "PROTEIN", 121, 125], ["Figure S1 Multiple sequence alignment", "TEST", 0, 37], ["neighbourjoining phylogenetic tree across seven species", "PROBLEM", 42, 97]]], ["A) Alignment of the sigma class GSTs of trematodes shows the extent of identity and similarity across this class of GSTs.", [["sigma class GSTs", "GENE_OR_GENE_PRODUCT", 20, 36], ["GSTs", "GENE_OR_GENE_PRODUCT", 116, 120], ["sigma class GSTs", "PROTEIN", 20, 36], ["GSTs", "PROTEIN", 116, 120], ["trematodes", "OBSERVATION", 40, 50], ["extent", "OBSERVATION_MODIFIER", 61, 67]]], ["Boxed residues indicate complete identity between all sequences.", [["Boxed residues", "PROBLEM", 0, 14]]], ["Residues shaded in grey indicate conserved residues.", [["conserved residues", "OBSERVATION", 33, 51]]], ["B) Neighbour-joining tree placing mammalian and trematode GSTs within the same broad Sigma class.", [["GSTs", "GENE_OR_GENE_PRODUCT", 58, 62], ["Neighbour-joining tree", "DNA", 3, 25], ["mammalian and trematode GSTs", "PROTEIN", 34, 62]]], ["A distinct separation of clusters within this Sigma class is observed as with the recently reclassified 'Nu' class of GSTs from nematodes [49] .", [["GSTs", "GENE_OR_GENE_PRODUCT", 118, 122], ["GSTs", "PROTEIN", 118, 122], ["distinct", "OBSERVATION_MODIFIER", 2, 10], ["separation", "OBSERVATION_MODIFIER", 11, 21], ["clusters", "OBSERVATION_MODIFIER", 25, 33]]], ["Phylogenetic neighbourjoining bootstrap trees were produced and viewed within TREE-VIEW [33] .", [["TREE", "DNA", 78, 82], ["Phylogenetic neighbourjoining bootstrap trees", "TREATMENT", 0, 45]]]], "5d2567c6aea77c3945552b9b490de51b7d640099": [["symptom in European patients, but not in Asian patients [6, 7] .", [["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 47, 55], ["symptom", "PROBLEM", 0, 7]]], ["In a multicenter study in Europe, as many as 85.6% and 88.0% of mild-to-moderate COVID-19 patients showed anosmia and dysgeusia [6] .", [["anosmia", "DISEASE", 106, 113], ["dysgeusia", "DISEASE", 118, 127], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["a multicenter study", "TEST", 3, 22], ["COVID", "TEST", 81, 86], ["anosmia", "PROBLEM", 106, 113], ["dysgeusia", "PROBLEM", 118, 127], ["dysgeusia", "OBSERVATION", 118, 127]]], ["These symptoms preceded other symptoms in 11.8% of patients and were not accompanied by symptoms of nasal obstruction or rhinorrhea [6] .", [["nasal", "ANATOMY", 100, 105], ["nasal obstruction", "DISEASE", 100, 117], ["rhinorrhea", "DISEASE", 121, 131], ["patients", "ORGANISM", 51, 59], ["nasal", "ORGANISM_SUBDIVISION", 100, 105], ["patients", "SPECIES", 51, 59], ["These symptoms", "PROBLEM", 0, 14], ["other symptoms", "PROBLEM", 24, 38], ["symptoms", "PROBLEM", 88, 96], ["nasal obstruction", "PROBLEM", 100, 117], ["rhinorrhea", "PROBLEM", 121, 131], ["nasal", "ANATOMY", 100, 105], ["obstruction", "OBSERVATION", 106, 117], ["rhinorrhea", "OBSERVATION", 121, 131]]], ["In a single-center study in US, approximately 68% (40/59) and 71% (42/59) of COVID-19 patients reported olfactory disturbance and dysgeusia [8] .", [["olfactory", "ANATOMY", 104, 113], ["olfactory disturbance", "DISEASE", 104, 125], ["dysgeusia", "DISEASE", 130, 139], ["patients", "ORGANISM", 86, 94], ["olfactory", "ORGAN", 104, 113], ["patients", "SPECIES", 86, 94], ["COVID", "TEST", 77, 82], ["olfactory disturbance", "PROBLEM", 104, 125], ["dysgeusia", "PROBLEM", 130, 139]]], ["Moreover, studies from the United Kingdom have even stated that olfactory dysfunction could be the only symptom of COVID-19 [7, 9] .", [["olfactory", "ANATOMY", 64, 73], ["olfactory dysfunction", "DISEASE", 64, 85], ["COVID-19", "CHEMICAL", 115, 123], ["olfactory", "ORGAN", 64, 73], ["olfactory dysfunction", "PROBLEM", 64, 85], ["COVID", "TEST", 115, 120]]], ["Thus, abrupt olfactory or gustatory dysfunction might be a clue that a patient has COVID-19.", [["olfactory", "ANATOMY", 13, 22], ["gustatory", "ANATOMY", 26, 35], ["abrupt olfactory or gustatory dysfunction", "DISEASE", 6, 47], ["olfactory", "ORGAN", 13, 22], ["gustatory", "ORGAN", 26, 35], ["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["abrupt olfactory", "PROBLEM", 6, 22], ["gustatory dysfunction", "PROBLEM", 26, 47], ["COVID", "TEST", 83, 88], ["abrupt", "OBSERVATION_MODIFIER", 6, 12], ["gustatory dysfunction", "OBSERVATION", 26, 47]]], ["Only 0.93% (2/214) of COVID-19 patients from Wuhan had olfactory disturbance [10] .", [["olfactory", "ANATOMY", 55, 64], ["olfactory disturbance", "DISEASE", 55, 76], ["patients", "ORGANISM", 31, 39], ["olfactory", "ORGAN", 55, 64], ["patients", "SPECIES", 31, 39], ["COVID", "TEST", 22, 27], ["olfactory disturbance", "PROBLEM", 55, 76]]], ["First, it is possible that olfactory disturbance could be underdiagnosed in Asian populations.", [["olfactory", "ANATOMY", 27, 36], ["olfactory disturbance", "DISEASE", 27, 48], ["olfactory", "ORGAN", 27, 36], ["olfactory disturbance", "PROBLEM", 27, 48]]], ["A study of internet search activities using Google Trends in Europe and the United States demonstrated a strong correlation between the number of COVID-19 patients and searches for olfaction-related information, which led researchers to hypothesize that olfactory disturbance could be a previously unrecognized symptom [11] .", [["olfactory", "ANATOMY", 254, 263], ["olfactory disturbance", "DISEASE", 254, 275], ["patients", "ORGANISM", 155, 163], ["olfactory", "ORGAN", 254, 263], ["patients", "SPECIES", 155, 163], ["A study", "TEST", 0, 7], ["olfactory disturbance", "PROBLEM", 254, 275], ["a previously unrecognized symptom", "PROBLEM", 285, 318]]], ["Second, it has been suggested that regional differences in the viral spike protein genotypes of SARS-CoV-2 between Asia and Europe could result in differences in viral invasiveness of the olfactory system [12] .", [["olfactory system", "ANATOMY", 188, 204], ["SARS", "DISEASE", 96, 100], ["SARS-CoV-2", "ORGANISM", 96, 106], ["SARS-CoV", "SPECIES", 96, 104], ["the viral spike protein genotypes", "TEST", 59, 92], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["regional", "OBSERVATION_MODIFIER", 35, 43], ["viral invasiveness", "OBSERVATION", 162, 180]]], ["Finally, during the last decade, many studies have documented the presence of different endotypes of sinonasal inflammation, such as chronic rhinosinusitis (CRS).", [["sinonasal", "ANATOMY", 101, 110], ["sinonasal inflammation", "DISEASE", 101, 123], ["chronic rhinosinusitis", "DISEASE", 133, 155], ["CRS", "DISEASE", 157, 160], ["sinonasal", "ORGAN", 101, 110], ["many studies", "TEST", 33, 45], ["sinonasal inflammation", "PROBLEM", 101, 123], ["chronic rhinosinusitis", "PROBLEM", 133, 155], ["different", "OBSERVATION_MODIFIER", 78, 87], ["sinonasal inflammation", "OBSERVATION", 101, 123], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["rhinosinusitis", "OBSERVATION", 141, 155]]], ["Since CRS is characterized by an imbalance between external stimuli and the host response, the possibility of regional differences in the mucosal response to SARS-CoV-2 might be cautiously suggested.", [["mucosal", "ANATOMY", 138, 145], ["CRS", "DISEASE", 6, 9], ["SARS", "DISEASE", 158, 162], ["mucosal", "ORGAN", 138, 145], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 158, 168], ["CRS", "PROBLEM", 6, 9], ["external stimuli", "TEST", 51, 67], ["regional differences", "PROBLEM", 110, 130], ["SARS", "TEST", 158, 162], ["CoV", "TEST", 163, 166], ["imbalance", "OBSERVATION", 33, 42], ["host response", "OBSERVATION", 76, 89], ["mucosal", "ANATOMY", 138, 145]]], ["COVID-19 is highly infectious and has caused catastrophic impacts on populations throughout the globe.", [["COVID-19", "CHEMICAL", 0, 8], ["globe", "ORGANISM_SUBDIVISION", 96, 101], ["COVID", "TEST", 0, 5], ["highly infectious", "PROBLEM", 12, 29], ["catastrophic impacts on populations throughout the globe", "PROBLEM", 45, 101], ["highly", "OBSERVATION_MODIFIER", 12, 18], ["infectious", "OBSERVATION", 19, 29], ["catastrophic", "OBSERVATION_MODIFIER", 45, 57], ["impacts", "OBSERVATION_MODIFIER", 58, 65], ["populations", "OBSERVATION_MODIFIER", 69, 80], ["globe", "ANATOMY", 96, 101]]]], "a06b054ac060108a8563363fa40ce617eb7af258": [["NIOSH staff were deployed serially (a team of two initially and later, two persons at two different times) within larger teams stationed first in Taipei and then in Kaohsiung.", [["persons", "SPECIES", 75, 82]]], ["During the peak of the SARS epidemic, CDC environmental support focused on immediate steps to isolate SARS patients, protect healthcare workers and other personnel during fever screening and patient care, and provide advice on disinfection, direct contact, and airborne precautions.", [["SARS", "DISEASE", 23, 27], ["SARS", "DISEASE", 102, 106], ["fever", "DISEASE", 171, 176], ["patients", "ORGANISM", 107, 115], ["patient", "ORGANISM", 191, 198], ["patients", "SPECIES", 107, 115], ["patient", "SPECIES", 191, 198], ["the SARS epidemic", "PROBLEM", 19, 36], ["fever screening", "TEST", 171, 186], ["disinfection", "TREATMENT", 227, 239], ["airborne precautions", "TREATMENT", 261, 281]]], ["As the epidemic waned, efforts turned to assessing the implementation of infection control practices, strategies for handling future SARS patients, facility designs for effective patient isolation and fever screening stations, personal protective equipment practices, and training of healthcare workers.", [["infection", "DISEASE", 73, 82], ["SARS", "DISEASE", 133, 137], ["fever", "DISEASE", 201, 206], ["patients", "ORGANISM", 138, 146], ["patient", "ORGANISM", 179, 186], ["patients", "SPECIES", 138, 146], ["patient", "SPECIES", 179, 186], ["infection control practices", "TREATMENT", 73, 100], ["effective patient isolation", "TREATMENT", 169, 196], ["fever", "PROBLEM", 201, 206], ["infection", "OBSERVATION", 73, 82]]], ["Thirty-two hospitals or medical centers that were either accepting and treating SARS patients or were under consideration for use as dedicated SARS treatment facilities in anticipation of a more widely disseminated epidemic were visited.", [["SARS", "DISEASE", 80, 84], ["SARS", "DISEASE", 143, 147], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["SARS treatment facilities", "TREATMENT", 143, 168]]]], "PMC7255551": [["Introduction and backgroundCoronavirus disease 2019 (COVID-19) has been declared a pandemic on the 11th of March, 2020 by the World Health Organization.", [["Coronavirus disease", "DISEASE", 27, 46], ["COVID-19", "CHEMICAL", 53, 61], ["backgroundCoronavirus disease", "PROBLEM", 17, 46], ["COVID", "TEST", 53, 58], ["Coronavirus disease", "OBSERVATION", 27, 46]]], ["The epicenter of this pandemic has shifted in quick succession from China to Europe to the United States of America in a matter of weeks.", [["epicenter", "OBSERVATION_MODIFIER", 4, 13], ["shifted", "OBSERVATION_MODIFIER", 35, 42]]], ["Since the middle of March 2020, South-east Asia has also seen a rise in the number of affected persons and it remains to be seen if there will be another twist in the story of this pandemic.", [["persons", "ORGANISM", 95, 102], ["persons", "SPECIES", 95, 102], ["this pandemic", "PROBLEM", 176, 189], ["middle", "ANATOMY_MODIFIER", 10, 16], ["rise", "OBSERVATION_MODIFIER", 64, 68]]], ["One of the essential weapons to fight a pandemic of this stature is to gather as much knowledge as possible about the transmission dynamics and clinical manifestations while the quest for an effective vaccine keeps continuing.Introduction and backgroundEven though severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed to mainly affect the respiratory system, neurological involvements have already been reported in some published work.", [["respiratory system", "ANATOMY", 365, 383], ["neurological", "ANATOMY", 385, 397], ["acute respiratory syndrome coronavirus", "DISEASE", 272, 310], ["neurological involvements", "DISEASE", 385, 410], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 265, 312], ["SARS-CoV-2", "ORGANISM", 314, 324], ["severe acute respiratory syndrome coronavirus", "SPECIES", 265, 310], ["SARS-CoV-2", "SPECIES", 314, 324], ["an effective vaccine", "TREATMENT", 188, 208], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 265, 310], ["CoV", "TEST", 319, 322], ["essential", "OBSERVATION_MODIFIER", 11, 20], ["weapons", "OBSERVATION", 21, 28], ["severe", "OBSERVATION_MODIFIER", 265, 271], ["acute", "OBSERVATION_MODIFIER", 272, 277], ["respiratory syndrome", "OBSERVATION", 278, 298], ["respiratory system", "ANATOMY", 365, 383]]], ["Several medical news bulletins, blogs, and articles across the globe have also raised concerns about brain invasion by this particular strain of coronavirus.", [["brain", "ANATOMY", 101, 106], ["coronavirus", "DISEASE", 145, 156], ["brain", "ORGAN", 101, 106], ["coronavirus", "ORGANISM", 145, 156], ["brain invasion", "PROBLEM", 101, 115], ["coronavirus", "PROBLEM", 145, 156], ["globe", "ANATOMY", 63, 68], ["brain", "ANATOMY", 101, 106], ["invasion", "OBSERVATION", 107, 115]]], ["This is actually not surprising given our previous experience of neuro-invasion by severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome-related coronavirus (MERS-CoV).", [["neuro-invasion", "DISEASE", 65, 79], ["acute respiratory syndrome coronavirus", "DISEASE", 90, 128], ["SARS-CoV)", "DISEASE", 130, 139], ["respiratory syndrome", "DISEASE", 160, 180], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 83, 128], ["SARS-CoV", "ORGANISM", 130, 138], ["Middle East respiratory syndrome-related coronavirus", "ORGANISM", 148, 200], ["MERS-CoV", "ORGANISM", 202, 210], ["severe acute respiratory syndrome coronavirus", "SPECIES", 83, 128], ["SARS-CoV", "SPECIES", 130, 138], ["Middle East respiratory syndrome-related coronavirus", "SPECIES", 148, 200], ["MERS-CoV", "SPECIES", 202, 210], ["neuro-invasion", "PROBLEM", 65, 79], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 83, 128], ["the Middle East respiratory syndrome", "PROBLEM", 144, 180], ["coronavirus", "PROBLEM", 189, 200], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome coronavirus", "OBSERVATION", 96, 128], ["Middle", "ANATOMY_MODIFIER", 148, 154], ["respiratory syndrome", "OBSERVATION", 160, 180], ["coronavirus", "OBSERVATION", 189, 200]]], ["The body of literature on neurological aspects of SARS-CoV-2 is small but growing.", [["body", "ANATOMY", 4, 8], ["neurological", "ANATOMY", 26, 38], ["SARS", "DISEASE", 50, 54], ["SARS", "PROBLEM", 50, 54], ["body", "ANATOMY_MODIFIER", 4, 8], ["small", "OBSERVATION_MODIFIER", 64, 69], ["growing", "OBSERVATION_MODIFIER", 74, 81]]], ["However, we believe, an organized summary of the available information at this point would be indispensable to neurologists across the globe.", [["globe", "ANATOMY", 135, 140]]], ["Being well informed about the neurological presentations would not only help them have a high index of clinical suspicion but also take necessary precautions.", [["neurological", "ANATOMY", 30, 42], ["necessary precautions", "TREATMENT", 136, 157]]], ["Therefore, a brief literature review along with a critical appraisal of the evidence gathered so far is presented here from the perspective of a neurologist.Introduction and backgroundIn the present paper, we have reviewed the recently published or pre-print original articles, case reports, and existing open-source data-sets in order to delineate the spectrum of neurological disorders in SARS-CoV-2 positive cases.ReviewMechanism of neuro-invasionReviewThe putative mechanisms described to explain the neuro-invasion by a coronavirus (and one similar another RNA virus, influenza A) are hematogenous spread and retrograde axonal transport [1-4].", [["neurological", "ANATOMY", 365, 377], ["axonal", "ANATOMY", 625, 631], ["neurological disorders", "DISEASE", 365, 387], ["SARS", "DISEASE", 391, 395], ["coronavirus", "DISEASE", 525, 536], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 391, 401], ["coronavirus", "ORGANISM", 525, 536], ["SARS-CoV", "SPECIES", 391, 399], ["neurological disorders", "PROBLEM", 365, 387], ["SARS", "TEST", 391, 395], ["CoV", "TEST", 396, 399], ["the neuro-invasion", "PROBLEM", 501, 519], ["a coronavirus", "PROBLEM", 523, 536], ["another RNA virus", "PROBLEM", 554, 571], ["influenza", "PROBLEM", 573, 582], ["hematogenous spread", "PROBLEM", 590, 609], ["retrograde axonal transport", "TEST", 614, 641], ["hematogenous", "OBSERVATION_MODIFIER", 590, 602]]], ["However, in light of contemporary evidence, some of the other possible routes of neuroinvasion by the SARS-CoV-2 deserve to be mentioned.", [["neuroinvasion", "DISEASE", 81, 94], ["SARS", "DISEASE", 102, 106], ["SARS-CoV-2", "ORGANISM", 102, 112], ["neuroinvasion", "PROBLEM", 81, 94], ["the SARS", "TEST", 98, 106], ["neuroinvasion", "OBSERVATION", 81, 94]]], ["Direct viral invasion of the brain leading to clinical encephalitis has been suspected after the treatment team of Beijing Ditan Hospital confirmed the presence of SARS-CoV-2 in the cerebrospinal fluid (CSF) of patients with COVID-19 by genome sequencing [5].", [["brain", "ANATOMY", 29, 34], ["cerebrospinal fluid", "ANATOMY", 182, 201], ["viral invasion of the brain", "DISEASE", 7, 34], ["encephalitis", "DISEASE", 55, 67], ["brain", "ORGAN", 29, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 164, 174], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 182, 201], ["CSF", "ORGANISM_SUBSTANCE", 203, 206], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["SARS-CoV", "SPECIES", 164, 172], ["Direct viral invasion of the brain", "PROBLEM", 0, 34], ["clinical encephalitis", "PROBLEM", 46, 67], ["SARS", "PROBLEM", 164, 168], ["CoV", "TEST", 169, 172], ["the cerebrospinal fluid", "TEST", 178, 201], ["COVID", "TEST", 225, 230], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["invasion", "OBSERVATION", 13, 21], ["brain", "ANATOMY", 29, 34], ["encephalitis", "OBSERVATION", 55, 67], ["cerebrospinal fluid", "ANATOMY", 182, 201]]], ["COVID-19 is widely known to cause respiratory insufficiency, and therefore, hypoxia needs to be considered among the major putative mechanisms of brain injury [6].", [["respiratory", "ANATOMY", 34, 45], ["brain", "ANATOMY", 146, 151], ["COVID-19", "CHEMICAL", 0, 8], ["respiratory insufficiency", "DISEASE", 34, 59], ["hypoxia", "DISEASE", 76, 83], ["brain injury", "DISEASE", 146, 158], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["brain", "ORGAN", 146, 151], ["COVID", "TEST", 0, 5], ["respiratory insufficiency", "PROBLEM", 34, 59], ["hypoxia", "PROBLEM", 76, 83], ["brain injury", "PROBLEM", 146, 158], ["respiratory insufficiency", "OBSERVATION", 34, 59], ["brain", "ANATOMY", 146, 151], ["injury", "OBSERVATION", 152, 158]]], ["Cytokine storm, which is a well known immune reaction of this particular viral infection, may lead to inflammation and injury of the central nervous system (CNS) tissue.", [["central nervous system", "ANATOMY", 133, 155], ["CNS", "ANATOMY", 157, 160], ["tissue", "ANATOMY", 162, 168], ["viral infection", "DISEASE", 73, 88], ["inflammation", "DISEASE", 102, 114], ["injury of the central nervous system", "DISEASE", 119, 155], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["central nervous system", "ANATOMICAL_SYSTEM", 133, 155], ["CNS) tissue", "TISSUE", 157, 168], ["Cytokine storm", "PROBLEM", 0, 14], ["a well known immune reaction", "PROBLEM", 25, 53], ["this particular viral infection", "PROBLEM", 57, 88], ["inflammation", "PROBLEM", 102, 114], ["injury of the central nervous system", "PROBLEM", 119, 155], ["storm", "OBSERVATION", 9, 14], ["viral", "OBSERVATION_MODIFIER", 73, 78], ["infection", "OBSERVATION", 79, 88], ["may lead to", "UNCERTAINTY", 90, 101], ["inflammation", "OBSERVATION", 102, 114], ["injury", "OBSERVATION", 119, 125], ["central", "ANATOMY_MODIFIER", 133, 140], ["nervous system", "ANATOMY", 141, 155], ["CNS", "ANATOMY", 157, 160]]], ["This idea is further supported by the observation that interleukin (IL)-6, an important member of the cytokine storm, is positively correlated with the severity of COVID-19 symptoms [7].", [["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 55, 73], ["interleukin (IL)-6", "PROTEIN", 55, 73], ["cytokine", "PROTEIN", 102, 110], ["interleukin (IL)", "TREATMENT", 55, 71], ["COVID", "TEST", 164, 169], ["symptoms", "PROBLEM", 173, 181]]], ["The affinity of the viral particle towards angiotensin-converting enzyme-2 (ACE-2), a cardio-cerebral vascular protection factor, has been in discussion in recent papers [8].", [["vascular", "ANATOMY", 102, 110], ["angiotensin", "CHEMICAL", 43, 54], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 43, 74], ["ACE-2", "GENE_OR_GENE_PRODUCT", 76, 81], ["vascular", "MULTI-TISSUE_STRUCTURE", 102, 110], ["angiotensin-converting enzyme-2", "PROTEIN", 43, 74], ["ACE", "PROTEIN", 76, 79], ["the viral particle", "PROBLEM", 16, 34], ["angiotensin", "TEST", 43, 54], ["ACE", "TEST", 76, 79], ["a cardio-cerebral vascular protection factor", "TREATMENT", 84, 128], ["viral particle", "OBSERVATION", 20, 34], ["cardio", "ANATOMY", 86, 92], ["cerebral vascular", "ANATOMY", 93, 110]]], ["The expression of ACE-2 in the nervous system and skeletal muscles can indeed explain some of the neurological features reported so far.", [["nervous system", "ANATOMY", 31, 45], ["skeletal muscles", "ANATOMY", 50, 66], ["neurological", "ANATOMY", 98, 110], ["ACE-2", "GENE_OR_GENE_PRODUCT", 18, 23], ["nervous system", "ANATOMICAL_SYSTEM", 31, 45], ["skeletal muscles", "ORGAN", 50, 66], ["ACE-2", "PROTEIN", 18, 23], ["ACE-2", "TREATMENT", 18, 23], ["the neurological features", "PROBLEM", 94, 119], ["nervous system", "ANATOMY", 31, 45], ["skeletal muscles", "ANATOMY", 50, 66]]], ["It has been postulated that the viral attachment to the ACE-2 at the level of the blood-brain barrier may jeopardize the protective mechanism surrounding the encephalon, giving way to viral encephalitis.", [["blood-brain barrier", "ANATOMY", 82, 101], ["encephalon", "ANATOMY", 158, 168], ["viral encephalitis", "DISEASE", 184, 202], ["ACE-2", "GENE_OR_GENE_PRODUCT", 56, 61], ["blood", "MULTI-TISSUE_STRUCTURE", 82, 87], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 88, 101], ["encephalon", "CANCER", 158, 168], ["ACE", "PROTEIN", 56, 59], ["the viral attachment", "PROBLEM", 28, 48], ["the blood-brain barrier", "TREATMENT", 78, 101], ["viral encephalitis", "PROBLEM", 184, 202], ["viral attachment", "OBSERVATION", 32, 48], ["blood", "ANATOMY", 82, 87], ["brain", "ANATOMY", 88, 93], ["viral encephalitis", "OBSERVATION", 184, 202]]], ["In a similar vein, spinal cord membranes expressing ACE-2 can culminate into myelitis-like features following SARS-CoV-2 infection.", [["vein", "ANATOMY", 13, 17], ["spinal cord membranes", "ANATOMY", 19, 40], ["myelitis", "DISEASE", 77, 85], ["infection", "DISEASE", 121, 130], ["vein", "MULTI-TISSUE_STRUCTURE", 13, 17], ["cord membranes", "MULTI-TISSUE_STRUCTURE", 26, 40], ["ACE-2", "GENE_OR_GENE_PRODUCT", 52, 57], ["SARS-CoV-2", "ORGANISM", 110, 120], ["ACE", "PROTEIN", 52, 55], ["myelitis", "PROBLEM", 77, 85], ["SARS", "PROBLEM", 110, 114], ["CoV-2 infection", "PROBLEM", 115, 130], ["similar vein", "ANATOMY", 5, 17], ["spinal cord", "ANATOMY", 19, 30], ["myelitis", "OBSERVATION", 77, 85], ["infection", "OBSERVATION", 121, 130]]], ["Concern has also been raised that the viral particles binding to ACE-2 in cerebral blood vessels may actually raise the luminal pressure of those vessels leading to intracerebral hemorrhage [9].", [["cerebral blood vessels", "ANATOMY", 74, 96], ["luminal", "ANATOMY", 120, 127], ["vessels", "ANATOMY", 146, 153], ["intracerebral", "ANATOMY", 165, 178], ["luminal", "CHEMICAL", 120, 127], ["intracerebral hemorrhage", "DISEASE", 165, 189], ["ACE-2", "GENE_OR_GENE_PRODUCT", 65, 70], ["cerebral blood vessels", "MULTI-TISSUE_STRUCTURE", 74, 96], ["luminal", "IMMATERIAL_ANATOMICAL_ENTITY", 120, 127], ["vessels", "MULTI-TISSUE_STRUCTURE", 146, 153], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 165, 178], ["ACE", "PROTEIN", 65, 68], ["the viral particles binding", "PROBLEM", 34, 61], ["ACE", "TEST", 65, 68], ["intracerebral hemorrhage", "PROBLEM", 165, 189], ["viral particles", "OBSERVATION", 38, 53], ["cerebral", "ANATOMY_MODIFIER", 74, 82], ["blood vessels", "ANATOMY", 83, 96], ["luminal", "ANATOMY_MODIFIER", 120, 127], ["pressure", "OBSERVATION_MODIFIER", 128, 136], ["vessels", "ANATOMY", 146, 153], ["intracerebral", "OBSERVATION_MODIFIER", 165, 178], ["hemorrhage", "OBSERVATION", 179, 189]]], ["Thus there are multiple mechanisms elaborated so far in the available literature that can explain the observed as well as anticipated neurological features of this ailment.ReviewClassification and features of neurological involvementReviewEarly data on COVID-19 suggest neurological involvement in a variable percentage of cases with particular expression in more severe patients [10].", [["neurological", "ANATOMY", 134, 146], ["neurological", "ANATOMY", 209, 221], ["neurological", "ANATOMY", 270, 282], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 371, 379], ["multiple mechanisms", "PROBLEM", 15, 34], ["this ailment", "PROBLEM", 159, 171], ["neurological involvement", "PROBLEM", 209, 233], ["COVID", "TEST", 253, 258], ["neurological involvement", "PROBLEM", 270, 294], ["multiple", "OBSERVATION_MODIFIER", 15, 23]]], ["Neurological involvement in COVID-19 can be discussed in three sections: (1) neurological features of viral infection, (2) post-infective neurological complications, (3) infection in patients with neurological co-morbidity.", [["Neurological", "ANATOMY", 0, 12], ["sections", "ANATOMY", 63, 71], ["neurological", "ANATOMY", 77, 89], ["neurological", "ANATOMY", 138, 150], ["neurological", "ANATOMY", 197, 209], ["viral infection", "DISEASE", 102, 117], ["neurological complications", "DISEASE", 138, 164], ["infection", "DISEASE", 170, 179], ["neurological co-morbidity", "DISEASE", 197, 222], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["viral infection", "PROBLEM", 102, 117], ["post-infective neurological complications", "PROBLEM", 123, 164], ["infection", "PROBLEM", 170, 179], ["neurological co-morbidity", "PROBLEM", 197, 222], ["viral", "OBSERVATION_MODIFIER", 102, 107], ["infection", "OBSERVATION", 108, 117], ["infective", "OBSERVATION_MODIFIER", 128, 137], ["neurological complications", "OBSERVATION", 138, 164], ["infection", "OBSERVATION", 170, 179]]], ["Another issue that deserves to be mentioned is the precautions to be taken for neurologically ill patients who require immunosuppressive agents.", [["neurologically ill", "DISEASE", 79, 97], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["the precautions", "TREATMENT", 47, 62], ["immunosuppressive agents", "TREATMENT", 119, 143]]], ["The latter group mostly consists of multiple sclerosis, myasthenia gravis, and autoimmune encephalitis.ReviewNeurological features of viral invasionReviewNeurological manifestations of viral infection reported so far can further be subdivided into CNS and peripheral nervous system (PNS) features.", [["CNS", "ANATOMY", 248, 251], ["peripheral nervous system", "ANATOMY", 256, 281], ["PNS", "ANATOMY", 283, 286], ["multiple sclerosis", "DISEASE", 36, 54], ["myasthenia gravis", "DISEASE", 56, 73], ["autoimmune encephalitis", "DISEASE", 79, 102], ["viral invasion", "DISEASE", 134, 148], ["viral infection", "DISEASE", 185, 200], ["CNS", "ANATOMICAL_SYSTEM", 248, 251], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 256, 281], ["PNS", "ANATOMICAL_SYSTEM", 283, 286], ["multiple sclerosis", "PROBLEM", 36, 54], ["myasthenia gravis", "PROBLEM", 56, 73], ["autoimmune encephalitis", "PROBLEM", 79, 102], ["viral invasion", "PROBLEM", 134, 148], ["viral infection", "PROBLEM", 185, 200], ["multiple", "OBSERVATION_MODIFIER", 36, 44], ["sclerosis", "OBSERVATION", 45, 54], ["myasthenia gravis", "OBSERVATION", 56, 73], ["autoimmune encephalitis", "OBSERVATION", 79, 102], ["viral", "OBSERVATION_MODIFIER", 134, 139], ["invasion", "OBSERVATION", 140, 148], ["viral", "OBSERVATION_MODIFIER", 185, 190], ["infection", "OBSERVATION", 191, 200], ["peripheral", "ANATOMY_MODIFIER", 256, 266], ["nervous system", "ANATOMY", 267, 281]]], ["CNS features include headache, dizziness, ataxia, alteration of sensorium, encephalitis, stroke, and seizures, while PNS features mostly refer to skeletal muscle injury and peripheral nerve involvement in the form of hyposmia and hypogeusia.ReviewHeadache can be a symptom of viral infection and usually remains associated with fever.", [["CNS", "ANATOMY", 0, 3], ["PNS", "ANATOMY", 117, 120], ["skeletal muscle", "ANATOMY", 146, 161], ["peripheral nerve", "ANATOMY", 173, 189], ["headache", "DISEASE", 21, 29], ["dizziness", "DISEASE", 31, 40], ["ataxia", "DISEASE", 42, 48], ["alteration of sensorium", "DISEASE", 50, 73], ["encephalitis", "DISEASE", 75, 87], ["stroke", "DISEASE", 89, 95], ["seizures", "DISEASE", 101, 109], ["skeletal muscle injury", "DISEASE", 146, 168], ["hyposmia", "DISEASE", 217, 225], ["hypogeusia", "DISEASE", 230, 240], ["Headache", "DISEASE", 247, 255], ["viral infection", "DISEASE", 276, 291], ["fever", "DISEASE", 328, 333], ["CNS", "ANATOMICAL_SYSTEM", 0, 3], ["skeletal muscle", "TISSUE", 146, 161], ["peripheral nerve", "MULTI-TISSUE_STRUCTURE", 173, 189], ["headache", "PROBLEM", 21, 29], ["dizziness", "PROBLEM", 31, 40], ["ataxia", "PROBLEM", 42, 48], ["alteration of sensorium", "PROBLEM", 50, 73], ["encephalitis", "PROBLEM", 75, 87], ["stroke", "PROBLEM", 89, 95], ["seizures", "PROBLEM", 101, 109], ["PNS features", "PROBLEM", 117, 129], ["skeletal muscle injury", "PROBLEM", 146, 168], ["peripheral nerve involvement", "PROBLEM", 173, 201], ["hyposmia", "PROBLEM", 217, 225], ["hypogeusia", "PROBLEM", 230, 240], ["Headache", "PROBLEM", 247, 255], ["viral infection", "PROBLEM", 276, 291], ["fever", "PROBLEM", 328, 333], ["headache", "OBSERVATION", 21, 29], ["encephalitis", "OBSERVATION", 75, 87], ["stroke", "OBSERVATION", 89, 95], ["skeletal muscle", "ANATOMY", 146, 161], ["injury", "OBSERVATION", 162, 168], ["peripheral", "ANATOMY_MODIFIER", 173, 183], ["nerve", "ANATOMY", 184, 189], ["hyposmia", "OBSERVATION", 217, 225], ["viral", "OBSERVATION_MODIFIER", 276, 281], ["infection", "OBSERVATION", 282, 291], ["fever", "OBSERVATION", 328, 333]]], ["Studies have reported an incidence of headaches ranging from 6 to 13% in COVID-19 cases [10-13].", [["headaches", "DISEASE", 38, 47], ["headaches", "PROBLEM", 38, 47], ["COVID", "TEST", 73, 78], ["headaches", "OBSERVATION", 38, 47]]], ["However, concerns have already been raised in recent correspondence if this particular symptom is a manifestation of viral meningitis or, for that matter, encephalitis, which may reveal itself subsequently in the form of drowsiness and seizures.", [["meningitis", "DISEASE", 123, 133], ["encephalitis", "DISEASE", 155, 167], ["seizures", "DISEASE", 236, 244], ["this particular symptom", "PROBLEM", 71, 94], ["viral meningitis", "PROBLEM", 117, 133], ["encephalitis", "PROBLEM", 155, 167], ["drowsiness", "PROBLEM", 221, 231], ["seizures", "PROBLEM", 236, 244], ["viral", "OBSERVATION_MODIFIER", 117, 122], ["meningitis", "OBSERVATION", 123, 133], ["encephalitis", "OBSERVATION", 155, 167]]], ["Japanese colleagues shared their recent experience in dealing with a young male patient without any contact or travel history who presented features of meningitis before being diagnosed with the infection of SARS-CoV-2 [14].", [["meningitis", "DISEASE", 152, 162], ["infection", "DISEASE", 195, 204], ["SARS", "DISEASE", 208, 212], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["SARS-CoV", "SPECIES", 208, 216], ["meningitis", "PROBLEM", 152, 162], ["the infection of SARS", "PROBLEM", 191, 212], ["CoV", "TEST", 213, 216], ["meningitis", "OBSERVATION", 152, 162], ["infection", "OBSERVATION", 195, 204]]], ["The issue becomes more substantial as one considers the report of virus detection in CSF of a COVID-19 patient.", [["CSF", "ORGANISM_SUBSTANCE", 85, 88], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["virus detection", "TEST", 66, 81]]], ["Another very recent report describes the occurrence of acute hemorrhagic necrotizing encephalopathy in COVID-19 patient [15].", [["encephalopathy", "DISEASE", 85, 99], ["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119], ["acute hemorrhagic necrotizing encephalopathy", "PROBLEM", 55, 99], ["COVID", "TEST", 103, 108], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["hemorrhagic", "OBSERVATION_MODIFIER", 61, 72], ["necrotizing", "OBSERVATION_MODIFIER", 73, 84], ["encephalopathy", "OBSERVATION", 85, 99]]], ["In this particular case, however, the CSF examination for SARS-CoV-2 was not carried out, although bacterial culture and tests for other viruses were essentially negative.", [["SARS", "DISEASE", 58, 62], ["CSF", "GENE_OR_GENE_PRODUCT", 38, 41], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV", "SPECIES", 58, 66], ["the CSF examination", "TEST", 34, 53], ["SARS-CoV-2", "TEST", 58, 68], ["bacterial culture", "TEST", 99, 116], ["tests", "TEST", 121, 126], ["other viruses", "PROBLEM", 131, 144]]], ["Therefore, neurologist needs to pay attention and analyze even a simple symptom such as headache in a known COVID-19 case, especially if the headache is out of proportion to rise in temperature and is associated with certain other features such as vomiting and altered sensorium.ReviewAnother noteworthy observation is the occurrence of cerebrovascular events (CVE) associated with this ailment.", [["cerebrovascular", "ANATOMY", 337, 352], ["headache", "DISEASE", 88, 96], ["headache", "DISEASE", 141, 149], ["vomiting", "DISEASE", 248, 256], ["sensorium", "DISEASE", 269, 278], ["cerebrovascular events", "DISEASE", 337, 359], ["CVE", "DISEASE", 361, 364], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 337, 352], ["a simple symptom", "PROBLEM", 63, 79], ["headache", "PROBLEM", 88, 96], ["the headache", "PROBLEM", 137, 149], ["rise in temperature", "PROBLEM", 174, 193], ["vomiting", "PROBLEM", 248, 256], ["altered sensorium", "PROBLEM", 261, 278], ["cerebrovascular events", "PROBLEM", 337, 359], ["this ailment", "PROBLEM", 382, 394], ["cerebrovascular", "ANATOMY", 337, 352]]], ["The initial retrospective case series study from Wuhan, China, reported that 5.7% (5/76) of the cases showing neurological involvement could be attributed to acute CVE [10].", [["neurological", "ANATOMY", 110, 122], ["CVE", "DISEASE", 164, 167], ["neurological involvement", "PROBLEM", 110, 134], ["acute CVE", "PROBLEM", 158, 167], ["acute", "OBSERVATION_MODIFIER", 158, 163]]], ["Notably, four cases had an ischemic stroke, while cerebral hemorrhage was found in a single patient who died later on.", [["cerebral", "ANATOMY", 50, 58], ["ischemic stroke", "DISEASE", 27, 42], ["cerebral hemorrhage", "DISEASE", 50, 69], ["cerebral", "ORGAN", 50, 58], ["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["an ischemic stroke", "PROBLEM", 24, 42], ["cerebral hemorrhage", "PROBLEM", 50, 69], ["ischemic", "OBSERVATION_MODIFIER", 27, 35], ["stroke", "OBSERVATION", 36, 42], ["cerebral", "ANATOMY", 50, 58], ["hemorrhage", "OBSERVATION", 59, 69]]], ["Another recent paper from the same center, which analyzed 221 participants, elaborates that 5.88% (13/221) cases had some sort of new-onset CVE [16].", [["CVE", "DISEASE", 140, 143], ["participants", "SPECIES", 62, 74], ["new", "OBSERVATION_MODIFIER", 130, 133]]], ["The majority of them presented acute ischemic stroke (11 patients), while hemorrhagic stroke (one patient) and cerebral venous sinus thrombosis (one patient) were also found but uncommonly.", [["cerebral venous sinus", "ANATOMY", 111, 132], ["ischemic stroke", "DISEASE", 37, 52], ["hemorrhagic stroke", "DISEASE", 74, 92], ["cerebral venous sinus thrombosis", "DISEASE", 111, 143], ["patients", "ORGANISM", 57, 65], ["patient", "ORGANISM", 98, 105], ["cerebral venous sinus", "MULTI-TISSUE_STRUCTURE", 111, 132], ["patient", "ORGANISM", 149, 156], ["patients", "SPECIES", 57, 65], ["patient", "SPECIES", 98, 105], ["patient", "SPECIES", 149, 156], ["acute ischemic stroke", "PROBLEM", 31, 52], ["hemorrhagic stroke", "PROBLEM", 74, 92], ["cerebral venous sinus thrombosis", "PROBLEM", 111, 143], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["ischemic", "OBSERVATION_MODIFIER", 37, 45], ["stroke", "OBSERVATION", 46, 52], ["hemorrhagic", "OBSERVATION_MODIFIER", 74, 85], ["stroke", "OBSERVATION", 86, 92], ["cerebral", "ANATOMY", 111, 119], ["venous sinus", "ANATOMY", 120, 132], ["thrombosis", "OBSERVATION", 133, 143]]], ["Therefore, thrombotic manifestations were way more frequent than hemorrhage.", [["thrombotic", "DISEASE", 11, 21], ["hemorrhage", "DISEASE", 65, 75], ["thrombotic manifestations", "PROBLEM", 11, 36], ["hemorrhage", "PROBLEM", 65, 75], ["thrombotic", "OBSERVATION", 11, 21], ["more frequent", "OBSERVATION_MODIFIER", 46, 59], ["hemorrhage", "OBSERVATION", 65, 75]]], ["This observation may possibly be linked to the finding that patients with CVE were more likely to have enhanced inflammatory response as reflected in their C-reactive protein (CRP) and D-dimer levels.", [["CVE", "DISEASE", 74, 77], ["patients", "ORGANISM", 60, 68], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 156, 174], ["CRP", "GENE_OR_GENE_PRODUCT", 176, 179], ["D-dimer", "GENE_OR_GENE_PRODUCT", 185, 192], ["C-reactive protein", "PROTEIN", 156, 174], ["CRP", "PROTEIN", 176, 179], ["patients", "SPECIES", 60, 68], ["CVE", "PROBLEM", 74, 77], ["enhanced inflammatory response", "PROBLEM", 103, 133], ["CRP", "TEST", 176, 179], ["D-dimer levels", "TEST", 185, 199], ["inflammatory", "OBSERVATION", 112, 124]]], ["It is within the realm of possibilities that the viral infection may have given way to an inflammatory storm that ultimately culminated in accelerated thrombosis.", [["viral infection", "DISEASE", 49, 64], ["thrombosis", "DISEASE", 151, 161], ["the viral infection", "PROBLEM", 45, 64], ["an inflammatory storm", "PROBLEM", 87, 108], ["accelerated thrombosis", "PROBLEM", 139, 161], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["infection", "OBSERVATION", 55, 64], ["inflammatory", "OBSERVATION", 90, 102], ["accelerated", "OBSERVATION_MODIFIER", 139, 150], ["thrombosis", "OBSERVATION", 151, 161]]], ["The term \"accelerated thrombosis\" seems more meaningful if seen in the context of another finding in this particular retrospective study.", [["thrombosis", "DISEASE", 22, 32], ["The term \"accelerated thrombosis", "PROBLEM", 0, 32], ["this particular retrospective study", "TEST", 101, 136], ["accelerated", "OBSERVATION_MODIFIER", 10, 21], ["thrombosis", "OBSERVATION", 22, 32]]], ["Patients with CVE were not only significantly older than those without CVE but also were more likely to have pre-existent vascular risk factors.", [["vascular", "ANATOMY", 122, 130], ["CVE", "DISEASE", 14, 17], ["CVE", "DISEASE", 71, 74], ["Patients", "ORGANISM", 0, 8], ["vascular", "MULTI-TISSUE_STRUCTURE", 122, 130], ["Patients", "SPECIES", 0, 8], ["CVE", "PROBLEM", 14, 17], ["CVE", "PROBLEM", 71, 74], ["pre-existent vascular risk factors", "PROBLEM", 109, 143], ["vascular", "ANATOMY", 122, 130]]], ["This observation is particularly relevant in the Indian scenario because vascular risk factors are common in the population, and so is the incidence of stroke.", [["vascular", "ANATOMY", 73, 81], ["stroke", "DISEASE", 152, 158], ["vascular", "MULTI-TISSUE_STRUCTURE", 73, 81], ["vascular risk factors", "PROBLEM", 73, 94], ["stroke", "PROBLEM", 152, 158], ["vascular", "ANATOMY", 73, 81], ["stroke", "OBSERVATION", 152, 158]]], ["Moreover, any viral infection in a stroke patient not only delays recovery but also may actually worsen the neurological deficit, the latter being sometimes attributed to hemorrhagic transformation.", [["neurological", "ANATOMY", 108, 120], ["viral infection", "DISEASE", 14, 29], ["stroke", "DISEASE", 35, 41], ["neurological deficit", "DISEASE", 108, 128], ["hemorrhagic", "DISEASE", 171, 182], ["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["any viral infection", "PROBLEM", 10, 29], ["a stroke", "PROBLEM", 33, 41], ["the neurological deficit", "PROBLEM", 104, 128], ["hemorrhagic transformation", "PROBLEM", 171, 197], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 20, 29], ["hemorrhagic", "OBSERVATION_MODIFIER", 171, 182], ["transformation", "OBSERVATION", 183, 197]]], ["The mortality rate was indeed found to be higher in COVID-19 stroke patients, with 38% indicating a worse prognosis in this group of patients.", [["stroke", "DISEASE", 61, 67], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 133, 141], ["The mortality rate", "TEST", 0, 18], ["higher", "OBSERVATION_MODIFIER", 42, 48]]], ["The above discussion brings out the two-way relationship between COVID-19 and stroke, which a neurologist has to bear in mind while attending patients in these difficult circumstances.", [["stroke", "DISEASE", 78, 84], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["COVID", "TEST", 65, 70], ["stroke", "PROBLEM", 78, 84], ["stroke", "OBSERVATION", 78, 84]]], ["The issue becomes more complicated when one considers treating a patient with ischemic stroke in the background of coronavirus infection.", [["ischemic stroke", "DISEASE", 78, 93], ["coronavirus infection", "DISEASE", 115, 136], ["patient", "ORGANISM", 65, 72], ["coronavirus", "ORGANISM", 115, 126], ["patient", "SPECIES", 65, 72], ["ischemic stroke", "PROBLEM", 78, 93], ["coronavirus infection", "PROBLEM", 115, 136], ["ischemic", "OBSERVATION_MODIFIER", 78, 86], ["stroke", "OBSERVATION", 87, 93], ["coronavirus", "OBSERVATION_MODIFIER", 115, 126], ["infection", "OBSERVATION", 127, 136]]], ["The application of antiplatelets and anticoagulants is tricky because the virus is known to cause prominent respiratory involvement, and according to some authors, the involvement of the nervous system may be partly responsible for respiratory impairment.ReviewImpaired consciousness has so far been reported in 7.5% hospitalized patients of COVID-19 [10].", [["respiratory", "ANATOMY", 108, 119], ["nervous system", "ANATOMY", 187, 201], ["respiratory", "ANATOMY", 232, 243], ["respiratory impairment", "DISEASE", 232, 254], ["ReviewImpaired consciousness", "DISEASE", 255, 283], ["COVID-19", "CHEMICAL", 342, 350], ["antiplatelets", "SIMPLE_CHEMICAL", 19, 32], ["nervous system", "ANATOMICAL_SYSTEM", 187, 201], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 330, 338], ["antiplatelets", "TREATMENT", 19, 32], ["anticoagulants", "TREATMENT", 37, 51], ["the virus", "PROBLEM", 70, 79], ["prominent respiratory involvement", "PROBLEM", 98, 131], ["respiratory impairment", "PROBLEM", 232, 254], ["COVID", "TEST", 342, 347], ["prominent", "OBSERVATION_MODIFIER", 98, 107], ["respiratory involvement", "OBSERVATION", 108, 131], ["nervous", "ANATOMY", 187, 194]]], ["Severely affected patients are more likely to present impaired consciousness.", [["impaired consciousness", "DISEASE", 54, 76], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["Severely affected", "PROBLEM", 0, 17], ["impaired consciousness", "PROBLEM", 54, 76], ["more likely to", "UNCERTAINTY", 31, 45], ["impaired", "OBSERVATION", 54, 62]]], ["There can be multiple underlying reasons for a patient with COVID-19 to present with altered sensorium, which include viral encephalitis, metabolic perturbation, infectious toxic encephalopathy, seizures with post-ictal confusion, and stroke (either strategic area involvement or large lesion with edema).", [["area", "ANATOMY", 260, 264], ["lesion", "ANATOMY", 286, 292], ["edema", "ANATOMY", 298, 303], ["sensorium", "DISEASE", 93, 102], ["viral encephalitis", "DISEASE", 118, 136], ["metabolic perturbation", "DISEASE", 138, 160], ["infectious toxic encephalopathy", "DISEASE", 162, 193], ["seizures", "DISEASE", 195, 203], ["confusion", "DISEASE", 220, 229], ["stroke", "DISEASE", 235, 241], ["edema", "DISEASE", 298, 303], ["patient", "ORGANISM", 47, 54], ["edema", "PATHOLOGICAL_FORMATION", 298, 303], ["patient", "SPECIES", 47, 54], ["COVID", "TEST", 60, 65], ["altered sensorium", "PROBLEM", 85, 102], ["viral encephalitis", "PROBLEM", 118, 136], ["metabolic perturbation", "PROBLEM", 138, 160], ["infectious toxic encephalopathy", "PROBLEM", 162, 193], ["seizures", "PROBLEM", 195, 203], ["post-ictal confusion", "PROBLEM", 209, 229], ["stroke", "PROBLEM", 235, 241], ["strategic area involvement", "PROBLEM", 250, 276], ["large lesion", "PROBLEM", 280, 292], ["edema", "PROBLEM", 298, 303], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["sensorium", "OBSERVATION", 93, 102], ["viral encephalitis", "OBSERVATION", 118, 136], ["metabolic perturbation", "OBSERVATION", 138, 160], ["infectious", "OBSERVATION_MODIFIER", 162, 172], ["stroke", "OBSERVATION", 235, 241], ["large", "OBSERVATION_MODIFIER", 280, 285], ["lesion", "OBSERVATION", 286, 292], ["edema", "OBSERVATION", 298, 303]]], ["A recent document, (published in Neurology Today Online) by Italian neurologists (addressed to their US colleagues) mentions the importance of recognizing poorly defined neurological features in confirmed as well as presumptive cases of COVID-19.", [["neurological", "ANATOMY", 170, 182], ["COVID", "TEST", 237, 242]]], ["Among these symptoms, altered sensorium indeed has drawn the attention of the neurologists mostly because it delays diagnostic procedures as the virus is widely known to be a respiratory pathogen.", [["respiratory", "ANATOMY", 175, 186], ["sensorium", "DISEASE", 30, 39], ["these symptoms", "PROBLEM", 6, 20], ["altered sensorium", "PROBLEM", 22, 39], ["diagnostic procedures", "TREATMENT", 116, 137], ["the virus", "PROBLEM", 141, 150], ["a respiratory pathogen", "PROBLEM", 173, 195], ["respiratory", "ANATOMY", 175, 186], ["pathogen", "OBSERVATION", 187, 195]]], ["A detailed look at the description of a single case of encephalopathy in association with COVID-19 reveals that an altered level of consciousness may precede typical respiratory symptoms by days [17].", [["respiratory", "ANATOMY", 166, 177], ["encephalopathy", "DISEASE", 55, 69], ["respiratory symptoms", "DISEASE", 166, 186], ["encephalopathy", "PROBLEM", 55, 69], ["COVID", "TEST", 90, 95], ["an altered level of consciousness", "PROBLEM", 112, 145], ["typical respiratory symptoms", "PROBLEM", 158, 186], ["encephalopathy", "OBSERVATION", 55, 69]]], ["Given the transmission dynamics of the infection, this information is extremely important as health care providers at the emergency department may get inadvertent exposure while handling patients with altered sensorium.", [["infection", "DISEASE", 39, 48], ["sensorium", "DISEASE", 209, 218], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["the infection", "PROBLEM", 35, 48], ["altered sensorium", "PROBLEM", 201, 218], ["infection", "OBSERVATION", 39, 48]]], ["In a consecutive series of COVID-19 related acute respiratory distress syndrome (ARDS) patients (n=58) reported from France, altered consciousness, including agitation and confusion, has been documented in more than two-thirds of the cases.", [["respiratory", "ANATOMY", 50, 61], ["acute respiratory distress syndrome", "DISEASE", 44, 79], ["ARDS", "DISEASE", 81, 85], ["agitation", "DISEASE", 158, 167], ["confusion", "DISEASE", 172, 181], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["COVID", "TEST", 27, 32], ["acute respiratory distress syndrome", "PROBLEM", 44, 79], ["ARDS", "PROBLEM", 81, 85], ["altered consciousness", "PROBLEM", 125, 146], ["agitation", "PROBLEM", 158, 167], ["confusion", "PROBLEM", 172, 181], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["respiratory distress", "OBSERVATION", 50, 70]]], ["Additionally, 67% of the recruited patients in this study had prominent cortico-spinal signs [18].", [["cortico", "ANATOMY", 72, 79], ["spinal", "ANATOMY", 80, 86], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["this study", "TEST", 47, 57], ["prominent cortico-spinal signs", "PROBLEM", 62, 92], ["prominent", "OBSERVATION_MODIFIER", 62, 71], ["spinal", "ANATOMY", 80, 86]]], ["In this context, telephonic conversation with the physician in charge of an infectious disease hospital in Kolkata (India) reveals that headache is more of a generalized symptom in both old and young patients, while delirium is a frequent presentation among the elderly.", [["infectious disease", "DISEASE", 76, 94], ["headache", "DISEASE", 136, 144], ["delirium", "DISEASE", 216, 224], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["headache", "PROBLEM", 136, 144], ["a generalized symptom", "PROBLEM", 156, 177], ["delirium", "PROBLEM", 216, 224], ["infectious", "OBSERVATION", 76, 86]]], ["The hospital presently is catering to more than 60 confirmed cases of COVID-19, while around 250 presumptive cases are in isolation.ReviewIn the Wuhan study, ataxia was found in only one patient, although a detailed description or anatomical substrate of this particular symptom was not available in this paper [10].", [["ataxia", "DISEASE", 158, 164], ["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 187, 194], ["COVID", "TEST", 70, 75], ["the Wuhan study", "TEST", 141, 156], ["ataxia", "PROBLEM", 158, 164], ["this particular symptom", "PROBLEM", 255, 278]]], ["We at our center recently encountered a 72-year-old man presenting with acute onset cerebellar ataxia followed by encephalopathy, who was finally diagnosed with SARS-CoV-2 induced pneumonia.", [["cerebellar", "ANATOMY", 84, 94], ["cerebellar ataxia", "DISEASE", 84, 101], ["encephalopathy", "DISEASE", 114, 128], ["SARS", "DISEASE", 161, 165], ["pneumonia", "DISEASE", 180, 189], ["man", "ORGANISM", 52, 55], ["man", "SPECIES", 52, 55], ["acute onset cerebellar ataxia", "PROBLEM", 72, 101], ["encephalopathy", "PROBLEM", 114, 128], ["SARS", "PROBLEM", 161, 165], ["CoV", "PROBLEM", 166, 169], ["pneumonia", "PROBLEM", 180, 189], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["cerebellar", "ANATOMY", 84, 94], ["ataxia", "OBSERVATION", 95, 101], ["encephalopathy", "OBSERVATION", 114, 128], ["pneumonia", "OBSERVATION", 180, 189]]], ["Notably, in our patient neurological manifestation preceded respiratory features by days.ReviewThe association of seizure and COVID-19 can be multi-faceted.", [["neurological", "ANATOMY", 24, 36], ["respiratory", "ANATOMY", 60, 71], ["seizure", "DISEASE", 114, 121], ["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["seizure", "PROBLEM", 114, 121], ["COVID", "TEST", 126, 131]]], ["An early report suggested a very low incidence (0.5%) of seizure disorder [10].", [["seizure disorder", "DISEASE", 57, 73], ["a very low incidence", "PROBLEM", 26, 46], ["seizure disorder", "PROBLEM", 57, 73]]], ["However, as numbers start growing across the globe, this issue is anticipated to become a non-negligible one.", [["globe", "ANATOMY", 45, 50]]], ["Firstly, a seizure may be a manifestation of viral invasion into the CNS.", [["CNS", "ANATOMY", 69, 72], ["seizure", "DISEASE", 11, 18], ["CNS", "ANATOMICAL_SYSTEM", 69, 72], ["a seizure", "PROBLEM", 9, 18], ["viral invasion into the CNS", "PROBLEM", 45, 72], ["viral", "OBSERVATION_MODIFIER", 45, 50], ["invasion", "OBSERVATION", 51, 59], ["CNS", "ANATOMY", 69, 72]]], ["Secondly, this particular infection is known to cause fatal pneumonia that gives way to severe hypoxemia, which may result in brain injury and seizures thereof.", [["brain", "ANATOMY", 126, 131], ["infection", "DISEASE", 26, 35], ["pneumonia", "DISEASE", 60, 69], ["hypoxemia", "DISEASE", 95, 104], ["brain injury", "DISEASE", 126, 138], ["seizures", "DISEASE", 143, 151], ["brain", "ORGAN", 126, 131], ["this particular infection", "PROBLEM", 10, 35], ["fatal pneumonia", "PROBLEM", 54, 69], ["severe hypoxemia", "PROBLEM", 88, 104], ["brain injury", "PROBLEM", 126, 138], ["seizures thereof", "PROBLEM", 143, 159], ["infection", "OBSERVATION", 26, 35], ["known to cause", "UNCERTAINTY", 39, 53], ["fatal", "OBSERVATION_MODIFIER", 54, 59], ["pneumonia", "OBSERVATION", 60, 69], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["hypoxemia", "OBSERVATION", 95, 104], ["brain", "ANATOMY", 126, 131], ["injury", "OBSERVATION", 132, 138]]], ["Metabolic perturbations and septic encephalopathy are some of the other concerns that need to be taken care of while attending a patient with seizure.", [["encephalopathy", "DISEASE", 35, 49], ["seizure", "DISEASE", 142, 149], ["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136], ["Metabolic perturbations", "PROBLEM", 0, 23], ["septic encephalopathy", "PROBLEM", 28, 49], ["seizure", "PROBLEM", 142, 149], ["septic encephalopathy", "OBSERVATION", 28, 49]]], ["The latter causes belong to the so-called group of \"acute symptomatic seizure\".", [["seizure", "DISEASE", 70, 77], ["\"acute symptomatic seizure\"", "PROBLEM", 51, 78]]], ["Thirdly, known epileptic patients with COVID-19 may experience increased frequency and severity of seizures, particularly because of threshold lowering that remains associated with fever.", [["epileptic", "DISEASE", 15, 24], ["seizures", "DISEASE", 99, 107], ["fever", "DISEASE", 181, 186], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["known epileptic patients", "PROBLEM", 9, 33], ["COVID", "TEST", 39, 44], ["increased frequency", "PROBLEM", 63, 82], ["seizures", "PROBLEM", 99, 107], ["threshold lowering", "PROBLEM", 133, 151], ["fever", "PROBLEM", 181, 186], ["epileptic", "OBSERVATION_MODIFIER", 15, 24], ["seizures", "OBSERVATION", 99, 107]]], ["A patient (mentioned above) with the encephalopathic presentation of COVID-19 had underlying gliosis in the right temporal region resulting from an old embolic stroke.", [["right temporal region", "ANATOMY", 108, 129], ["COVID", "DISEASE", 69, 74], ["gliosis", "DISEASE", 93, 100], ["embolic stroke", "DISEASE", 152, 166], ["patient", "ORGANISM", 2, 9], ["patient", "SPECIES", 2, 9], ["COVID", "TEST", 69, 74], ["underlying gliosis in the right temporal region", "PROBLEM", 82, 129], ["an old embolic stroke", "PROBLEM", 145, 166], ["encephalopathic", "OBSERVATION_MODIFIER", 37, 52], ["gliosis", "OBSERVATION", 93, 100], ["right", "ANATOMY_MODIFIER", 108, 113], ["temporal", "ANATOMY_MODIFIER", 114, 122], ["old", "OBSERVATION_MODIFIER", 148, 151], ["embolic", "OBSERVATION_MODIFIER", 152, 159], ["stroke", "OBSERVATION", 160, 166]]], ["He received prophylactic antiepileptic given the probability of subclinical seizures in the background of a structural brain lesion [17].", [["brain", "ANATOMY", 119, 124], ["seizures", "DISEASE", 76, 84], ["brain lesion", "DISEASE", 119, 131], ["brain", "ORGAN", 119, 124], ["prophylactic antiepileptic", "TREATMENT", 12, 38], ["subclinical seizures", "PROBLEM", 64, 84], ["a structural brain lesion", "PROBLEM", 106, 131], ["subclinical", "OBSERVATION_MODIFIER", 64, 75], ["seizures", "OBSERVATION", 76, 84], ["brain", "ANATOMY", 119, 124], ["lesion", "OBSERVATION", 125, 131]]], ["Seizures supposedly would complicate the clinical situation by the agency of skeletal muscle injury, which is already a well-known manifestation of the disease.", [["skeletal muscle", "ANATOMY", 77, 92], ["Seizures", "DISEASE", 0, 8], ["skeletal muscle injury", "DISEASE", 77, 99], ["skeletal muscle", "TISSUE", 77, 92], ["Seizures", "PROBLEM", 0, 8], ["skeletal muscle injury", "PROBLEM", 77, 99], ["the disease", "PROBLEM", 148, 159], ["skeletal muscle", "ANATOMY", 77, 92], ["injury", "OBSERVATION", 93, 99], ["disease", "OBSERVATION", 152, 159]]], ["The fact that neurological complications are more frequent in severely ill patients and also cardiovascular risk factors are predictors of severity, the drug interaction potential of several antiepileptic drugs would deserve attention in such clinical situations.", [["neurological", "ANATOMY", 14, 26], ["cardiovascular", "ANATOMY", 93, 107], ["neurological complications", "DISEASE", 14, 40], ["ill", "DISEASE", 71, 74], ["patients", "ORGANISM", 75, 83], ["cardiovascular", "ANATOMICAL_SYSTEM", 93, 107], ["patients", "SPECIES", 75, 83], ["neurological complications", "PROBLEM", 14, 40], ["cardiovascular risk factors", "PROBLEM", 93, 120], ["severity", "PROBLEM", 139, 147], ["several antiepileptic drugs", "TREATMENT", 183, 210], ["neurological", "OBSERVATION_MODIFIER", 14, 26], ["complications", "OBSERVATION", 27, 40]]], ["Therefore from a neurologist's perspective, seizure in a COVID-19 patient will have some important implications both from diagnostic as well as therapeutic perspectives.ReviewSymptoms of skeletal muscle damage often associated with liver and kidney involvement have already been noted.", [["skeletal muscle", "ANATOMY", 187, 202], ["liver", "ANATOMY", 232, 237], ["kidney", "ANATOMY", 242, 248], ["seizure", "DISEASE", 44, 51], ["skeletal muscle damage", "DISEASE", 187, 209], ["liver and kidney involvement", "DISEASE", 232, 260], ["patient", "ORGANISM", 66, 73], ["skeletal muscle", "TISSUE", 187, 202], ["liver", "ORGAN", 232, 237], ["kidney", "ORGAN", 242, 248], ["patient", "SPECIES", 66, 73], ["seizure", "PROBLEM", 44, 51], ["skeletal muscle damage", "PROBLEM", 187, 209], ["liver and kidney involvement", "PROBLEM", 232, 260], ["skeletal muscle", "ANATOMY", 187, 202], ["damage", "OBSERVATION", 203, 209], ["liver", "ANATOMY", 232, 237], ["kidney", "ANATOMY", 242, 248]]], ["The reported incidence is 10.7%, and like other neurological features, this one is also associated with a severe form of the illness [10].", [["neurological", "ANATOMY", 48, 60], ["illness", "DISEASE", 125, 132], ["other neurological features", "PROBLEM", 42, 69], ["10.7%", "OBSERVATION_MODIFIER", 26, 31]]], ["It can be speculated that patients with pre-existing renal or hepatic impairment will be highly vulnerable to develop features of multi-organ failure in the backdrop of skeletal muscle injury.", [["renal", "ANATOMY", 53, 58], ["hepatic", "ANATOMY", 62, 69], ["multi-organ", "ANATOMY", 130, 141], ["skeletal muscle", "ANATOMY", 169, 184], ["renal or hepatic impairment", "DISEASE", 53, 80], ["multi-organ failure", "DISEASE", 130, 149], ["skeletal muscle injury", "DISEASE", 169, 191], ["patients", "ORGANISM", 26, 34], ["renal", "ORGAN", 53, 58], ["hepatic", "ORGAN", 62, 69], ["multi-organ", "ORGAN", 130, 141], ["skeletal muscle", "TISSUE", 169, 184], ["patients", "SPECIES", 26, 34], ["pre-existing renal or hepatic impairment", "PROBLEM", 40, 80], ["multi-organ failure", "PROBLEM", 130, 149], ["skeletal muscle injury", "PROBLEM", 169, 191], ["renal", "ANATOMY", 53, 58], ["hepatic", "ANATOMY", 62, 69], ["impairment", "OBSERVATION", 70, 80], ["multi-organ", "OBSERVATION_MODIFIER", 130, 141], ["failure", "OBSERVATION", 142, 149], ["skeletal muscle", "ANATOMY", 169, 184], ["injury", "OBSERVATION", 185, 191]]], ["Muscle enzymes, including creatine kinase and lactate dehydrogenase (LDH), are seen to be highly elevated in the symptomatic patients - an observation that confirms muscle membrane damage.", [["Muscle", "ANATOMY", 0, 6], ["muscle membrane", "ANATOMY", 165, 180], ["creatine", "CHEMICAL", 26, 34], ["lactate", "CHEMICAL", 46, 53], ["muscle membrane damage", "DISEASE", 165, 187], ["creatine", "CHEMICAL", 26, 34], ["lactate", "CHEMICAL", 46, 53], ["Muscle", "ORGAN", 0, 6], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 26, 41], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 46, 67], ["LDH", "GENE_OR_GENE_PRODUCT", 69, 72], ["patients", "ORGANISM", 125, 133], ["muscle membrane", "MULTI-TISSUE_STRUCTURE", 165, 180], ["Muscle enzymes", "PROTEIN", 0, 14], ["creatine kinase", "PROTEIN", 26, 41], ["lactate dehydrogenase", "PROTEIN", 46, 67], ["LDH", "PROTEIN", 69, 72], ["patients", "SPECIES", 125, 133], ["Muscle enzymes", "TEST", 0, 14], ["creatine kinase", "TEST", 26, 41], ["lactate dehydrogenase", "TEST", 46, 67], ["LDH", "TEST", 69, 72], ["an observation", "TEST", 136, 150], ["muscle membrane damage", "PROBLEM", 165, 187], ["elevated", "OBSERVATION_MODIFIER", 97, 105], ["muscle", "ANATOMY", 165, 171], ["membrane damage", "OBSERVATION", 172, 187]]], ["The exact mechanism of muscle damage, however, has not been established.", [["muscle", "ANATOMY", 23, 29], ["muscle damage", "DISEASE", 23, 36], ["muscle", "ORGAN", 23, 29], ["muscle damage", "PROBLEM", 23, 36], ["muscle", "ANATOMY", 23, 29], ["damage", "OBSERVATION", 30, 36]]], ["Possibilities include viral muscle invasion through ACE-2 receptor tropism and immune-mediated muscle fiber damage.", [["muscle", "ANATOMY", 28, 34], ["muscle fiber", "ANATOMY", 95, 107], ["muscle fiber damage", "DISEASE", 95, 114], ["muscle", "ORGAN", 28, 34], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 52, 66], ["muscle fiber", "MULTI-TISSUE_STRUCTURE", 95, 107], ["ACE", "PROTEIN", 52, 55], ["viral muscle invasion", "PROBLEM", 22, 43], ["ACE", "TEST", 52, 55], ["immune-mediated muscle fiber damage", "PROBLEM", 79, 114], ["viral", "OBSERVATION_MODIFIER", 22, 27], ["muscle", "ANATOMY", 28, 34], ["invasion", "OBSERVATION", 35, 43], ["muscle", "ANATOMY", 95, 101], ["fiber damage", "OBSERVATION", 102, 114]]], ["Further studies will be required to elucidate the mechanisms underlying skeletal muscle injury in COVID-19.ReviewIt has been reported that hypogeusia, as well as hyposmia, are fairly consistent symptoms of SARS-CoV-2 infection [10, 19].", [["skeletal muscle", "ANATOMY", 72, 87], ["skeletal muscle injury", "DISEASE", 72, 94], ["hypogeusia", "DISEASE", 139, 149], ["hyposmia", "DISEASE", 162, 170], ["SARS-CoV-2 infection", "DISEASE", 206, 226], ["skeletal muscle", "TISSUE", 72, 87], ["SARS-CoV-2", "ORGANISM", 206, 216], ["SARS-CoV", "SPECIES", 206, 214], ["Further studies", "TEST", 0, 15], ["skeletal muscle injury", "PROBLEM", 72, 94], ["COVID", "TEST", 98, 103], ["hypogeusia", "PROBLEM", 139, 149], ["hyposmia", "PROBLEM", 162, 170], ["SARS", "PROBLEM", 206, 210], ["CoV-2 infection", "PROBLEM", 211, 226], ["skeletal muscle", "ANATOMY", 72, 87], ["injury", "OBSERVATION", 88, 94], ["hypogeusia", "OBSERVATION", 139, 149]]], ["Hypoplasia has also been reported but infrequently.", [["Hypoplasia", "DISEASE", 0, 10], ["Hypoplasia", "PROBLEM", 0, 10]]], ["These are all categorized as manifestations of peripheral nerve involvement, while another reported feature is neuralgia.", [["peripheral nerve", "ANATOMY", 47, 63], ["peripheral nerve involvement", "DISEASE", 47, 75], ["neuralgia", "DISEASE", 111, 120], ["peripheral nerve", "MULTI-TISSUE_STRUCTURE", 47, 63], ["peripheral nerve involvement", "PROBLEM", 47, 75], ["neuralgia", "PROBLEM", 111, 120], ["peripheral", "ANATOMY_MODIFIER", 47, 57], ["nerve", "ANATOMY", 58, 63], ["neuralgia", "OBSERVATION", 111, 120]]], ["However, noteworthy is that the olfactory nerve is considered part of the CNS, and hyposmia may actually be a reflection of olfactory bulb involvement rather than peripheral neuropathy.", [["olfactory nerve", "ANATOMY", 32, 47], ["CNS", "ANATOMY", 74, 77], ["olfactory bulb", "ANATOMY", 124, 138], ["hyposmia", "DISEASE", 83, 91], ["peripheral neuropathy", "DISEASE", 163, 184], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 32, 47], ["CNS", "ANATOMICAL_SYSTEM", 74, 77], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 124, 138], ["hyposmia", "PROBLEM", 83, 91], ["olfactory bulb involvement", "PROBLEM", 124, 150], ["peripheral neuropathy", "PROBLEM", 163, 184], ["olfactory nerve", "ANATOMY", 32, 47], ["CNS", "ANATOMY", 74, 77], ["olfactory bulb", "OBSERVATION", 124, 138], ["peripheral", "ANATOMY_MODIFIER", 163, 173], ["neuropathy", "OBSERVATION", 174, 184]]], ["Similarly, hypoplasia, if due to optic neuropathy, may reflect CNS manifestation because optic nerve, as per classical teaching, is an extension of the brain.ReviewPost-infective neurological complicationsReviewWith more number of patients recovering from the SARS-CoV-2 infection, it is imperative that post-infective complications would draw attention with time.", [["optic", "ANATOMY", 33, 38], ["CNS", "ANATOMY", 63, 66], ["optic nerve", "ANATOMY", 89, 100], ["brain", "ANATOMY", 152, 157], ["neurological", "ANATOMY", 179, 191], ["hypoplasia", "DISEASE", 11, 21], ["optic neuropathy", "DISEASE", 33, 49], ["neurological complications", "DISEASE", 179, 205], ["SARS", "DISEASE", 260, 264], ["infection", "DISEASE", 271, 280], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 89, 100], ["brain", "ORGAN", 152, 157], ["patients", "ORGANISM", 231, 239], ["SARS-CoV-2", "ORGANISM", 260, 270], ["patients", "SPECIES", 231, 239], ["SARS-CoV", "SPECIES", 260, 268], ["hypoplasia", "PROBLEM", 11, 21], ["optic neuropathy", "PROBLEM", 33, 49], ["CNS manifestation", "PROBLEM", 63, 80], ["an extension of the brain", "PROBLEM", 132, 157], ["infective neurological complications", "PROBLEM", 169, 205], ["the SARS-CoV-2 infection", "PROBLEM", 256, 280], ["post-infective complications", "PROBLEM", 304, 332], ["hypoplasia", "OBSERVATION", 11, 21], ["if due to", "UNCERTAINTY", 23, 32], ["optic neuropathy", "OBSERVATION", 33, 49], ["may reflect", "UNCERTAINTY", 51, 62], ["optic nerve", "ANATOMY", 89, 100], ["brain", "ANATOMY", 152, 157], ["infective", "OBSERVATION_MODIFIER", 169, 178], ["neurological complications", "OBSERVATION", 179, 205], ["infection", "OBSERVATION", 271, 280]]], ["CNS demyelinations have been documented previously following coronavirus infection [20].", [["CNS", "ANATOMY", 0, 3], ["coronavirus infection", "DISEASE", 61, 82], ["CNS demyelinations", "PATHOLOGICAL_FORMATION", 0, 18], ["coronavirus", "ORGANISM", 61, 72], ["CNS demyelinations", "PROBLEM", 0, 18], ["coronavirus infection", "PROBLEM", 61, 82]]], ["An early report of Guillain-Barre syndrome (GBS) is available from China, although there is a concern regarding the causality in this particular case [21].", [["Guillain-Barre syndrome", "DISEASE", 19, 42], ["GBS", "DISEASE", 44, 47], ["Guillain-Barre", "ORGANISM", 19, 33], ["Guillain-Barre syndrome", "PROBLEM", 19, 42], ["GBS", "PROBLEM", 44, 47], ["early", "OBSERVATION_MODIFIER", 3, 8], ["Barre syndrome", "OBSERVATION", 28, 42]]], ["The patient developed typical symptoms of SARS-CoV-2 infection after seven days of hospitalization for GBS.", [["SARS-CoV-2 infection", "DISEASE", 42, 62], ["GBS", "DISEASE", 103, 106], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["typical symptoms", "PROBLEM", 22, 38], ["SARS", "PROBLEM", 42, 46], ["CoV", "PROBLEM", 47, 50], ["2 infection", "PROBLEM", 51, 62], ["GBS", "PROBLEM", 103, 106], ["SARS", "OBSERVATION", 42, 46], ["GBS", "OBSERVATION", 103, 106]]], ["Retrospective analysis, however, supports that she might have been harboring the infection since the beginning, as reflected in her blood counts (lymphocytopenia and thrombocytopenia).", [["blood", "ANATOMY", 132, 137], ["infection", "DISEASE", 81, 90], ["lymphocytopenia", "DISEASE", 146, 161], ["thrombocytopenia", "DISEASE", 166, 182], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["Retrospective analysis", "TEST", 0, 22], ["the infection", "PROBLEM", 77, 90], ["her blood counts", "TEST", 128, 144], ["lymphocytopenia", "PROBLEM", 146, 161], ["thrombocytopenia", "PROBLEM", 166, 182], ["infection", "OBSERVATION", 81, 90], ["lymphocytopenia", "OBSERVATION", 146, 161], ["thrombocytopenia", "OBSERVATION", 166, 182]]], ["The authors duly speculate that the initial symptoms may have been too mild to be detected in this patient (as fever is present in less than half of the cases during the initial phase).", [["fever", "DISEASE", 111, 116], ["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["the initial symptoms", "PROBLEM", 32, 52], ["fever", "PROBLEM", 111, 116]]], ["A very recent correspondence describes five cases of GBS collected from three hospitals of northern Italy among 100 to 1200 cases of SARS-CoV-2 infection over three weeks [21].", [["GBS", "DISEASE", 53, 56], ["SARS-CoV-2 infection", "DISEASE", 133, 153], ["SARS-CoV-2", "ORGANISM", 133, 143], ["CoV-2", "SPECIES", 138, 143], ["SARS-CoV-2", "SPECIES", 133, 143], ["GBS", "PROBLEM", 53, 56], ["SARS", "PROBLEM", 133, 137], ["CoV-2 infection", "PROBLEM", 138, 153]]], ["Three of these cases fit criteria for the axonal variant of GBS, while the remaining two had prolonged distal latencies suggesting demyelinating neuropathy.", [["axonal", "ANATOMY", 42, 48], ["GBS", "DISEASE", 60, 63], ["demyelinating neuropathy", "DISEASE", 131, 155], ["GBS", "PROBLEM", 60, 63], ["prolonged distal latencies", "PROBLEM", 93, 119], ["demyelinating neuropathy", "PROBLEM", 131, 155], ["GBS", "OBSERVATION", 60, 63], ["distal", "ANATOMY_MODIFIER", 103, 109], ["latencies", "OBSERVATION", 110, 119], ["suggesting", "UNCERTAINTY", 120, 130], ["demyelinating neuropathy", "OBSERVATION", 131, 155]]], ["Although each of these cases had a usual latency of five to ten days before the onset of neurological symptoms, one of the patients, similar to the previous one reported from China, was found negative on viral reverse transcription-polymerase chain reaction (RT-PCR) at the outset only to be detected positive subsequently.", [["neurological", "ANATOMY", 89, 101], ["neurological symptoms", "DISEASE", 89, 110], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["neurological symptoms", "PROBLEM", 89, 110], ["viral reverse transcription", "PROBLEM", 204, 231], ["polymerase chain reaction", "PROBLEM", 232, 257], ["RT-PCR", "TEST", 259, 265]]], ["This observation is ominous because of two reasons: (1) there is a chance of inadvertent exposure to the infectious virus in the neurology ward both for attending health care staffs and other patients; (2) GBS is a disorder known to rapidly affect respiratory muscles particularly if bulbar involvement sets in which can cause sudden poorly explained worsening of a patient's status if the diagnosis of COVID-19 has not already been established.ReviewAnother report from China describes a case of acute myelitis, possibly affecting the cervical spinal cord, as evidenced by the clinical features, in a known patient of SARS-CoV-2 infection [22].", [["respiratory muscles", "ANATOMY", 248, 267], ["bulbar", "ANATOMY", 284, 290], ["cervical spinal cord", "ANATOMY", 536, 556], ["GBS", "DISEASE", 206, 209], ["disorder", "DISEASE", 215, 223], ["COVID-19", "CHEMICAL", 403, 411], ["myelitis", "DISEASE", 503, 511], ["SARS-CoV-2 infection", "DISEASE", 619, 639], ["COVID-19", "CHEMICAL", 403, 411], ["patients", "ORGANISM", 192, 200], ["respiratory muscles", "ORGANISM_SUBDIVISION", 248, 267], ["bulbar", "ORGAN", 284, 290], ["patient", "ORGANISM", 366, 373], ["cervical", "ORGAN", 536, 544], ["spinal cord", "ORGAN", 545, 556], ["patient", "ORGANISM", 608, 615], ["SARS-CoV-2", "ORGANISM", 619, 629], ["patients", "SPECIES", 192, 200], ["patient", "SPECIES", 366, 373], ["patient", "SPECIES", 608, 615], ["SARS-CoV", "SPECIES", 619, 627], ["the infectious virus", "PROBLEM", 101, 121], ["GBS", "PROBLEM", 206, 209], ["a disorder", "PROBLEM", 213, 223], ["respiratory muscles", "PROBLEM", 248, 267], ["bulbar involvement sets", "PROBLEM", 284, 307], ["COVID", "TEST", 403, 408], ["acute myelitis", "PROBLEM", 497, 511], ["SARS", "PROBLEM", 619, 623], ["CoV-2 infection", "PROBLEM", 624, 639], ["infectious", "OBSERVATION", 105, 115], ["respiratory muscles", "ANATOMY", 248, 267], ["acute", "OBSERVATION_MODIFIER", 497, 502], ["myelitis", "OBSERVATION", 503, 511], ["cervical", "ANATOMY_MODIFIER", 536, 544], ["spinal cord", "ANATOMY", 545, 556]]], ["In this particular description also the neurological symptoms were co-incident with the febrile period of the illness pointing towards para-infectious demyelination rather than post-infective complication in true sense.", [["neurological", "ANATOMY", 40, 52], ["febrile", "DISEASE", 88, 95], ["illness", "DISEASE", 110, 117], ["demyelination", "DISEASE", 151, 164], ["the neurological symptoms", "PROBLEM", 36, 61], ["the illness", "PROBLEM", 106, 117], ["para-infectious demyelination", "PROBLEM", 135, 164], ["post-infective complication in true sense", "PROBLEM", 177, 218]]], ["Lymphocytopenia accompanied by raised markers of inflammation (CRP and procalcitonin) was documented by the treating physicians.", [["Lymphocytopenia", "DISEASE", 0, 15], ["inflammation", "DISEASE", 49, 61], ["CRP", "GENE_OR_GENE_PRODUCT", 63, 66], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 71, 84], ["CRP", "PROTEIN", 63, 66], ["procalcitonin", "PROTEIN", 71, 84], ["Lymphocytopenia", "PROBLEM", 0, 15], ["raised markers of inflammation", "PROBLEM", 31, 61], ["CRP", "TEST", 63, 66], ["procalcitonin", "TEST", 71, 84], ["inflammation", "OBSERVATION", 49, 61]]], ["The patient received anti-viral therapy along with immune-suppressive and recovered from his limb weakness.", [["limb", "ANATOMY", 93, 97], ["limb weakness", "DISEASE", 93, 106], ["patient", "ORGANISM", 4, 11], ["limb", "ORGANISM_SUBDIVISION", 93, 97], ["patient", "SPECIES", 4, 11], ["anti-viral therapy", "TREATMENT", 21, 39], ["immune-suppressive", "TREATMENT", 51, 69], ["his limb weakness", "PROBLEM", 89, 106], ["anti-viral therapy", "OBSERVATION", 21, 39], ["limb", "ANATOMY", 93, 97], ["weakness", "OBSERVATION", 98, 106]]], ["Although the literature is scarce at this point in time, the idea that SARS-CoV-2 can cause para-/post-infective complications affecting the neuroaxis at different levels seems realistic, and supposedly patients with the inflammatory storm will be more likely to manifest this.", [["SARS", "DISEASE", 71, 75], ["SARS-CoV-2", "ORGANISM", 71, 81], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["para-/post-infective complications", "PROBLEM", 92, 126], ["the neuroaxis", "PROBLEM", 137, 150], ["the inflammatory storm", "PROBLEM", 217, 239], ["infective", "OBSERVATION_MODIFIER", 103, 112], ["complications", "OBSERVATION", 113, 126], ["inflammatory", "OBSERVATION", 221, 233]]], ["Additionally, since about 10% of hospitalized patients need assistance in intensive care wards, neurological monitoring must also be aimed at verifying the onset of the so-called \"critical illness neuro-myopathy\" type PNS problems.", [["neurological", "ANATOMY", 96, 108], ["neuro-myopathy", "DISEASE", 197, 211], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["neurological monitoring", "TEST", 96, 119], ["type PNS problems", "PROBLEM", 213, 230]]], ["These issues are known to delay weaning from ventilation and pose a significant burden on the health care delivery system.ReviewPatients with neurological co-morbidityReviewDuring this hour of the pandemic, another group of patients will deserve the attention of neurologists.", [["neurological", "ANATOMY", 142, 154], ["neurological co-morbidity", "DISEASE", 142, 167], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 224, 232], ["ventilation", "TREATMENT", 45, 56], ["neurological co-morbidity", "PROBLEM", 142, 167]]], ["This group comprises of neurologically ill patients who have already been in follow-up for some time.", [["neurologically ill", "DISEASE", 24, 42], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51]]], ["The need for different groups of patients will vary according to the nature of their illness.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41]]], ["Data is insufficient at this point in time to conclude if chronic neurology patients are more predisposed to acquire infection.", [["infection", "DISEASE", 117, 126], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["acquire infection", "PROBLEM", 109, 126], ["infection", "OBSERVATION", 117, 126]]], ["However, patients with reduced mobility and those on immune-suppression therapy may be anticipated to be more susceptible to infection.ReviewRecent correspondence has already discussed the challenges that will be faced by dementia patients during this period of social distancing and home isolation [23].", [["infection", "DISEASE", 125, 134], ["dementia", "DISEASE", 222, 230], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 231, 239], ["reduced mobility", "PROBLEM", 23, 39], ["immune-suppression therapy", "TREATMENT", 53, 79], ["infection", "PROBLEM", 125, 134], ["dementia", "PROBLEM", 222, 230], ["home isolation", "TREATMENT", 284, 298], ["infection", "OBSERVATION", 125, 134]]], ["Obviously the crisis will be more for those subjects who depend on others for daily life activities.", [["the crisis", "PROBLEM", 10, 20]]], ["The situation will be similar for patients with prominent motor problems.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["prominent motor problems", "PROBLEM", 48, 72], ["prominent", "OBSERVATION_MODIFIER", 48, 57], ["motor problems", "OBSERVATION", 58, 72]]], ["Due to their restricted mobility, social distancing is supposed to affect them for worse.", [["restricted", "OBSERVATION_MODIFIER", 13, 23], ["mobility", "OBSERVATION", 24, 32]]], ["Reduced mobility and dementia may also predispose a patient to have a viral infection.", [["dementia", "DISEASE", 21, 29], ["viral infection", "DISEASE", 70, 85], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Reduced mobility", "PROBLEM", 0, 16], ["dementia", "PROBLEM", 21, 29], ["a viral infection", "PROBLEM", 68, 85], ["mobility", "OBSERVATION", 8, 16], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["infection", "OBSERVATION", 76, 85]]], ["So once again, the association becomes two-way.ReviewContemporary neurology has seen wide use of immune-suppressive agents to combat several disorders of both CNS and PNS.", [["CNS", "ANATOMY", 159, 162], ["PNS", "ANATOMY", 167, 170], ["disorders of both CNS and PNS", "DISEASE", 141, 170], ["CNS", "ANATOMICAL_SYSTEM", 159, 162], ["PNS", "ANATOMICAL_SYSTEM", 167, 170], ["immune-suppressive agents", "TREATMENT", 97, 122], ["several disorders of both CNS and PNS", "PROBLEM", 133, 170], ["CNS", "ANATOMY", 159, 162], ["PNS", "ANATOMY", 167, 170]]], ["The prototypical among these disorders is multiple sclerosis that calls for long term immunosuppression.", [["multiple sclerosis", "DISEASE", 42, 60], ["multiple sclerosis", "PROBLEM", 42, 60], ["long term immunosuppression", "TREATMENT", 76, 103], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["sclerosis", "OBSERVATION", 51, 60]]], ["The data so far on COVID-19 reveals that old age, as well as immune-dysregulated subjects, are more likely not only to acquire the infection but also to manifest increased severity.", [["infection", "DISEASE", 131, 140], ["COVID-19", "CELL", 19, 27], ["The data", "TEST", 0, 8], ["COVID", "TEST", 19, 24], ["immune-dysregulated subjects", "PROBLEM", 61, 89], ["the infection", "PROBLEM", 127, 140], ["increased severity", "PROBLEM", 162, 180], ["infection", "OBSERVATION", 131, 140], ["increased", "OBSERVATION_MODIFIER", 162, 171], ["severity", "OBSERVATION_MODIFIER", 172, 180]]], ["Therefore, similar to the oncology ward, patients in the neurology ward admitted receiving cyclic immunosuppressive drugs need attention.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["cyclic immunosuppressive drugs", "TREATMENT", 91, 121]]], ["Appropriate caution has to be practiced while dealing with such cases both from the part of the neurologist as well as the patient's relatives.", [["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130]]], ["A recent article on this topic recommends that the benefits of continuing immunotherapy in patients with multiple sclerosis (MS) and related disorders may outweigh the risks of medication withdrawal in the apprehension of COVID-19.", [["multiple sclerosis", "DISEASE", 105, 123], ["MS", "DISEASE", 125, 127], ["COVID-19", "CHEMICAL", 222, 230], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["continuing immunotherapy", "TREATMENT", 63, 87], ["multiple sclerosis (MS)", "PROBLEM", 105, 128], ["related disorders", "PROBLEM", 133, 150], ["medication withdrawal", "PROBLEM", 177, 198], ["COVID", "TEST", 222, 227], ["sclerosis", "OBSERVATION", 114, 123]]], ["This is particularly because most infections, as in the general population, are anticipated to be mild an2d self-limiting.", [["infections", "DISEASE", 34, 44], ["most infections", "PROBLEM", 29, 44], ["infections", "OBSERVATION", 34, 44], ["mild", "OBSERVATION_MODIFIER", 98, 102]]], ["However, the authors emphasize the need for individualized decision-making in such circumstances because one size\" may not fit all, and some of the patients may land up in severe infection leading to discontinuation of therapy [24].ReviewLong term impactReviewWith the growing number in recovery from SARS-CoV-2 infection, rehabilitation issue is supposed to become a crucial one.", [["infection", "DISEASE", 179, 188], ["SARS-CoV-2 infection", "DISEASE", 301, 321], ["patients", "ORGANISM", 148, 156], ["CoV-2", "ORGANISM", 306, 311], ["patients", "SPECIES", 148, 156], ["SARS-CoV", "SPECIES", 301, 309], ["severe infection", "PROBLEM", 172, 188], ["therapy", "TREATMENT", 219, 226], ["SARS", "PROBLEM", 301, 305], ["2 infection", "PROBLEM", 310, 321], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["infection", "OBSERVATION", 179, 188], ["growing", "OBSERVATION_MODIFIER", 269, 276], ["infection", "OBSERVATION", 312, 321]]], ["Personal communication with neurologists working in the field in Italy reveals that there is early evidence for the need for rehabilitation, including neurological aspects, in clinically recovered patients.", [["neurological", "ANATOMY", 151, 163], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["rehabilitation", "TREATMENT", 125, 139]]], ["It can be assumed that the psycho-social effects of long term social distancing and home isolation will require adequate psychological rehabilitation measures as the pandemic will start waning off.ReviewSince the onset of the SARS-CoV-2 outbreak, if there is one pulmonary manifestation that has received maximum focus, it is ARDS.", [["pulmonary", "ANATOMY", 263, 272], ["SARS", "DISEASE", 226, 230], ["ARDS", "DISEASE", 326, 330], ["pulmonary", "ORGAN", 263, 272], ["SARS-CoV", "SPECIES", 226, 234], ["home isolation", "TREATMENT", 84, 98], ["adequate psychological rehabilitation measures", "TREATMENT", 112, 158], ["the SARS", "PROBLEM", 222, 230], ["ARDS", "PROBLEM", 326, 330], ["pulmonary", "ANATOMY", 263, 272], ["manifestation", "OBSERVATION", 273, 286], ["ARDS", "OBSERVATION", 326, 330]]], ["Evidence suggests a significant percentage of ARDS survivors may suffer long-term cognitive impairment [25].", [["ARDS", "DISEASE", 46, 50], ["cognitive impairment", "DISEASE", 82, 102], ["ARDS survivors", "PROBLEM", 46, 60], ["long-term cognitive impairment", "PROBLEM", 72, 102], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["percentage", "OBSERVATION_MODIFIER", 32, 42], ["ARDS", "OBSERVATION", 46, 50]]], ["Several factors, including mechanical ventilation, have been observed to cause a decline in higher brain functions following ARDS.", [["brain", "ANATOMY", 99, 104], ["ARDS", "DISEASE", 125, 129], ["brain", "ORGAN", 99, 104], ["mechanical ventilation", "TREATMENT", 27, 49], ["a decline in higher brain functions", "PROBLEM", 79, 114], ["ARDS", "PROBLEM", 125, 129], ["mechanical ventilation", "OBSERVATION", 27, 49], ["ARDS", "OBSERVATION", 125, 129]]], ["Acute injury to the blood-brain barrier has been implicated as the underlying mechanism for cognitive impairment following ARDS.", [["blood-brain barrier", "ANATOMY", 20, 39], ["cognitive impairment", "DISEASE", 92, 112], ["ARDS", "DISEASE", 123, 127], ["blood", "MULTI-TISSUE_STRUCTURE", 20, 25], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 26, 39], ["Acute injury", "PROBLEM", 0, 12], ["the blood-brain barrier", "PROBLEM", 16, 39], ["cognitive impairment", "PROBLEM", 92, 112], ["ARDS", "PROBLEM", 123, 127], ["injury", "OBSERVATION", 6, 12], ["blood", "ANATOMY", 20, 25], ["brain", "ANATOMY", 26, 31], ["ARDS", "OBSERVATION", 123, 127]]], ["The effect of such injury may be amplified if there is a pre-existing cognitive impairment that corresponds to chronic blood-brain barrier damage.", [["blood", "ANATOMY", 119, 124], ["brain", "ANATOMY", 125, 130], ["cognitive impairment", "DISEASE", 70, 90], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 125, 138], ["such injury", "PROBLEM", 14, 25], ["a pre-existing cognitive impairment", "PROBLEM", 55, 90], ["chronic blood-brain barrier damage", "PROBLEM", 111, 145], ["chronic", "OBSERVATION_MODIFIER", 111, 118], ["brain", "ANATOMY", 125, 130], ["barrier damage", "OBSERVATION", 131, 145]]], ["Patients with brain injury, on the other hand, have been found to develop neurogenic pulmonary edema.", [["brain", "ANATOMY", 14, 19], ["pulmonary", "ANATOMY", 85, 94], ["brain injury", "DISEASE", 14, 26], ["neurogenic pulmonary edema", "DISEASE", 74, 100], ["Patients", "ORGANISM", 0, 8], ["brain", "ORGAN", 14, 19], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 85, 100], ["Patients", "SPECIES", 0, 8], ["brain injury", "PROBLEM", 14, 26], ["neurogenic pulmonary edema", "PROBLEM", 74, 100], ["brain", "ANATOMY", 14, 19], ["injury", "OBSERVATION", 20, 26], ["neurogenic", "OBSERVATION_MODIFIER", 74, 84], ["pulmonary", "ANATOMY", 85, 94], ["edema", "OBSERVATION", 95, 100]]], ["Therefore, it is postulated that the so-called brain-lung axis works both ways.", [["brain", "ANATOMY", 47, 52], ["lung", "ANATOMY", 53, 57], ["brain", "ORGAN", 47, 52], ["lung", "ORGAN", 53, 57], ["brain", "ANATOMY", 47, 52], ["lung", "ANATOMY", 53, 57], ["axis", "ANATOMY_MODIFIER", 58, 62]]], ["The above observations are particularly relevant in the present circumstances, given the need for mechanical ventilation in the majority of the severely affected COVID-19 patients.", [["COVID", "DISEASE", 162, 167], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["mechanical ventilation", "TREATMENT", 98, 120]]], ["As the pandemic continues to unfold, the number of people getting off mechanical ventilation will rise, and long-term cognitive outcomes will come into view.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["mechanical ventilation", "TREATMENT", 70, 92]]], ["It can be anticipated that not only we shall witness cognitive decline lasting for months in this group of patients, but also some of them may progress to premature onset of dementia.ReviewOver time, the need to raise awareness among the neurologists is being increasingly recognized.", [["cognitive decline", "DISEASE", 53, 70], ["dementia", "DISEASE", 174, 182], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["cognitive decline", "PROBLEM", 53, 70], ["dementia", "PROBLEM", 174, 182], ["dementia", "OBSERVATION", 174, 182]]], ["The case record protocol for \"First Few Cases (FFX) and their close contacts\" published by WHO has a separate column to mention the neurological findings in addition to respiratory signs and symptoms [26].", [["neurological", "ANATOMY", 132, 144], ["respiratory", "ANATOMY", 169, 180], ["respiratory signs", "DISEASE", 169, 186], ["the neurological findings", "PROBLEM", 128, 153], ["respiratory signs", "PROBLEM", 169, 186], ["symptoms", "PROBLEM", 191, 199]]], ["This underlines the importance of recognizing the neurological manifestation of the illness.", [["neurological", "ANATOMY", 50, 62], ["illness", "DISEASE", 84, 91], ["the illness", "PROBLEM", 80, 91]]], ["A recently published guideline from China lists some important precautionary measures that need to adapt by the neurologists to combat the pandemic [27].", [["precautionary measures", "TREATMENT", 63, 85]]], ["The bottom line is to have a high index of clinical suspicion, particularly when working in an endemic zone.", [["The bottom line", "TREATMENT", 0, 15], ["bottom line", "OBSERVATION", 4, 15], ["high index", "OBSERVATION_MODIFIER", 29, 39], ["endemic", "OBSERVATION", 95, 102]]], ["This will not only help early initiation of therapy but also will halt the chain of transmission.ConclusionsThe pandemic of COVID-19 presents for a neurologist some unique challenges.", [["COVID-19", "CHEMICAL", 124, 132], ["therapy", "TREATMENT", 44, 51], ["COVID", "TEST", 124, 129]]], ["We observe that SARS-CoV-2 may have various neurological manifestations, and in many cases, neurological features may precede typical respiratory symptoms.", [["neurological", "ANATOMY", 44, 56], ["neurological", "ANATOMY", 92, 104], ["respiratory", "ANATOMY", 134, 145], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 16, 26], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV", "TEST", 21, 24], ["various neurological manifestations", "PROBLEM", 36, 71], ["neurological features", "PROBLEM", 92, 113], ["typical respiratory symptoms", "PROBLEM", 126, 154]]], ["Holistic knowledge of the spectrum of neurological consequences of COVID-19 is important to get a hold on the spread of the virus.", [["neurological", "ANATOMY", 38, 50], ["COVID-19", "CHEMICAL", 67, 75], ["COVID", "TEST", 67, 72], ["the virus", "PROBLEM", 120, 129]]], ["The most vital clinical information which we gather is that impaired consciousness may be a presenting feature of COVID-19, and therefore, a high index of suspicion for such patients will be the key to prevent or, at least, lessen exposure to health care providers and other patients.", [["impaired consciousness", "DISEASE", 60, 82], ["patients", "ORGANISM", 174, 182], ["patients", "ORGANISM", 275, 283], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 275, 283], ["impaired consciousness", "PROBLEM", 60, 82], ["COVID", "TEST", 114, 119]]], ["With the gradual subsidence of the outbreak, it can be anticipated that several post-infectious complications will surface up while rehabilitation measures will also deserve attention.", [["-infectious complications", "PROBLEM", 84, 109], ["rehabilitation measures", "TREATMENT", 132, 155], ["gradual", "OBSERVATION_MODIFIER", 9, 16], ["subsidence", "OBSERVATION_MODIFIER", 17, 27], ["infectious", "OBSERVATION_MODIFIER", 85, 95]]], ["Adequate caution has to be practiced while managing chronic neurology patients, particularly those requiring immune-modulator therapy since formulated guidelines are lacking at this point.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["immune-modulator therapy", "TREATMENT", 109, 133]]], ["The above summary of the neurological manifestations of COVID-19 will help neurologists have a basic preparation, which is of utmost importance to prevent horizontal infections.", [["neurological", "ANATOMY", 25, 37], ["infections", "DISEASE", 166, 176], ["COVID-19", "CHEMICAL", 56, 64], ["a basic preparation", "TREATMENT", 93, 112], ["horizontal infections", "PROBLEM", 155, 176], ["infections", "OBSERVATION", 166, 176]]]], "bff6fa28f1d3ac4771308cfbe1636cab0762eeb5": [["The SARS-cov-2 virus that is believed to have originated in Wuhan, China in December of 2019 [1] has spread over 200 countries affecting over 7 million people and killing 400 thousand people as of the 8th of June 2020.", [["SARS-cov-2 virus", "ORGANISM", 4, 20], ["people", "ORGANISM", 152, 158], ["people", "ORGANISM", 184, 190], ["people", "SPECIES", 152, 158], ["people", "SPECIES", 184, 190], ["SARS-cov-2 virus", "SPECIES", 4, 20], ["The SARS-cov-2 virus", "PROBLEM", 0, 20]]], ["[2] On the 30 th of January, the World Health Organization (WHO) declared a global health emergency [3] , and on the 19 th of March, they advised the use of face masks or mouth coverings to prevent the spread of the disease.", [["mouth", "ANATOMY", 171, 176], ["mouth", "ORGANISM_SUBDIVISION", 171, 176], ["face masks", "TREATMENT", 157, 167], ["mouth coverings", "TREATMENT", 171, 186], ["the disease", "PROBLEM", 212, 223], ["disease", "OBSERVATION", 216, 223]]], ["[4] Droplets exhaled from infected individuals' respiratory tracts via coughing, breathing, sneezing and speaking are seen to be the main form of transmission ( Fig. 1 ) [5] .", [["respiratory tracts", "ANATOMY", 48, 66], ["[4] Droplets", "SIMPLE_CHEMICAL", 0, 12], ["respiratory tracts", "MULTI-TISSUE_STRUCTURE", 48, 66], ["Droplets exhaled", "PROBLEM", 4, 20], ["infected individuals' respiratory tracts", "PROBLEM", 26, 66], ["coughing", "PROBLEM", 71, 79], ["breathing", "PROBLEM", 81, 90], ["sneezing", "PROBLEM", 92, 100], ["infected", "OBSERVATION_MODIFIER", 26, 34], ["respiratory tracts", "ANATOMY", 48, 66]]], ["When the droplets are emitted, they transfer the virus by three contact methods.", [["droplets", "ANATOMY", 9, 17]]], ["[6] Droplets that are inhaled directly are referred to as airborne, droplets that land on an individual's hand or body and are then transferred to the face are contact and droplets that land on a surface and are then transferred are referred to as fomites.", [["hand", "ANATOMY", 106, 110], ["body", "ANATOMY", 114, 118], ["face", "ANATOMY", 151, 155], ["surface", "ANATOMY", 196, 203], ["[6] Droplets", "SIMPLE_CHEMICAL", 0, 12], ["hand", "ORGANISM_SUBDIVISION", 106, 110], ["body", "ORGANISM_SUBDIVISION", 114, 118], ["surface", "CELLULAR_COMPONENT", 196, 203], ["body", "ANATOMY", 114, 118]]], ["The use of face masks and respirators have now become recommend in several European countries such as Ireland [7] but are not enacted into law.", [["face masks", "TREATMENT", 11, 21], ["respirators", "TREATMENT", 26, 37]]], ["Mask prevention of transmission of the airborne virus.", [["Mask", "TREATMENT", 0, 4], ["the airborne virus", "PROBLEM", 35, 53], ["airborne virus", "OBSERVATION", 39, 53]]], ["[5] The pandemic has resulted in an increase in demand for PPE all over the world with six times the amount of surgical mask and three times that of respirators being required.", [["PPE", "TREATMENT", 59, 62], ["surgical mask", "TREATMENT", 111, 124], ["respirators", "TREATMENT", 149, 160], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["surgical mask", "OBSERVATION", 111, 124]]], ["[11] , [12] Strict testing and requirements have been set in place previously to ensure that these face masks and respirators meet certain standards.", [["Strict testing", "TEST", 12, 26], ["these face masks", "TREATMENT", 93, 109], ["respirators", "TREATMENT", 114, 125]]], ["Filtration efficiency examines the masks ability to filter four different filtrates; particulates, bacterial, viral and NaCl.", [["NaCl", "CHEMICAL", 120, 124], ["NaCl", "CHEMICAL", 120, 124], ["NaCl", "SIMPLE_CHEMICAL", 120, 124], ["Filtration efficiency", "TREATMENT", 0, 21], ["four different filtrates", "PROBLEM", 59, 83], ["bacterial", "PROBLEM", 99, 108], ["NaCl", "TREATMENT", 120, 124], ["filtrates", "OBSERVATION", 74, 83], ["bacterial", "OBSERVATION_MODIFIER", 99, 108]]], ["[13] The face masks and respirators are tested for fluid [14] and flame [15] resistance to ensure the materials are not susceptible to penetration, but liquids and can withstand acceptable heath levels.", [["The face masks", "TREATMENT", 5, 19], ["respirators", "TREATMENT", 24, 35], ["fluid", "TEST", 51, 56], ["flame", "TEST", 66, 71], ["penetration", "PROBLEM", 135, 146]]], ["The fit of the face masks and respirators is also tested to ensure a suitable seal is obtained and that they are comfortable.", [["the face masks", "TREATMENT", 11, 25], ["respirators", "TREATMENT", 30, 41]]], ["[16] Nonwoven materials are the main material used in the filtration of aerosols.", [["Nonwoven materials", "TREATMENT", 5, 23], ["the filtration of aerosols", "TREATMENT", 54, 80], ["main", "OBSERVATION_MODIFIER", 32, 36]]], ["[17] These can be made from man-made or natural fibres (paper not included) whereby a web or a coat of the materials are secured together.", [["a coat of the materials", "TREATMENT", 93, 116]]], ["Melt blown fibre are produced by a hot polymer being blown out of a thin tube, these being deposited onto a collector to cool and form a web of material.", [["tube", "TISSUE", 73, 77], ["Melt blown fibre", "PROBLEM", 0, 16], ["a hot polymer", "PROBLEM", 33, 46], ["a thin tube", "TREATMENT", 66, 77], ["blown fibre", "OBSERVATION", 5, 16], ["hot polymer", "OBSERVATION_MODIFIER", 35, 46], ["tube", "OBSERVATION", 73, 77]]], ["N95 masks produced by 3M are made up of multiple materials.", [["N95 masks", "TREATMENT", 0, 9]]], ["Straps are composed of thermoplastic elastomer; nose clips are made from aluminium, nose foam form polyurethane, the filter from polypropylene and the shell and cover web are made from polyester.", [["aluminium", "CHEMICAL", 73, 82], ["aluminium", "CHEMICAL", 73, 82], ["polyurethane", "CHEMICAL", 99, 111], ["polypropylene", "CHEMICAL", 129, 142], ["polyester", "CHEMICAL", 185, 194], ["aluminium", "SIMPLE_CHEMICAL", 73, 82], ["nose", "ORGANISM_SUBDIVISION", 84, 88], ["Straps", "TREATMENT", 0, 6], ["thermoplastic elastomer", "TREATMENT", 23, 46], ["nose clips", "TREATMENT", 48, 58], ["aluminium, nose foam form polyurethane", "TREATMENT", 73, 111], ["the filter from polypropylene and the shell", "TREATMENT", 113, 156], ["thermoplastic elastomer", "OBSERVATION", 23, 46], ["nose clips", "OBSERVATION", 48, 58], ["polyurethane", "OBSERVATION", 99, 111], ["filter", "OBSERVATION", 117, 123]]], ["[18] N95 masks consist of multiple layers; the layers that are accountable for filtering efficiency are \"polypropylene layers with an embedded electrostatic charge\" [19] (Fig. 2) .", [["[18] N95", "CHEMICAL", 0, 8], ["polypropylene", "CHEMICAL", 105, 118], ["[18] N95", "SIMPLE_CHEMICAL", 0, 8], ["layers", "TISSUE", 47, 53], ["N95 masks", "TREATMENT", 5, 14], ["filtering efficiency", "PROBLEM", 79, 99], ["polypropylene layers", "TREATMENT", 105, 125], ["an embedded electrostatic charge\"", "TREATMENT", 131, 164], ["multiple", "OBSERVATION_MODIFIER", 26, 34], ["layers", "OBSERVATION_MODIFIER", 35, 41], ["layers", "OBSERVATION_MODIFIER", 47, 53]]], ["[20] Surgical mask is comprised of three layers; the layers are made from non-woven fabric that have a material that is melt-blown between them [21] ; these can be made from multiple materials.", [["layers", "TISSUE", 53, 59], ["Surgical mask", "TREATMENT", 5, 18], ["layers", "OBSERVATION_MODIFIER", 41, 47], ["layers", "OBSERVATION_MODIFIER", 53, 59], ["blown", "OBSERVATION_MODIFIER", 125, 130]]], ["N95 mask layers [20] Disposable masks can be made from a variety of polymers such as polyethylene, polycarbonate and polyester.", [["polyethylene, polycarbonate", "CHEMICAL", 85, 112], ["polyethylene", "CHEMICAL", 85, 97], ["polycarbonate", "CHEMICAL", 99, 112], ["polyester", "CHEMICAL", 117, 126], ["polyethylene", "SIMPLE_CHEMICAL", 85, 97], ["polycarbonate", "SIMPLE_CHEMICAL", 99, 112], ["N95 mask layers", "TREATMENT", 0, 15], ["Disposable masks", "TREATMENT", 21, 37], ["a variety of polymers", "TREATMENT", 55, 76], ["polyethylene, polycarbonate and polyester", "TREATMENT", 85, 126]]], ["[23] These have three different layers with the outer layer being a waterproof nonwoven fibre, a melt-blown middle layer that filters most of the particulates and a soft fibre inner layer.", [["outer layer", "ANATOMY", 48, 59], ["inner layer", "ANATOMY", 176, 187], ["soft fibre inner layer", "TISSUE", 165, 187], ["a waterproof nonwoven fibre", "TREATMENT", 66, 93], ["a soft fibre inner layer", "TREATMENT", 163, 187], ["layers", "OBSERVATION_MODIFIER", 32, 38], ["outer", "OBSERVATION_MODIFIER", 48, 53], ["layer", "OBSERVATION_MODIFIER", 54, 59], ["waterproof", "OBSERVATION", 68, 78], ["nonwoven fibre", "OBSERVATION", 79, 93], ["blown", "OBSERVATION_MODIFIER", 102, 107], ["middle layer", "OBSERVATION_MODIFIER", 108, 120], ["filters", "OBSERVATION", 126, 133], ["particulates", "OBSERVATION_MODIFIER", 146, 158], ["soft fibre", "OBSERVATION_MODIFIER", 165, 175], ["inner", "OBSERVATION_MODIFIER", 176, 181], ["layer", "OBSERVATION_MODIFIER", 182, 187]]], ["Mask using filters are \"fibrous\"; they use layers of unwoven fibres to trap particulates.", [["fibres", "ANATOMY", 61, 67], ["Mask", "TREATMENT", 0, 4], ["filters", "TREATMENT", 11, 18], ["fibrous", "OBSERVATION_MODIFIER", 24, 31]]], ["The size of the particulate they can trap depends on the thickness of the fibres, the openings left between the fibres and how many layers are present.", [["fibres", "ANATOMY", 74, 80], ["fibres", "ANATOMY", 112, 118], ["fibres", "CELLULAR_COMPONENT", 74, 80], ["fibres", "CELLULAR_COMPONENT", 112, 118], ["layers", "TISSUE", 132, 138], ["size", "OBSERVATION_MODIFIER", 4, 8], ["particulate", "OBSERVATION_MODIFIER", 16, 27], ["trap", "OBSERVATION", 37, 41], ["fibres", "OBSERVATION_MODIFIER", 74, 80], ["openings", "OBSERVATION_MODIFIER", 86, 94], ["left", "ANATOMY_MODIFIER", 95, 99], ["fibres", "ANATOMY_MODIFIER", 112, 118], ["many", "OBSERVATION_MODIFIER", 127, 131], ["layers", "OBSERVATION_MODIFIER", 132, 138]]], ["[24] The variety and the necessity of PPE testing are depending on the probable health risk to the user and the equipment's intended use.", [["PPE testing", "TEST", 38, 49]]], ["Among all the examples of the PPE, wearing the face masks and respirators in public areas and hazardous workplaces are considered as an effective solution, which can hinder the dissemination of an infectious disease by avoiding the infectious droplets exhalation and spreading as well as the inhalation of their subsequent.", [["infectious disease", "DISEASE", 197, 215], ["the PPE", "TREATMENT", 26, 33], ["the face masks", "TREATMENT", 43, 57], ["an infectious disease", "PROBLEM", 194, 215], ["the infectious droplets exhalation", "PROBLEM", 228, 262], ["hazardous workplaces", "OBSERVATION", 94, 114], ["infectious", "OBSERVATION", 197, 207], ["infectious", "OBSERVATION_MODIFIER", 232, 242]]], ["In the event of the recent worldwide spread of COVID-19, which is affecting the respiratory system, the request for face masks and respirators is significantly increased by the public.Introduction[26], [27] Some general categories of PPE testing and their examples (along with their corresponding American National Standard, ANSI, [28] ) are shown in Table 2 .Introduction[26] The procedure/surgical masks can provide certified respiratory protection if they are tested, designed, and government-certified as a respirator.", [["respiratory", "ANATOMY", 428, 439], ["COVID", "TEST", 47, 52], ["face masks", "TREATMENT", 116, 126], ["respirators", "TREATMENT", 131, 142], ["PPE testing", "TEST", 234, 245], ["The procedure/surgical masks", "TREATMENT", 377, 405], ["certified respiratory protection", "TREATMENT", 418, 450], ["a respirator", "TREATMENT", 509, 521], ["respiratory system", "ANATOMY", 80, 98], ["significantly", "OBSERVATION_MODIFIER", 146, 159], ["increased", "OBSERVATION_MODIFIER", 160, 169]]], ["[29] The PPE tests, which are used in the United States, should comply with the US occupational safety and health administration (OSHA), as well as the requirements of product-specific American National Standards.", [["The PPE tests", "TEST", 5, 18]]], ["For those, which are used or sold in Europe, it is necessary to meet Europe's PPE Directive and the EU's forthcoming PPE Regulation.Introduction[26]IntroductionGenerally, If the user expects the performance of both a particulate respirator and a mask, they should select the PPE type which is tested and certified as a particulate respirator by the national institute for occupational safety and health (NIOSH) [30] , and produced according to the food and drug administration (FDA) for the procedure/surgical mask.", [["Europe's PPE Directive", "TREATMENT", 69, 91], ["the EU's forthcoming PPE Regulation", "TREATMENT", 96, 131], ["a particulate respirator", "TREATMENT", 215, 239], ["a mask", "TREATMENT", 244, 250], ["the procedure", "TREATMENT", 487, 500], ["surgical mask", "TREATMENT", 501, 514], ["surgical mask", "OBSERVATION", 501, 514]]], ["[29]Common tests for respirators and surgical masksThe ASTM standards are issued by the food and drug administration FDA, as the authorized standard in the US.", [["Common tests", "TEST", 4, 16], ["respirators", "TREATMENT", 21, 32], ["surgical masks", "TREATMENT", 37, 51], ["The ASTM standards", "TREATMENT", 51, 69], ["surgical masks", "OBSERVATION", 37, 51]]], ["There are several basic standard ASTM F2100-11 (2011), which specifies the performance necessities for the respirators and the face masks.", [["several basic standard ASTM F2100", "TEST", 10, 43], ["the respirators", "TREATMENT", 103, 118], ["the face masks", "TREATMENT", 123, 137], ["several", "OBSERVATION_MODIFIER", 10, 17], ["basic", "OBSERVATION_MODIFIER", 18, 23], ["standard ASTM", "OBSERVATION_MODIFIER", 24, 37]]], ["[33] The ASTM F2100-11 specification explains the required properties and the testing protocols for the utilized material in the face masks production, which are used in the hospital, health care, and patient care.", [["patient", "ORGANISM", 201, 208], ["patient", "SPECIES", 201, 208], ["The ASTM F2100", "TEST", 5, 19], ["the testing protocols", "TEST", 74, 95]]], ["The face masks are classified based on their performance according to various testing such as flammability, fluid resistance, breathability, bacterial filtration efficiency etc. [34] , which are illustrated in Fig. 3 .", [["fluid", "ANATOMY", 108, 113], ["various testing", "TEST", 70, 85], ["fluid resistance", "TEST", 108, 124], ["breathability", "PROBLEM", 126, 139], ["bacterial filtration efficiency", "PROBLEM", 141, 172], ["fluid resistance", "OBSERVATION", 108, 124]]], ["In the following sections, various testing methods are comprehensively explained.Filtration Efficiency (FE)There are different methods to measure the filtration efficiency in the 42 CFR Part 84 certification protocol, such as the particulate filtration efficiency (PFE), bacterial filtration efficiency (BFE), viral filtration efficiency (VFE), and NIOSH.", [["sections", "ANATOMY", 17, 25], ["various testing methods", "TEST", 27, 50], ["Filtration Efficiency (FE)", "TREATMENT", 81, 107], ["different methods", "TREATMENT", 117, 134], ["the filtration efficiency", "TREATMENT", 146, 171], ["the particulate filtration efficiency", "TREATMENT", 226, 263], ["bacterial filtration efficiency", "PROBLEM", 271, 302], ["viral filtration efficiency", "PROBLEM", 310, 337], ["bacterial filtration efficiency", "OBSERVATION", 271, 302], ["viral", "OBSERVATION", 310, 315], ["filtration efficiency", "OBSERVATION", 316, 337]]], ["[13] , [30] The PFE and BFE methods are associated with material efficiency, which is used as the barrier to protect the wearer against the aqueous viral aerosols.", [["PFE", "SIMPLE_CHEMICAL", 16, 19], ["BFE", "SIMPLE_CHEMICAL", 24, 27], ["The PFE and BFE methods", "TEST", 12, 35], ["material efficiency", "PROBLEM", 56, 75], ["the barrier", "TREATMENT", 94, 105], ["material efficiency", "OBSERVATION", 56, 75]]], ["The filtration efficiency assessment is conducted according to the ASTM F2100-19E1 protocol utilizing the salt aerosol with a size of 100-nm.", [["F2100-19E1", "CHEMICAL", 72, 82], ["The filtration efficiency assessment", "TEST", 0, 36], ["the salt aerosol", "TREATMENT", 102, 118], ["filtration efficiency", "OBSERVATION", 4, 25]]], ["[35] In general, the filtration efficiency of the masks and respirators measure by equation (1), in which the C u and C d are the averages of particle concentrations per each upstream and the downstream test specimen.", [["specimen", "ANATOMY", 208, 216], ["the masks", "TREATMENT", 46, 55], ["the C u and C d", "PROBLEM", 106, 121], ["the downstream test specimen", "TEST", 188, 216]]], ["[27] FEFiltration Efficiency (FE)(1)Particulate Filtration Efficiency (PFE)The PFE method is led according to the American society of testing and materials (ASTM) F2299 protocol, and indicates the quality of the procedure/surgical masks; however, it cannot be considered as the indicator of respiratory protection performance.", [["respiratory", "ANATOMY", 291, 302], ["[27] FEFiltration", "CHEMICAL", 0, 17], ["FEFiltration Efficiency (FE)", "TREATMENT", 5, 33], ["Particulate Filtration Efficiency (PFE)", "TREATMENT", 36, 75], ["the procedure", "TREATMENT", 208, 221], ["surgical masks", "TREATMENT", 222, 236]]], ["[3] In other words, the PFE test procedures measure the quality of the masks for filtering the particles with different sizes.", [["the PFE test procedures", "TEST", 20, 43], ["the masks", "TREATMENT", 67, 76], ["sizes", "OBSERVATION_MODIFIER", 120, 125]]], ["[29] According to the FDA guidance document, the PFE test can be conducted utilizing the 0.1-Micron Polystyrene Latex particles.", [["Polystyrene", "CHEMICAL", 100, 111], ["the PFE test", "TEST", 45, 57], ["the 0.1-Micron Polystyrene Latex particles", "TREATMENT", 85, 127]]], ["The use of latex spheres offers a precise test for estimating a submicron efficiency performance.", [["latex spheres", "TREATMENT", 11, 24], ["a precise test", "TEST", 32, 46]]], ["[36] The Polystyrene Latex particles have been suspended in water, and the aerosols were created by means of a particle generator, which is adjustable and can provide the favorable of particles concentration.", [["Polystyrene", "CHEMICAL", 9, 20], ["Polystyrene", "CHEMICAL", 9, 20], ["Polystyrene Latex particles", "SIMPLE_CHEMICAL", 9, 36], ["The Polystyrene Latex particles", "TREATMENT", 5, 36], ["the aerosols", "TREATMENT", 71, 83], ["a particle generator", "TREATMENT", 109, 129]]], ["The particles can be counted utilizing a particle counter downstream.", [["a particle counter downstream", "TREATMENT", 39, 68], ["particles", "OBSERVATION", 4, 13]]], ["The concentration of the aerosol can be adjusted (from 10000 to 15000 particles) by passing through the drying chamber by means of HEPA filtered air, and after passing through the convex side of the test sample, it has been placed into a filter holder.", [["the aerosol", "TREATMENT", 21, 32], ["HEPA filtered air", "TREATMENT", 131, 148], ["the test sample", "TEST", 195, 210], ["a filter holder", "TREATMENT", 236, 251], ["air", "OBSERVATION", 145, 148], ["filter", "OBSERVATION", 238, 244]]], ["According to the FDA protocols, the used particles are not charge neutralized.", [["the used particles", "TREATMENT", 32, 50]]], ["[36] Besides, according to the ASTM 2299 protocol, the PFE testing has been carried out with a velocity between 1 cm/sec to 25 cm/sec utilizing the entire N95 FFRs, 90 cm 2 surgical mask material, and surgical N95 FFRs.", [["the PFE testing", "TEST", 51, 66], ["a velocity", "TEST", 93, 103], ["2 surgical mask material", "TREATMENT", 171, 195], ["surgical N95 FFRs", "TREATMENT", 201, 218], ["25 cm", "OBSERVATION_MODIFIER", 124, 129]]], ["Furthermore, before PFE testing, the samples have been preconditioned at a relative humidity in the range of 30-50% at 21 \u00b1 3\u00b0C. [37] The particulate filtering efficiency follows equation (2):Particulate Filtration Efficiency (PFE)Where C u and C d are the averages of upstream and the downstream counts, the PFE results are between 1 to 99.99%.", [["samples", "ANATOMY", 37, 44], ["PFE testing", "TEST", 20, 31], ["a relative humidity", "TEST", 73, 92], ["Particulate Filtration Efficiency", "PROBLEM", 192, 225], ["the downstream counts", "TEST", 282, 303], ["the PFE", "TEST", 305, 312]]], ["The higher the percentage represents better mask filtration.", [["better mask filtration", "TREATMENT", 37, 59], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["percentage", "OBSERVATION_MODIFIER", 15, 25], ["better", "OBSERVATION_MODIFIER", 37, 43], ["mask filtration", "OBSERVATION", 44, 59]]], ["For the PFE test, the used particle size can be in the size of 0.1 to 5.0 microns range.", [["the PFE test", "TEST", 4, 16], ["size", "OBSERVATION_MODIFIER", 36, 40], ["size", "OBSERVATION_MODIFIER", 55, 59]]], ["The size of the used particle (e.g. 0.6 to 1.0 \u00b5) must be considered while the test results are being compared since the use of the particle with a larger size cause a misleading PFE assessment.", [["the test", "TEST", 75, 83], ["a misleading PFE assessment", "TEST", 166, 193], ["size", "OBSERVATION_MODIFIER", 4, 8], ["particle", "OBSERVATION_MODIFIER", 21, 29], ["larger", "OBSERVATION_MODIFIER", 148, 154], ["size", "OBSERVATION_MODIFIER", 155, 159]]], ["[38] The minimum value of filtering efficiency for mask using non-oily (NaCl) particles is 30%.Particulate Filtration Efficiency (PFE)[39]Bacterial Filtration Efficiency (BFE)The BFE method is conducted according to the ASTM F2101 protocol that requires aqueous bacterial aerosol droplets (with the diameter size of 3 microns), [40] and measures the capability of the masks to stop the large particles from coughing, speech, and sneezing, with the size distribution from 0.6 microns up to thousands of microns expelling by the mask's wearer.", [["NaCl", "CHEMICAL", 72, 76], ["coughing", "DISEASE", 407, 415], ["NaCl", "CHEMICAL", 72, 76], ["mask", "TREATMENT", 51, 55], ["non-oily (NaCl) particles", "TREATMENT", 62, 87], ["Particulate Filtration Efficiency", "PROBLEM", 95, 128], ["Bacterial Filtration Efficiency (BFE)", "TREATMENT", 138, 175], ["the ASTM F2101 protocol", "TREATMENT", 216, 239], ["aqueous bacterial aerosol droplets", "TREATMENT", 254, 288], ["the diameter size", "TREATMENT", 295, 312], ["coughing", "PROBLEM", 407, 415], ["sneezing", "PROBLEM", 429, 437], ["Filtration Efficiency", "OBSERVATION", 107, 128], ["aerosol droplets", "OBSERVATION", 272, 288], ["large", "OBSERVATION_MODIFIER", 386, 391], ["particles", "OBSERVATION", 392, 401], ["coughing", "OBSERVATION", 407, 415], ["sneezing", "OBSERVATION", 429, 437], ["size", "OBSERVATION_MODIFIER", 448, 452]]], ["[41] , [42] , [43] This method cannot be used to assess the filtration efficiency of the respirators, and it is not suitable to estimate the ability of the masks to protect the wearer from the external contaminants.", [["[42]", "SIMPLE_CHEMICAL", 7, 11], ["This method", "TREATMENT", 19, 30], ["the masks", "TREATMENT", 152, 161]]], ["[29] , [44] According to the ASTM F2101, the mask material sample is clamped between a six-stage cascade impactor and an aerosol chamber.", [["the mask material sample", "TREATMENT", 41, 65], ["a six-stage cascade impactor", "TREATMENT", 85, 113], ["an aerosol chamber", "TREATMENT", 118, 136], ["aerosol chamber", "OBSERVATION", 121, 136]]], ["The staphylococcus aureus aerosol is introduced into the chamber and drawn through the mask material utilizing a vacuum, which is attached to the cascade impactor.", [["staphylococcus aureus", "ORGANISM", 4, 25], ["staphylococcus aureus", "SPECIES", 4, 25], ["staphylococcus aureus", "SPECIES", 4, 25], ["The staphylococcus aureus aerosol", "TREATMENT", 0, 33], ["the mask material", "TREATMENT", 83, 100], ["a vacuum", "TREATMENT", 111, 119], ["the cascade impactor", "TREATMENT", 142, 162], ["staphylococcus", "OBSERVATION_MODIFIER", 4, 18], ["aureus aerosol", "OBSERVATION", 19, 33], ["chamber", "OBSERVATION_MODIFIER", 57, 64], ["vacuum", "OBSERVATION", 113, 119], ["cascade impactor", "OBSERVATION", 146, 162]]], ["[40] Before fixing the test sample, the air flow rate is adjusted at 28 L/min.", [["the test sample", "TEST", 19, 34], ["the air flow rate", "TEST", 36, 53], ["air flow", "OBSERVATION", 40, 48]]], ["The bacteria suspension is conducted to the nebulizer for 1 min, and the air pressure and cascade impactor run through the sampler for 2 minutes.", [["The bacteria suspension", "TREATMENT", 0, 23], ["the nebulizer", "TREATMENT", 40, 53], ["the air pressure", "TEST", 69, 85], ["cascade impactor", "TREATMENT", 90, 106], ["bacteria suspension", "OBSERVATION", 4, 23], ["air pressure", "OBSERVATION", 73, 85]]], ["The concentration of the bacteria suspension needs to be controlled; however, it can be maintained at (2200 \u00b1 500) CFU per test, to avoid any adjustment during the test.", [["the bacteria suspension", "TREATMENT", 21, 44], ["the test", "TEST", 160, 168], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["bacteria suspension", "OBSERVATION", 25, 44]]], ["[39] , [40] The measured mean value of the bacteria aerosol diameter should be in the range of 3.0\u00b10.3 \u03bcm, and the geometric standard deviation should not exceed the value of 1.5.", [["The measured mean value", "TEST", 12, 35], ["the bacteria aerosol diameter", "TEST", 39, 68], ["bacteria", "OBSERVATION_MODIFIER", 43, 51], ["aerosol diameter", "OBSERVATION", 52, 68]]], ["[39] Fig. 4 displays the instrument of BFE test.", [["the instrument of BFE test", "TEST", 21, 47]]], ["[40] Fig. 4 . graphical representation of the BFE test instrument.", [["the BFE test instrument", "TEST", 42, 65]]], ["[40] The bacterial filtering efficiency of masks is given by equation 3:Bacterial Filtration Efficiency (BFE)Where presents the average colony-forming units (the bacteria-containing aerosol) without the test filter, and CFU is the average of colony-forming units with the test filters.", [["colony", "ANATOMY", 136, 142], ["colony", "ANATOMY", 242, 248], ["The bacterial filtering efficiency of masks", "TREATMENT", 5, 48], ["Bacterial Filtration Efficiency", "PROBLEM", 72, 103], ["the bacteria-containing aerosol", "TREATMENT", 158, 189], ["the test filter", "TREATMENT", 199, 214], ["the test filters", "TREATMENT", 268, 284], ["Filtration Efficiency", "OBSERVATION", 82, 103]]], ["The number of the particle units per each test is CFU specified through the ASTM F2101 protocol.", [["the ASTM F2101 protocol", "TREATMENT", 72, 95]]], ["The BFE value varies between 1 to 99.9% depending upon the calculation's methods and the test parameters.", [["The BFE value", "TEST", 0, 13], ["the calculation's methods", "TEST", 55, 80], ["the test parameters", "TEST", 85, 104]]], ["[29] Furthermore, for a device, it is named a surgical or medical mask, if the minimum value of BFE rate is 95%.", [["a device", "TREATMENT", 22, 30], ["a surgical or medical mask", "TREATMENT", 44, 70], ["BFE rate", "TEST", 96, 104]]], ["Also, the high protection and medium protection masks shall provide a minimum BFE rate of 98% and more than 99%.Bacterial Filtration Efficiency (BFE)[44]Viral Filtration Efficiency (VFE)The virions, as one of the smallest bioaerosol particles with a size diameter of 20-300 nm, can simply enter through the respiratory organ and result in various epidemic infections.", [["respiratory organ", "ANATOMY", 307, 324], ["infections", "DISEASE", 356, 366], ["organ", "ORGAN", 319, 324], ["the high protection", "TREATMENT", 6, 25], ["medium protection masks", "TREATMENT", 30, 53], ["a minimum BFE rate", "TEST", 68, 86], ["Bacterial Filtration Efficiency (BFE)", "PROBLEM", 112, 149], ["Viral Filtration Efficiency (VFE)", "TREATMENT", 153, 186], ["The virions", "TREATMENT", 186, 197], ["various epidemic infections", "PROBLEM", 339, 366], ["high", "OBSERVATION_MODIFIER", 10, 14], ["Filtration Efficiency", "OBSERVATION", 122, 143], ["smallest", "OBSERVATION_MODIFIER", 213, 221], ["bioaerosol particles", "OBSERVATION", 222, 242], ["size", "OBSERVATION_MODIFIER", 250, 254], ["diameter", "OBSERVATION_MODIFIER", 255, 263], ["respiratory organ", "ANATOMY", 307, 324], ["various", "OBSERVATION_MODIFIER", 339, 346], ["epidemic", "OBSERVATION_MODIFIER", 347, 355], ["infections", "OBSERVATION", 356, 366]]], ["The masks and respirators as protection equipment shall be tested in terms of virus filtration ability.", [["The masks", "TREATMENT", 0, 9], ["respirators", "TREATMENT", 14, 25], ["protection equipment", "TREATMENT", 29, 49], ["virus filtration", "TREATMENT", 78, 94]]], ["[45] The viral filtration efficiency (VFE) is one of the efficient methods, which has not been documented as a standard test protocol but has been modified by Nelson Laboratories [46] according to the ASTM F2101 protocol.", [["The viral filtration efficiency", "PROBLEM", 5, 36], ["a standard test protocol", "TEST", 109, 133], ["viral", "OBSERVATION", 9, 14], ["filtration efficiency", "OBSERVATION", 15, 36]]], ["The resistance of the PPE equipment against the virus's penetration can be determined through the viral penetration testing, which is a kind of pass and fail test, and shall be conducted based on the ASTM F1671 [47] , AAMI PB70, which was confirmed by the FDA in 2004.", [["PPE", "ORGANISM", 22, 25], ["the PPE equipment", "TREATMENT", 18, 35], ["the virus's penetration", "PROBLEM", 44, 67], ["the viral penetration testing", "TEST", 94, 123], ["the ASTM F1671", "TEST", 196, 210], ["AAMI PB70", "TEST", 218, 227], ["resistance", "OBSERVATION_MODIFIER", 4, 14]]], ["The ANSI/AAMI PB70 and ASTM F1671 standard provide a classification protocol for PPEs such as isolation gowns, and surgical gowns utilize used in the health services, depending upon their liquid resistance ability This standard also specifies the test procedures for estimating the compliance of the PPEs with liquid barrier claims or liquid-borne microbial barrier claims.", [["The ANSI", "TEST", 0, 8], ["a classification protocol", "TEST", 51, 76], ["PPEs", "TREATMENT", 81, 85], ["isolation gowns", "TREATMENT", 94, 109], ["surgical gowns", "TREATMENT", 115, 129], ["the test procedures", "TEST", 243, 262], ["the PPEs", "TREATMENT", 296, 304], ["liquid barrier claims", "TREATMENT", 310, 331]]], ["[48] , [49] In addition to the VFE test requirement for the PPE manufacturers, this test has also been applied by the textile producers to guarantee the quality of the used materials for PPEs.", [["PPEs", "SIMPLE_CHEMICAL", 187, 191], ["the VFE test requirement", "TEST", 27, 51], ["the PPE manufacturers", "TREATMENT", 56, 77], ["this test", "TEST", 79, 88], ["PPEs", "TREATMENT", 187, 191]]], ["[46] The virus filtration efficiency test can be performed through the aerosol filtration test device, which is shown in Fig. 5 .", [["virus", "ORGANISM", 9, 14], ["The virus filtration efficiency test", "TEST", 5, 41], ["the aerosol filtration test device", "TREATMENT", 67, 101]]], ["[20] The test set up is assembled at Microbac per modified ASTM F2101-14 [50] and has been utilized to test the filtering ability of various masks against the penetration of influenza and rhinovirus so far.", [["influenza", "DISEASE", 174, 183], ["Microbac", "SIMPLE_CHEMICAL", 37, 45], ["rhinovirus", "ORGANISM", 188, 198], ["The test", "TEST", 5, 13], ["various masks", "TREATMENT", 133, 146], ["influenza", "PROBLEM", 174, 183], ["rhinovirus", "PROBLEM", 188, 198], ["influenza", "OBSERVATION", 174, 183]]], ["The samples are located between two chambers (upstream and downstream).", [["samples", "ANATOMY", 4, 11], ["upstream and downstream", "DNA", 46, 69], ["The samples", "TEST", 0, 11], ["chambers", "OBSERVATION_MODIFIER", 36, 44]]], ["The schematic illustration of the viral filtration test set up.", [["the viral filtration test", "TEST", 30, 55]]], ["[20] During the viral penetration test, the concentration of the segments should be considered both inside and outside of the samples (such as face respirators or the masks).", [["samples", "ANATOMY", 126, 133], ["the viral penetration test", "TEST", 12, 38]]], ["The penetration value is presented as the fraction of the particles in a certain diameter, which can penetrate and pass from the barrier.", [["barrier", "TISSUE", 129, 136], ["The penetration value", "TEST", 0, 21], ["particles", "OBSERVATION_MODIFIER", 58, 67], ["certain diameter", "OBSERVATION_MODIFIER", 73, 89]]], ["[45] The filtration ability of personal protective devices can be described through different calculation terms such as in equations (1), (2) , and (3), which has been shown in the previous sections, or it can be defined by the term \"assigned protection factor (APF)\" [51] which is given by equation (4) as follows: ( 4) Where the C u and C d follows a similar definition as previous equations, the APF value describes the capability of the masks and the respirators to decrease exposure determined under the conditions, which can replicate the workplace conditions most.", [["sections", "ANATOMY", 190, 198], ["The filtration", "TREATMENT", 5, 19], ["personal protective devices", "TREATMENT", 31, 58]]], ["[52] equation (5) shows the relationship between the filtration efficiency percentage and the APF as follows:Viral Filtration Efficiency (VFE)The face masks and respirator performance can also be determined through equation (6), which defines the penetration efficiency (PE) of the devices as follows:Viral Filtration Efficiency (VFE)Furthermore, the penetration of a PPE device can be calculated through equation (7) as follows:Viral Filtration Efficiency (VFE)In which, C1, C2, present the aerosol concentration in front of the filter, behind the filter, respectively, and C0 stands for the aerosol concentration photometer reading for clean air.", [["the filtration efficiency percentage", "PROBLEM", 49, 85], ["Viral Filtration Efficiency", "TREATMENT", 109, 136], ["The face masks", "TREATMENT", 142, 156], ["respirator performance", "TREATMENT", 161, 183], ["the penetration efficiency", "PROBLEM", 243, 269], ["PE", "PROBLEM", 271, 273], ["the devices", "TREATMENT", 278, 289], ["Viral Filtration Efficiency", "PROBLEM", 301, 328], ["a PPE device", "TREATMENT", 366, 378], ["Viral Filtration Efficiency (VFE)In which, C1, C2", "PROBLEM", 429, 478], ["the aerosol concentration", "TREATMENT", 488, 513], ["the filter", "TREATMENT", 526, 536], ["the filter", "TREATMENT", 545, 555], ["the aerosol concentration photometer", "TREATMENT", 589, 625], ["filtration efficiency", "OBSERVATION", 53, 74], ["penetration efficiency", "OBSERVATION", 247, 269], ["PE", "OBSERVATION", 271, 273], ["C1", "ANATOMY", 472, 474], ["C2", "ANATOMY", 476, 478], ["aerosol concentration", "OBSERVATION", 492, 513], ["filter", "OBSERVATION", 530, 536], ["filter", "OBSERVATION", 549, 555], ["clean air", "OBSERVATION", 638, 647]]], ["[53] C Raina MacIntyre et al. [54] studied the viral infections among the workers in hazardous places such as in a hospital.", [["viral infections", "DISEASE", 47, 63], ["the viral infections", "PROBLEM", 43, 63], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["infections", "OBSERVATION", 53, 63]]], ["They summarized the efficiency of different masks ( such as cloth masks and medical masks, etc., ), which indicated that the medical masks are more efficient than the cloth masks since the penetration efficiency for cloth masks (97%) was much higher than that of medical masks(44%).Viral Filtration Efficiency (VFE)The particle concentrations and the size distributions of the tested samples can be estimated by exploiting the widerange particle spectrometer (WPS), which is the combination of three various instruments, called the differential mobility diameter (DMA), the laser particle spectrometer (LPS), and the condensation particle counter (CPC).", [["samples", "ANATOMY", 384, 391], ["DMA", "CHEMICAL", 564, 567], ["different masks", "TREATMENT", 34, 49], ["cloth masks", "TREATMENT", 60, 71], ["medical masks", "TREATMENT", 76, 89], ["the medical masks", "TREATMENT", 121, 138], ["the cloth masks", "TREATMENT", 163, 178], ["the penetration efficiency", "PROBLEM", 185, 211], ["cloth masks", "TREATMENT", 216, 227], ["medical masks", "TREATMENT", 263, 276], ["Viral Filtration Efficiency (VFE)", "TREATMENT", 282, 315], ["The particle concentrations", "TREATMENT", 315, 342], ["the tested samples", "TEST", 373, 391], ["the laser particle spectrometer (LPS)", "TREATMENT", 570, 607], ["the condensation particle counter (CPC", "TREATMENT", 613, 651], ["Filtration Efficiency", "OBSERVATION", 288, 309], ["particle", "OBSERVATION_MODIFIER", 319, 327], ["concentrations", "OBSERVATION_MODIFIER", 328, 342], ["size", "OBSERVATION_MODIFIER", 351, 355], ["differential", "OBSERVATION_MODIFIER", 532, 544], ["mobility", "OBSERVATION_MODIFIER", 545, 553], ["diameter", "OBSERVATION_MODIFIER", 554, 562]]], ["The presence of DMA and CPC provides the ability to count the particles with a diameter of 10-500 nm, while the LPS allows the particles of 350-10000 nm.", [["DMA", "CHEMICAL", 16, 19], ["CPC", "CHEMICAL", 24, 27], ["LPS", "CHEMICAL", 112, 115], ["DMA", "CHEMICAL", 16, 19], ["DMA", "SIMPLE_CHEMICAL", 16, 19], ["LPS", "SIMPLE_CHEMICAL", 112, 115], ["DMA", "PROBLEM", 16, 19], ["CPC", "TREATMENT", 24, 27], ["the LPS", "TEST", 108, 115], ["DMA", "OBSERVATION", 16, 19]]], ["The DMA technique is the most effective method for assessing the aerosol particle size distribution with the size in the nanometer range, such as MS 2 virions [45] , SARS-CoV-2 [55] , COVID-19 [56] .", [["DMA", "CHEMICAL", 4, 7], ["DMA", "CHEMICAL", 4, 7], ["DMA", "SIMPLE_CHEMICAL", 4, 7], ["The DMA technique", "TREATMENT", 0, 17], ["MS 2 virions", "TEST", 146, 158], ["SARS-CoV", "TEST", 166, 174], ["COVID", "TEST", 184, 189], ["size", "OBSERVATION_MODIFIER", 82, 86], ["size", "OBSERVATION_MODIFIER", 109, 113]]], ["Besides, based on the WPS manufacturer, fractional concentration of the particles can be calculated between 1 particle/cm 3 to 10,000 particles/cm 3 .[57]NIOSH NaCl methodThe face masks which are intended as respirator precertification might need valve leak DOP, NaCl, and inhalation/exhalation tests to fulfil the NIOSH standards.", [["valve", "ANATOMY", 247, 252], ["NaCl", "CHEMICAL", 160, 164], ["DOP", "CHEMICAL", 258, 261], ["NaCl", "CHEMICAL", 263, 267], ["NaCl", "CHEMICAL", 160, 164], ["DOP", "CHEMICAL", 258, 261], ["NaCl", "CHEMICAL", 263, 267], ["the WPS manufacturer", "TREATMENT", 18, 38], ["fractional concentration of the particles", "TREATMENT", 40, 81], ["The face masks", "TREATMENT", 171, 185], ["respirator precertification", "TREATMENT", 208, 235], ["valve leak DOP", "TREATMENT", 247, 261], ["NaCl", "TREATMENT", 263, 267], ["inhalation/exhalation tests", "TEST", 273, 300]]], ["[58] The sodium chloride (NaCl) aerosol-based method is one of the most common testing methods for the face respirators meeting the requirements of the NIOSH protocol.", [["sodium chloride", "CHEMICAL", 9, 24], ["NaCl", "CHEMICAL", 26, 30], ["sodium chloride", "CHEMICAL", 9, 24], ["NaCl", "CHEMICAL", 26, 30], ["sodium chloride", "SIMPLE_CHEMICAL", 9, 24], ["NaCl", "SIMPLE_CHEMICAL", 26, 30], ["The sodium chloride (NaCl) aerosol", "TREATMENT", 5, 39], ["the face respirators", "TREATMENT", 99, 119], ["the NIOSH protocol", "TREATMENT", 148, 166]]], ["[59] ,[60] There are various conditions and requirements for NaCl aerosol-based test set up, including a) Nontoxic polydisperse, uncharged aerosol particles (NaCl) which are used as the particle generator and provide the particles range sizes between 10 nm to 10 \u03bcm,( the average diameter of 300 nm) [45] .b) the generation, mixing, and collection chambers, where the introduced aerosol mixed and passed through the mixing chamber in contact with the test specimen, and along with an air inlet, c) an airflow rate about 28 lpm (litres per minute), which is held on a tube linking the two chambers.", [["specimen", "ANATOMY", 456, 464], ["NaCl", "CHEMICAL", 61, 65], ["NaCl", "CHEMICAL", 158, 162], ["NaCl", "CHEMICAL", 61, 65], ["NaCl", "CHEMICAL", 158, 162], ["tube", "TISSUE", 567, 571], ["NaCl aerosol", "TREATMENT", 61, 73], ["a) Nontoxic polydisperse", "TREATMENT", 103, 127], ["uncharged aerosol particles (NaCl)", "TREATMENT", 129, 163], ["the particle generator", "TREATMENT", 182, 204], ["collection chambers", "TREATMENT", 337, 356], ["the test specimen", "TEST", 447, 464], ["an air inlet", "TREATMENT", 481, 493], ["an airflow rate", "TEST", 498, 513], ["a tube", "TREATMENT", 565, 571], ["air inlet", "OBSERVATION", 484, 493], ["tube", "OBSERVATION", 567, 571]]], ["Where, the C u value, and the C d term, present aerosol, which is sampled before and after passing (upstream and downstream) through the specimen. (the), respectively.", [["the C u value", "TEST", 7, 20], ["the C d term", "TREATMENT", 26, 38], ["present aerosol", "TREATMENT", 40, 55]]], ["Schematic illustration of filtering set up [27] For instance, P2 or N95 face pieces, as one of the most common respirators can be certified through this method according to the NIOSH 42 CFR 84 protocol.", [["N95 face pieces", "TREATMENT", 68, 83]]], ["[30] The particulate respirators such as N95 protect the wearer only against the particles (not vapours or gases).", [["N95", "SIMPLE_CHEMICAL", 41, 44], ["The particulate respirators", "TREATMENT", 5, 32]]], ["Therefore, the airborne biological agents (e.g. bacteria or viruses) as particles, can be filtered using the disposable N95 face masks.", [["the airborne biological agents", "TREATMENT", 11, 41], ["bacteria", "PROBLEM", 48, 56], ["viruses", "PROBLEM", 60, 67], ["the disposable N95 face masks", "TREATMENT", 105, 134]]], ["Generally, the \"p\" term in the classification of the disposable high particulate is attributed to the size of the particle, which the face mask is intended to protect the wearer against that.", [["the face mask", "TREATMENT", 130, 143], ["size", "OBSERVATION_MODIFIER", 102, 106]]], ["The classified particulate filters are labelled as P1 (low-efficiency filters), P2 (medium efficiency filters) or P3 (high-efficiency filters).", [["The classified particulate filters", "TREATMENT", 0, 34], ["P1 (low-efficiency filters", "TREATMENT", 51, 77], ["P2 (medium efficiency filters", "TREATMENT", 80, 109], ["P3", "PROBLEM", 114, 116], ["high-efficiency filters", "TREATMENT", 118, 141], ["particulate filters", "OBSERVATION", 15, 34], ["efficiency filters", "OBSERVATION", 123, 141]]], ["[61] N95 respirators/masks and P2 respirators/masks are the same, and they are being applied to the similar conditions, however, there are slight differences in their testing and the certification performance between USA and Australia, which are shown in Table 3 .", [["masks", "TREATMENT", 21, 26], ["P2 respirators", "TREATMENT", 31, 45], ["masks", "TREATMENT", 46, 51], ["their testing", "TEST", 161, 174], ["slight", "OBSERVATION_MODIFIER", 139, 145], ["differences", "OBSERVATION_MODIFIER", 146, 157]]], ["[61] The surgical masks cannot be certified through the NIOSH protocol.", [["The surgical masks", "TREATMENT", 5, 23], ["surgical masks", "OBSERVATION", 9, 23]]], ["It has been reported that the penetration of the aerosol particles by N95 filtering devices cannot be greater than 5%, therefore according to equation (6) and (7), FE(%) shall be at least 95%.", [["N95", "SIMPLE_CHEMICAL", 70, 73], ["the aerosol particles", "TREATMENT", 45, 66], ["N95 filtering devices", "TREATMENT", 70, 91], ["FE", "TEST", 164, 166]]], ["[45] S. Rengasamy [13] have compared the filtration efficiency of three models of surgical N95 FFRs, three models of SMs, and six models of NIOSH-approved non-FDA cleared N95 FFRs.Fluid ResistanceThis test assesses the ability of the masks and respirators to lessen the squirted synthetic blood or any splashed or sprayed fluid that can penetrate the outer layer of the mask and transfer through the inner part by changing the pressure.", [["blood", "ANATOMY", 289, 294], ["fluid", "ANATOMY", 322, 327], ["outer layer", "ANATOMY", 351, 362], ["inner part", "ANATOMY", 400, 410], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["inner part", "MULTI-TISSUE_STRUCTURE", 400, 410], ["Fluid Resistance", "TEST", 180, 196], ["This test", "TEST", 196, 205], ["the masks", "TREATMENT", 230, 239], ["respirators", "TREATMENT", 244, 255], ["the squirted synthetic blood", "PROBLEM", 266, 294], ["any splashed or sprayed fluid", "PROBLEM", 298, 327], ["the mask", "TREATMENT", 366, 374], ["the pressure", "TEST", 423, 435], ["Resistance", "OBSERVATION_MODIFIER", 186, 196], ["outer", "OBSERVATION_MODIFIER", 351, 356], ["layer", "OBSERVATION_MODIFIER", 357, 362], ["pressure", "OBSERVATION_MODIFIER", 427, 435]]], ["The fluid resistance of the surgical masks and the surgical N95 is regulated according to the ASTM test technique F1862, \"resistance to penetration by synthetic blood,\" [62] , which is also utilized to measure the respirators' fluid resistance.", [["fluid", "ANATOMY", 4, 9], ["blood", "ANATOMY", 161, 166], ["F1862", "CHEMICAL", 114, 119], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["fluid", "ORGANISM_SUBSTANCE", 227, 232], ["N95", "DNA", 60, 63], ["the surgical masks", "TREATMENT", 24, 42], ["the surgical N95", "TREATMENT", 47, 63], ["the ASTM test technique", "TEST", 90, 113], ["fluid resistance", "OBSERVATION", 4, 20], ["surgical masks", "OBSERVATION", 28, 42], ["fluid resistance", "OBSERVATION", 227, 243]]], ["[63] According to the ASTM F 1862 protocol, the penetration resistance ability of the medical face mask is estimated using the high-velocity synthetic blood, which is in contact with the surface of the test sample (including a fixed volume in a specific time between 0 s to 2.5 s).", [["blood", "ANATOMY", 151, 156], ["surface", "ANATOMY", 187, 194], ["sample", "ANATOMY", 207, 213], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["surface", "CELLULAR_COMPONENT", 187, 194], ["the medical face mask", "TREATMENT", 82, 103], ["the high-velocity synthetic blood", "PROBLEM", 123, 156], ["the test sample", "TEST", 198, 213], ["a fixed volume", "TEST", 225, 239]]], ["[64] Several factors have a strong effect on the penetration and the wetting of the body fluids including, polarity, viscosity, and the surface tension, the structure, and the relative hydrophobicity or hydrophilicity of the face mask material.", [["body", "ANATOMY", 84, 88], ["surface", "ANATOMY", 136, 143], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["the penetration", "PROBLEM", 45, 60], ["the body fluids", "TREATMENT", 80, 95], ["the surface tension", "PROBLEM", 132, 151], ["the relative hydrophobicity", "PROBLEM", 172, 199], ["hydrophilicity of the face mask material", "PROBLEM", 203, 243], ["strong effect", "OBSERVATION_MODIFIER", 28, 41], ["surface tension", "OBSERVATION", 136, 151], ["hydrophobicity", "OBSERVATION_MODIFIER", 185, 199], ["hydrophilicity", "OBSERVATION_MODIFIER", 203, 217], ["face", "ANATOMY", 225, 229]]], ["[64] The wetting characteristic of the blood can be simulated through adjusting the surface tension of synthetic blood, which should be lower than the surface tension range for body fluids, blood and also excluding saliva that is approximately between approximately 0,042 Nm -1 to 0,060 Nm -1 .", [["blood", "ANATOMY", 39, 44], ["surface", "ANATOMY", 84, 91], ["blood", "ANATOMY", 113, 118], ["surface", "ANATOMY", 151, 158], ["body fluids", "ANATOMY", 177, 188], ["blood", "ANATOMY", 190, 195], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["body fluids", "ORGANISM_SUBSTANCE", 177, 188], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["saliva", "ORGANISM_SUBSTANCE", 215, 221], ["synthetic blood", "PROBLEM", 103, 118], ["body fluids", "TEST", 177, 188], ["saliva", "PROBLEM", 215, 221], ["synthetic blood", "OBSERVATION", 103, 118]]], ["[65] The surface tension for synthetic blood is in the range of 0,042 \u00b1 0,002 Nm -1 .", [["surface", "ANATOMY", 9, 16], ["blood", "ANATOMY", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["The surface tension", "TEST", 5, 24], ["synthetic blood", "TEST", 29, 44]]], ["[64] Fig. 7 displays the complete apparatus of the fluid resistance test, where the face mask sample is placed in the device by means of specimen-holding fixture and the synthetic blood is splashed on at the specific area of the face mask sample.Flame ResistanceThe hospitals contain different sources of the heat, oxygen, and fuel, the ASTM F2100-11 standards requires a test regarding the flame resistance for all the medical masks.", [["fluid", "ANATOMY", 51, 56], ["face mask sample", "ANATOMY", 84, 100], ["blood", "ANATOMY", 180, 185], ["face", "ANATOMY", 229, 233], ["oxygen", "CHEMICAL", 315, 321], ["oxygen", "CHEMICAL", 315, 321], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["oxygen", "SIMPLE_CHEMICAL", 315, 321], ["the fluid resistance test", "TEST", 47, 72], ["the face mask sample", "TREATMENT", 80, 100], ["specimen-holding fixture", "TREATMENT", 137, 161], ["the synthetic blood", "TEST", 166, 185], ["Flame Resistance", "TEST", 246, 262], ["oxygen", "TREATMENT", 315, 321], ["the ASTM F2100", "TEST", 333, 347], ["a test", "TEST", 370, 376], ["the flame resistance", "TREATMENT", 387, 407], ["fluid resistance", "OBSERVATION", 51, 67], ["face", "ANATOMY", 229, 233]]], ["The used material for masks and respirators should not present any hazards for the users, and their flammability shall not be high.", [["masks", "TREATMENT", 22, 27], ["respirators", "TREATMENT", 32, 43]]], ["The flammability factor is determined based on the 16 CFR part 1610 for clothing textiles.", [["flammability factor", "PROTEIN", 4, 23], ["The flammability factor", "TEST", 0, 23], ["clothing textiles", "TREATMENT", 72, 89]]], ["[66] During the flammability test, the mask's material should not be flamed or remain flamed after five seconds from burning.", [["the flammability test", "TEST", 12, 33], ["the mask's material", "TREATMENT", 35, 54], ["burning", "PROBLEM", 117, 124]]], ["The flame spread test calculates the required time for the flame to reach the mask material in 5 inches distance (127 mm).", [["The flame spread test", "TEST", 0, 21], ["the flame", "TREATMENT", 55, 64]]], ["\"Class 1\" represents the category of the material, which shows normal flame resistance, and they are suitable for the use in face masks and respirators.", [["normal", "OBSERVATION", 63, 69], ["flame resistance", "OBSERVATION", 70, 86]]], ["The tested material cannot be utilized after the flame resistance test.", [["the flame resistance test", "TEST", 45, 70]]], ["[67]Differential Pressure (Delta-P)The differential pressure test is an indicator of airflow resistance of the masks as well as their comfort and breathability.", [["Differential Pressure", "TEST", 4, 25], ["The differential pressure test", "TEST", 35, 65], ["the masks", "TREATMENT", 107, 116], ["airflow resistance", "OBSERVATION", 85, 103]]], ["[68] During this test, airflow passes through the mask in a controlled manner, and the various pressures are calculated for the inner and outer layers of the mask.", [["inner", "ANATOMY", 128, 133], ["outer layers", "ANATOMY", 138, 150], ["inner", "TISSUE", 128, 133], ["outer layers", "TISSUE", 138, 150], ["this test", "TEST", 12, 21], ["the mask", "TREATMENT", 46, 54], ["the various pressures", "TEST", 83, 104], ["the inner and outer layers of the mask", "TREATMENT", 124, 162], ["various", "OBSERVATION_MODIFIER", 87, 94], ["pressures", "OBSERVATION_MODIFIER", 95, 104], ["outer", "OBSERVATION_MODIFIER", 138, 143], ["layers", "OBSERVATION_MODIFIER", 144, 150]]], ["The differential value is divided by the surface area (cm 2 ) of the mask to estimate the breathability, where the higher Delta P values indicated a harder breath for the users. \u25b3P can be measured through equation (8), where P M represents the mean value of the differential pressure of the test sample, in Pa.", [["surface area", "ANATOMY", 41, 53], ["Delta P", "PROTEIN", 122, 129], ["P", "DNA", 179, 180], ["The differential value", "TEST", 0, 22], ["the mask", "TREATMENT", 65, 73], ["the test sample", "TEST", 287, 302], ["surface", "OBSERVATION_MODIFIER", 41, 48]]], ["[39] (8)Differential Pressure (Delta-P)According to the ASTM F2100-11 protocol, the minimum value for Delta P should be less than 5.0 mm H 2 O/cm 2 (or should not be greater than 49 Pa).", [["Delta P", "PROTEIN", 102, 109], ["Differential Pressure", "TEST", 8, 29], ["the ASTM F2100", "TEST", 52, 66], ["Delta P", "TEST", 102, 109]]], ["The Delta P values less than 0.2 or more than 0.5 are not considered as standard values for the general surgical application.", [["The Delta P values", "TEST", 0, 18], ["the general surgical application", "TREATMENT", 92, 124], ["Delta", "OBSERVATION_MODIFIER", 4, 9], ["surgical", "OBSERVATION", 104, 112]]], ["[69] The standard requirements (ASTM F2100-11) for the performance of materials utilized in face masks are summarized in Table 6 .", [["The standard requirements (ASTM F2100", "TEST", 5, 42], ["the performance of materials", "TREATMENT", 51, 79]]], ["[33]Facepiece Fit TestingThe masks and respirator devices are worn by the wearer in high hazard environments.", [["Facepiece Fit", "TREATMENT", 4, 17], ["The masks", "TREATMENT", 25, 34], ["respirator devices", "TREATMENT", 39, 57]]], ["Thus, to increase the effectiveness of the devices, the wearers shall know how to use the devices correctly.", [["the devices", "TREATMENT", 39, 50], ["the devices", "TREATMENT", 86, 97]]], ["The fit test aims to check and avoid any leakage existence before using the masks or respirators.", [["The fit test", "TEST", 0, 12], ["any leakage existence", "PROBLEM", 37, 58], ["the masks", "TREATMENT", 72, 81], ["leakage", "OBSERVATION", 41, 48]]], ["[70] The purpose of fit testing is to provide a perfect fit and appropriate seal for all tight facemasks and respirator facepieces, which can be done through two main methods.", [["fit testing", "TEST", 20, 31], ["appropriate seal", "TREATMENT", 64, 80], ["all tight facemasks", "TREATMENT", 85, 104], ["respirator facepieces", "TREATMENT", 109, 130]]], ["The quantitative fit test, as astringent pass/fail test, is an effective method for full-face and half-face respirators that includes a laboratory test chamber or transferrable fit testing set up, which is utilized to measure the fit factor (FF) of the PPE.", [["The quantitative fit test", "TEST", 0, 25], ["astringent pass/fail test", "TEST", 30, 55], ["a laboratory test chamber", "TEST", 134, 159], ["transferrable fit testing", "TEST", 163, 188]]], ["[52] In the basis of the control of substances hazardous to health (COSHH) [72] protocols, there are different conditions in which the fit testing shall be repeated.", [["the fit testing", "TEST", 131, 146]]], ["These conditions are including a) the wearer has gained or lost weight, b) the wearer has experienced any dental work, c) the wearer has faced any imperfections such as scars, moles, etc., on his face, d) the wearer has changed the respiratory protective equipment (RPE) type, model, size, or material.", [["scars", "ANATOMY", 169, 174], ["respiratory", "ANATOMY", 232, 243], ["RPE", "ANATOMY", 266, 269], ["scars", "PATHOLOGICAL_FORMATION", 169, 174], ["RPE", "TISSUE", 266, 269], ["scars, moles", "PROBLEM", 169, 181], ["the respiratory protective equipment", "TREATMENT", 228, 264], ["scars", "OBSERVATION", 169, 174], ["size", "OBSERVATION_MODIFIER", 284, 288]]], ["Fig. 8 illustrates how to put on the FFP3 respirators through five steps [73] , and Fig. 9 shows how to perform the fit check.Facepiece Fit Testing[73]Fit Testing TechniquesFacepieces fitting depends on its design features including (a) \"negative pressure\" or \"positive pressure\" method, which the respirator is functioning in, (b) The facepiece form and its ability to cover the face.", [["the FFP3 respirators", "TREATMENT", 33, 53], ["the fit check", "TEST", 112, 125], ["Facepiece Fit Testing", "TEST", 126, 147], ["The facepiece form", "TREATMENT", 332, 350], ["face", "ANATOMY", 380, 384]]], ["In this case, for the respirators which operate in the \"negative pressure\" mode, the wearer should draw the air through a filter or chemical container into the facepiece, which makes a negative pressure inside the respirator compared to the pressure outside the facepiece, while the \"positive pressure\" respirator, pushes clean air into the facepiece by using a compressor or a fan, which produces a positive pressure inside the facepiece in comparison with the outside.", [["facepiece", "ANATOMY", 341, 350], ["the respirators", "TREATMENT", 18, 33], ["a filter", "TREATMENT", 120, 128], ["the \"positive pressure\" respirator", "TREATMENT", 279, 313], ["a compressor", "TREATMENT", 360, 372], ["negative pressure", "OBSERVATION", 185, 202], ["positive pressure", "OBSERVATION", 400, 417]]], ["[74] Besides, the design of the respirator affects the fit of the facepieces as fitting a half-facepiece respirators, which only cover the mouth and nose, is more difficult compared to that of full-facepiece respirators which also cover the eyes.", [["facepieces", "ANATOMY", 66, 76], ["mouth", "ANATOMY", 139, 144], ["nose", "ANATOMY", 149, 153], ["eyes", "ANATOMY", 241, 245], ["mouth", "ORGANISM_SUBDIVISION", 139, 144], ["nose", "ORGAN", 149, 153], ["eyes", "ORGAN", 241, 245], ["a half-facepiece respirators", "TREATMENT", 88, 116], ["full-facepiece respirators", "TREATMENT", 193, 219], ["mouth", "ANATOMY", 139, 144], ["nose", "ANATOMY", 149, 153], ["eyes", "ANATOMY", 241, 245]]], ["[74] As was already mentioned, the fit-test for respiratory facepieces is mainly categorized into two groups, a) qualitative, and b) quantitative, that each can be done through different methods, which are summarized in Fig. 10 .", [["[74] As", "CHEMICAL", 0, 7], ["respiratory facepieces", "PROBLEM", 48, 70]]], ["[71] , [16] For the qualitative test, a hood and a taste or odour solution are utilized to investigate the capability of the wearer to smell or taste the sample.", [["the qualitative test", "TEST", 16, 36], ["odour solution", "TREATMENT", 60, 74]]], ["Therefore, the qualitative method is a pass/fail test, which depends on the sensory detection of the wearer in terms of the taste and smell of the test agent, or the involuntary cough as a response to irritant smoke.", [["cough", "DISEASE", 178, 183], ["a pass/fail test", "TEST", 37, 53], ["the test agent", "TEST", 143, 157], ["the involuntary cough", "PROBLEM", 162, 183], ["irritant smoke", "OBSERVATION", 201, 215]]], ["Furthermore, a quantitative method utilizes an instrument to calculate the efficiency of the respirator numerically using electronic equipment, which calculates the air leakage into the face masks.", [["face", "ANATOMY", 186, 190], ["an instrument", "TREATMENT", 44, 57], ["electronic equipment", "TREATMENT", 122, 142], ["the air leakage into the face masks", "PROBLEM", 161, 196], ["air leakage", "OBSERVATION", 165, 176], ["face masks", "OBSERVATION", 186, 196]]], ["[75] equation (10) describes the calculation procedure of overall fit factors: (10) Overall Fit Factor = + + + ... +C inWhere \"N\" stands for the number of the exercises and the FF i , i= are the fit factor value for the individual {1,2,3,...,N} exercise.", [["the calculation procedure", "TREATMENT", 29, 54], ["Fit Factor", "TEST", 92, 102]]], ["[75] If the N95 face mask is well fitted, it has the ability to filter out the small size particles less than 0.5 microns from the air.", [["N95", "ORGANISM", 12, 15], ["the N95 face mask", "TREATMENT", 8, 25], ["small", "OBSERVATION_MODIFIER", 79, 84], ["size", "OBSERVATION_MODIFIER", 85, 89], ["air", "ANATOMY", 131, 134]]], ["[61]ConclusionsFace mask and respirators are to become and integral part of day to day life with the COVID pandemic.", [["Face mask", "TREATMENT", 15, 24], ["respirators", "TREATMENT", 29, 40]]], ["PPE undergoes analysis for a variety of tests to evaluate their performance and suitability for different environments.", [["a variety of tests", "TEST", 27, 45]]], ["Face mask and respirators each have different standards to be met with respirators having the higher of the two.", [["Face mask", "TREATMENT", 0, 9], ["respirators", "TREATMENT", 14, 25], ["respirators", "TREATMENT", 71, 82]]], ["Particulate filtration, bacterial filtration viral filtration and NaCL method are evaluated to ascertain their efficiency in the filtration of each of the named bodies.", [["Particulate filtration", "TREATMENT", 0, 22], ["bacterial filtration viral filtration", "TREATMENT", 24, 61], ["NaCL method", "TREATMENT", 66, 77], ["bacterial filtration", "OBSERVATION", 24, 44], ["viral filtration", "OBSERVATION", 45, 61], ["bodies", "ANATOMY_MODIFIER", 161, 167]]], ["Particulate filtration is measured using 0.1-Micron latex spheres, and a percentage of how many are filtered through the maks from 1-99.99% with the higher the percentage, the better.", [["Particulate filtration", "TEST", 0, 22], ["Micron latex spheres", "TREATMENT", 45, 65], ["filtration", "OBSERVATION", 12, 22], ["higher", "OBSERVATION_MODIFIER", 149, 155], ["percentage", "OBSERVATION_MODIFIER", 160, 170]]], ["Bacterial filtration efficiency measures the filtration of aerosol droplets of 3 microns in diameter as well ad well droplets formed from speaking coughing and sneezing down to the size of 0.6 microns, surgical or medical mask must obtain an efficiency of at least 95%.", [["Bacterial filtration efficiency", "PROBLEM", 0, 31], ["the filtration of aerosol droplets", "TREATMENT", 41, 75], ["coughing", "PROBLEM", 147, 155], ["sneezing", "PROBLEM", 160, 168], ["surgical or medical mask", "TREATMENT", 202, 226], ["filtration efficiency", "OBSERVATION", 10, 31], ["aerosol droplets", "OBSERVATION", 59, 75]]], ["Viral efficiency examines the assigned protection factor; this evaluates the face mask and respirators ability to reduce exposure to a virus in workplace conditions.", [["Viral efficiency", "PROBLEM", 0, 16], ["the face mask", "TREATMENT", 73, 86], ["a virus in workplace conditions", "PROBLEM", 133, 164]]], ["The NaCl method measures particles that are sized between 10 nm and 10\u00b5m with N95 masks receiving a penetration of no more than 5%.", [["NaCl", "CHEMICAL", 4, 8], ["NaCl", "CHEMICAL", 4, 8], ["The NaCl method measures particles", "TREATMENT", 0, 34], ["N95 masks", "TREATMENT", 78, 87], ["NaCl method", "OBSERVATION", 4, 15], ["sized", "OBSERVATION_MODIFIER", 44, 49], ["10 nm", "OBSERVATION_MODIFIER", 58, 63]]], ["The masks are further tested for their fluid and flame resistance, differential pressure and fit testing.", [["The masks", "TREATMENT", 0, 9], ["their fluid and flame resistance", "TEST", 33, 65], ["differential pressure", "TEST", 67, 88], ["fit testing", "TEST", 93, 104], ["flame resistance", "OBSERVATION", 49, 65]]], ["Fluid resistance examines the penetration of and wetting of fluids on the mask, with bodily fluids, synthetic blood and saliva being measure.", [["blood", "ANATOMY", 110, 115], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["saliva", "ORGANISM_SUBSTANCE", 120, 126], ["Fluid resistance", "TEST", 0, 16], ["fluids", "TREATMENT", 60, 66], ["the mask", "TREATMENT", 70, 78], ["bodily fluids", "TREATMENT", 85, 98], ["synthetic blood and saliva", "TREATMENT", 100, 126], ["resistance", "OBSERVATION", 6, 16]]], ["Flame resistance examines the flammability of materials used in masks, how much and how long the material will burn and how quickly the flame will spread.", [["Flame resistance", "TREATMENT", 0, 16], ["flammability", "OBSERVATION_MODIFIER", 30, 42]]], ["Differential pressure is used to measure the comfort and breathability of the masks and airflow resistance, the higher the differential pressure, the harder it is to breathe in the mask.", [["Differential pressure", "TEST", 0, 21], ["the comfort", "TREATMENT", 41, 52], ["the masks", "TREATMENT", 74, 83], ["airflow resistance", "PROBLEM", 88, 106], ["the mask", "TREATMENT", 177, 185], ["pressure", "OBSERVATION_MODIFIER", 13, 21], ["airflow resistance", "OBSERVATION", 88, 106], ["higher", "OBSERVATION_MODIFIER", 112, 118], ["differential", "OBSERVATION_MODIFIER", 123, 135], ["pressure", "OBSERVATION_MODIFIER", 136, 144]]], ["Facepiece Fit Testing examines both qualitative and quantitative methods, with negative or positive pressure methods to study how well the mask or respirator fits on an individual face.", [["fits", "DISEASE", 158, 162], ["Facepiece Fit Testing", "TEST", 0, 21], ["positive pressure methods", "TREATMENT", 91, 116], ["the mask", "TREATMENT", 135, 143]]], ["By using all of these standards and their testing methods face masks and respirators can be approved for use in the prevention of the spread of COVID-19.", [["COVID-19", "CHEMICAL", 144, 152], ["these standards", "TREATMENT", 16, 31], ["their testing methods face masks", "TREATMENT", 36, 68], ["respirators", "TREATMENT", 73, 84], ["COVID", "TEST", 144, 149]]]], "17f3661470bab1be9cdada1f4d2eab8e487baf57": [["BACKGROUNDIn late December 2019, a cluster of acute respiratory illnesses, now known as novel coronavirus pneumonia (NCP), occurred in Wuhan, Hubei Province, China.BACKGROUND[1] The NCP rapidly spread worldwide, posing a severe threats to international public health.", [["respiratory", "ANATOMY", 52, 63], ["acute respiratory illnesses", "DISEASE", 46, 73], ["coronavirus pneumonia", "DISEASE", 94, 115], ["NCP", "DISEASE", 117, 120], ["coronavirus pneumonia", "SPECIES", 94, 115], ["acute respiratory illnesses", "PROBLEM", 46, 73], ["novel coronavirus pneumonia", "PROBLEM", 88, 115], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory illnesses", "OBSERVATION", 52, 73], ["coronavirus", "OBSERVATION_MODIFIER", 94, 105], ["pneumonia", "OBSERVATION", 106, 115]]], ["[2, 3] Subsequebtly, the World Health Organization (WHO) declared a Public Health Emergency of International Concern over the global outbreak of coronavirus disease 2019 in January 31, 2020.", [["coronavirus disease", "DISEASE", 145, 164], ["coronavirus", "ORGANISM", 145, 156], ["coronavirus disease", "PROBLEM", 145, 164], ["coronavirus disease", "OBSERVATION", 145, 164]]], ["Some COVID-19 infections can be severe, particularly in older adults with underlying medical conditions.", [["infections", "DISEASE", 14, 24], ["Some COVID-19 infections", "PROBLEM", 0, 24], ["underlying medical conditions", "PROBLEM", 74, 103], ["infections", "OBSERVATION", 14, 24], ["severe", "OBSERVATION_MODIFIER", 32, 38]]], ["[4, 5] The disease onset may result in progressive respiratory failure due to alveolar damage, and even death.", [["respiratory", "ANATOMY", 51, 62], ["alveolar", "ANATOMY", 78, 86], ["respiratory failure", "DISEASE", 51, 70], ["alveolar damage", "DISEASE", 78, 93], ["death", "DISEASE", 104, 109], ["alveolar", "TISSUE", 78, 86], ["The disease onset", "PROBLEM", 7, 24], ["progressive respiratory failure", "PROBLEM", 39, 70], ["alveolar damage", "PROBLEM", 78, 93], ["disease", "OBSERVATION", 11, 18], ["may result in", "UNCERTAINTY", 25, 38], ["progressive", "OBSERVATION_MODIFIER", 39, 50], ["respiratory failure", "OBSERVATION", 51, 70], ["alveolar damage", "OBSERVATION", 78, 93]]], ["It is believed that vaccines and medicines can be developed to control and prevent this disease.", [["vaccines", "TREATMENT", 20, 28], ["medicines", "TREATMENT", 33, 42], ["this disease", "PROBLEM", 83, 95]]], ["However, the development of vaccines is usually hysteretic and currently there are no clinically confirmed specific antiviral treatments for COVID-19.", [["vaccines", "TREATMENT", 28, 36], ["specific antiviral treatments", "TREATMENT", 107, 136], ["COVID", "TEST", 141, 146], ["vaccines", "OBSERVATION", 28, 36]]], ["Therefore, it is necessary to urgently conduct clinical trials of medicines to identify suitable treatments for COVID-19.", [["medicines", "TREATMENT", 66, 75], ["COVID", "TEST", 112, 117]]], ["Previous studies have indicated thatthe combination of lopinavir and ritonavir may be beneficial for patients infected with SARS-CoV and MERS-CoV.", [["lopinavir", "CHEMICAL", 55, 64], ["ritonavir", "CHEMICAL", 69, 78], ["SARS", "DISEASE", 124, 128], ["lopinavir", "CHEMICAL", 55, 64], ["ritonavir", "CHEMICAL", 69, 78], ["lopinavir", "SIMPLE_CHEMICAL", 55, 64], ["ritonavir", "SIMPLE_CHEMICAL", 69, 78], ["patients", "ORGANISM", 101, 109], ["SARS-CoV", "ORGANISM", 124, 132], ["MERS-CoV", "ORGANISM", 137, 145], ["patients", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 124, 132], ["MERS-CoV", "SPECIES", 137, 145], ["Previous studies", "TEST", 0, 16], ["lopinavir", "TREATMENT", 55, 64], ["ritonavir", "TREATMENT", 69, 78], ["SARS", "PROBLEM", 124, 128]]], ["[6, 7] However, corticosteroids have not been found to reduce the mortality of SARS-CoV and MERS-CoV infection based on the WHO interim guidance.", [["SARS", "DISEASE", 79, 83], ["MERS-CoV infection", "DISEASE", 92, 110], ["corticosteroids", "CHEMICAL", 16, 31], ["corticosteroids", "SIMPLE_CHEMICAL", 16, 31], ["SARS-CoV", "ORGANISM", 79, 87], ["MERS-CoV", "ORGANISM", 92, 100], ["SARS-CoV", "SPECIES", 79, 87], ["MERS-CoV", "SPECIES", 92, 100], ["corticosteroids", "TREATMENT", 16, 31], ["SARS", "PROBLEM", 79, 83], ["CoV", "PROBLEM", 84, 87], ["MERS", "PROBLEM", 92, 96], ["CoV infection", "PROBLEM", 97, 110], ["infection", "OBSERVATION", 101, 110]]], ["[7] Chinese herbal medicine (CHM) has been used to control infectious diseases for thousands of years, and previous studies suggest that combining Chinese with Western medicine is useful in the treatment of SARS caused by coronavirus infection.", [["CHM", "CHEMICAL", 29, 32], ["infectious diseases", "DISEASE", 59, 78], ["SARS", "DISEASE", 207, 211], ["coronavirus infection", "DISEASE", 222, 243], ["coronavirus", "ORGANISM", 222, 233], ["Chinese herbal medicine", "TREATMENT", 4, 27], ["infectious diseases", "PROBLEM", 59, 78], ["previous studies", "TEST", 107, 123], ["Western medicine", "TREATMENT", 160, 176], ["SARS", "PROBLEM", 207, 211], ["coronavirus infection", "PROBLEM", 222, 243], ["coronavirus", "OBSERVATION_MODIFIER", 222, 233], ["infection", "OBSERVATION", 234, 243]]], ["[8, 9] CHM is a potentially effective method for controlling the newly emerged NCP.", [["[8, 9] CHM", "CHEMICAL", 0, 10], ["[8, 9] CHM", "CHEMICAL", 0, 10], ["[8, 9] CHM", "SIMPLE_CHEMICAL", 0, 10]]], ["From the perspective of CHM, COVID-19 belongs to the category of 'epidemic disease', and the total pathogenesis can be summarised as dampness, poison, blood stasis and deficiency.", [["blood", "ANATOMY", 151, 156], ["CHM", "DISEASE", 24, 27], ["blood stasis", "DISEASE", 151, 163], ["COVID-19", "CELL", 29, 37], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["COVID-19", "DNA", 29, 37], ["CHM", "PROBLEM", 24, 27], ["COVID", "TEST", 29, 34], ["'epidemic disease'", "PROBLEM", 65, 83], ["the total pathogenesis", "PROBLEM", 89, 111], ["dampness", "PROBLEM", 133, 141], ["blood stasis", "PROBLEM", 151, 163], ["deficiency", "PROBLEM", 168, 178], ["blood", "ANATOMY", 151, 156], ["stasis", "OBSERVATION", 157, 163]]], ["CHM treatment focuses on mobilising the body's own disease resistance, and has unique advantages in improving clinical symptoms, reducing complications, and improving quality of life.", [["body", "ANATOMY", 40, 44], ["CHM", "CHEMICAL", 0, 3], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["CHM treatment", "TREATMENT", 0, 13], ["disease resistance", "PROBLEM", 51, 69], ["improving clinical symptoms", "PROBLEM", 100, 127], ["reducing complications", "PROBLEM", 129, 151], ["disease", "OBSERVATION", 51, 58]]], ["A variety of Chinese medicine treatment compounds are recommended in the Chinese 6 th edition guidelines.", [["Chinese medicine treatment", "TREATMENT", 13, 39], ["variety", "OBSERVATION_MODIFIER", 2, 9]]], ["It is highly feasible to identify and develop active components against novel coronaviruses from these compounds.BACKGROUNDIn this study, we conducted a non-randomized controlled trial (NRCT) at Jinyintan Hospital in Wuhan.BACKGROUNDWe aimed to evaluate the efficacy and safety of CHM and Lopinavir-Ritonavir treatment in adult patients with COVID-19.Study design and settingA prospective, single-center, NRCT design was conducted from January 30 to March 23, 2020 at Jingyintan Hospital in Wuhan, Hubei province, China.", [["CHM", "CHEMICAL", 281, 284], ["Lopinavir-Ritonavir", "CHEMICAL", 289, 308], ["Lopinavir", "CHEMICAL", 289, 298], ["Ritonavir", "CHEMICAL", 299, 308], ["coronaviruses", "ORGANISM", 78, 91], ["CHM", "SIMPLE_CHEMICAL", 281, 284], ["Lopinavir-Ritonavir", "SIMPLE_CHEMICAL", 289, 308], ["patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 328, 336], ["active components", "PROBLEM", 46, 63], ["novel coronaviruses", "PROBLEM", 72, 91], ["this study", "TEST", 126, 136], ["a non-randomized controlled trial (NRCT)", "TREATMENT", 151, 191], ["CHM", "TREATMENT", 281, 284], ["Lopinavir", "TREATMENT", 289, 298], ["Ritonavir treatment", "TREATMENT", 299, 318], ["COVID", "TEST", 342, 347]]], ["All treatments were generally conducted, and baseline symptoms of patients with COVID-19 were assessed, within 24 h of enrolling.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["All treatments", "TREATMENT", 0, 14], ["baseline symptoms", "PROBLEM", 45, 62], ["COVID", "TEST", 80, 85]]], ["When the respiratory symptoms obviously improved and two consecutive novel coronavirus nucleic acid tests showed negative results (the interval between sampling was a minimum of one day), patients were discharged from quarantine.Study design and settingThe patients were non-randomly divided into three treatment groups with the patients' informed consent:Study design and setting(1) Group A: Lopinavir-Ritonavir, n = 20; (2) Group B: Huashi Baidu Formula (a Chinese medicine formula made by the China Academy of Chinese Medical Sciences to treat COVID-19, which is now in the clinical trial periodformula) and Lopinavir-Ritonavir, n = 20; and (3) Group C: Huashi Baidu Formula, n = 20.", [["respiratory", "ANATOMY", 9, 20], ["nucleic acid", "CHEMICAL", 87, 99], ["Lopinavir", "CHEMICAL", 393, 402], ["Ritonavir", "CHEMICAL", 403, 412], ["COVID-19", "CHEMICAL", 547, 555], ["Lopinavir", "CHEMICAL", 611, 620], ["Ritonavir", "CHEMICAL", 621, 630], ["Lopinavir", "CHEMICAL", 393, 402], ["Ritonavir", "CHEMICAL", 403, 412], ["Lopinavir", "CHEMICAL", 611, 620], ["coronavirus", "ORGANISM", 75, 86], ["patients", "ORGANISM", 188, 196], ["patients", "ORGANISM", 257, 265], ["patients", "ORGANISM", 329, 337], ["Lopinavir", "SIMPLE_CHEMICAL", 393, 402], ["Lopinavir", "SIMPLE_CHEMICAL", 611, 620], ["patients", "SPECIES", 188, 196], ["patients", "SPECIES", 257, 265], ["patients", "SPECIES", 329, 337], ["the respiratory symptoms", "PROBLEM", 5, 29], ["two consecutive novel coronavirus nucleic acid tests", "TEST", 53, 105], ["Study design", "TEST", 229, 241], ["Lopinavir-Ritonavir", "TREATMENT", 393, 412], ["a Chinese medicine formula", "TREATMENT", 457, 483], ["COVID", "TEST", 547, 552], ["Lopinavir", "TREATMENT", 611, 620], ["Ritonavir", "TREATMENT", 621, 630]]], ["The use of antibiotics, antiviruses, and corticosteroids was permitted in Groups A and B.Study design and settingTraditional Chinese medicine injections were permitted in Group C. The detailed treatments of the three groups were as follows: Lopinavir-Ritonavir (500 mg twice daily, orally), antibiotics (such as cefoperazone, 2 g twice daily, intravenous injection; moxifloxacin hydrochloride tablets, 0.4 g once daily, orally), corticosteroids (such as methylprednisolone, 40 mg once daily, intravenous injection; prednisone, 30 mg once daily, orally), antiviruses (such as arbidol capsule, 0.2 g three times daily, orally), Huashi Baidu Formula (137 g twice daily, orally), ShenMai injection (60 mL once daily, intravenous injection), XiYanPing injection (100 mg twice daily, intravenous injection), and XueBiJing injection (100 mLtwice daily, intravenous injection).", [["intravenous", "ANATOMY", 343, 354], ["intravenous", "ANATOMY", 492, 503], ["intravenous", "ANATOMY", 713, 724], ["intravenous", "ANATOMY", 778, 789], ["intravenous", "ANATOMY", 846, 857], ["Lopinavir", "CHEMICAL", 241, 250], ["Ritonavir", "CHEMICAL", 251, 260], ["cefoperazone", "CHEMICAL", 312, 324], ["moxifloxacin hydrochloride", "CHEMICAL", 366, 392], ["methylprednisolone", "CHEMICAL", 454, 472], ["prednisone", "CHEMICAL", 515, 525], ["arbidol", "CHEMICAL", 575, 582], ["ShenMai", "CHEMICAL", 676, 683], ["XiYanPing", "CHEMICAL", 737, 746], ["XueBiJing", "CHEMICAL", 806, 815], ["corticosteroids", "CHEMICAL", 41, 56], ["Lopinavir", "CHEMICAL", 241, 250], ["Ritonavir", "CHEMICAL", 251, 260], ["cefoperazone", "CHEMICAL", 312, 324], ["moxifloxacin hydrochloride", "CHEMICAL", 366, 392], ["methylprednisolone", "CHEMICAL", 454, 472], ["prednisone", "CHEMICAL", 515, 525], ["arbidol", "CHEMICAL", 575, 582], ["Lopinavir-Ritonavir", "SIMPLE_CHEMICAL", 241, 260], ["cefoperazone", "SIMPLE_CHEMICAL", 312, 324], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 343, 354], ["moxifloxacin", "SIMPLE_CHEMICAL", 366, 378], ["corticosteroids", "SIMPLE_CHEMICAL", 429, 444], ["methylprednisolone", "SIMPLE_CHEMICAL", 454, 472], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 492, 503], ["prednisone", "SIMPLE_CHEMICAL", 515, 525], ["antiviruses", "SIMPLE_CHEMICAL", 554, 565], ["arbidol", "SIMPLE_CHEMICAL", 575, 582], ["ShenMai", "SIMPLE_CHEMICAL", 676, 683], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 713, 724], ["XiYanPing", "SIMPLE_CHEMICAL", 737, 746], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 778, 789], ["XueBiJing", "SIMPLE_CHEMICAL", 806, 815], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 846, 857], ["antibiotics", "TREATMENT", 11, 22], ["antiviruses", "TREATMENT", 24, 35], ["corticosteroids", "TREATMENT", 41, 56], ["Traditional Chinese medicine injections", "TREATMENT", 113, 152], ["Lopinavir", "TREATMENT", 241, 250], ["Ritonavir", "TREATMENT", 251, 260], ["antibiotics", "TREATMENT", 291, 302], ["cefoperazone", "TREATMENT", 312, 324], ["intravenous injection", "TREATMENT", 343, 364], ["moxifloxacin hydrochloride tablets", "TREATMENT", 366, 400], ["corticosteroids", "TREATMENT", 429, 444], ["methylprednisolone", "TREATMENT", 454, 472], ["intravenous injection", "TREATMENT", 492, 513], ["prednisone", "TREATMENT", 515, 525], ["antiviruses (such as arbidol capsule", "TREATMENT", 554, 590], ["Huashi Baidu Formula", "TREATMENT", 626, 646], ["ShenMai injection", "TREATMENT", 676, 693], ["XiYanPing injection", "TREATMENT", 737, 756], ["XueBiJing injection", "TREATMENT", 806, 825]]], ["All groups received supportive therapy, including oxygen inhalation, symptomatic treatment and/or immunoglobulin intravenous injection and/or serum albumin intravenous injection, and treatment for basic diseases.PatientsThe test population was clinically diagnosed with COVID-19 in accordance with the diagnostic criteria for the diagnosis and treatment of NCP (trial edition 4) issued by the National Health Commission of the People's Republic of China and the National Administration of Traditional Chinese Medicine.", [["intravenous", "ANATOMY", 113, 124], ["serum", "ANATOMY", 142, 147], ["intravenous", "ANATOMY", 156, 167], ["oxygen", "CHEMICAL", 50, 56], ["NCP", "DISEASE", 357, 360], ["oxygen", "CHEMICAL", 50, 56], ["oxygen", "SIMPLE_CHEMICAL", 50, 56], ["immunoglobulin", "SIMPLE_CHEMICAL", 98, 112], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 124], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["albumin", "ORGANISM_SUBSTANCE", 148, 155], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 167], ["Patients", "ORGANISM", 212, 220], ["immunoglobulin", "PROTEIN", 98, 112], ["Patients", "SPECIES", 212, 220], ["supportive therapy", "TREATMENT", 20, 38], ["oxygen inhalation", "TREATMENT", 50, 67], ["symptomatic treatment", "TREATMENT", 69, 90], ["immunoglobulin intravenous injection", "TREATMENT", 98, 134], ["serum albumin intravenous injection", "TREATMENT", 142, 177], ["treatment", "TREATMENT", 183, 192], ["basic diseases", "PROBLEM", 197, 211], ["The test population", "TEST", 220, 239], ["COVID", "TEST", 270, 275], ["NCP (trial edition", "TREATMENT", 357, 375], ["Traditional Chinese Medicine", "TREATMENT", 489, 517], ["diseases", "OBSERVATION", 203, 211]]], ["Male and non-pregnant/non-lactating female patients aged 18 to 85 years were eligible if they met the diagnostic criteria for COVID-19 in the diagnosis and treatment of novel coronavirus pneumonia (trial edition 4).PatientsExclusion criteria included patients infected with critically severe COVID-19, patients who were over 15 days of symptom onset or who had severe primary respiratory system diseases, patients who have difficulty with oral and nasal feeding, patients with serous basic diseases, including malignant tumours, mental illness, and other malignant diseases, patients who had continuously used of immunosuppressants or received organ transplants within the past six months, and those who had an allergic constitution or were allergic to Huashi Baidu Formula.", [["primary respiratory system", "ANATOMY", 368, 394], ["oral", "ANATOMY", 439, 443], ["nasal", "ANATOMY", 448, 453], ["serous", "ANATOMY", 477, 483], ["malignant tumours", "ANATOMY", 510, 527], ["organ", "ANATOMY", 644, 649], ["COVID-19", "CHEMICAL", 126, 134], ["coronavirus pneumonia", "DISEASE", 175, 196], ["primary respiratory system diseases", "DISEASE", 368, 403], ["serous basic diseases", "DISEASE", 477, 498], ["malignant tumours", "DISEASE", 510, 527], ["mental illness", "DISEASE", 529, 543], ["malignant diseases", "DISEASE", 555, 573], ["allergic constitution", "DISEASE", 711, 732], ["allergic", "DISEASE", 741, 749], ["patients", "ORGANISM", 43, 51], ["coronavirus", "ORGANISM", 175, 186], ["Patients", "ORGANISM", 215, 223], ["patients", "ORGANISM", 251, 259], ["patients", "ORGANISM", 302, 310], ["patients", "ORGANISM", 405, 413], ["oral", "ORGANISM_SUBDIVISION", 439, 443], ["nasal", "ORGANISM_SUBDIVISION", 448, 453], ["patients", "ORGANISM", 463, 471], ["malignant tumours", "CANCER", 510, 527], ["patients", "ORGANISM", 575, 583], ["organ", "ORGAN", 644, 649], ["patients", "SPECIES", 43, 51], ["Patients", "SPECIES", 215, 223], ["patients", "SPECIES", 251, 259], ["patients", "SPECIES", 302, 310], ["patients", "SPECIES", 405, 413], ["patients", "SPECIES", 463, 471], ["patients", "SPECIES", 575, 583], ["COVID", "TEST", 126, 131], ["treatment", "TREATMENT", 156, 165], ["novel coronavirus pneumonia", "PROBLEM", 169, 196], ["critically severe COVID", "PROBLEM", 274, 297], ["severe primary respiratory system diseases", "PROBLEM", 361, 403], ["oral and nasal feeding", "TREATMENT", 439, 461], ["serous basic diseases", "PROBLEM", 477, 498], ["malignant tumours", "PROBLEM", 510, 527], ["mental illness", "PROBLEM", 529, 543], ["other malignant diseases", "PROBLEM", 549, 573], ["immunosuppressants", "TREATMENT", 613, 631], ["organ transplants", "TREATMENT", 644, 661], ["an allergic constitution", "PROBLEM", 708, 732], ["allergic", "PROBLEM", 741, 749], ["coronavirus", "OBSERVATION_MODIFIER", 175, 186], ["pneumonia", "OBSERVATION", 187, 196], ["severe", "OBSERVATION_MODIFIER", 361, 367], ["primary", "OBSERVATION_MODIFIER", 368, 375], ["respiratory system diseases", "OBSERVATION", 376, 403], ["malignant", "OBSERVATION_MODIFIER", 510, 519], ["tumours", "OBSERVATION", 520, 527], ["malignant", "OBSERVATION_MODIFIER", 555, 564]]], ["The withdrawal criteria included patients who underwent severe adverse events and could not continue to take medicines as primary groups during the observation period, those whose condition worsened or resulted in death, and those who were transferred to another hospital, left the present hospital, or received a confirmed misdiagnosis.", [["death", "DISEASE", 214, 219], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["severe adverse events", "PROBLEM", 56, 77], ["medicines", "TREATMENT", 109, 118]]], ["Written informed consent was obtained from all participants.Trial OversightThe trial was designed by the China Centre for Evidence-Based Traditional Chinese Medicine and implemented in partnership with Jinyintan Hospital in Wuhan, and was supported by grants from the National Key R&D Program of China (No. 2020YFC0841500) and the China Academy of Chinese Medical Sciences SARS-CoV-2.", [["participants", "SPECIES", 47, 59]]], ["The members of the writing group were responsible for the collection and analysis of the data and for the preparation of the manuscript.", [["the data", "TEST", 85, 93]]], ["ChiCTR2000029400/ChiMCTR2000002940).Outcome measuresThe primary outcomes were clinical remission time (interval from admission to the first time the patient tested negatively for novel coronavirus or an obvious improvement was observed from chest CT) and clinical remission rate (number of patients whose clinical time was within 16 days/total number of patients).Outcome measuresThe secondary outcomes were the time of release from quarantine (interval from admission to discharge), the rate of being released from quarantine (number of patients discharged within 16 days/ total number of patients), and clinical biochemical indicators.", [["coronavirus", "DISEASE", 185, 196], ["patient", "ORGANISM", 149, 156], ["coronavirus", "ORGANISM", 185, 196], ["patients", "ORGANISM", 290, 298], ["patients", "ORGANISM", 354, 362], ["patients", "ORGANISM", 538, 546], ["patients", "ORGANISM", 590, 598], ["patient", "SPECIES", 149, 156], ["patients", "SPECIES", 290, 298], ["patients", "SPECIES", 354, 362], ["patients", "SPECIES", 538, 546], ["patients", "SPECIES", 590, 598], ["novel coronavirus", "PROBLEM", 179, 196], ["chest CT", "TEST", 241, 249], ["clinical remission rate", "TEST", 255, 278], ["chest", "ANATOMY", 241, 246]]], ["Other outcomes were safety indexes, such as liver function (ALT, AST), kidney function (creatinine), and myocardial damage.Statistical analysisContinuous variables were described using mean \u00b1 standard deviation or median \u00b1 interquartile range (IQR).", [["liver", "ANATOMY", 44, 49], ["kidney", "ANATOMY", 71, 77], ["myocardial", "ANATOMY", 105, 115], ["creatinine", "CHEMICAL", 88, 98], ["myocardial damage", "DISEASE", 105, 122], ["creatinine", "CHEMICAL", 88, 98], ["liver", "ORGAN", 44, 49], ["ALT", "SIMPLE_CHEMICAL", 60, 63], ["AST", "SIMPLE_CHEMICAL", 65, 68], ["kidney", "ORGAN", 71, 77], ["creatinine", "SIMPLE_CHEMICAL", 88, 98], ["myocardial", "MULTI-TISSUE_STRUCTURE", 105, 115], ["safety indexes", "TEST", 20, 34], ["liver function", "TEST", 44, 58], ["ALT", "TEST", 60, 63], ["AST", "TEST", 65, 68], ["kidney function", "TEST", 71, 86], ["creatinine", "TEST", 88, 98], ["myocardial damage", "PROBLEM", 105, 122], ["Statistical analysisContinuous variables", "PROBLEM", 123, 163], ["liver", "ANATOMY", 44, 49], ["kidney", "ANATOMY", 71, 77], ["myocardial", "ANATOMY", 105, 115], ["damage", "OBSERVATION", 116, 122]]], ["In addition, the clinical remission time and time of release from quarantine were portrayed by Kaplan-Meier plots and compared with the log-rank test.", [["the log-rank test", "TEST", 132, 149]]], ["The count data were expressed as the number of cases or percentages.", [["The count data", "TEST", 0, 14]]], ["Differences between groups were assessed using analysis of variance or Welch's variance analysis for continuous variables and the Chi-square test or Fisher's exact test for categorical variables.", [["analysis of variance", "TEST", 47, 67], ["Welch's variance analysis", "TEST", 71, 96], ["the Chi-square test", "TEST", 126, 145], ["Fisher's exact test", "TEST", 149, 168]]], ["Comparisons were made between baselines and outcomes of groups using paired t-tests.", [["paired t-tests", "TEST", 69, 83]]], ["21.0 (IBM Corp, Armonk, NY, USA) was used for all statistical analyses.", [["all statistical analyses", "TEST", 46, 70]]], ["For all comparisons, differences were tested with two-tailed tests, and P < 0.05 was considered statistically significant.General characteristics of patients with COVID-19A total of 111 patients were evaluated for eligibility, and 44 patients were excluded according to the inclusion and exclusion criteria.", [["patients", "ORGANISM", 149, 157], ["patients", "ORGANISM", 186, 194], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 234, 242], ["two-tailed tests", "TEST", 50, 66], ["COVID", "TEST", 163, 168], ["eligibility", "TEST", 214, 225]]], ["The remaining 67 patients were assigned by non-randomized grouping, of which 22 patients were assigned to Group A, 23 patients to Group B, and 22 patients to Group C. In Group A, one patient refused Lopinavir-Ritonavir treatment, and one patient died in hospital, In Group B, three patients refused Lopinavir-Ritonavir treatment, and in Group C, two patients refused traditional Chinese medicine treatment (flow program).General characteristics of patients with COVID-19In the study, 66.7% (40/60) of patients were male and 33.3% (20/60) were female.", [["Lopinavir-Ritonavir", "CHEMICAL", 199, 218], ["Lopinavir-Ritonavir", "CHEMICAL", 299, 318], ["Lopinavir", "CHEMICAL", 199, 208], ["Ritonavir", "CHEMICAL", 209, 218], ["Lopinavir", "CHEMICAL", 299, 308], ["Ritonavir", "CHEMICAL", 309, 318], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 146, 154], ["patient", "ORGANISM", 183, 190], ["Lopinavir", "SIMPLE_CHEMICAL", 199, 208], ["Ritonavir", "SIMPLE_CHEMICAL", 209, 218], ["patient", "ORGANISM", 238, 245], ["patients", "ORGANISM", 282, 290], ["Lopinavir-Ritonavir", "SIMPLE_CHEMICAL", 299, 318], ["patients", "ORGANISM", 350, 358], ["patients", "ORGANISM", 448, 456], ["patients", "ORGANISM", 501, 509], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 146, 154], ["patient", "SPECIES", 183, 190], ["patient", "SPECIES", 238, 245], ["patients", "SPECIES", 282, 290], ["patients", "SPECIES", 350, 358], ["patients", "SPECIES", 448, 456], ["patients", "SPECIES", 501, 509], ["Lopinavir", "TREATMENT", 199, 208], ["Ritonavir treatment", "TREATMENT", 209, 228], ["Lopinavir", "TREATMENT", 299, 308], ["Ritonavir treatment", "TREATMENT", 309, 328], ["traditional Chinese medicine treatment", "TREATMENT", 367, 405], ["COVID", "TEST", 462, 467], ["the study", "TEST", 473, 482]]], ["The median age of the patients was 54.5 years (IQR, 45.0 to 64.8 years).", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["The most common chronic medical illnesses were cardiovascular and cerebrovascular diseases, followed by endocrine system disease.", [["cardiovascular", "ANATOMY", 47, 61], ["cerebrovascular", "ANATOMY", 66, 81], ["endocrine system", "ANATOMY", 104, 120], ["cardiovascular and cerebrovascular diseases", "DISEASE", 47, 90], ["endocrine system disease", "DISEASE", 104, 128], ["cardiovascular", "ANATOMICAL_SYSTEM", 47, 61], ["cerebrovascular", "ANATOMICAL_SYSTEM", 66, 81], ["endocrine system", "MULTI-TISSUE_STRUCTURE", 104, 120], ["The most common chronic medical illnesses", "PROBLEM", 0, 41], ["cerebrovascular diseases", "PROBLEM", 66, 90], ["endocrine system disease", "PROBLEM", 104, 128], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["chronic", "OBSERVATION_MODIFIER", 16, 23], ["cerebrovascular", "ANATOMY", 66, 81], ["diseases", "OBSERVATION", 82, 90]]], ["Group B had a lower proportion of males than the other two groups.", [["males", "OBSERVATION", 34, 39]]], ["Except for lactate dehydrogenase and creatine kinase, no other major differences in age, chronic medical illness history, number of patients with a fever, and physical and chemical indexes of the three groups were observed at baseline (P > 0.050) ( Table 1, Table 2 ).", [["lactate", "CHEMICAL", 11, 18], ["creatine", "CHEMICAL", 37, 45], ["chronic medical illness", "DISEASE", 89, 112], ["fever", "DISEASE", 148, 153], ["lactate", "CHEMICAL", 11, 18], ["creatine", "CHEMICAL", 37, 45], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 11, 32], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 37, 52], ["patients", "ORGANISM", 132, 140], ["lactate dehydrogenase", "PROTEIN", 11, 32], ["creatine kinase", "PROTEIN", 37, 52], ["patients", "SPECIES", 132, 140], ["lactate dehydrogenase", "TEST", 11, 32], ["creatine kinase", "TEST", 37, 52], ["chronic medical illness", "PROBLEM", 89, 112], ["a fever", "PROBLEM", 146, 153], ["no other", "UNCERTAINTY", 54, 62], ["major", "OBSERVATION_MODIFIER", 63, 68], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["fever", "OBSERVATION", 148, 153]]], ["According to the log-rank test, there was a significant difference among the three groups (P = 0.013).", [["significant", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION", 56, 66]]], ["Pairwise comparisons were conducted using the LSD method, and statistical differences were identified between Group C and Group A as well as Group C and Group B (P < 0.050) ( Table 3 ), suggesting that the curative effect of the Huashi Baidu Formula was better than that of the other two treatments.The time and rate of release from quarantineThe time taken before being released from quarantine was 16.7 \u00b1 6.6 days in Group A, 15.0 \u00b1 6.6 days in Group B, and 14.5 \u00b1 7.9 days in Group C. There were no statistical differences (P > 0.050) among the three groups ( Table 3 ).", [["the LSD method", "TEST", 42, 56], ["Group C and Group B (P", "TREATMENT", 141, 163], ["the Huashi Baidu Formula", "TREATMENT", 225, 249], ["statistical differences", "PROBLEM", 502, 525], ["P", "TEST", 527, 528], ["no", "UNCERTAINTY", 499, 501]]], ["The rates of release from quarantine in Groups A, B, and C were 60.0%Comparative analysis of clinical characteristics of patients with COVID-19The number and proportion of patients with improvements in biochemical indicators are described inTable 2.", [["B", "CELL", 50, 51], ["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 172, 180], ["Comparative analysis", "TEST", 69, 89], ["COVID", "TEST", 135, 140]]], ["The recovery rate of lactate dehydrogenase in Group B and C was 71.4% (5/7), while in Group A was 60.0% (9/15).The recovery rate of leukocytes in Group A was 100.0% (3/3), while in Group B and C was 50.0% (3/6) and 75.0% (3/4) respectively.", [["leukocytes", "ANATOMY", 132, 142], ["lactate", "CHEMICAL", 21, 28], ["lactate", "CHEMICAL", 21, 28], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 21, 42], ["C", "CELL", 58, 59], ["leukocytes", "CELL", 132, 142], ["lactate dehydrogenase", "PROTEIN", 21, 42], ["leukocytes", "CELL_TYPE", 132, 142], ["lactate dehydrogenase", "TEST", 21, 42], ["Group B and C", "TEST", 46, 59], ["leukocytes", "TEST", 132, 142], ["Group A", "TEST", 146, 153], ["Group B and C", "TEST", 181, 194], ["leukocytes", "OBSERVATION", 132, 142]]], ["In terms of creatine kinase, the recovery rate was 77.8% (7/9) in Group A, 57.1% (4/7) in Group B and 50.0% (3/6) in Group C. In terms of lymphocytes and interleukin 6, the recovery rate in Group C (83.3%[5/6] and 40.0% [4/10]) was significantly higher than in Group A and B.Comparative analysis of clinical characteristics of patients with COVID-19A paired t-test was used for comparisons before and after treatments, and the results (Table 4) showed that there were significant differences in neutrophil, lymphocyte, albumin, glutamic-oxalacetic transaminase, serum creatinine, creatine kinase, lactate dehydrogenase, and C-reactive protein levels as well as in prothrombin, and activated partial thrombin activity times both before and after treatment in Group A (P < 0.050).", [["lymphocytes", "ANATOMY", 138, 149], ["neutrophil", "ANATOMY", 495, 505], ["lymphocyte", "ANATOMY", 507, 517], ["serum", "ANATOMY", 562, 567], ["creatine", "CHEMICAL", 12, 20], ["glutamic-oxalacetic", "CHEMICAL", 528, 547], ["creatinine", "CHEMICAL", 568, 578], ["creatine", "CHEMICAL", 580, 588], ["lactate", "CHEMICAL", 597, 604], ["creatine", "CHEMICAL", 12, 20], ["glutamic", "CHEMICAL", 528, 536], ["creatinine", "CHEMICAL", 568, 578], ["creatine", "CHEMICAL", 580, 588], ["lactate", "CHEMICAL", 597, 604], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 12, 27], ["lymphocytes", "CELL", 138, 149], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 154, 167], ["patients", "ORGANISM", 327, 335], ["neutrophil", "CELL", 495, 505], ["lymphocyte", "CELL", 507, 517], ["albumin", "GENE_OR_GENE_PRODUCT", 519, 526], ["glutamic-oxalacetic transaminase", "GENE_OR_GENE_PRODUCT", 528, 560], ["serum", "ORGANISM_SUBSTANCE", 562, 567], ["creatinine", "SIMPLE_CHEMICAL", 568, 578], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 580, 595], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 597, 618], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 624, 642], ["prothrombin", "GENE_OR_GENE_PRODUCT", 664, 675], ["thrombin", "GENE_OR_GENE_PRODUCT", 699, 707], ["creatine kinase", "PROTEIN", 12, 27], ["lymphocytes", "CELL_TYPE", 138, 149], ["interleukin 6", "PROTEIN", 154, 167], ["neutrophil", "CELL_TYPE", 495, 505], ["albumin", "PROTEIN", 519, 526], ["glutamic-oxalacetic transaminase", "PROTEIN", 528, 560], ["serum creatinine", "PROTEIN", 562, 578], ["creatine kinase", "PROTEIN", 580, 595], ["lactate dehydrogenase", "PROTEIN", 597, 618], ["C-reactive protein", "PROTEIN", 624, 642], ["prothrombin", "PROTEIN", 664, 675], ["thrombin", "PROTEIN", 699, 707], ["patients", "SPECIES", 327, 335], ["creatine kinase", "TEST", 12, 27], ["the recovery rate", "TEST", 29, 46], ["Group B", "TEST", 90, 97], ["lymphocytes", "TEST", 138, 149], ["interleukin", "TEST", 154, 165], ["the recovery rate", "TEST", 169, 186], ["Group C", "TEST", 190, 197], ["COVID", "TEST", 341, 346], ["t-test", "TEST", 358, 364], ["treatments", "TREATMENT", 407, 417], ["neutrophil", "TEST", 495, 505], ["lymphocyte", "TEST", 507, 517], ["albumin", "TEST", 519, 526], ["glutamic", "TEST", 528, 536], ["oxalacetic transaminase", "TEST", 537, 560], ["serum creatinine", "TEST", 562, 578], ["creatine kinase", "TEST", 580, 595], ["lactate dehydrogenase", "TEST", 597, 618], ["C-reactive protein levels", "PROBLEM", 624, 649], ["prothrombin", "TEST", 664, 675], ["activated partial thrombin activity", "TREATMENT", 681, 716], ["treatment", "TREATMENT", 745, 754], ["lymphocytes", "ANATOMY", 138, 149], ["significant", "OBSERVATION_MODIFIER", 468, 479], ["reactive protein levels", "OBSERVATION", 626, 649], ["partial", "OBSERVATION_MODIFIER", 691, 698], ["thrombin activity", "OBSERVATION", 699, 716]]], ["Significant differences were observed in haemoglobin, albumin, total bilirubin, creatine kinase, lactate dehydrogenase, interleukin-6, and C-reactive protein level as well as prothrombin and activated partial thrombin activity times both before and after treatment in Group B (P < 0.050).", [["bilirubin", "CHEMICAL", 69, 78], ["creatine", "CHEMICAL", 80, 88], ["lactate", "CHEMICAL", 97, 104], ["bilirubin", "CHEMICAL", 69, 78], ["creatine", "CHEMICAL", 80, 88], ["lactate", "CHEMICAL", 97, 104], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 41, 52], ["albumin", "GENE_OR_GENE_PRODUCT", 54, 61], ["bilirubin", "SIMPLE_CHEMICAL", 69, 78], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 80, 95], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 97, 118], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 120, 133], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 139, 157], ["prothrombin", "GENE_OR_GENE_PRODUCT", 175, 186], ["thrombin", "GENE_OR_GENE_PRODUCT", 209, 217], ["haemoglobin", "PROTEIN", 41, 52], ["albumin", "PROTEIN", 54, 61], ["total bilirubin", "PROTEIN", 63, 78], ["creatine kinase", "PROTEIN", 80, 95], ["lactate dehydrogenase", "PROTEIN", 97, 118], ["interleukin-6", "PROTEIN", 120, 133], ["prothrombin", "PROTEIN", 175, 186], ["thrombin", "PROTEIN", 209, 217], ["Significant differences", "PROBLEM", 0, 23], ["haemoglobin", "TEST", 41, 52], ["albumin", "TEST", 54, 61], ["total bilirubin", "TEST", 63, 78], ["creatine kinase", "TEST", 80, 95], ["lactate dehydrogenase", "TEST", 97, 118], ["interleukin", "TEST", 120, 131], ["C-reactive protein level", "PROBLEM", 139, 163], ["prothrombin", "TEST", 175, 186], ["activated partial thrombin activity", "TREATMENT", 191, 226], ["treatment", "TREATMENT", 255, 264], ["partial", "OBSERVATION_MODIFIER", 201, 208], ["thrombin activity", "OBSERVATION", 209, 226]]], ["In Group C, significant differences were observed in neutrophil, haemoglobin, albumin, glutamic-oxalacetic transaminase, creatine kinase, lactate dehydrogenase, interleukin-6, and C-reactive protein levels both before and after treatment (P < 0.050).Safety indexesIn this study, the safety indexes were biochemical indicators (normal / abnormal).", [["neutrophil", "ANATOMY", 53, 63], ["glutamic-oxalacetic", "CHEMICAL", 87, 106], ["creatine", "CHEMICAL", 121, 129], ["lactate", "CHEMICAL", 138, 145], ["glutamic", "CHEMICAL", 87, 95], ["creatine", "CHEMICAL", 121, 129], ["lactate", "CHEMICAL", 138, 145], ["neutrophil", "CELL", 53, 63], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 65, 76], ["albumin", "GENE_OR_GENE_PRODUCT", 78, 85], ["glutamic-oxalacetic transaminase", "GENE_OR_GENE_PRODUCT", 87, 119], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 121, 136], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 138, 159], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 161, 174], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 180, 198], ["neutrophil", "CELL_TYPE", 53, 63], ["haemoglobin", "PROTEIN", 65, 76], ["albumin", "PROTEIN", 78, 85], ["glutamic-oxalacetic transaminase", "PROTEIN", 87, 119], ["creatine kinase", "PROTEIN", 121, 136], ["lactate dehydrogenase", "PROTEIN", 138, 159], ["interleukin-6", "PROTEIN", 161, 174], ["neutrophil", "TEST", 53, 63], ["haemoglobin", "TEST", 65, 76], ["albumin", "TEST", 78, 85], ["glutamic", "TEST", 87, 95], ["oxalacetic transaminase", "TEST", 96, 119], ["creatine kinase", "TEST", 121, 136], ["lactate dehydrogenase", "TEST", 138, 159], ["interleukin", "TEST", 161, 172], ["C-reactive protein levels", "TEST", 180, 205], ["this study", "TEST", 267, 277], ["the safety indexes", "TEST", 279, 297], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["There was no significant difference among the three groups or within the groups in terms of the safety indexes at baseline (P > 0.050).", [["significant difference", "PROBLEM", 13, 35], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["After different treatments, the proportion of patients with abnormal creatinine in Group A increased significantly, while that in Group C increased slightly and in Group B did not change, indicating that Group B treatment was marginally safer in terms of renal function than those of the other two groups.", [["renal", "ANATOMY", 255, 260], ["creatinine", "CHEMICAL", 69, 79], ["creatinine", "CHEMICAL", 69, 79], ["patients", "ORGANISM", 46, 54], ["creatinine", "SIMPLE_CHEMICAL", 69, 79], ["renal", "ORGAN", 255, 260], ["patients", "SPECIES", 46, 54], ["different treatments", "TREATMENT", 6, 26], ["abnormal creatinine", "PROBLEM", 60, 79], ["Group B treatment", "TREATMENT", 204, 221], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["slightly", "OBSERVATION_MODIFIER", 148, 156], ["renal", "ANATOMY", 255, 260], ["function", "OBSERVATION", 261, 269]]], ["Besides, Glutamic-pyruvic and oxalacetic transaminases could reflect liver function, and there was no statistical difference among the three groups (P > 0.050).", [["liver", "ANATOMY", 69, 74], ["Glutamic-pyruvic", "CHEMICAL", 9, 25], ["Glutamic-pyruvic", "CHEMICAL", 9, 25], ["oxalacetic", "CHEMICAL", 30, 40], ["Glutamic-pyruvic", "SIMPLE_CHEMICAL", 9, 25], ["oxalacetic transaminases", "SIMPLE_CHEMICAL", 30, 54], ["liver", "ORGAN", 69, 74], ["Glutamic-pyruvic", "TEST", 9, 25], ["oxalacetic transaminases", "TEST", 30, 54], ["liver function", "TEST", 69, 83], ["statistical difference", "PROBLEM", 102, 124], ["liver", "ANATOMY", 69, 74], ["no", "UNCERTAINTY", 99, 101]]], ["The proportion of patients with these two abnormal indicators in Group A and C decreased, while in Group B increased.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["these two abnormal indicators", "PROBLEM", 32, 61], ["decreased", "OBSERVATION_MODIFIER", 79, 88], ["increased", "OBSERVATION_MODIFIER", 107, 116]]], ["In addition, the proportion of patients with abnormal creatine kinase in the three groups decreased, which suggested that the three treatments exhibited no significant harm on cardiac function.", [["cardiac", "ANATOMY", 176, 183], ["creatine", "CHEMICAL", 54, 62], ["creatine", "CHEMICAL", 54, 62], ["patients", "ORGANISM", 31, 39], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 54, 69], ["cardiac", "ORGAN", 176, 183], ["abnormal creatine kinase", "PROTEIN", 45, 69], ["patients", "SPECIES", 31, 39], ["abnormal creatine kinase", "PROBLEM", 45, 69], ["significant harm on cardiac function", "PROBLEM", 156, 192], ["creatine kinase", "OBSERVATION", 54, 69], ["no", "UNCERTAINTY", 153, 155], ["significant", "OBSERVATION_MODIFIER", 156, 167], ["harm", "OBSERVATION", 168, 172], ["cardiac", "ANATOMY", 176, 183], ["function", "OBSERVATION", 184, 192]]], ["In total, the patients in the three groups suffered no obvious adverse events (Table 5 ).Current treatments and the potential value of TCM treatment for COVID-19To date, no targeted vaccine or specific drugs have been developed for the prevention or treatment of NCP.", [["NCP", "DISEASE", 263, 266], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["obvious adverse events", "PROBLEM", 55, 77], ["Current treatments", "TREATMENT", 89, 107], ["TCM treatment", "TREATMENT", 135, 148], ["COVID", "TEST", 153, 158], ["targeted vaccine", "TREATMENT", 173, 189], ["specific drugs", "TREATMENT", 193, 207], ["NCP", "PROBLEM", 263, 266], ["no", "UNCERTAINTY", 52, 54], ["obvious", "OBSERVATION_MODIFIER", 55, 62]]], ["Based on previous experiences relating to the treatment of SARS, MERS, or other novel influenza viruses, Lopinavir/Ritonavir, Redesivir, nucleoside analogues, neuraminidase inhibitors, and Abidor have been used in the clinical treatment of patients with COVID-19, but their clinical efficacy and safety need to be confirmed in further clinical trials.", [["SARS", "DISEASE", 59, 63], ["MERS", "DISEASE", 65, 69], ["influenza viruses", "DISEASE", 86, 103], ["Lopinavir", "CHEMICAL", 105, 114], ["Ritonavir", "CHEMICAL", 115, 124], ["Redesivir", "CHEMICAL", 126, 135], ["nucleoside", "CHEMICAL", 137, 147], ["Abidor", "CHEMICAL", 189, 195], ["COVID-19", "CHEMICAL", 254, 262], ["Lopinavir", "CHEMICAL", 105, 114], ["Ritonavir", "CHEMICAL", 115, 124], ["Redesivir", "CHEMICAL", 126, 135], ["nucleoside", "CHEMICAL", 137, 147], ["COVID-19", "CHEMICAL", 254, 262], ["Lopinavir", "SIMPLE_CHEMICAL", 105, 114], ["Ritonavir", "SIMPLE_CHEMICAL", 115, 124], ["Redesivir", "SIMPLE_CHEMICAL", 126, 135], ["nucleoside analogues", "SIMPLE_CHEMICAL", 137, 157], ["neuraminidase inhibitors", "SIMPLE_CHEMICAL", 159, 183], ["Abidor", "SIMPLE_CHEMICAL", 189, 195], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["SARS", "PROBLEM", 59, 63], ["MERS", "PROBLEM", 65, 69], ["other novel influenza viruses", "PROBLEM", 74, 103], ["Lopinavir", "TREATMENT", 105, 114], ["Ritonavir", "TREATMENT", 115, 124], ["Redesivir", "TREATMENT", 126, 135], ["nucleoside analogues", "TREATMENT", 137, 157], ["neuraminidase inhibitors", "TREATMENT", 159, 183], ["Abidor", "TREATMENT", 189, 195], ["COVID", "TEST", 254, 259]]], ["[11] Recent studies [12] have identified Redesivir as a potential treatment for NCP.", [["NCP", "DISEASE", 80, 83], ["Redesivir", "CHEMICAL", 41, 50], ["Redesivir", "SIMPLE_CHEMICAL", 41, 50], ["Recent studies", "TEST", 5, 19], ["Redesivir", "TREATMENT", 41, 50], ["NCP", "PROBLEM", 80, 83]]], ["Currently, Phase 3 clinical drug trials have been launched in China, but the above studies are in the exploratory phase.", [["the above studies", "TEST", 73, 90]]], ["For the treatment of inflammation, corticosteroids have been used frequently for severe patients with severe cases of SARS-CoV, [13, 14] MERS-CoV, [15, 16] and COVID-19.", [["inflammation", "DISEASE", 21, 33], ["SARS-CoV", "DISEASE", 118, 126], ["corticosteroids", "CHEMICAL", 35, 50], ["corticosteroids", "SIMPLE_CHEMICAL", 35, 50], ["patients", "ORGANISM", 88, 96], ["[13, 14] MERS-CoV", "SIMPLE_CHEMICAL", 128, 145], ["[15, 16]", "SIMPLE_CHEMICAL", 147, 155], ["COVID-19", "SIMPLE_CHEMICAL", 160, 168], ["patients", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 118, 126], ["inflammation", "PROBLEM", 21, 33], ["corticosteroids", "TREATMENT", 35, 50], ["severe cases of SARS", "PROBLEM", 102, 122], ["CoV", "TEST", 123, 126], ["CoV", "TEST", 142, 145], ["COVID", "TEST", 160, 165], ["inflammation", "OBSERVATION", 21, 33]]], ["However, current evidence for SARS and MERS suggests that corticosteroids have no effect on mortality, but rather delay viral clearance.", [["SARS", "DISEASE", 30, 34], ["corticosteroids", "CHEMICAL", 58, 73], ["corticosteroids", "SIMPLE_CHEMICAL", 58, 73], ["SARS", "PROBLEM", 30, 34], ["MERS", "PROBLEM", 39, 43], ["corticosteroids", "TREATMENT", 58, 73], ["rather delay viral clearance", "PROBLEM", 107, 135]]], ["In the present study, the median time of release from quarantine after Lopinavir-Ritonavir treatment was 15.0 (13.0-19.0) days, which is a similar result to that in a previous study (14 (12) (13) (14) (15) (16) (17) ) days), [24] indicating that the therapeutic effect of Lopinavir-Ritonavir treatment is relatively consistent.", [["Lopinavir-Ritonavir", "CHEMICAL", 71, 90], ["Lopinavir-Ritonavir", "CHEMICAL", 272, 291], ["Lopinavir", "CHEMICAL", 71, 80], ["Lopinavir", "CHEMICAL", 272, 281], ["Ritonavir", "CHEMICAL", 282, 291], ["Lopinavir", "SIMPLE_CHEMICAL", 71, 80], ["Lopinavir-Ritonavir", "SIMPLE_CHEMICAL", 272, 291], ["Lopinavir", "TREATMENT", 71, 80], ["Ritonavir treatment", "TREATMENT", 81, 100], ["a previous study", "TEST", 165, 181], ["Lopinavir", "TREATMENT", 272, 281], ["Ritonavir treatment", "TREATMENT", 282, 301]]], ["In Group A,Evaluation of the clinical efficacy of Huashi Baidu Formula treatment on COVID-19In Group C, we adopted the method of CHM syndrome differentiation, and administered individual treatment plans according to each patient's condition, including oral Chinese medicine decoction and Chinese patent medicine, and some patients were administered traditional Chinese medicine injections.Evaluation of the clinical efficacy of Huashi Baidu Formula treatment on COVID-19In addition, some patients used a combination of CHM decoction and injection at the early stage of admission, which was inconsistent with the use of CHM injection recommended only for severe and critically ill patients in the national program.", [["oral", "ANATOMY", 252, 256], ["CHM syndrome", "DISEASE", 129, 141], ["COVID-19In", "CHEMICAL", 462, 472], ["CHM decoction", "CHEMICAL", 519, 532], ["CHM", "CHEMICAL", 619, 622], ["critically ill", "DISEASE", 665, 679], ["patient", "ORGANISM", 221, 228], ["oral", "ORGANISM_SUBDIVISION", 252, 256], ["patients", "ORGANISM", 322, 330], ["COVID-19In", "SIMPLE_CHEMICAL", 462, 472], ["patients", "ORGANISM", 488, 496], ["patients", "ORGANISM", 680, 688], ["patient", "SPECIES", 221, 228], ["patients", "SPECIES", 322, 330], ["patients", "SPECIES", 488, 496], ["patients", "SPECIES", 680, 688], ["Evaluation", "TEST", 11, 21], ["Huashi Baidu Formula treatment", "TREATMENT", 50, 80], ["COVID", "TREATMENT", 84, 89], ["CHM syndrome differentiation", "PROBLEM", 129, 157], ["individual treatment plans", "TREATMENT", 176, 202], ["oral Chinese medicine decoction", "TREATMENT", 252, 283], ["Chinese patent medicine", "TREATMENT", 288, 311], ["traditional Chinese medicine injections", "TREATMENT", 349, 388], ["Evaluation", "TEST", 389, 399], ["Huashi Baidu Formula treatment", "TREATMENT", 428, 458], ["COVID", "TREATMENT", 462, 467], ["CHM decoction", "TREATMENT", 519, 532], ["injection", "TREATMENT", 537, 546], ["CHM injection", "TREATMENT", 619, 632]]], ["However, this study found that the combination of theSafety indexes of the three groups in the treatment of COVID-19Several patients in this study had abnormal creatinine levels after Lopinavir-Ritonavir treatment.", [["creatinine", "CHEMICAL", 160, 170], ["Lopinavir-Ritonavir", "CHEMICAL", 184, 203], ["creatinine", "CHEMICAL", 160, 170], ["Lopinavir", "CHEMICAL", 184, 193], ["Ritonavir", "CHEMICAL", 194, 203], ["patients", "ORGANISM", 124, 132], ["creatinine", "SIMPLE_CHEMICAL", 160, 170], ["Lopinavir-Ritonavir", "SIMPLE_CHEMICAL", 184, 203], ["patients", "SPECIES", 124, 132], ["this study", "TEST", 9, 19], ["theSafety indexes", "PROBLEM", 50, 67], ["COVID", "TREATMENT", 108, 113], ["this study", "TEST", 136, 146], ["abnormal creatinine levels", "PROBLEM", 151, 177], ["Lopinavir", "TREATMENT", 184, 193], ["Ritonavir treatment", "TREATMENT", 194, 213]]], ["The number of patients with abnormal glutamic-pyruvic and oxalacetic transaminase levels after the combination of Lopinavir-Ritonavir and Huashi Baidu Formula treatment also slightly increased.Safety indexes of the three groups in the treatment of COVID-19However, there was no significant difference in safety indexes between and within the groups (P > 0.05).", [["glutamic-pyruvic", "CHEMICAL", 37, 53], ["oxalacetic", "CHEMICAL", 58, 68], ["Lopinavir-Ritonavir", "CHEMICAL", 114, 133], ["glutamic-pyruvic", "CHEMICAL", 37, 53], ["oxalacetic", "CHEMICAL", 58, 68], ["Lopinavir", "CHEMICAL", 114, 123], ["Ritonavir", "CHEMICAL", 124, 133], ["patients", "ORGANISM", 14, 22], ["glutamic-pyruvic", "SIMPLE_CHEMICAL", 37, 53], ["oxalacetic transaminase", "GENE_OR_GENE_PRODUCT", 58, 81], ["Lopinavir-Ritonavir", "SIMPLE_CHEMICAL", 114, 133], ["patients", "SPECIES", 14, 22], ["abnormal glutamic-pyruvic", "PROBLEM", 28, 53], ["oxalacetic transaminase levels", "TEST", 58, 88], ["Lopinavir", "TREATMENT", 114, 123], ["Ritonavir", "TREATMENT", 124, 133], ["Huashi Baidu Formula treatment", "TREATMENT", 138, 168], ["significant difference in safety indexes", "PROBLEM", 278, 318], ["P", "TEST", 350, 351], ["slightly", "OBSERVATION_MODIFIER", 174, 182], ["increased", "OBSERVATION_MODIFIER", 183, 192], ["no", "UNCERTAINTY", 275, 277], ["significant", "OBSERVATION_MODIFIER", 278, 289], ["difference", "OBSERVATION_MODIFIER", 290, 300]]], ["Although one patient died during hospitalization in Group A, researchers determined that it was not related to the intervention.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["the intervention", "TREATMENT", 111, 127]]], ["In total, none of the patient in the study experienced severe adverse events.AUTHOR CONTRIBUTIONSLH is the corresponding author, others are joint first authors.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["the study", "TEST", 33, 42], ["severe adverse events", "PROBLEM", 55, 76], ["joint", "ANATOMY", 140, 145]]], ["HS, LH, CL, ZS, RC, LL, JL, YX, YT and BL designed the study.", [["HS", "TEST", 0, 2], ["LH", "TEST", 4, 6], ["the study", "TEST", 51, 60], ["LH", "ANATOMY", 4, 6], ["CL", "OBSERVATION", 8, 10], ["RC", "ANATOMY", 16, 18], ["LL", "ANATOMY", 20, 22], ["JL", "ANATOMY", 24, 26]]], ["WW, JG, BY, YC, LL, DL, YX, YC, CX, GW, XC and XX collected the data.", [["WW", "TEST", 0, 2], ["JG", "TEST", 4, 6], ["CX", "TEST", 32, 34], ["JG", "ANATOMY", 4, 6], ["LL", "ANATOMY", 16, 18], ["DL", "ANATOMY", 20, 22]]], ["WL, SC, JW, YB, WQ, JY and JS were involved in data cleaning and verification.", [["SC", "ANATOMY", 4, 6]]], ["MX, BW, GD, JL, LZ, QM, HL, BL, HZ and JJ analyzed the data.", [["MX", "TEST", 0, 2], ["BW", "TEST", 4, 6], ["BL", "TEST", 28, 30], ["HZ", "TEST", 32, 34], ["LZ", "ANATOMY", 16, 18]]], ["NS and LG drafted the manuscript.", [["NS", "TREATMENT", 0, 2], ["LG", "ANATOMY", 7, 9]]], ["LQ contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content.", [["LQ", "CHEMICAL", 0, 2], ["critical revision", "TREATMENT", 56, 73], ["important intellectual content", "PROBLEM", 96, 126]]], ["All data were generated in-house, and no paper mill was used.", [["All data", "TEST", 0, 8]]], ["All authors agree to be accountable for all aspects of work ensuring integrity and accuracy.AUTHOR CONTRIBUTIONS6 LIMITATIONS AND STRENGTHS There were several limitations to this study.", [["accuracy", "TEST", 83, 91], ["this study", "TEST", 174, 184]]], ["First, the trial was non-randomized and unblinded, thus, findings of statistical tests and P-values should be interpreted with caution, and non-significant P-values did not necessarily rule out differences between the three groups.", [["statistical tests", "TEST", 69, 86]]], ["Second, due to the small sample size and single centre site, it was difficult to assess host risk factors for disease severity and mortality using multivariable adjusted methods.", [["the small sample size and single centre site", "PROBLEM", 15, 59], ["disease severity", "PROBLEM", 110, 126], ["multivariable adjusted methods", "TREATMENT", 147, 177], ["small", "OBSERVATION_MODIFIER", 19, 24], ["sample", "OBSERVATION_MODIFIER", 25, 31], ["size", "OBSERVATION_MODIFIER", 32, 36]]], ["A larger randomised control trial would assist in defining the clinical epidemiological characteristics and risk factors.", [["A larger randomised control trial", "TREATMENT", 0, 33], ["larger", "OBSERVATION_MODIFIER", 2, 8]]], ["Third, the interventions in this study were not completely in accordance with the three groups.", [["the interventions", "TREATMENT", 7, 24], ["this study", "TEST", 28, 38]]], ["Further studies in outpatient, primary care, or community settings are needed to follow-up the prognosis and recovery of patients.AUTHOR CONTRIBUTIONSThe present study also has some strengths.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["Further studies", "TEST", 0, 15]]], ["First, it is one of few clinical control trials to explore the efficacy and safety of CHMs and western medicines in COVID-19 treatment.", [["CHMs", "CHEMICAL", 86, 90], ["COVID-19", "CHEMICAL", 116, 124], ["CHMs", "SIMPLE_CHEMICAL", 86, 90], ["CHMs", "TREATMENT", 86, 90], ["western medicines", "TREATMENT", 95, 112], ["COVID-19 treatment", "TREATMENT", 116, 134]]], ["Second, we used many indicators to describe the efficacy and safety of the medicines, such as clinical remission rate, clinical remission time, and rate of release from quarantine, making the outcomes more diversified.CONCLUSIONSLopinavir-Ritonavir had an effect as a treatment for COVID-19, and this effect was enhanced whenCOMPETING INTERESTSAll authors declare that no support from any organization for the submitted work; no financial relationships with any organization that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.COMPETING INTERESTSThe authors declare no competing interests.", [["CONCLUSIONSLopinavir", "CHEMICAL", 218, 238], ["Ritonavir", "CHEMICAL", 239, 248], ["CONCLUSIONSLopinavir", "CHEMICAL", 218, 238], ["Ritonavir", "CHEMICAL", 239, 248], ["Ritonavir", "SIMPLE_CHEMICAL", 239, 248], ["the medicines", "TREATMENT", 71, 84], ["clinical remission rate", "TEST", 94, 117], ["CONCLUSIONSLopinavir", "TREATMENT", 218, 238], ["Ritonavir", "TREATMENT", 239, 248], ["a treatment", "TREATMENT", 266, 277], ["COVID", "TEST", 282, 287]]], ["Scientific background and explanation of rationale 3 2bETHICAL APPROVALSpecific objectives or hypotheses 3Trial design 3aDescription of trial design (such as parallel, factorial) including allocation ratio 3-4 3bTrial design 3aImportant changes to methods after trial commencement (such as eligibility criteria), with reasons -Participants 4aEligibility criteria for participants 4 4bParticipants 4aSettings and locations where the data were collected 3-4 Interventions 5Participants 4aThe interventions for each group with sufficient details to allow replication, including how and when they were actually administered 4 Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 4 6bParticipants 4aAny changes to trial outcomes after the trial commenced, with reasons -Sample size 7a How sample size was determined -7bParticipants 4aWhen applicable, explanation of any interim analyses and stopping guidelines -Randomisation:Participants 4aSequence generation 8a Method used to generate the random allocation sequence -8bParticipants 4aType of randomisation; details of any restriction (such as blocking and block size) -Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned -Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions -Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing -14 outcomes) and how 11bParticipants 4aIf relevant, description of the similarity of interventions -Statistical methods 12aParticipants 4aStatistical methods used to compare groups for primary and secondary outcomes 4-5 12bParticipants 4aMethods for additional analyses, such as subgroup analyses and adjusted analyses 5ResultsParticipant flow (a diagram is strongly recommended)Results13aResultsFor each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome 5 13bResultsFor each group, losses and exclusions after randomisation, together with reasons 5 Recruitment 14aResultsDates defining the periods of recruitment and follow-up 3 14bResultsWhy the trial ended or was stopped -Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table file,1 Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups 5 Outcomes and estimation 17aResultsFor each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)", [["sample", "ANATOMY", 858, 864], ["Participants", "SPECIES", 327, 339], ["participants", "SPECIES", 367, 379], ["Participants", "SPECIES", 995, 1007], ["participants", "SPECIES", 1492, 1504], ["participants", "SPECIES", 1523, 1535], ["participants", "SPECIES", 1640, 1652], ["participants", "SPECIES", 2114, 2126], ["participants", "SPECIES", 2604, 2616], ["trial design", "TREATMENT", 136, 148], ["allocation ratio", "TEST", 189, 205], ["the random allocation sequence", "TEST", 1057, 1087], ["any restriction", "PROBLEM", 1140, 1155], ["blocking and block size)", "TREATMENT", 1165, 1189], ["Allocation concealment mechanism", "TREATMENT", 1191, 1223], ["the random allocation sequence", "TREATMENT", 1254, 1284], ["interventions", "TREATMENT", 1772, 1785], ["additional analyses", "TEST", 1937, 1956], ["subgroup analyses", "TEST", 1966, 1983], ["adjusted analyses", "TEST", 1988, 2005], ["the analysis", "TEST", 2669, 2681], ["the estimated effect size", "PROBLEM", 2818, 2843], ["size", "OBSERVATION_MODIFIER", 865, 869], ["size", "OBSERVATION_MODIFIER", 2839, 2843]]]], "PMC7149557": [["Virus as Moving Targets ::: The ChallengeThe potential deleteriousness of mutational load (excessive number of mutations in the same genome) is symbolized in Figure 9.1 by the genomes drawn as discontinuous lines that contain five mutations, here assumed to be a sufficiently large number to decrease fitness and, therefore, the frequency of their potential descendants in subsequent replication rounds.", [["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5], ["mutational load", "PROBLEM", 74, 89], ["excessive number of mutations", "PROBLEM", 91, 120], ["discontinuous lines", "TREATMENT", 193, 212], ["mutational load", "OBSERVATION", 74, 89]]], ["Quasispecies dynamics imposes, however, that those genomes that move from a high frequency to a low frequency level be replaced by newly arising mutants that display higher fitness.", [["higher fitness", "OBSERVATION", 166, 180]]], ["The mutant cloud is highly dynamic with newly arising genomes incessantly exposed to the scrutiny of selection and the lottery of random drift.", [["cloud", "OBSERVATION_MODIFIER", 11, 16], ["highly", "OBSERVATION_MODIFIER", 20, 26], ["dynamic", "OBSERVATION_MODIFIER", 27, 34], ["random drift", "OBSERVATION", 130, 142]]], ["The image here portrayed through mutations is even more complex if we add recombination and genome segment reassortment in the case of viruses with segmented or multipartite genomes (Chapters 2 and 3).", [["multipartite genomes", "DNA", 161, 181], ["The image", "TEST", 0, 9], ["mutations", "PROBLEM", 33, 42], ["recombination and genome segment reassortment", "TREATMENT", 74, 119], ["viruses", "PROBLEM", 135, 142], ["viruses", "OBSERVATION", 135, 142], ["multipartite genomes", "OBSERVATION", 161, 181]]], ["From the point of view of antiviral interventions, viruses are true \u201cmoving targets,\u201d in the sense that the repertoire of variants that we should inhibit at one time point is not exactly the same to be inhibited at a subsequent time point.", [["antiviral interventions", "TREATMENT", 26, 49], ["viruses", "PROBLEM", 51, 58], ["antiviral", "OBSERVATION", 26, 35]]], ["The difference may be irrelevant regarding the efficacy of an antiviral treatment, or it may not.", [["an antiviral treatment", "TREATMENT", 59, 81], ["may be", "UNCERTAINTY", 15, 21], ["antiviral treatment", "OBSERVATION", 62, 81]]], ["The impact of the dynamic change is unpredictable.", [["dynamic change", "OBSERVATION", 18, 32], ["unpredictable", "OBSERVATION_MODIFIER", 36, 49]]], ["Applied to clinical practice, it means that a specific inhibitor combination may be effective for many infected individuals for a long time, or only for a few individuals for a short time, with a range of possible intermediate outcomes.", [["a specific inhibitor combination", "TREATMENT", 44, 76]]], ["The new antiviral strategies discussed in this chapter take into consideration the moving target feature of the viruses to be controlled, and they have been proposed by an increasing number of experts aware of the quasispecies challenge.Combination Treatments ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsStudies on the advantage of the combined administration of two drugs were pioneered by H.J. Eggers and I. Tamm (Eggers and Tamm, 1963; Eggers, 1976).", [["The new antiviral strategies", "TREATMENT", 0, 28], ["the viruses", "PROBLEM", 108, 119], ["Antiviral Inhibitors", "TREATMENT", 343, 363], ["two drugs", "TREATMENT", 422, 431], ["new", "OBSERVATION_MODIFIER", 4, 7], ["antiviral", "OBSERVATION", 8, 17], ["viruses", "OBSERVATION", 112, 119]]], ["Combination therapy applied to human immunodeficiency virus type 1 (HIV-1) has been the great success for the control of acquired immunodeficiency syndrome (AIDS) that has drastically reduced AIDS-related mortality.", [["human immunodeficiency virus type 1 (HIV-1", "CHEMICAL", 31, 73], ["acquired immunodeficiency syndrome", "DISEASE", 121, 155], ["AIDS", "DISEASE", 157, 161], ["AIDS", "DISEASE", 192, 196], ["human immunodeficiency virus type 1", "ORGANISM", 31, 66], ["HIV-1", "ORGANISM", 68, 73], ["human immunodeficiency virus type 1", "SPECIES", 31, 66], ["HIV-1", "SPECIES", 68, 73], ["human immunodeficiency virus type 1", "SPECIES", 31, 66], ["HIV-1", "SPECIES", 68, 73], ["Combination therapy", "TREATMENT", 0, 19], ["human immunodeficiency virus type", "PROBLEM", 31, 64], ["acquired immunodeficiency syndrome", "PROBLEM", 121, 155], ["drastically reduced AIDS", "PROBLEM", 172, 196], ["immunodeficiency syndrome", "OBSERVATION", 130, 155], ["reduced", "OBSERVATION_MODIFIER", 184, 191], ["AIDS", "OBSERVATION", 192, 196]]], ["This type of treatment for HIV-1 is termed highly active antiretroviral therapy (HAART) and it is ideally implemented with three different antiretroviral agents.", [["HIV-1", "ORGANISM", 27, 32], ["HIV-1", "SPECIES", 27, 32], ["HIV-1", "SPECIES", 27, 32], ["treatment", "TREATMENT", 13, 22], ["HIV", "PROBLEM", 27, 30], ["active antiretroviral therapy", "TREATMENT", 50, 79], ["HAART", "TREATMENT", 81, 86], ["three different antiretroviral agents", "TREATMENT", 123, 160], ["active", "OBSERVATION_MODIFIER", 50, 56], ["antiretroviral therapy", "OBSERVATION", 57, 79]]], ["HAART efficacy has steadily improved due to availability of new inhibitors directed at different HIV-1 targets.", [["HIV-1", "ORGANISM", 97, 102], ["HIV-1", "SPECIES", 97, 102], ["HAART efficacy", "PROBLEM", 0, 14], ["new inhibitors", "TREATMENT", 60, 74]]], ["Success is only partial due to side effects (that may be derived from off-target activities of the drugs), incomplete patient adherence to the treatment, selection of multidrug-resistant viral variants and, above all, to the retroviral nature of HIV-1 that renders virus extinction from the organism a difficult endeavor.", [["patient", "ORGANISM", 118, 125], ["HIV-1", "ORGANISM", 246, 251], ["patient", "SPECIES", 118, 125], ["HIV-1", "SPECIES", 246, 251], ["HIV-1", "SPECIES", 246, 251], ["side effects", "PROBLEM", 31, 43], ["the drugs", "TREATMENT", 95, 104], ["the treatment", "TREATMENT", 139, 152], ["multidrug-resistant viral variants", "PROBLEM", 167, 201], ["HIV", "PROBLEM", 246, 249], ["virus extinction", "PROBLEM", 265, 281], ["resistant", "OBSERVATION_MODIFIER", 177, 186], ["viral variants", "OBSERVATION", 187, 201], ["retroviral", "ANATOMY", 225, 235]]], ["In retroviruses and hepadnaviruses, the viral DNA is not only hidden from antiviral drugs but it can serve as an archive of genomes that can reactivate replication upon treatment discontinuation.", [["retroviruses", "ORGANISM", 3, 15], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["viral DNA", "DNA", 40, 49], ["hepadnaviruses", "TREATMENT", 20, 34], ["the viral DNA", "PROBLEM", 36, 49], ["antiviral drugs", "TREATMENT", 74, 89], ["treatment discontinuation", "TREATMENT", 169, 194], ["retroviruses", "OBSERVATION", 3, 15], ["viral DNA", "OBSERVATION", 40, 49]]], ["If combination therapy could be coupled with an efficient elimination of the proviral reservoirs in host DNA (De Crignis and Mahmoudi, 2014), HIV-1 could probably be eliminated from the infected organism, as achieved in the case of HCV infections in some patients.Combination Treatments ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsThe general advantage of combination therapy over monotherapy is a consequence of quasispecies dynamics, and it has been amply evidenced by clinical practice, and supported by straightforward statistical considerations and theoretical models of virus dynamics (Domingo, 1989, Domingo and Holland, 1992, Ho, 1995, Bonhoeffer et al., 1997, Pol et al., 1999, Ribeiro and Bonhoeffer, 2000, Le Moing et al., 2002, Van Vaerenbergh et al., 2002, Domingo et al., 2008, M\u00fcller and Bonhoeffer, 2008, Nijhuis et al., 2009) (see Section 8.4 in Chapter 8).", [["HCV infections", "DISEASE", 232, 246], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["HIV-1", "ORGANISM", 142, 147], ["HCV", "ORGANISM", 232, 235], ["patients", "ORGANISM", 255, 263], ["HIV-1", "SPECIES", 142, 147], ["patients", "SPECIES", 255, 263], ["HIV-1", "SPECIES", 142, 147], ["HCV", "SPECIES", 232, 235], ["combination therapy", "TREATMENT", 3, 22], ["the proviral reservoirs", "TREATMENT", 73, 96], ["HIV", "PROBLEM", 142, 145], ["the infected organism", "PROBLEM", 182, 203], ["HCV infections", "PROBLEM", 232, 246], ["Antiviral Inhibitors", "TREATMENT", 370, 390], ["combination therapy", "TREATMENT", 415, 434], ["monotherapy", "TREATMENT", 440, 451], ["quasispecies dynamics", "PROBLEM", 472, 493], ["proviral reservoirs", "OBSERVATION", 77, 96], ["infected", "OBSERVATION", 186, 194], ["HCV", "OBSERVATION", 232, 235]]], ["Furthermore, use of combination therapies conforms to the \u201chit early, hit hard\u201d dictum of D.D. Ho, justified in Section 8.10 of Chapter 8.", [["combination therapies", "TREATMENT", 20, 41]]], ["There is the misconception (among some experts, but mainly among politicians!) that only patients in advanced phases of a viral infection (i.e., only precirrhotic or cirrhotic patients infected with HCV) should be treated aggressively with drug combinations.", [["viral infection", "DISEASE", 122, 137], ["cirrhotic", "DISEASE", 166, 175], ["HCV", "DISEASE", 199, 202], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 176, 184], ["HCV", "ORGANISM", 199, 202], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 176, 184], ["HCV", "SPECIES", 199, 202], ["a viral infection", "PROBLEM", 120, 137], ["precirrhotic", "PROBLEM", 150, 162], ["cirrhotic patients", "PROBLEM", 166, 184], ["HCV", "PROBLEM", 199, 202], ["drug combinations", "TREATMENT", 240, 257], ["viral", "OBSERVATION_MODIFIER", 122, 127], ["infection", "OBSERVATION", 128, 137], ["cirrhotic", "OBSERVATION_MODIFIER", 166, 175]]], ["This is not what evolutionary virology teaches us: patients should be treated as strongly as possible and as early as possible, provided side effects can be controlled.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["Viruses should be given no chance to walk in sequence space in search of adaptive pathways (Chapter 3).", [["Viruses", "PROBLEM", 0, 7]]], ["Adequate combination treatments can fulfill such purpose.Split Treatments ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsA second proposed strategy is to divide an antiviral treatment in two steps: an induction and a maintenance step (von Kleist et al., 2011).", [["Antiviral InhibitorsA second proposed strategy", "TREATMENT", 157, 203], ["an antiviral treatment", "TREATMENT", 217, 239], ["an induction", "TREATMENT", 254, 266], ["antiviral", "OBSERVATION", 220, 229]]], ["It is based on a theoretical model developed for the treatment of HIV-1 infections.", [["HIV-1 infections", "DISEASE", 66, 82], ["HIV-1", "ORGANISM", 66, 71], ["HIV-1", "SPECIES", 66, 71], ["HIV-1", "SPECIES", 66, 71], ["HIV-1 infections", "PROBLEM", 66, 82]]], ["The key argument is that when a treatment has to be changed after confirmation of treatment failure (virus rebound), mutants resistant to the ineffective drug have had the opportunity to replicate in the patient, increasing the viral load and supplying a proviral archive with inhibitor-resistant latent viruses, thus excluding the drug as a component of future combinations.", [["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["a treatment", "TREATMENT", 30, 41], ["treatment failure", "PROBLEM", 82, 99], ["virus rebound", "PROBLEM", 101, 114], ["mutants", "PROBLEM", 117, 124], ["the ineffective drug", "TREATMENT", 138, 158], ["the viral load", "PROBLEM", 224, 238], ["inhibitor", "TREATMENT", 277, 286], ["resistant latent viruses", "PROBLEM", 287, 311], ["viral load", "OBSERVATION", 228, 238], ["latent", "OBSERVATION_MODIFIER", 297, 303], ["viruses", "OBSERVATION", 304, 311]]], ["A treatment with an induction regimen should be followed by a shift to a maintenance regimen at a point in time in which the second drug finds a low viral load and limited numbers of mutants resistant to the initial treatment.", [["A treatment", "TREATMENT", 0, 11], ["an induction regimen", "TREATMENT", 17, 37], ["a maintenance regimen", "TREATMENT", 71, 92], ["a low viral load", "PROBLEM", 143, 159], ["the initial treatment", "TREATMENT", 204, 225]]], ["Critical issues for the implementation of this proposal are the timing of treatment switch, the decrease of viral load as a result of the induction regimen, and the genetic and phenotypic barriers to the maintenance regimen.", [["Critical issues", "PROBLEM", 0, 15], ["this proposal", "TREATMENT", 42, 55], ["treatment switch", "TREATMENT", 74, 90], ["viral load", "PROBLEM", 108, 118], ["the induction regimen", "TREATMENT", 134, 155], ["the genetic and phenotypic barriers", "TREATMENT", 161, 196], ["the maintenance regimen", "TREATMENT", 200, 223], ["viral load", "OBSERVATION", 108, 118]]], ["Clinical trials are needed to explore this interesting proposal.Targeting Cellular Functions ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsMany cellular functions are needed to complete any step of a virus replication cycle.", [["cellular", "ANATOMY", 201, 209], ["cellular", "CELL", 201, 209], ["Antiviral Inhibitors", "TREATMENT", 176, 196], ["a virus replication cycle", "TREATMENT", 255, 280], ["Cellular Functions", "OBSERVATION", 74, 92]]], ["A good deal of research in virology has as its main objective to identify and characterize cellular functions that participate in virus entry into the cell, intracellular multiplication, or release from cells.", [["cellular", "ANATOMY", 91, 99], ["cell", "ANATOMY", 151, 155], ["intracellular", "ANATOMY", 157, 170], ["cells", "ANATOMY", 203, 208], ["cellular", "CELL", 91, 99], ["cell", "CELL", 151, 155], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 170], ["cells", "CELL", 203, 208], ["intracellular multiplication", "TEST", 157, 185], ["good", "OBSERVATION_MODIFIER", 2, 6]]], ["Since cellular proteins cannot vary in response to the presence of an inhibitor (at least within the time frame of a viral infection), an obvious thought is to administer inhibitors of those cellular functions (often proteins) that are needed to sustain viral replication; such inhibitors should suppress viral replication without selection of inhibitor-resistant mutants (Geller et al., 2007, Hopkins et al., 2010, Garbelli et al., 2011, Kumar et al., 2011, Vidalain et al., 2015).", [["cellular", "ANATOMY", 6, 14], ["cellular", "ANATOMY", 191, 199], ["viral infection", "DISEASE", 117, 132], ["cellular", "CELL", 6, 14], ["cellular", "CELL", 191, 199], ["cellular proteins", "PROTEIN", 6, 23], ["cellular proteins", "PROBLEM", 6, 23], ["an inhibitor", "TREATMENT", 67, 79], ["a viral infection", "PROBLEM", 115, 132], ["inhibitors", "TREATMENT", 171, 181], ["viral replication", "TREATMENT", 254, 271], ["such inhibitors", "TREATMENT", 273, 288], ["viral replication", "TREATMENT", 305, 322], ["selection of inhibitor", "TREATMENT", 331, 353], ["viral", "OBSERVATION_MODIFIER", 117, 122], ["infection", "OBSERVATION", 123, 132]]], ["Despite potential benefits, two major problems may be encountered with antiviral agents directed to cellular proteins: (i) toxic effects derived from suppression or alteration of activities in which the target protein is involved and (ii) selection of viral mutants that are insensitive to the presence of the inhibitor, despite the inhibitor not being directed to the virus.", [["cellular", "ANATOMY", 100, 108], ["cellular", "CELL", 100, 108], ["cellular proteins", "PROTEIN", 100, 117], ["target protein", "PROTEIN", 203, 217], ["antiviral agents", "TREATMENT", 71, 87], ["toxic effects", "PROBLEM", 123, 136], ["alteration of activities", "PROBLEM", 165, 189], ["viral mutants", "PROBLEM", 252, 265], ["the inhibitor", "TREATMENT", 306, 319], ["the inhibitor", "TREATMENT", 329, 342], ["the virus", "PROBLEM", 365, 374], ["viral mutants", "OBSERVATION", 252, 265]]], ["If the cellular protein which is the target of the inhibitor forms a complex with a viral protein in the course of viral replication, amino acid substitutions in the viral protein may permit progression of the infection in the presence of the inhibitor.", [["cellular", "ANATOMY", 7, 15], ["amino acid", "CHEMICAL", 134, 144], ["infection", "DISEASE", 210, 219], ["amino acid", "CHEMICAL", 134, 144], ["cellular", "CELL", 7, 15], ["amino acid", "AMINO_ACID", 134, 144], ["cellular protein", "PROTEIN", 7, 23], ["viral protein", "PROTEIN", 84, 97], ["viral protein", "PROTEIN", 166, 179], ["the cellular protein", "TEST", 3, 23], ["a viral protein", "PROBLEM", 82, 97], ["viral replication", "TREATMENT", 115, 132], ["amino acid substitutions", "TREATMENT", 134, 158], ["the viral protein", "PROBLEM", 162, 179], ["the infection", "PROBLEM", 206, 219], ["the inhibitor", "TREATMENT", 239, 252], ["cellular protein", "OBSERVATION", 7, 23], ["viral replication", "OBSERVATION", 115, 132], ["acid substitutions", "OBSERVATION", 140, 158], ["infection", "OBSERVATION", 210, 219]]], ["This is the case of HCV resistance to the nonimmunosuppressive cyclophilin inhibitor SCY-635.", [["SCY-635", "CHEMICAL", 85, 92], ["SCY-635", "CHEMICAL", 85, 92], ["HCV", "ORGANISM", 20, 23], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 63, 74], ["SCY-635", "SIMPLE_CHEMICAL", 85, 92], ["HCV", "SPECIES", 20, 23], ["HCV resistance", "PROBLEM", 20, 34], ["the nonimmunosuppressive cyclophilin inhibitor SCY", "TREATMENT", 38, 88], ["HCV", "OBSERVATION", 20, 23]]], ["NS5A interacts with cyclophilins and with NS5B; amino acid substitutions in NS5A (T17A, E295K, and V44A) and in NS5B (T77K and I432V) decrease the sensitivity of the virus to SCY-635, although the precise molecular mechanism of resistance has been debated (Chatterji et al., 2010, Sarrazin and Zeuzem, 2010, Delang et al., 2011, Kwong et al., 2011, Vermehren and Sarrazin, 2011).Targeting Cellular Functions ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsWhen inhibitors are targeted to the cellular receptor for a virus, mutants may be selected that can enter cells through an alternative receptor.", [["cellular", "ANATOMY", 547, 555], ["cells", "ANATOMY", 617, 622], ["amino acid", "CHEMICAL", 48, 58], ["SCY-635", "CHEMICAL", 175, 182], ["amino acid", "CHEMICAL", 48, 58], ["SCY-635", "CHEMICAL", 175, 182], ["NS5A", "GENE_OR_GENE_PRODUCT", 0, 4], ["cyclophilins", "GENE_OR_GENE_PRODUCT", 20, 32], ["NS5B", "GENE_OR_GENE_PRODUCT", 42, 46], ["amino acid", "AMINO_ACID", 48, 58], ["NS5A", "GENE_OR_GENE_PRODUCT", 76, 80], ["NS5B", "GENE_OR_GENE_PRODUCT", 112, 116], ["SCY-635", "GENE_OR_GENE_PRODUCT", 175, 182], ["cellular", "CELL", 547, 555], ["cells", "CELL", 617, 622], ["NS5A", "PROTEIN", 0, 4], ["cyclophilins", "PROTEIN", 20, 32], ["NS5B", "PROTEIN", 42, 46], ["NS5A", "PROTEIN", 76, 80], ["T17A", "PROTEIN", 82, 86], ["E295K", "PROTEIN", 88, 93], ["V44A", "PROTEIN", 99, 103], ["NS5B", "PROTEIN", 112, 116], ["I432V", "PROTEIN", 127, 132], ["cellular receptor", "PROTEIN", 547, 564], ["alternative receptor", "PROTEIN", 634, 654], ["NS5A", "TREATMENT", 0, 4], ["cyclophilins", "TREATMENT", 20, 32], ["NS5B", "TREATMENT", 42, 46], ["amino acid substitutions", "TREATMENT", 48, 72], ["NS5A", "TREATMENT", 76, 80], ["T17A", "TEST", 82, 86], ["E295K", "TEST", 88, 93], ["NS5B", "TEST", 112, 116], ["the virus", "PROBLEM", 162, 171], ["SCY", "TEST", 175, 178], ["Sarrazin", "TREATMENT", 281, 289], ["Antiviral Inhibitors", "TREATMENT", 491, 511], ["inhibitors", "TREATMENT", 516, 526], ["a virus", "PROBLEM", 569, 576], ["an alternative receptor", "TREATMENT", 631, 654], ["Cellular Functions", "OBSERVATION", 389, 407]]], ["This has been documented with HIV-1 that can use coreceptor CCR5, CXCR4, or both (dual-tropic viruses).", [["HIV-1", "ORGANISM", 30, 35], ["CCR5", "GENE_OR_GENE_PRODUCT", 60, 64], ["CXCR4", "GENE_OR_GENE_PRODUCT", 66, 71], ["coreceptor CCR5", "PROTEIN", 49, 64], ["CXCR4", "PROTEIN", 66, 71], ["HIV-1", "SPECIES", 30, 35], ["HIV-1", "SPECIES", 30, 35], ["HIV", "PROBLEM", 30, 33], ["coreceptor CCR5", "TREATMENT", 49, 64], ["CXCR4", "TEST", 66, 71]]], ["A modified RANTES [regulated on activation, normal T cell expressed, and secreted; also termed chemokine (C\u2014C motif) ligand 5 or CCL5] selected coreceptor switch variants in a SCID (severe combined immunodeficiency) mouse model (Mosier et al., 1999).", [["T cell", "ANATOMY", 51, 57], ["SCID", "DISEASE", 176, 180], ["immunodeficiency", "DISEASE", 198, 214], ["RANTES", "GENE_OR_GENE_PRODUCT", 11, 17], ["T cell", "CELL", 51, 57], ["C\u2014C motif) ligand 5", "GENE_OR_GENE_PRODUCT", 106, 125], ["CCL5", "GENE_OR_GENE_PRODUCT", 129, 133], ["mouse", "ORGANISM", 216, 221], ["RANTES", "PROTEIN", 11, 17], ["chemokine", "PROTEIN", 95, 104], ["C\u2014C motif) ligand 5", "PROTEIN", 106, 125], ["CCL5", "PROTEIN", 129, 133], ["coreceptor switch variants", "PROTEIN", 144, 170], ["mouse", "SPECIES", 216, 221], ["mouse", "SPECIES", 216, 221], ["A modified RANTES", "TREATMENT", 0, 17], ["chemokine (C\u2014C motif) ligand", "TREATMENT", 95, 123], ["selected coreceptor switch variants", "TREATMENT", 135, 170], ["a SCID (severe combined immunodeficiency)", "PROBLEM", 174, 215], ["RANTES", "OBSERVATION", 11, 17]]], ["The mutants with amino acid substitutions in loop V3 of Env protein were selected to use CXCR4 rather than CCR5 as coreceptor (see also Section 4.4 in Chapter 4).Targeting Cellular Functions ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsAn alternative mechanism to overcome the inhibition of a cellular protein is that viral mutants are selected that can utilize the cellular protein in complex with the inhibitor.", [["cellular", "ANATOMY", 351, 359], ["cellular", "ANATOMY", 424, 432], ["amino acid", "CHEMICAL", 17, 27], ["amino acid", "CHEMICAL", 17, 27], ["amino acid", "AMINO_ACID", 17, 27], ["CXCR4", "GENE_OR_GENE_PRODUCT", 89, 94], ["CCR5", "GENE_OR_GENE_PRODUCT", 107, 111], ["cellular", "CELL", 351, 359], ["cellular", "CELL", 424, 432], ["loop V3", "PROTEIN", 45, 52], ["Env protein", "PROTEIN", 56, 67], ["CXCR4", "PROTEIN", 89, 94], ["CCR5", "PROTEIN", 107, 111], ["coreceptor", "PROTEIN", 115, 125], ["cellular protein", "PROTEIN", 351, 367], ["cellular protein", "PROTEIN", 424, 440], ["amino acid substitutions", "TREATMENT", 17, 41], ["loop V3 of Env protein", "TREATMENT", 45, 67], ["CXCR4", "TREATMENT", 89, 94], ["Antiviral Inhibitors", "TREATMENT", 274, 294], ["a cellular protein", "TREATMENT", 349, 367], ["viral mutants", "PROBLEM", 376, 389], ["the inhibitor", "TREATMENT", 457, 470], ["acid substitutions", "OBSERVATION", 23, 41], ["Cellular Functions", "OBSERVATION", 172, 190]]], ["This is the case of HIV-1 mutants resistant to small coreceptor CCR5-binding inhibitors; mutants with amino acid substitution in the V3 loop region or elsewhere in Env can use either free or inhibitor-bound CCR5 to enter cells, with an efficiency that depends on the CCR5 expression level and the host cell type (Pugach et al., 2007, Pugach et al., 2009).", [["cells", "ANATOMY", 221, 226], ["cell", "ANATOMY", 302, 306], ["amino acid", "CHEMICAL", 102, 112], ["amino acid", "CHEMICAL", 102, 112], ["HIV-1", "ORGANISM", 20, 25], ["CCR5", "GENE_OR_GENE_PRODUCT", 64, 68], ["amino acid", "AMINO_ACID", 102, 112], ["Env", "GENE_OR_GENE_PRODUCT", 164, 167], ["CCR5", "GENE_OR_GENE_PRODUCT", 207, 211], ["cells", "CELL", 221, 226], ["CCR5", "GENE_OR_GENE_PRODUCT", 267, 271], ["host cell", "CELL", 297, 306], ["CCR5", "PROTEIN", 64, 68], ["V3 loop region", "PROTEIN", 133, 147], ["Env", "PROTEIN", 164, 167], ["CCR5", "PROTEIN", 207, 211], ["CCR5", "PROTEIN", 267, 271], ["HIV-1", "SPECIES", 20, 25], ["HIV-1", "SPECIES", 20, 25], ["HIV", "PROBLEM", 20, 23], ["small coreceptor CCR5-binding inhibitors", "TREATMENT", 47, 87], ["amino acid substitution in the V3 loop region", "TREATMENT", 102, 147], ["inhibitor", "TREATMENT", 191, 200], ["an efficiency", "PROBLEM", 233, 246], ["host cell", "OBSERVATION_MODIFIER", 297, 306]]], ["These examples illustrate the multiple pathways that viruses can exploit to overcome inhibitors directed to cellular proteins.", [["cellular", "ANATOMY", 108, 116], ["cellular", "CELL", 108, 116], ["cellular proteins", "PROTEIN", 108, 125], ["overcome inhibitors", "TREATMENT", 76, 95]]], ["They constitute additional evidence that \u201cabundant sources of genetic variation exist for viruses to learn new tricks, \u2026\u201d emphasized by J. Lederberg in connection with viral disease emergence and reemergence (quoted also in Section 7.7.1 of Chapter 7).", [["viral disease", "DISEASE", 168, 181], ["genetic variation", "PROBLEM", 62, 79], ["viruses", "PROBLEM", 90, 97], ["viral disease emergence", "PROBLEM", 168, 191], ["viral disease", "OBSERVATION", 168, 181]]], ["Since many viruses can use alternative receptors for entry into cells (Section 4.4 in Chapter 4), inhibitors directed to viral receptors may promote selection of virus subpopulations that can use a different receptor.Use of Drugs That Stimulate the Host Innate Immune System ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsSome inhibitors of enzymes of the de novo pyrimidine biosynthesis pathway (DD264, bequinar, and A3) stimulate the innate immune response, and behave as broad-spectrum antiviral inhibitors (Lucas-Hourani et al., 2013, Munier-Lehmann et al., 2015, Vidalain et al., 2015).", [["cells", "ANATOMY", 64, 69], ["pyrimidine", "CHEMICAL", 420, 430], ["pyrimidine", "CHEMICAL", 420, 430], ["cells", "CELL", 64, 69], ["pyrimidine", "SIMPLE_CHEMICAL", 420, 430], ["DD264", "SIMPLE_CHEMICAL", 453, 458], ["viral receptors", "PROTEIN", 121, 136], ["alternative receptors", "TREATMENT", 27, 48], ["inhibitors", "TREATMENT", 98, 108], ["viral receptors", "TREATMENT", 121, 136], ["virus subpopulations", "PROBLEM", 162, 182], ["a different receptor", "TREATMENT", 196, 216], ["Drugs", "TREATMENT", 224, 229], ["Antiviral Inhibitors", "TREATMENT", 358, 378], ["enzymes", "TEST", 397, 404], ["the de novo pyrimidine biosynthesis pathway", "TREATMENT", 408, 451], ["DD264", "TEST", 453, 458], ["broad-spectrum antiviral inhibitors", "TREATMENT", 530, 565], ["viruses", "OBSERVATION", 11, 18], ["virus", "OBSERVATION", 162, 167]]], ["The observed effect is one among other connections that have been established between nucleotide and DNA metabolism and immune stimulation (Motani et al., 2015).", [["nucleotide", "CHEMICAL", 86, 96], ["nucleotide", "CHEMICAL", 86, 96], ["nucleotide", "SIMPLE_CHEMICAL", 86, 96], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["nucleotide and DNA metabolism", "TREATMENT", 86, 115], ["immune stimulation", "TREATMENT", 120, 138]]], ["For some of the pyrimidine biosynthesis inhibitors, additional mechanisms of antiviral activity might be involved, as in the inhibition of lymphocytic choriomeningitis virus (LCMV) replication and transcription by A3 (Ortiz-Riano et al., 2014).", [["pyrimidine", "CHEMICAL", 16, 26], ["lymphocytic choriomeningitis virus", "DISEASE", 139, 173], ["pyrimidine", "CHEMICAL", 16, 26], ["pyrimidine", "SIMPLE_CHEMICAL", 16, 26], ["lymphocytic choriomeningitis virus", "ORGANISM", 139, 173], ["LCMV", "ORGANISM", 175, 179], ["lymphocytic choriomeningitis virus", "SPECIES", 139, 173], ["lymphocytic choriomeningitis virus", "SPECIES", 139, 173], ["LCMV", "SPECIES", 175, 179], ["the pyrimidine biosynthesis inhibitors", "TREATMENT", 12, 50], ["antiviral activity", "TREATMENT", 77, 95], ["lymphocytic choriomeningitis virus", "PROBLEM", 139, 173], ["lymphocytic choriomeningitis", "OBSERVATION", 139, 167]]], ["Stimulation of the innate immune response may restrict the selection of escape mutants because the virus must mutate at several sites to overcome the different branches of the response, as is the case with interferon (IFN) resistance (Perales et al., 2014).", [["interferon", "GENE_OR_GENE_PRODUCT", 206, 216], ["interferon", "PROTEIN", 206, 216], ["IFN", "PROTEIN", 218, 221], ["Stimulation", "TREATMENT", 0, 11], ["escape mutants", "PROBLEM", 72, 86], ["the virus", "PROBLEM", 95, 104], ["interferon (IFN) resistance", "TREATMENT", 206, 233], ["different", "OBSERVATION_MODIFIER", 150, 159], ["branches", "OBSERVATION_MODIFIER", 160, 168]]], ["Multifactorial antiviral responses increase the genetic and phenotypic barriers to resistance (Section 8.4.2 in Chapter 8).Combined Use of Immunotherapy and Chemotherapy ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsAn extension of the advantage of combination therapy to decrease the selection of antiviral-resistant mutants consists in the combined use of immunotherapy (administration of neutralizing antibodies or other means of immune stimulation such as vaccination) together with antiviral inhibitors.", [["neutralizing antibodies", "PROTEIN", 448, 471], ["Multifactorial antiviral responses", "PROBLEM", 0, 34], ["Immunotherapy", "TREATMENT", 139, 152], ["Chemotherapy", "TREATMENT", 157, 169], ["Antiviral Inhibitors", "TREATMENT", 253, 273], ["combination therapy", "TREATMENT", 306, 325], ["antiviral-resistant mutants", "TREATMENT", 355, 382], ["immunotherapy", "TREATMENT", 415, 428], ["neutralizing antibodies", "TREATMENT", 448, 471], ["immune stimulation", "TREATMENT", 490, 508], ["vaccination)", "TREATMENT", 517, 529], ["antiviral inhibitors", "TREATMENT", 544, 564], ["antiviral responses", "OBSERVATION", 15, 34], ["increase", "OBSERVATION_MODIFIER", 35, 43]]], ["The concept was pioneered by R.G. Webster and colleagues, and was proposed as a strategy for the control of influenza viruses (Webster et al., 1985).", [["influenza viruses", "DISEASE", 108, 125], ["influenza viruses", "ORGANISM", 108, 125], ["a strategy", "TREATMENT", 78, 88], ["influenza viruses", "PROBLEM", 108, 125]]], ["The authors showed that the simultaneous administration of inactivated H5N2 vaccine and the inhibitor amantadine conferred protection against H5N2 influenza virus A/Chick/Pennsylvania/83 in chickens (Webster et al., 1986).", [["amantadine", "CHEMICAL", 102, 112], ["amantadine", "CHEMICAL", 102, 112], ["H5N2", "ORGANISM", 71, 75], ["amantadine", "SIMPLE_CHEMICAL", 102, 112], ["H5N2 influenza virus", "ORGANISM", 142, 162], ["Chick/Pennsylvania/83", "ORGANISM", 165, 186], ["chickens", "ORGANISM", 190, 198], ["H5N2 influenza virus", "SPECIES", 142, 162], ["chickens", "SPECIES", 190, 198], ["H5N2 influenza virus A/Chick/Pennsylvania/83", "SPECIES", 142, 186], ["chickens", "SPECIES", 190, 198], ["the simultaneous administration", "TREATMENT", 24, 55], ["inactivated H5N2 vaccine", "TREATMENT", 59, 83], ["the inhibitor amantadine", "TREATMENT", 88, 112], ["protection", "TREATMENT", 123, 133], ["H5N2", "PROBLEM", 142, 146]]], ["Related notions have been investigated with other viruses and different components of the immune response (Seiler et al., 2000, Li et al., 2005).", [["other viruses", "PROBLEM", 44, 57], ["viruses", "OBSERVATION", 50, 57]]], ["However, additional model in vivo experiments with animals and clinical trials with patients are necessary to investigate the effectiveness of combined immunotherapeutic approaches.Combined Use of Immunotherapy and Chemotherapy ::: Practiced and Proposed Strategies to Confront the Moving Target Challenge with Antiviral InhibitorsAs a general outlook on the strategies summarized in previous sections, the potential of combining two (or even more) of the proposals listed in Box 9.1 is encouraging, provided off-target effects of drugs or immune interventions can be controlled and side effects minimized.", [["sections", "ANATOMY", 393, 401], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["combined immunotherapeutic approaches", "TREATMENT", 143, 180], ["Immunotherapy", "TREATMENT", 197, 210], ["Chemotherapy", "TREATMENT", 215, 227], ["Antiviral Inhibitors", "TREATMENT", 311, 331], ["drugs", "TREATMENT", 531, 536], ["immune interventions", "TREATMENT", 540, 560], ["side effects", "PROBLEM", 583, 595]]], ["A trend toward \u201ccomplex\u201d treatment protocols is the expected response to the adaptive capacity of viral quasispecies.", [["\u201ccomplex\u201d treatment protocols", "TREATMENT", 15, 44], ["viral quasispecies", "PROBLEM", 98, 116], ["viral quasispecies", "OBSERVATION", 98, 116]]], ["The introduction of mutagenic agents in antiviral designs is an important departure that exploits one of the corollaries of quasispecies behavior: the error threshold relationship (introduced in Section 3.6.3 of Chapter 3).", [["mutagenic agents", "TREATMENT", 20, 36], ["antiviral designs", "TREATMENT", 40, 57]]], ["It is the basis of lethal mutagenesis discussed next.Reconciliation of Theory and Experiment: A Proposal ::: Lethal Mutagenesis and the Error ThresholdSeveral theoretical models have been presented to explain lethal mutagenesis of viruses (review in Tejero et al., 2016).", [["lethal mutagenesis", "TREATMENT", 19, 37], ["Lethal Mutagenesis", "PROBLEM", 109, 127], ["the Error Threshold", "PROBLEM", 132, 151], ["lethal mutagenesis of viruses", "PROBLEM", 209, 238]]], ["The models are conceptually diverse, and at times with remarkably counterintuitive proposals.", [["diverse", "OBSERVATION_MODIFIER", 28, 35]]], ["Some deny a connection between the error threshold of quasispecies theory and the extinction of viruses by enhanced mutagenesis.", [["quasispecies theory", "PROBLEM", 54, 73]]], ["In one of the models discussed by H. Tejero and colleagues, it was suggested that error catastrophe could not occur in the presence of lethal genotypes, a proposal that was considered peculiar by experimentalists, and that it was proven incorrect by Takeuchi and Hogeweg (2007) [see also references in that publication and in Tejero et al. (2016)].", [["error catastrophe", "DISEASE", 82, 99], ["error catastrophe", "PROBLEM", 82, 99], ["lethal genotypes", "PROBLEM", 135, 151]]], ["Other models that have suggested that lethal mutagenesis is unrelated to the error threshold have defined an extinction threshold to mean the mutation rate at which a viral population goes extinct.", [["lethal mutagenesis", "PROBLEM", 38, 56], ["the error threshold", "PROBLEM", 73, 92], ["an extinction threshold", "PROBLEM", 106, 129], ["the mutation rate", "TEST", 138, 155], ["a viral population", "PROBLEM", 165, 183]]], ["A rather counterintuitive proposal is that the error threshold is caused by the \u201csurvival of the flattest,\u201d which means dominance of genomes with low replicative capacity and high tolerance to mutations (robustness) that would hinder virus extinction (Tejero et al., 2011) (see Section 5.7 in Chapter 5 on the advantage of the flattest in a fitness landscape).Reconciliation of Theory and Experiment: A Proposal ::: Lethal Mutagenesis and the Error ThresholdC.", [["Error ThresholdC", "DNA", 443, 459], ["low replicative capacity", "PROBLEM", 146, 170], ["high tolerance to mutations", "PROBLEM", 175, 202], ["Lethal Mutagenesis", "TREATMENT", 416, 434], ["low replicative", "OBSERVATION_MODIFIER", 146, 161]]], ["The main stream of experimental results can be summarized as follows.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["stream", "OBSERVATION_MODIFIER", 9, 15]]], ["The first studies, that were an extension of those carried out in J.J. Holland\u2019s laboratory, confirmed a connection between a mutagenic activity and decrease of viral infectivity and showed that low viral load and low viral fitness favored virus extinction (Loeb et al., 1999, Sierra et al., 2000).", [["The first studies", "TEST", 0, 17], ["a mutagenic activity", "PROBLEM", 124, 144], ["viral infectivity", "PROBLEM", 161, 178], ["low viral load", "PROBLEM", 195, 209], ["low viral fitness", "PROBLEM", 214, 231], ["viral infectivity", "OBSERVATION", 161, 178], ["low", "OBSERVATION_MODIFIER", 195, 198], ["viral load", "OBSERVATION", 199, 209]]], ["Then, following the important discovery that the nucleoside analog ribavirin (1-\u03b2-d-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is mutagenic for PV (Crotty et al., 2000) it was observed that ribavirin decreased PV-specific infectivity (the ratio of infectivity to the amount of viral RNA) (Crotty et al., 2001).", [["nucleoside", "CHEMICAL", 49, 59], ["ribavirin", "CHEMICAL", 67, 76], ["1-\u03b2-d-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide", "CHEMICAL", 78, 130], ["ribavirin", "CHEMICAL", 195, 204], ["nucleoside", "CHEMICAL", 49, 59], ["ribavirin", "CHEMICAL", 67, 76], ["1-\u03b2-d-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide", "CHEMICAL", 78, 130], ["ribavirin", "CHEMICAL", 195, 204], ["nucleoside", "SIMPLE_CHEMICAL", 49, 59], ["ribavirin", "SIMPLE_CHEMICAL", 67, 76], ["1-\u03b2-d-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide", "SIMPLE_CHEMICAL", 78, 130], ["ribavirin", "SIMPLE_CHEMICAL", 195, 204], ["viral RNA", "RNA", 282, 291], ["PV", "SPECIES", 149, 151], ["PV", "SPECIES", 215, 217], ["the nucleoside analog ribavirin", "TREATMENT", 45, 76], ["d-ribofuranosyl", "TREATMENT", 82, 97], ["triazole", "TREATMENT", 108, 116], ["ribavirin", "TREATMENT", 195, 204], ["ribavirin", "OBSERVATION", 195, 204], ["viral RNA", "OBSERVATION", 282, 291]]], ["A decrease of specific infectivity, together with increase of mutation frequency is now considered the standard way to distinguish lethal mutagenesis from mere inhibition (Box 9.2).", [["A decrease of specific infectivity", "PROBLEM", 0, 34], ["mutation frequency", "PROBLEM", 62, 80], ["lethal mutagenesis", "PROBLEM", 131, 149], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["specific", "OBSERVATION_MODIFIER", 14, 22], ["infectivity", "OBSERVATION_MODIFIER", 23, 34]]], ["[This is not to mean that decreases of specific infectivity are exclusive of lethal mutagenesis.", [["specific infectivity", "PROBLEM", 39, 59], ["lethal mutagenesis", "PROBLEM", 77, 95], ["decreases", "OBSERVATION_MODIFIER", 26, 35], ["lethal mutagenesis", "OBSERVATION", 77, 95]]], ["They have been also documented as a result of codon deoptimization (Section 4.3 of Chapter 4) and in viral clones subjected to many plaque-to-plaque transfers (Section 6.5.2 in Chapter 6)].Box 9.2Main Observations on Viral Extinction by Mutagenic Agents\u2022Low viral load and low viral fitness favor extinction.\u2022During the transition toward extinction, the viral population:Decreases its specific infectivity.Increases its mutant spectrum complexity (movement toward usually unfavored regions of sequence space).Maintains an invariant consensus sequence.\u2022Reduction in viral load per se is not the mechanism of virus extinction.", [["plaque", "ANATOMY", 132, 138], ["plaque", "ANATOMY", 142, 148], ["viral clones", "CELL_LINE", 101, 113], ["invariant consensus sequence", "DNA", 522, 550], ["codon deoptimization", "TREATMENT", 46, 66], ["viral clones", "PROBLEM", 101, 113], ["many plaque", "PROBLEM", 127, 138], ["Box", "TEST", 189, 192], ["Viral Extinction", "TREATMENT", 217, 233], ["Mutagenic Agents", "TREATMENT", 237, 253], ["Low viral load", "PROBLEM", 254, 268], ["low viral fitness", "PROBLEM", 273, 290], ["the viral population", "PROBLEM", 350, 370], ["Reduction in viral load", "PROBLEM", 552, 575], ["virus extinction", "PROBLEM", 607, 623], ["viral clones", "OBSERVATION", 101, 113], ["many", "OBSERVATION_MODIFIER", 127, 131], ["plaque", "OBSERVATION", 132, 138], ["plaque", "OBSERVATION", 142, 148], ["viral load", "OBSERVATION", 258, 268], ["low", "OBSERVATION_MODIFIER", 273, 276], ["viral fitness", "OBSERVATION", 277, 290], ["extinction", "OBSERVATION", 297, 307], ["viral population", "OBSERVATION", 354, 370], ["infectivity", "OBSERVATION_MODIFIER", 394, 405], ["spectrum", "OBSERVATION_MODIFIER", 427, 435], ["complexity", "OBSERVATION_MODIFIER", 436, 446], ["viral load", "OBSERVATION", 565, 575], ["virus", "OBSERVATION", 607, 612]]], ["A load decrease by a mutagenic agent may extinguish the virus while the same decrease with an inhibitor may not.\u2022Viruses displaying different replicative features respond to mutagenic agents in a very similar way: the strategy is of general applicability provided a virus-specific mutagenic agent is available.\u2022The use of mutagens as antiviral agents has been validated in vivo.", [["mutagens", "CHEMICAL", 322, 330], ["A load decrease", "PROBLEM", 0, 15], ["a mutagenic agent", "TREATMENT", 19, 36], ["the virus", "PROBLEM", 52, 61], ["an inhibitor", "TREATMENT", 91, 103], ["Viruses", "PROBLEM", 113, 120], ["different replicative features", "PROBLEM", 132, 162], ["mutagenic agents", "TREATMENT", 174, 190], ["a virus", "TREATMENT", 264, 271], ["mutagens", "TREATMENT", 322, 330], ["antiviral agents", "TREATMENT", 334, 350], ["different", "OBSERVATION_MODIFIER", 132, 141], ["replicative", "OBSERVATION", 142, 153]]]], "756bd018d5a855b451352af3998452d5a74c227f": [["I. INTRODUCTIONThe search for new molecules capable of exhibiting specific target properties is a long-standing problem in chemistry.", [["new molecules", "PROBLEM", 30, 43], ["a long-standing problem in chemistry", "PROBLEM", 96, 132]]], ["New molecules could improve technologies in many industrial and pharmaceutical areas.", [["New molecules", "PROBLEM", 0, 13], ["molecules", "OBSERVATION", 4, 13], ["many", "OBSERVATION_MODIFIER", 44, 48], ["industrial", "OBSERVATION_MODIFIER", 49, 59], ["pharmaceutical", "OBSERVATION_MODIFIER", 64, 78], ["areas", "OBSERVATION_MODIFIER", 79, 84]]], ["For example, new molecules with specific target properties can become new drugs that can improve treatments for diseases or even cure new diseases 1 .", [["new molecules", "PROBLEM", 13, 26], ["new drugs", "TREATMENT", 70, 79], ["diseases", "PROBLEM", 112, 120], ["even cure new diseases", "PROBLEM", 124, 146], ["new", "OBSERVATION_MODIFIER", 13, 16], ["molecules", "OBSERVATION", 17, 26]]], ["Many approaches are used to explore the chemical space such as high throughput screening [1, 2] and evolutionary algorithms [3] .", [["Many approaches", "TREATMENT", 0, 15], ["evolutionary algorithms", "TEST", 100, 123]]], ["Alternative approaches use Machine Learning models to predict properties of pre-defined or commercial compounds, e.g. using Recursive Neural Networks [4, 5] .", [["Learning models", "TREATMENT", 35, 50]]], ["In recent years the machine learning community has devoted much effort in the study of machine/deep learning models that are capable of generating candidate molecules that are likely to exhibit some pre-specified properties [6] .", [["the study", "TEST", 74, 83], ["deep learning models", "PROBLEM", 95, 115]]], ["Thanks to the development of increasingly effective deep learning models and the presence of large datasets, this approach achieved promising results.I. INTRODUCTIONIn literature, there are many proposals for generative models for molecules, that are often applied to the drug generation domain.", [["drug generation domain", "PROTEIN", 272, 294], ["increasingly effective deep learning models", "PROBLEM", 29, 72], ["large datasets", "PROBLEM", 93, 107], ["generative models", "TREATMENT", 209, 226], ["increasingly", "OBSERVATION_MODIFIER", 29, 41], ["effective", "OBSERVATION_MODIFIER", 42, 51], ["large", "OBSERVATION_MODIFIER", 93, 98], ["datasets", "OBSERVATION", 99, 107]]], ["The majority of them are based on the following approaches: 1) variational autoencoders [7] ; 2) generative adversarial networks [8] ; 3) recurrent neural networks [9, 10] ; 4) adversarial autoencoders [11] .", [["neural networks", "ANATOMY", 148, 163], ["neural networks", "MULTI-TISSUE_STRUCTURE", 148, 163], ["variational autoencoders", "PROBLEM", 63, 87], ["recurrent neural networks", "PROBLEM", 138, 163]]], ["To be able to compare all these different families of approaches, some frameworks have been developed as baselines, such us MOSES [12] , and GuacaMol [13] .I. INTRODUCTIONIn this work, we focus on the variational autoencoder approach, which seems to deliver the best trade-off between generative capabilities and ease of training.", [["the variational autoencoder approach", "TREATMENT", 197, 233]]], ["In fact, adversarial based models are quite problematic to train, while models based on recurrent neural networks make it difficult to control the \"shape\" of the latent space and thus its sampling for the generation of novel compounds.I. INTRODUCTIONEarly works adopting the variational autoencoder approach [14, 15, 16] share the capability of generating new molecules using SMILES [17, 18, 19] representations, which are strings describing the structure of the molecules.", [["neural networks", "ANATOMY", 98, 113], ["neural networks", "MULTI-TISSUE_STRUCTURE", 98, 113], ["adversarial based models", "PROBLEM", 9, 33], ["recurrent neural networks", "PROBLEM", 88, 113], ["the variational autoencoder approach", "TREATMENT", 271, 307], ["latent", "OBSERVATION_MODIFIER", 162, 168]]], ["In particular, Grammar VAE [15] adds a context-free grammar to the standard variational autoencoder [14] to guide the correct generation of SMILE strings, while Syntax Directed VAE [16] adds a more expressive grammar, the attribute grammar [20] , capable of generating a higher number of valid SMILES strings.", [["SMILE strings", "PROBLEM", 140, 153], ["a more expressive grammar", "TREATMENT", 191, 216]]], ["Specifically, Junction Tree VAE [21] represents molecules using graphs composed of chemical substructures that are extracted from the training set.", [["chemical substructures", "PROBLEM", 83, 105], ["chemical substructures", "OBSERVATION", 83, 105]]], ["New molecular graphs are obtained by first generating a tree-structured scaffold formed by substructures (the junction tree), and then combining the substructures together using a graph message passing network.", [["junction tree", "MULTI-TISSUE_STRUCTURE", 110, 123], ["New molecular graphs", "TEST", 0, 20], ["molecular graphs", "OBSERVATION", 4, 20]]], ["Regularized Graph VAE [22] transforms the constrained molecule generation problem into a regularized unconstrained problem, applying a generalization of the Lagrangian function in order to move all the constrains into the optimization function.", [["Regularized Graph VAE", "PROBLEM", 0, 21], ["the constrained molecule generation problem", "PROBLEM", 38, 81], ["a regularized unconstrained problem", "PROBLEM", 87, 122]]], ["State-of-the-art Constrained Graph VAE (CGVAE) [23] uses a variational autoencoder to generate a latent space normal distribution from which the model samples a point for each atom, differently from previously models that sample only one point per molecule.I. INTRODUCTIONA common and crucial feature of the above models is to embed chemical background knowledge, e.g. to increase the number of generated valid molecules Syntax Directed VAE exploits a chemical-based context-free grammar, while CGVAE uses the valence of each atom to guide the generation of the bonds.I. INTRODUCTIONAlthough CGVAE returns state-of-the-art results, we argue that its choice to sample the latent space independently for each atom of the generated molecule, constitutes a limitation of the model.", [["VAE", "PROTEIN", 437, 440], ["CGVAE", "PROTEIN", 495, 500], ["a variational autoencoder", "TREATMENT", 57, 82]]], ["Thus, introducing a form of dependence among atoms, should help the model to better learn the distribution of the molecular structures in input.I. INTRODUCTIONIn order to remove this independence assumption, in this paper we present the Conditional Constrained Graph VAE (CCGVAE) model, in which histograms of valences of the molecules are used to make the generation of atoms from the latent space dependent on the already sampled atoms.", [["latent", "OBSERVATION_MODIFIER", 386, 392], ["space", "OBSERVATION", 393, 398]]], ["Specifically, given a valid target valence histogram for the molecule to be generated, the atom generation process is designed so to keep the current valence histogram obtained by the already generated atoms to stay compatible with the target histogram.", [["a valid target valence histogram", "TEST", 20, 52], ["the molecule", "PROBLEM", 57, 69], ["the current valence histogram", "TEST", 138, 167], ["the target histogram", "TEST", 232, 252]]], ["In Section IV, we discuss the experimental evaluation of the model.", [["the experimental evaluation", "TEST", 26, 53]]], ["The code used for this work is published online 2 .II. CONSTRAINED GRAPH VAELet us start with some definitions.", [["II", "CHEMICAL", 51, 53]]], ["A graph is a tuple G = (V, E, L) where V = {v 1 , . . . , v m } is the set of nodes representing atoms, E is the set of edges representing bonds between atoms, and L is a function associating labels to nodes (the atom type) and edges (the bond type).II. CONSTRAINED GRAPH VAEConstrained Graph Variational Autoencoder (CGVAE) is a model proposed by Liu et al. [23] .", [["L", "PROTEIN", 164, 165], ["A graph", "TEST", 0, 7], ["a tuple G", "TEST", 11, 20], ["CONSTRAINED GRAPH VAEConstrained Graph Variational Autoencoder (CGVAE)", "TREATMENT", 254, 324], ["nodes", "OBSERVATION", 78, 83], ["bonds", "ANATOMY_MODIFIER", 139, 144], ["L", "ANATOMY_MODIFIER", 164, 165], ["nodes", "OBSERVATION", 202, 207], ["edges", "OBSERVATION_MODIFIER", 228, 233]]], ["This model is based on the variational autoencoder approach in which there are two main components: the encoder and the decoder.", [["the variational autoencoder approach", "TREATMENT", 23, 59], ["two", "OBSERVATION_MODIFIER", 79, 82], ["main", "OBSERVATION_MODIFIER", 83, 87], ["components", "OBSERVATION_MODIFIER", 88, 98]]], ["Given in input a molecule, the encoder learns to encode its atoms in a latent space defined by a normal distribution N (0, I), where I is the identity matrix.", [["matrix", "CELLULAR_COMPONENT", 151, 157], ["normal", "OBSERVATION", 97, 103], ["distribution", "OBSERVATION_MODIFIER", 104, 116]]], ["Since the latent space is defined by a standard normal distribution, it is possible to sample new points, i.e. atoms, from that distribution and to decode them into a valid molecule by the decoder.", [["latent", "OBSERVATION_MODIFIER", 10, 16], ["space", "OBSERVATION", 17, 22], ["distribution", "OBSERVATION_MODIFIER", 55, 67], ["possible to", "UNCERTAINTY", 75, 86]]], ["Specifically, at the beginning the model randomly selects an initial atom (focus) and adds (valid) bonds with other atoms till a stop criterion is satisfied.", [["adds (valid) bonds with other atoms", "TREATMENT", 86, 121]]], ["Whenever a new bound with an unconnected atom is inserted, the involved atom is inserted into a queue.", [["a new bound", "PROBLEM", 9, 20], ["an unconnected atom", "TREATMENT", 26, 45]]], ["When the focus atom reaches the stop criterion, an atom is extracted from the queue and it becomes the new focus atom.", [["new", "OBSERVATION_MODIFIER", 103, 106]]], ["The generation of new bounds is then resumed with the new focus atom.", [["new", "OBSERVATION_MODIFIER", 18, 21]]], ["It should be noticed that, the generation of a new (valid) bound (and its type) at a specific decoding point is conditioned on the current partial molecule built till that point.", [["a new (valid) bound", "PROBLEM", 45, 64], ["new", "OBSERVATION_MODIFIER", 47, 50]]], ["The decoding process stops when the queue is empty.", [["empty", "OBSERVATION", 45, 50]]], ["Finally, eventually isolated atoms are removed, and the obtained molecule is returned as output of the decoder.", [["atoms", "OBSERVATION_MODIFIER", 29, 34]]], ["This is achieved starting from random points in the latent space (i.e., set of atoms) and performing gradient ascent/descent in latent space with respect to the property of interest.II. CONSTRAINED GRAPH VAEIn the following, we summarize the main computational steps of the model, i.e. encoding, decoding, optimization, and training.A. EncodingThe first computational step of the CGVAE model is constituted by the encoder.", [["II", "CHEMICAL", 182, 184], ["gradient ascent/descent in latent space", "TREATMENT", 101, 140], ["latent", "OBSERVATION_MODIFIER", 52, 58], ["space", "OBSERVATION_MODIFIER", 59, 64]]], ["Specifically, a Gated Graph Recurrent Neural Network (GGRNN) [24] with residual connections is first used to devise a hidden representation of each atom (node) that embeds the information of its neighbors.", [["node", "MULTI-TISSUE_STRUCTURE", 154, 158], ["residual connections", "PROBLEM", 71, 91], ["node", "OBSERVATION", 154, 158]]], ["Then, the encoder uses two neural networks 3 in order to generate means and variances for each atom from the last updated hidden state values.", [["neural networks", "ANATOMY", 27, 42]]], ["The vector z v representing the atom v encoded in the latent space is then sampled according to the distribution N (\u00b5 v , \u03a3 v ).", [["vector z v", "DNA", 4, 14], ["The vector z v", "TREATMENT", 0, 14], ["the atom v", "PROBLEM", 28, 38], ["atom v", "OBSERVATION", 32, 38], ["latent", "OBSERVATION_MODIFIER", 54, 60], ["space", "OBSERVATION_MODIFIER", 61, 66]]], ["It should be emphasized that this model generates a probability distribution for each node in the graph, unlike other approaches [14, 15, 16, 21, 22, 25] that generate a probability distribution per molecule.", [["node", "ANATOMY", 86, 90], ["each node in the graph", "PROBLEM", 81, 103], ["node", "OBSERVATION", 86, 90]]], ["It follows that while in the other models the sampling of a point in the latent space implies the choice of a precise molecule, in this case one sampling in the latent space implies only the choice of a single atom, making it necessary to use more samples in the decoder to perform the generation of a new molecule.B. DecodingThe decoder receives as input a set of vectors {z v } v\u2208 [1,m] , where each z v represents an atom.", [["a new molecule", "PROBLEM", 300, 314], ["latent", "OBSERVATION_MODIFIER", 73, 79], ["space", "OBSERVATION", 80, 85], ["latent", "OBSERVATION_MODIFIER", 161, 167], ["space", "OBSERVATION", 168, 173], ["new", "OBSERVATION_MODIFIER", 302, 305]]], ["During the generation phase, z v 's are sampled from the normal distribution N (0, I ), where I is the identity matrix.", [["matrix", "CELLULAR_COMPONENT", 112, 118], ["the generation phase", "TEST", 7, 27], ["z v 's", "TEST", 29, 35], ["normal", "OBSERVATION", 57, 63], ["distribution", "OBSERVATION_MODIFIER", 64, 76]]], ["During training, the values z v are obtained by the distribution N (\u00b5 v , \u03a3 v ), using the reparameterization trick.", [["the values z v", "TEST", 17, 31], ["the reparameterization trick", "TREATMENT", 87, 115]]], ["The nodes are initially not connected with each other and they are associated with a stateB.", [["nodes", "ANATOMY", 4, 9], ["nodes", "MULTI-TISSUE_STRUCTURE", 4, 9], ["stateB", "DNA", 85, 91], ["nodes", "OBSERVATION", 4, 9]]], ["Decodingin which \u03c4 v is supposed to be a one-hot vector indicating the node type, obtained by sampling from a learned softmax transformation from the latent space to the atom type space, i.e. \u03c4 v \u223c sof tmax(f (z v )).", [["node", "ANATOMY", 71, 75], ["\u03c4 v", "GENE_OR_GENE_PRODUCT", 17, 20], ["\u03c4 v", "PROTEIN", 17, 20], ["a learned softmax transformation", "PROBLEM", 108, 140], ["node", "OBSERVATION", 71, 75], ["latent", "OBSERVATION_MODIFIER", 150, 156]]], ["Actually, in the software implementing the model it is a 100-dimensional vector embedding of the node type.B. DecodingOnce all the atoms hidden states are obtained, a vector H init considering global information conveyed by all initially disconnected nodes is computed at step t = 0 by averaging the vectors {h 0 v } v\u2208V .", [["node", "ANATOMY", 97, 101], ["H", "CHEMICAL", 174, 175], ["nodes", "MULTI-TISSUE_STRUCTURE", 251, 256], ["v\u2208V", "PROBLEM", 317, 320], ["node type", "OBSERVATION", 97, 106], ["nodes", "OBSERVATION", 251, 256]]], ["Subsequently, at each step t the vector H t is computed by considering only connected nodes, i.e., excluding isolated nodes.", [["nodes", "ANATOMY", 86, 91], ["nodes", "ANATOMY", 118, 123], ["nodes", "MULTI-TISSUE_STRUCTURE", 86, 91], ["isolated nodes", "MULTI-TISSUE_STRUCTURE", 109, 123], ["vector H t", "DNA", 33, 43], ["connected nodes", "PROBLEM", 76, 91], ["isolated nodes", "PROBLEM", 109, 123], ["nodes", "OBSERVATION", 86, 91], ["nodes", "OBSERVATION", 118, 123]]], ["The generation of bonds proceeds as described at the beginning of the section.B. DecodingWhenever a new bond is added and consequently the partially constructed graph is modified, the model uses a Gated Graph Recurrent Neural Network (GGRNN) to update the information of each node, generating new states h t+1 v for each step s \u2208 [0, 12]:B. Decodingwhere h t v is the hidden representation of the atom v at the time step t and the summation is over all the neighbors of node v connected by an arc of type l for each value of l.", [["node", "ANATOMY", 276, 280], ["node", "ANATOMY", 470, 474], ["node", "OBSERVATION", 276, 280], ["node", "OBSERVATION", 470, 474]]], ["E l is a neural network for edges of type l that preserves the dimension.B. DecodingIn order to decide which specific bound (and its type l) to add, the following distribution over candidate edges is used:B. Decodingis the distance calculated between nodes v and u over the graph currently generated, v \u2190 \u2192 u indicates the presence of a bond between the atoms v and u, and v l \u2190 \u2192 u indicates the presence of a bond of type l between v and u.", [["neural network", "ANATOMY", 9, 23], ["neural network", "MULTI-TISSUE_STRUCTURE", 9, 23], ["E l", "DNA", 0, 3], ["the graph", "TEST", 270, 279], ["neural network", "OBSERVATION", 9, 23], ["type l", "OBSERVATION_MODIFIER", 37, 43]]], ["With the vector \u03c6 t v,u that groups the local information of the nodes and the global information on the graph, the model uses the function C (\u03c6) to obtain the probability of existence of the edge, i.e. the bond, between the two atoms v and u.", [["the graph", "TEST", 101, 110], ["nodes", "OBSERVATION", 65, 70]]], ["C (\u03c6) and L l (\u03c6) are fully connected networks with a single hidden layer of 250 units and ReLU non-linearities.", [["a single hidden layer", "TREATMENT", 52, 73]]], ["During the generation of new molecules, the existence and the type of the bonds are sampled from the probabilities returned by the two functions, while during training teacher forcing is used.", [["new molecules", "PROBLEM", 25, 38], ["new", "OBSERVATION_MODIFIER", 25, 28], ["molecules", "OBSERVATION", 29, 38]]], ["The probabilities are defined as:B. Decodingwhere both C (\u03c6) and L l (\u03c6) are represented by neural networks in which the last layer has a softmax function on the probabilities of outputs weighted with the use of binary masks M t v\u2190 \u2192u and m t v l \u2190 \u2192u .", [["neural networks", "ANATOMY", 92, 107], ["neural networks", "MULTI-TISSUE_STRUCTURE", 92, 107], ["neural networks", "OBSERVATION", 92, 107]]], ["Similarly to those used in [15] , they are intended to prohibit bonds that violate certain chemical constraints in the construction of molecules.B. DecodingAs already said at the beginning of the section, the generation of bonds connected to the focus atom at time step t stops when a given criterion is met.", [["[15]", "SIMPLE_CHEMICAL", 27, 31], ["the section", "TREATMENT", 192, 203]]], ["The criterion is met when a connection with a special stop-node is created.", [["stop-node", "ANATOMY", 54, 63], ["-node", "MULTI-TISSUE_STRUCTURE", 58, 63], ["a special stop-node", "TREATMENT", 44, 63], ["node", "OBSERVATION", 59, 63]]], ["In this case the generation process proceeds by selecting a new node (i.e., the new focus atom) on which to apply the procedure again.", [["node", "ANATOMY", 64, 68], ["node", "MULTI-TISSUE_STRUCTURE", 64, 68], ["a new node", "PROBLEM", 58, 68], ["the procedure", "TREATMENT", 114, 127], ["new", "OBSERVATION_MODIFIER", 60, 63], ["node", "OBSERVATION", 64, 68]]], ["Every time a new atom is connected, it is pushed in a FIFO structure which is queried to obtain the next node to visit.", [["FIFO structure", "PROTEIN", 54, 68], ["node", "OBSERVATION", 105, 109]]], ["Thus, the model visits graph nodes using a breath first algorithm.", [["graph nodes", "MULTI-TISSUE_STRUCTURE", 23, 34], ["a breath first algorithm", "TEST", 41, 65], ["nodes", "OBSERVATION", 29, 34]]], ["At the end of the process, when the FIFO structure is empty i.e. all the (connected) nodes have been visited, all the bonds necessary for the validity of the molecule are completed by adding hydrogen atoms bonded with all the atoms whose valences are not correct.", [["hydrogen", "CHEMICAL", 191, 199], ["hydrogen atoms", "SIMPLE_CHEMICAL", 191, 205], ["FIFO structure", "PROTEIN", 36, 50], ["empty", "OBSERVATION", 54, 59], ["nodes", "OBSERVATION", 85, 90]]], ["A public online software was used to manage the molecular structure 4 .C. OptimizationCGVAE directly incorporates in the variational autoencoder the neural network O which has the purpose of optimizing the latent space towards molecules that exhibit better values for a target property.", [["neural network", "ANATOMY", 149, 163]]], ["Thanks to O it is possible to use gradient ascent/descent 5 on the latent space to find a new set of latent points that is decoded into a molecule with a better value for the target property.D. TrainingThe decoder is trained by supervising the creation of the arcs through breath first search.", [["gradient ascent/descent", "TREATMENT", 34, 57], ["new", "OBSERVATION_MODIFIER", 90, 93]]], ["Since the idea of this model is to generate the edges from a set of initially disconnected nodes, the model should compute the marginalized probability of each edge with respect to all possible node permutations.", [["node", "ANATOMY", 194, 198], ["nodes", "MULTI-TISSUE_STRUCTURE", 91, 96], ["initially disconnected nodes", "PROBLEM", 68, 96], ["node permutations", "TREATMENT", 194, 211], ["nodes", "OBSERVATION", 91, 96], ["node permutations", "OBSERVATION", 194, 211]]], ["Since this would be computationally expensive, Monte Carlo sampling is used to get an estimation.", [["Monte Carlo sampling", "TREATMENT", 47, 67], ["an estimation", "TEST", 83, 96]]], ["The loss function to minimize is:D. Trainingwhere L recon is the decoder loss and L latent is the variational autoencoder KullbackLeibler loss and L opt is the optimization network loss. \u03bb 1 and \u03bb 2 are two constant scalar values set to 0.3 and 10, respectively.", [["\u03bb 1", "GENE_OR_GENE_PRODUCT", 187, 190], ["\u03bb 2", "GENE_OR_GENE_PRODUCT", 195, 198], ["\u03bb 1 and \u03bb 2", "DNA", 187, 198], ["The loss function", "PROBLEM", 0, 17], ["the decoder loss", "PROBLEM", 61, 77], ["the variational autoencoder KullbackLeibler loss", "PROBLEM", 94, 142], ["constant scalar values", "TEST", 207, 229], ["constant", "OBSERVATION_MODIFIER", 207, 215], ["scalar values", "OBSERVATION", 216, 229]]], ["In particular, the L recon loss is calculated as the sum of the cross-entropy loss calculated on the predicted atom types probabilities with respect to the real atom types, and the cross-entropy loss calculated on the predicted bonds probabilities with regard to the real bonds at each time step.", [["the L recon loss", "PROBLEM", 15, 31], ["the cross-entropy loss", "PROBLEM", 60, 82], ["the cross-entropy loss", "PROBLEM", 177, 199], ["L", "OBSERVATION_MODIFIER", 19, 20], ["recon loss", "OBSERVATION", 21, 31], ["cross-entropy loss", "OBSERVATION", 64, 82], ["cross-entropy loss", "OBSERVATION", 181, 199]]], ["L opt loss is calculated as the Mean Squared Error between the predicted and the target property values.III. PROPOSED MODEL: CONDITIONAL CGVAEThis work is based on the CGVAE model (Section II).", [["L opt loss", "PROBLEM", 0, 10], ["loss", "OBSERVATION", 6, 10]]], ["By recalling that Carbon has valence 4, Oxygen has valence 2 and Hydrogen has valence 1, it can be noticed that the histogram of molecule A is compatible with that one of molecule B.III. PROPOSED MODEL: CONDITIONAL CGVAEDefinition 2 (Histograms distribution): Given a dataset of molecules T r in which each molecule is associated with its histogram of valences, the histograms distribution H T r is the probability distribution obtained considering all the histograms of valences of molecules in T r.III. PROPOSED MODEL: CONDITIONAL CGVAEDefinition 3 (Histogram compatibility): Let \u03b1 and \u03b2 be two histograms of valences belonging to two possibly different molecules, in which \u03bd \u2208 N is the maximum atom valence value for both molecules.", [["Oxygen", "CHEMICAL", 40, 46], ["Hydrogen", "CHEMICAL", 65, 73], ["Carbon", "CHEMICAL", 18, 24], ["Oxygen", "CHEMICAL", 40, 46], ["Hydrogen", "CHEMICAL", 65, 73], ["Oxygen", "SIMPLE_CHEMICAL", 40, 46], ["Hydrogen", "SIMPLE_CHEMICAL", 65, 73], ["H T", "GENE_OR_GENE_PRODUCT", 390, 393], ["T r.III", "GENE_OR_GENE_PRODUCT", 496, 503], ["Let \u03b1", "GENE_OR_GENE_PRODUCT", 578, 583], ["\u03b2", "GENE_OR_GENE_PRODUCT", 588, 589], ["B.III", "PROTEIN", 180, 185], ["\u03b1", "PROTEIN", 582, 583], ["\u03b2", "PROTEIN", 588, 589], ["T r.III", "SPECIES", 496, 503], ["the histograms distribution", "TEST", 362, 389]]], ["We say that \u03b1 is compatible with \u03b2:III.", [["\u03b2:III", "GENE_OR_GENE_PRODUCT", 33, 38], ["\u03b1", "PROTEIN", 12, 13], ["\u03b2:III", "PROTEIN", 33, 38], ["compatible with", "UNCERTAINTY", 17, 32]]], ["PROPOSED MODEL: CONDITIONAL CGVAEIn other words, histogram \u03b1 is compatible with a second histogram \u03b2 if and only if, for each valence, the value present in \u03b2 is greater than or equal to that in \u03b1.", [["\u03b2", "GENE_OR_GENE_PRODUCT", 156, 157], ["\u03b2", "PROTEIN", 156, 157], ["\u03b1.", "SPECIES", 194, 196], ["a second histogram", "TEST", 80, 98], ["the value", "TEST", 135, 144]]], ["Figure 1 shows an histograms compatibility example.III. PROPOSED MODEL: CONDITIONAL CGVAEThe basic idea is to exploit the histogram of valences to drive the atom type assignment process.", [["an histograms compatibility", "TEST", 15, 42], ["the histogram", "TEST", 118, 131]]], ["Specifically, at the beginning of the generation process, in addition to the number of atoms |V | = m, we provide a reference histogram \u03b1 0 with total count equal to m, selected at random from the ones computed from molecules in the training set.", [["a reference histogram", "TEST", 114, 135], ["total count", "TEST", 145, 156]]], ["The assignment of an atom type to each point sampled from the latent space is then conditioned to the already assigned atom types.", [["an atom type", "PROBLEM", 18, 30], ["latent", "OBSERVATION_MODIFIER", 62, 68], ["space", "OBSERVATION", 69, 74]]], ["Given a molecule in input to the model, we use its histogram of valences and the histograms distribution H T r to condition the decoder during the reconstruction phase.", [["its histogram", "TEST", 47, 60], ["the reconstruction phase", "TEST", 143, 167]]], ["In particular, in order to condition the decoder with the histogram of valences information, we modify the initial part of the decoder which assigns the atom type to each sample from the latent space, so to make it dependent on the atom type assignment history.", [["latent", "OBSERVATION_MODIFIER", 187, 193]]], ["We do that by introducing a new recurrent component at the first part of the decoder.", [["a new recurrent component", "PROBLEM", 26, 51], ["new", "OBSERVATION_MODIFIER", 28, 31], ["recurrent", "OBSERVATION_MODIFIER", 32, 41], ["component", "OBSERVATION_MODIFIER", 42, 51]]], ["Figure 2 provides an overview of the CCGVAE structure, where the new decoder is represented by two distinct phases which are placed in succession one after the other.", [["new", "OBSERVATION_MODIFIER", 65, 68], ["decoder", "OBSERVATION", 69, 76], ["distinct", "OBSERVATION_MODIFIER", 99, 107], ["phases", "OBSERVATION_MODIFIER", 108, 114]]], ["The first phase generates nodes, while the second phase generates bonds.", [["nodes", "OBSERVATION", 26, 31]]], ["While the second phase stays the same as defined in CGVAE, the first phase is modified as described in the following.A. Conditional Atom Type AssignmentHere we describe how the valence histograms are used to condition the atom type assignment to samples from the latent space.", [["the valence histograms", "TEST", 173, 195], ["latent space", "OBSERVATION", 263, 275]]], ["The decoder receives as input the m latent space points z v with v \u2208 {1, .., m}, the histograms distribution H T r and a histogram \u03b1 0 (of the considered molecule in reconstruction during training, or randomly sampled from H T r in generation). z v is sampled from the distribution N (\u00b5 v , \u03a3 v ) during the learning procedure and from N (0, I) during the generation procedure.", [["H T r", "GENE_OR_GENE_PRODUCT", 223, 228], ["z v", "GENE_OR_GENE_PRODUCT", 245, 248], ["the histograms distribution", "TEST", 81, 108], ["a histogram", "TEST", 119, 130], ["reconstruction during training", "TREATMENT", 166, 196], ["the learning procedure", "TREATMENT", 304, 326], ["the generation procedure", "TREATMENT", 352, 376]]], ["Let \u03b1 u 0 the histogram where all the valences are 0 and t \u2208 {1, .., m}, then each atom type is predicted using the following procedure:A. Conditional Atom Type Assignmentwhere:A. Conditional Atom Type Assignmentis a function that receives in input z t , the difference histogram \u03b1 d t and the updated histogram \u03b1 u t at each step t.", [["the histogram", "TEST", 10, 23], ["all the valences", "TEST", 30, 46]]], ["In the end, this function returns an atom hidden representation R t = [z t , e t ]; \u2022 F (R t ) is a function that receives in input an atom hidden representation R t , and generates a probability distribution on the atom types;A. Conditional Atom Type Assignmentis a function that samples the atom type from the distribution returned by the function F applying a binary mask in order to remove all the atoms whose valences have a zero-value in the histogram \u03b1 d t .", [["a binary mask", "TREATMENT", 361, 374]]], ["At training time teacher forcing is used, while at generation time and at reconstruction time, the binary mask is used in order to improve the accuracy; \u2022 Update(\u03c4 t , \u03b1 u t ) is a function that updates the histogram \u03b1 u t with the valence of the sampled atom type \u03c4 t ; \u2022 Sample distr (H, \u03b1 u t ) is a function that, at training time and during the reconstruction task, returns always the histogram \u03b1 v 0 .", [["the binary mask", "TREATMENT", 95, 110], ["Sample", "TEST", 273, 279], ["the reconstruction task", "TEST", 346, 369]]], ["During the generation of new molecules this function samples from H a new histogram \u03b1 t+1 with at least m atoms, such that \u03b1 u t is compatible with \u03b1 t+1 If there is no compatible histogram in H, a random sampling is done according to H with no further constraints.", [["\u03b1 t", "DNA", 148, 151], ["a new histogram", "TEST", 68, 83], ["a random sampling", "TEST", 196, 213], ["further constraints", "PROBLEM", 245, 264], ["no compatible", "UNCERTAINTY", 166, 179]]], ["The benefit of the above procedure consists in avoiding the generation of a set of atoms that is not compatible with the histograms of valences of the molecules in the training set, in principle constraining learning and generation to focus on the original generating distribution of the training set. .", [["the above procedure", "TREATMENT", 15, 34], ["not compatible", "UNCERTAINTY", 97, 111]]], ["The molecule in input to the encoder goes through the GGRNN with the edge-specific neural network E and then the encoder encodes the molecule in the latent space Z. The first part of the decoder receives in input the sampled points, the initial histogram \u03b1 0 and the histograms distribution H. K is a function that generates the embedding part for each atom, while F is a function that generates the atom types probabilities.B. Bonds GenerationThis part of the model receives as input the set of nodes generated by the previous phase and, using the same process as CGVAE, starting from a node it proceeds with the generation of the bonds towards the other atoms until the molecule is completed.IV. EXPERIMENTSFollowing [26] , we compared our model with several stateof-the-art proposals on two datasets, using different metrics in order to see the potential of each model.", [["neural network", "ANATOMY", 83, 97], ["GGRNN", "GENE_OR_GENE_PRODUCT", 54, 59], ["GGRNN", "DNA", 54, 59], ["The molecule", "PROBLEM", 0, 12], ["the initial histogram", "TEST", 233, 254], ["the histograms distribution", "TEST", 263, 290], ["a node", "TREATMENT", 586, 592], ["molecule", "OBSERVATION_MODIFIER", 4, 12], ["edge", "OBSERVATION_MODIFIER", 69, 73], ["neural network", "OBSERVATION", 83, 97], ["molecule", "OBSERVATION_MODIFIER", 133, 141], ["latent", "OBSERVATION_MODIFIER", 149, 155], ["Bonds Generation", "OBSERVATION", 428, 444], ["nodes", "OBSERVATION", 496, 501], ["node", "OBSERVATION", 588, 592]]], ["In particular, for each model we assessed the ability to reconstruct the input molecules and the ability to generate new ones.A. Datasets and MetricsWe consider two datasets of molecules: QM9 [27, 28] , composed by about 134,000 organic molecules with a maximum of 9 atoms, and ZINC [29] , composed by 250,000 drug-like molecules with up to 38 atoms.", [["ZINC", "CHEMICAL", 278, 282], ["ZINC [29]", "SIMPLE_CHEMICAL", 278, 287], ["ZINC", "TEST", 278, 282]]], ["We use the same training and test splits in each dataset for each model.", [["the same training", "TREATMENT", 7, 24]]], ["However, differently from [26] , we have chosen a different split of the data in the QM9 dataset as the test set in the original split did not reflect the distribution of molecules present in the training set very well.", [["QM9 dataset", "DNA", 85, 96], ["the test set", "TEST", 100, 112], ["molecules", "OBSERVATION", 171, 180]]], ["For this reason, we re-evaluated all the baseline models on the QM9 dataset.", [["QM9 dataset", "DNA", 64, 75]]], ["Thus, the results we report are slightly different from the ones in literature.", [["slightly", "OBSERVATION_MODIFIER", 32, 40], ["different", "OBSERVATION_MODIFIER", 41, 50]]], ["Figure 3 shows that, for both the QM9 and ZINC datasets, the histograms compatibility distributions are long tail distributions.", [["QM9 and ZINC datasets", "DNA", 34, 55], ["the QM9 and ZINC datasets", "TREATMENT", 30, 55], ["long tail", "OBSERVATION_MODIFIER", 104, 113]]], ["Moreover, it is possible to see that very often the molecules have the same histogram of valences i.e. the unique set of the histogram of valences is formed by less then 300 histograms for the QM9 dataset and less than 8000 for the ZINC dataset.A. Datasets and MetricsFollowing the indications of [26] we considered the following metrics:A. Datasets and Metrics\u2022 Reconstruction that, given an input molecule and a set of generated molecules, computes the percentage of generated molecules that are equal to the one in input; \u2022 Validity that, given a set of generated molecules, represents the percentage of them that is valid, i.e. that represent actual molecules; \u2022 Novelty that represents the percentage of generated molecules not in the training set; \u2022 Uniqueness that represents (in percentage) the ability of the model to generate different molecules in output, and is computed as the size of the unique set of valid generated molecules divided the total number of valid generated molecules; \u2022 Diversity that measures how much the generated molecules are different from those in the training set (comparing their substructures).", [["the QM9 dataset", "TEST", 189, 204], ["the ZINC dataset", "TREATMENT", 228, 244], ["Metrics\u2022 Reconstruction", "TREATMENT", 354, 377], ["an input molecule", "PROBLEM", 390, 407], ["actual molecules", "OBSERVATION", 647, 663], ["output", "OBSERVATION_MODIFIER", 859, 865], ["size", "OBSERVATION_MODIFIER", 890, 894], ["total", "OBSERVATION_MODIFIER", 954, 959], ["different", "OBSERVATION_MODIFIER", 1060, 1069]]], ["This is a heuristic that uses randomly selected substructures present in the molecules. \u2022 Natural Product (NP) which indicates how much the generated molecules structural space is similar to the one (a) dataset QM9.A. Datasets and Metrics(b) dataset ZINC.", [["Natural Product (NP)", "TREATMENT", 90, 110], ["Metrics(b) dataset ZINC", "TREATMENT", 231, 254]]], ["Fig. 3 : For each dataset, in the x-axis is reported the unique set of histograms, while, by focusing a precise histogram, on the y-axis there is the number of molecules (histograms) with which the histogram is compatible.A. Datasets and Metricscovered by natural products [30] ; \u2022 Solubility (Sol.) which indicates how much a molecule is soluble in water, an important property for drugs; \u2022 Synthetic Accessibility Score (SAS) which represents how easy (0) or difficult (100) it is to synthesize a molecule; \u2022 Quantitative Estimation Drug-likeness (QED) which indicates in percentage how likely it is that the molecule is a good candidate to become a drug.A. Datasets and MetricsThe Reconstruction metric is calculated on 5000 test set molecules encoded 20 times in their latent space probability distributions and decoded one time in a molecule.", [["water", "SIMPLE_CHEMICAL", 350, 355], ["a precise histogram", "TEST", 102, 121], ["the histogram", "TEST", 194, 207], ["Solubility (Sol.", "TREATMENT", 282, 298], ["drugs", "TREATMENT", 383, 388]]], ["This process was chosen because both the encoder P e (z|x, \u03b8 e ) and the decoder P d (x|z, \u03b8 d ) contain a probabilistic component and in this way we estimate the model's ability to reconstruct the molecule considering both factors.", [["P e", "DNA", 49, 52], ["P d", "DNA", 81, 84], ["\u03b8 d", "DNA", 91, 94], ["the decoder P d (x|z", "TEST", 69, 89], ["a probabilistic component", "PROBLEM", 105, 130]]], ["So we treat the reconstruction joint probability of the molecule x in input as:A. Datasets and Metricswhere \u03b8 e and \u03b8 d are the neural networks parameters of the considered model.A. Datasets and MetricsSince we are interested in the generation of new molecules, the other metrics are computed using a different process that consists of directly sampling 20,000 points from the standard normal distribution and decoding each point only once.", [["neural networks", "ANATOMY", 128, 143], ["neural networks", "MULTI-TISSUE_STRUCTURE", 128, 143], ["the reconstruction joint", "TREATMENT", 12, 36], ["the molecule", "PROBLEM", 52, 64], ["joint", "ANATOMY", 31, 36], ["distribution", "OBSERVATION_MODIFIER", 393, 405]]], ["Table II reports the average and standard deviation of the results obtained by the models on both the QM9 and ZINC datasets.", [["QM9", "DNA", 102, 105]]], ["The last line of each table reports the properties scores obtained from the molecules in the datasets, while the last column of each table reports the number of epochs required for the model training.", [["the model training", "TREATMENT", 181, 199]]], ["Note that, we used the same number of epochs as the CGVAE model.", [["the CGVAE model", "TREATMENT", 48, 63]]], ["As reported in section IV-A, all the results regarding the QM9 dataset are different from the results reported in [26] due to the different data split used for the training and evaluation of the models, while the results regarding the dataset ZINC are the same.", [["QM9 dataset", "DNA", 59, 70], ["the training", "TEST", 160, 172], ["evaluation of the models", "TEST", 177, 201], ["the dataset ZINC", "TEST", 231, 247]]], ["However, for each dataset, all the models use the same split of data and the same procedure for generating the molecules and to perform the reconstruction task.", [["the same procedure", "TREATMENT", 73, 91], ["the reconstruction task", "TREATMENT", 136, 159]]], ["In particular, using a test set in which the molecules are more similar to those in the training set, the models reconstruction ability tends to increase.", [["a test set", "TEST", 21, 31], ["the models reconstruction", "TREATMENT", 102, 127], ["increase", "OBSERVATION_MODIFIER", 145, 153]]], ["In fact, in all models except Junction Tree VAE, the reconstruction performances are improved compared to [26] .B. Reconstruction and Generation of new MoleculesWe can see from the table that our model improves the reconstruction performance over CGVAE on both the datasets.", [["MoleculesWe", "PROTEIN", 152, 163], ["the reconstruction performances", "TEST", 49, 80], ["Reconstruction", "TREATMENT", 115, 129], ["Junction", "ANATOMY_MODIFIER", 30, 38], ["Tree VAE", "OBSERVATION", 39, 47], ["improved", "OBSERVATION_MODIFIER", 85, 93]]], ["In particular, the reconstruction increases by 30.91% on the QM9 dataset and by 21.82% on the ZINC dataset.", [["the ZINC dataset", "TEST", 90, 106]]], ["Models based on the SMILES molecule representation, i.e. Character VAE, Grammar VAE and Syntax Directed VAE, usually present better reconstruction values than models based on the molecule graph representation, but have problems to generate valid molecules, i.e. validity values are low.", [["the SMILES molecule representation", "PROBLEM", 16, 50], ["Character VAE", "TEST", 57, 70], ["the molecule graph representation", "TEST", 175, 208], ["low", "OBSERVATION_MODIFIER", 282, 285]]], ["In fact, comparing our model reconstruction values with the other models results, we can see that in the QM9 dataset, CCGVAE is the best among the models that deal directly with the molecular graphs, i.e. Graph VAE, Regularized GVAE, Junction Tree VAE, CG-VAE.", [["QM9 dataset", "DNA", 105, 116], ["VAE", "CELL_LINE", 256, 259], ["our model reconstruction values", "TEST", 19, 50], ["the molecular graphs", "TEST", 178, 198], ["Graph VAE", "TEST", 205, 214], ["CG", "TEST", 253, 255], ["Tree VAE", "OBSERVATION", 243, 251]]], ["Considering the ZINC dataset and only the models that deal directly with the molecular graphs, the Junction Tree VAE model presents the best reconstruction value.", [["ZINC dataset", "DNA", 16, 28], ["the ZINC dataset", "TEST", 12, 28]]], ["This is due to the fact that JTVAE uses common substructures to build the final molecule, so when reconstructing very complex molecules as those in ZINC, it is easier to use substructures than to sample every single atom.", [["JTVAE", "CHEMICAL", 29, 34], ["JTVAE", "SIMPLE_CHEMICAL", 29, 34], ["ZINC", "SIMPLE_CHEMICAL", 148, 152], ["JTVAE", "PROTEIN", 29, 34], ["complex molecules", "PROTEIN", 118, 135], ["common substructures", "PROBLEM", 40, 60]]], ["However, due to the use of substructures, JTVAE presents a very low value on the diversity metric.", [["a very low value", "PROBLEM", 57, 73], ["very", "OBSERVATION_MODIFIER", 59, 63], ["low value", "OBSERVATION_MODIFIER", 64, 73]]], ["Overall, considering all the metrics (reconstruction, validity, novelty, uniqueness and diversity), we can see that also in this case our model shows improved performances compared to CGVAE, trading off higher reconstruction and diversity with a slight decrease in uniqueness.", [["higher reconstruction", "TREATMENT", 203, 224], ["a slight decrease in uniqueness", "PROBLEM", 244, 275], ["improved", "OBSERVATION_MODIFIER", 150, 158], ["slight", "OBSERVATION_MODIFIER", 246, 252], ["decrease", "OBSERVATION_MODIFIER", 253, 261]]], ["If we consider the molecules' properties, our model presents better values regarding the NP and the Sol. metrics than CGVAE, but in the same way, our model presents worse values on the SAS and the QED metrics.", [["the NP", "TREATMENT", 85, 91]]], ["Note that, if we consider the NP metric, in the QM9 dataset our model shows the highest values among the models results.", [["QM9", "DNA", 48, 51]]], ["MolGAN, that is the only model based on the generative adversarial approach and applicable only to the QM9 dataset for computational reasons, presents lower results if compared with our model.", [["MolGAN", "SIMPLE_CHEMICAL", 0, 6]]], ["Overall, our model improves CGVAE in both the datasets, especially the use of the histogram of valences improves the performance on the reconstruction task.B. Reconstruction and Generation of new MoleculesV.", [["CGVAE", "DNA", 28, 33], ["MoleculesV", "PROTEIN", 196, 206], ["the histogram", "TEST", 78, 91], ["the reconstruction task", "TEST", 132, 155], ["B. Reconstruction", "TREATMENT", 156, 173], ["new", "OBSERVATION_MODIFIER", 192, 195], ["MoleculesV", "OBSERVATION", 196, 206]]], ["CONCLUSIONS We have proposed Conditional Constrained Graph Variational Autoencoder (CCGVAE) that, starting from a state-ofthe-art model, uses the histogram of valences key-idea to guide the generation of the molecules, improving the performances of the base model in different performance metrics.B. Reconstruction and Generation of new MoleculesFuture work will analyze and improve the computational time required for training the model.", [["CCGVAE", "CELL_LINE", 84, 90], ["B. Reconstruction", "TREATMENT", 297, 314], ["training the model", "TREATMENT", 419, 437], ["base", "ANATOMY_MODIFIER", 253, 257], ["new", "OBSERVATION_MODIFIER", 333, 336]]], ["For each data-set: the symbol '*' denotes models where we used values for the parameters tuned by the authors for that data-set; entries with blue background highlight the best score obtained for each metric; up and down arrows in front of metrics name denote whether the metric should be maximized (\u2191) or minimized (\u2193).", [["blue background", "TEST", 142, 157]]], ["Average and standard deviation (where applicable) computed on the generated molecules are reported.", [["standard deviation", "OBSERVATION", 12, 30]]], ["Property scores for each data-set are reported as well.", [["each data", "TEST", 20, 29]]]]}